To	O
better	O
understand	O
the	O
RNA	O
-	O
binding	B-FUNC
properties	O
of	O
this	O
multifunctional	O
protein	O
,	O
the	O
N	O
protein	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
as	O
a	O
chimeric	O
protein	O
fused	O
to	O
glutathione	O
-	O
S	O
-	O
transferase	O
(	O
GST	O
).	O

Characterization	O
of	O
the	O
cleavage	O
activity	O
revealed	O
that	O
the	O
proteinase	B-FUNC
is	O
active	O
on	O
this	O
scissile	O
bond	O
when	O
expressed	O
in	O
vitro	O
in	O
rabbit	O
reticulocyte	O
lysates	O
and	O
can	O
act	O
on	O
the	O
same	O
substrate	O
in	O
trans	O
when	O
expressed	O
in	O
intact	O
cells	O
.	O

Acute	O
peritonitis	O
was	O
induced	O
in	O
36	O
rabbits	O
by	O
intraperitoneal	O
injection	O
of	O
zymosan	O
(	O
0	O
.	O
6	O
g	O
/	O
kg	O
)	O
suspended	O
in	O
mineral	O
oil	O
;	O
20	O
were	O
pretreated	O
with	O
a	O
murine	O
-	O
specific	O
IgG2a	O
anti	O
-	O
CD18	O
monoclonal	O
antibody	B-FUNC
,	O
16	O
(	O
controls	O
)	O
with	O
nonspecific	O
purified	O
murine	O
IgG	O
(	O
1	O
mg	O
/	O
kg	O
).	O

ABSTRACT	O
:	O
Previously	O
,	O
we	O
have	O
reported	O
protective	O
vaccination	O
of	O
mice	O
against	O
a	O
coronavirus	O
infection	O
using	O
rabbit	O
polyclonal	O
noninternal	O
image	O
Ab2gamma	O
anti	O
-	O
idiotypic	O
(	O
anti	O
-	O
Id	O
)	O
antibody	B-FUNC
specific	O
for	O
a	O
virus	O
-	O
neutralizing	O
and	O
protective	O
monoclonal	O
antibody	B-FUNC
(	O
mAb	O
)	O
7	O
-	O
10A	O
against	O
the	O
viral	O
surface	O
S	O
glycoprotein	O
.	O

ABSTRACT	O
:	O
A	O
582	O
-	O
base	B-FUNC
pair	I-FUNC
segment	O
located	O
in	O
the	O
nucleocapsid	O
protein	O
terminal	O
part	O
of	O
the	O
S1	O
gene	O
of	O
26	O
Arkansas	O
(	O
Ark	O
)-	O
type	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
isolates	O
from	O
Mississippi	O
broilers	O
was	O
amplified	O
and	O
sequenced	O
.	O

This	O
result	O
suggests	O
that	O
the	O
recombinant	O
PAS16	O
antibody	B-FUNC
can	O
be	O
applicable	O
for	O
the	O
rapid	O
immunohistochemical	O
diagnosis	O
of	O
PEDV	O
infection	O
.	O

This	O
nonapeptide	O
contains	O
a	O
functional	O
O	O
-	O
glycosylation	O
signal	O
as	O
well	O
as	O
an	O
epitope	O
recognized	O
by	O
an	O
MHV	O
-	O
specific	O
monoclonal	O
antibody	B-FUNC
,	O
both	O
of	O
which	O
were	O
expressed	O
by	O
the	O
recombinant	O
virus	O
.	O

In	O
order	O
to	O
identify	O
domains	O
in	O
the	O
N	O
protein	O
that	O
bind	B-FUNC
to	O
RNA	O
,	O
the	O
whole	O
protein	O
(	O
409	O
amino	O
acids	O
)	O
and	O
six	O
overlapping	O
fragments	O
were	O
expressed	O
as	O
fusion	O
polypeptides	O
with	O
six	O
histidine	O
-	O
tags	O
.	O

The	O
lower	O
molarities	O
of	O
the	O
carboxyl	O
fragment	O
compared	O
with	O
residue	O
1	O
-	O
274	O
fragment	O
needed	O
for	O
equivalent	O
shifts	O
suggested	O
that	O
the	O
binding	B-FUNC
avidity	O
for	O
RNA	O
at	O
the	O
carboxyl	O
domain	O
was	O
greater	O
than	O
the	O
amino	O
domain	O
.	O

TITLE	O
:	O
Structure	O
-	O
activity	O
relationships	O
and	O
binding	B-FUNC
mode	O
of	O
styrylquinolines	O
as	O
potent	O
inhibitors	O
of	O
HIV	O
-	O
1	O
integrase	O
and	O
replication	O
of	O
HIV	O
-	O
1	O
in	O
cell	O
culture	O
.	O

The	O
poly	O
(	O
A	O
)	O
tail	O
was	O
required	O
for	O
binding	B-FUNC
of	O
the	O
73	O
-	O
kDa	O
protein	O
.	O

The	O
cattle	O
with	O
HI	O
antibody	B-FUNC
titers	O
of	O
>	O
or	O
=	O
160	O
and	O
the	O
SN	O
titers	O
of	O
>	O
or	O
=	O
640	O
showed	O
no	O
clinical	O
signs	O
,	O
but	O
the	O
cattle	O
with	O
the	O
HI	O
antibody	B-FUNC
titer	O
<	O
80	O
and	O
the	O
SN	O
antibody	B-FUNC
titer	O
<	O
160	O
developed	O
watery	O
diarrhea	O
and	O
fever	O
after	O
challenge	O
.	O

The	O
PCR	O
products	O
of	O
PEDV	O
and	O
TGEV	O
had	O
molecular	O
sizes	O
of	O
412	O
and	O
612	O
base	B-FUNC
pairs	I-FUNC
,	O
respectively	O
.	O

ABSTRACT	O
:	O
Abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-FUNC
)	O
is	O
defined	O
as	O
cardiopulmonary	O
or	O
renal	O
dysfunction	O
caused	O
by	O
an	O
acute	O
increase	O
in	O
intraabdominal	O
pressure	O
.	O

In	O
our	O
previous	O
studies	O
,	O
the	O
proteinase	B-FUNC
was	O
identified	O
as	O
a	O
33	O
-	O
kDa	O
protein	O
in	O
IBV	O
-	O
infected	O
cells	O
,	O
and	O
its	O
catalytic	O
center	O
was	O
shown	O
to	O
consist	O
of	O
H	O
(	O
2820	O
)	O
and	O
C	O
(	O
2922	O
)	O
residues	O
.	O

The	O
S	O
-	O
1	O
nucleotide	O
sequences	O
generated	O
by	O
DACS	B-FUNC
were	O
aligned	O
and	O
analyzed	O
with	O
commercial	O
software	O
to	O
determine	O
their	O
relationship	O
to	O
the	O
S	O
-	O
1	O
nucleotide	O
sequences	O
of	O
IBV	O
strains	O
on	O
deposit	O
in	O
the	O
GenBank	O
and	O
EMBL	O
databases	O
.	O

The	O
DACS	B-FUNC
procedure	O
was	O
further	O
evaluated	O
with	O
a	O
panel	O
of	O
""""	O
unknowns	O
""""	O
comprised	O
of	O
IBV	O
reference	O
strains	O
,	O
field	O
isolates	O
,	O
and	O
variant	O
serotypes	O
collected	O
by	O
our	O
laboratory	O
.	O

The	O
S	O
-	O
1	O
nucleotide	O
sequences	O
for	O
the	O
amplified	O
PCR	O
products	O
of	O
reference	O
strains	O
Mass	O
41	O
,	O
Conn	O
,	O
Ark	O
DPI	O
,	O
JMK	O
,	O
and	O
DE	O
/	O
072	O
/	O
92	O
generated	O
by	O
DACS	B-FUNC
were	O
highly	O
homologous	O
(>	O
99	O
%	O
nucleotide	O
identity	O
)	O
with	O
their	O
respective	O
GenBank	O
database	O
sequences	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
inhibition	O
of	O
TNFalpha	O
and	O
NO	O
(	O
via	O
iNOS	O
)	O
production	O
as	O
well	O
as	O
the	O
increment	O
of	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
production	O
contribute	O
to	O
the	O
beneficial	O
effect	O
of	O
terbutaline	O
in	O
animals	O
with	O
endotoxic	O
shock	O
.	O

Because	O
inflammatory	O
mediators	O
such	O
as	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
(	O
TNF	O
)-	O
alpha	O
and	O
nitric	O
oxide	O
(	O
NO	O
)	O
produced	O
within	O
the	O
lungs	O
have	O
been	O
implicated	O
in	O
sepsis	O
-	O
induced	O
ARDS	O
,	O
we	O
aimed	O
to	O
determine	O
the	O
role	O
of	O
these	O
mediators	O
in	O
pancreatitis	O
-	O
induced	O
ARDS	O
using	O
a	O
model	O
whereby	O
ascites	O
from	O
animals	O
with	O
pancreatitis	O
is	O
transferred	O
to	O
otherwise	O
healthy	O
animals	O
resulting	O
in	O
pulmonary	O
injury	O
.	O

Pulmonary	O
NF	O
-	O
kappaB	O
activation	O
,	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
(	O
TNF	B-FUNC
)	O
gene	O
expression	O
,	O
and	O
neutrophil	O
infiltration	O
(	O
myeloperoxidase	O
)	O
were	O
determined	O
and	O
myeloperoxidase	O
experiments	O
repeated	O
in	O
p55	O
TNF	B-FUNC
receptor	O
-	O
deficient	O
(	O
TNF	B-FUNC
KO	O
)	O
animals	O
.	O

Adenovirus	O
DNA	O
was	O
detected	O
in	O
one	O
of	O
the	O
20	O
nasopharyngeal	O
swabs	O
of	O
healthy	O
controls	O
;	O
the	O
rest	B-FUNC
of	O
the	O
control	O
samples	O
were	O
negative	O
.	O

ABSTRACT	O
:	O
An	O
antibody	B-FUNC
-	O
capture	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
for	O
detection	O
of	O
antibody	B-FUNC
to	O
turkey	O
coronavirus	O
(	O
TCV	O
)	O
utilizing	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
antigen	O
was	O
developed	O
.	O

Goat	O
anti	O
-	O
turkey	O
immunoglobulin	B-FUNC
G	O
(	O
light	O
plus	O
heavy	O
chains	O
)	O
conjugated	O
with	O
horseradish	O
peroxidase	O
was	O
used	O
as	O
detector	O
antibody	B-FUNC
.	O

TITLE	O
:	O
Redesign	O
of	O
primer	O
and	O
application	O
of	O
the	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
test	O
to	O
the	O
DE072	O
strain	O
of	O
infectious	O
bronchitis	O
virus	O
.	O

ABSTRACT	O
:	O
Diagnosis	O
of	O
the	O
DE072	O
strain	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
by	O
the	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
serotype	O
identification	O
test	O
was	O
not	O
possible	O
because	O
the	O
primer	O
used	O
in	O
the	O
RT	O
-	O
PCR	O
did	O
not	O
amplify	O
the	O
S1	O
gene	O
of	O
the	O
DE072	O
strain	O
.	O

TITLE	O
:	O
Fibroblast	B-FUNC
growth	I-FUNC
factor	I-FUNC
2	O
(	O
FGF2	O
)	O
and	O
FGF	O
receptor	O
expression	O
in	O
an	O
experimental	O
demyelinating	O
disease	O
with	O
extensive	O
remyelination	O
.	O

In	O
this	O
study	O
,	O
the	O
immunoprophylactic	O
effects	O
of	O
chicken	O
egg	O
yolk	O
immunoglobulin	B-FUNC
(	O
Ig	O
Y	O
)	O
against	O
PEDV	O
were	O
investigated	O
in	O
neonatal	O
pigs	O
.	O

One	O
high	O
-	O
efficiency	O
N	O
-	O
binding	B-FUNC
site	O
was	O
identified	O
between	O
nucleotides	O
1441	O
and	O
1875	O
at	O
the	O
3	O
'	O
end	O
of	O
the	O
N	O
ORF	O
within	O
Drep	O
.	O

This	O
suggests	O
that	O
the	O
S2A	O
epitope	O
may	O
be	O
involved	O
in	O
binding	B-FUNC
the	O
virus	O
to	O
the	O
MHV	O
receptor	O
and	O
/	O
or	O
in	O
virus	O
-	O
cell	O
fusion	O
.	O

TITLE	O
:	O
Expression	O
of	O
Mig	O
(	O
monokine	O
induced	O
by	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
)	O
is	O
important	O
in	O
T	O
lymphocyte	O
recruitment	O
and	O
host	O
defense	O
following	O
viral	O
infection	O
of	O
the	O
central	O
nervous	O
system	O
.	O

Digestion	O
with	O
RNase	B-FUNC
T1	I-FUNC
at	O
1	O
-	O
10	O
units	O
/	O
microgram	O
RNA	O
resolved	O
RI	O
/	O
TIs	O
into	O
RF	O
/	O
TF	O
cores	O
and	O
left	O
native	O
RF	O
/	O
TFs	O
intact	O
,	O
whereas	O
RNase	O
A	O
at	O
concentrations	O
of	O
0	O
.	O
02	O
microgram	O
/	O
microgram	O
RNA	O
or	O
higher	O
degraded	O
both	O
native	O
RF	O
/	O
TFs	O
and	O
RI	O
/	O
TIs	O
.	O

Right	O
ventricular	O
function	O
was	O
evaluated	O
by	O
using	O
a	O
fast	B-FUNC
response	O
thermistor	O
pulmonary	O
artery	O
catheter	O
that	O
allowed	O
measurement	O
of	O
right	O
ventricular	O
ejection	O
fraction	O
and	O
calculation	O
of	O
right	O
ventricular	O
end	O
-	O
diastolic	O
and	O
end	O
-	O
systolic	O
volumes	O
.	O

Because	O
the	O
lungs	O
of	O
brain	O
-	O
dead	O
organ	O
donors	O
can	O
contain	O
high	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
we	O
hypothesized	O
that	O
this	O
may	O
predispose	O
to	O
early	O
graft	O
failure	O
in	O
the	O
recipient	O
after	O
lung	O
transplantation	O
.	O

In	O
vitro	O
analysis	O
of	O
milk	O
derived	O
from	O
different	O
transgenic	O
lines	O
revealed	O
a	O
linear	O
correlation	O
between	O
antibody	B-FUNC
expression	O
and	O
virus	O
-	O
neutralizing	O
activity	O
,	O
indicating	O
that	O
the	O
recombinant	O
antibody	B-FUNC
is	O
the	O
major	O
determinant	O
of	O
MHV	O
-	O
JHM	O
neutralization	O
in	O
murine	O
milk	O
.	O

Experimental	O
introduction	O
of	O
the	O
A528V	O
mutation	O
into	O
the	O
wild	O
-	O
type	O
spike	O
protein	O
resulted	O
in	O
the	O
loss	O
of	O
MAb	O
binding	B-FUNC
of	O
the	O
mutant	O
protein	O
,	O
confirming	O
that	O
the	O
single	O
point	O
mutation	O
was	O
responsible	O
for	O
the	O
escape	O
of	O
BCV	O
from	O
immunological	O
selective	O
pressure	O
.	O

Comparison	O
of	O
the	O
three	O
groups	O
at	O
4	O
hours	O
did	O
not	O
demonstrate	O
any	O
differences	O
in	O
serum	O
concentrations	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
.	O

TITLE	O
:	O
Heterogeneous	O
nuclear	O
ribonucleoprotein	O
a1	O
binds	B-FUNC
to	O
the	O
3	O
'-	O
untranslated	O
region	O
and	O
mediates	O
potential	O
5	O
'-	O
3	O
'-	O
end	O
cross	O
talks	O
of	O
mouse	O
hepatitis	O
virus	O
RNA	O
.	O

The	O
IgA	O
antibody	B-FUNC
response	O
in	O
serum	O
was	O
detected	O
up	O
to	O
17	O
months	O
post	O
-	O
infection	O
and	O
the	O
duration	O
showed	O
an	O
age	O
-	O
related	O
variation	O
indicating	O
a	O
more	O
prominent	O
IgA	O
memory	O
in	O
the	O
adult	O
cattle	O
and	O
in	O
the	O
older	O
calves	O
than	O
in	O
the	O
younger	O
ones	O
.	O

The	O
Surf	O
,	O
NO	O
,	O
and	O
SNO	B-FUNC
groups	O
had	O
higher	O
V	O
(	O
V	O
)	O
and	O
lower	O
CV	O
(	O
V	O
(	O
V	O
))	O
values	O
than	O
the	O
P	O
-	O
Control	O
,	O
but	O
modest	O
decrease	O
of	O
W	O
/	O
D	O
values	O
.	O

RESULTS	O
:	O
After	O
120	O
minutes	O
of	O
treatment	O
,	O
the	O
SNO	B-FUNC
group	O
had	O
the	O
highest	O
PaO2	O
and	O
Cdyn	O
values	O
,	O
close	O
to	O
that	O
of	O
the	O
N	O
-	O
Control	O
group	O
.	O

These	O
data	O
suggest	O
that	O
B	O
cells	O
may	O
function	O
as	O
antibody	B-FUNC
-	O
independent	O
innate	O
immune	O
response	O
during	O
JHMV	O
infection	O
in	O
vivo	O
.	O

All	O
18	O
shipping	O
boxes	O
were	O
transported	O
to	O
a	O
facility	O
housing	O
a	O
breeding	O
colony	O
of	O
mice	O
enzootically	O
infected	O
with	O
four	O
murine	O
viruses	O
,	O
including	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
and	O
were	O
placed	O
inside	O
the	O
colony	O
for	O
15	O
h	O
.	O
The	O
boxes	O
were	O
then	O
transported	O
to	O
a	O
commercial	O
testing	O
laboratory	O
,	O
at	O
which	O
the	O
animals	O
were	O
aseptically	O
removed	O
and	O
were	O
held	O
in	O
microisolation	O
cages	O
for	O
28	O
days	O
,	O
after	O
which	O
their	O
sera	B-FUNC
tested	O
for	O
antibody	B-FUNC
to	O
all	O
four	O
murine	O
viruses	O
.	O

All	O
serum	O
samples	O
from	O
mice	O
held	O
in	O
the	O
control	O
boxes	O
were	O
positive	O
for	O
antibody	B-FUNC
to	O
MHV	O
,	O
whereas	O
sera	B-FUNC
from	O
all	O
mice	O
held	O
in	O
filtered	O
boxes	O
were	O
negative	O
for	O
antibody	B-FUNC
to	O
any	O
of	O
the	O
four	O
viruses	O
.	O

In	O
experiment	O
3	O
,	O
1	O
-	O
day	O
-	O
old	O
piglets	O
fed	O
HCC	O
with	O
1	O
:	O
512	O
antibody	B-FUNC
titer	O
or	O
UCC	O
were	O
inoculated	O
and	O
necropsied	O
at	O
24	O
,	O
48	O
and	O
72	O
hr	O
after	O
the	O
inoculation	O
for	O
pathological	O
examination	O
.	O

TITLE	O
:	O
Fas	O
/	O
Fas	O
ligand	B-FUNC
system	O
mediates	O
epithelial	O
injury	O
,	O
but	O
not	O
pulmonary	O
host	O
defenses	O
,	O
in	O
response	O
to	O
inhaled	O
bacteria	O
.	O

ABSTRACT	O
:	O
Patients	O
with	O
systemic	O
inflammatory	O
response	O
syndrome	O
(	O
SIRS	O
)	O
and	O
sepsis	O
exhibit	O
decreased	O
plasma	O
selenium	O
and	O
glutathione	B-FUNC
peroxidase	I-FUNC
activity	I-FUNC
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
a	O
follow	O
-	O
up	O
was	O
made	O
between	O
1993	O
and	O
1997	O
from	O
broiler	O
breeders	O
at	O
birth	O
down	O
to	O
offspring	O
broilers	O
at	O
processing	O
,	O
through	O
vertically	O
integrated	O
registration	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
antibody	B-FUNC
titers	O
and	O
performance	O
data	O
.	O

In	O
a	O
patient	O
with	O
a	O
long	O
history	O
of	O
smoking	O
and	O
emphysema	O
,	O
PCP	O
may	O
trigger	O
-	O
macrophage	O
activation	O
and	O
an	O
excessive	O
release	O
of	O
leukocyte	O
elastase	O
,	O
leading	O
to	O
elastin	B-FUNC
destruction	O
in	O
the	O
alveoli	O
.	O

An	O
optimal	O
antibody	B-FUNC
response	O
was	O
achieved	O
with	O
100	O
microg	O
of	O
pcDNA	O
/	O
N	O
.	O
The	O
response	O
lasted	O
at	O
least	O
11	O
weeks	O
after	O
primary	O
immunization	O
.	O

Turkeys	O
infected	O
with	O
TCV	O
had	O
significantly	O
higher	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
antibody	B-FUNC
response	O
to	O
sheep	O
erythrocytes	O
than	O
noninfected	O
controls	O
at	O
7	O
d	O
PI	O
.	O

The	O
introduction	O
of	O
second	O
complementary	O
mutations	O
which	O
restored	O
the	O
predicted	O
base	B-FUNC
pairing	I-FUNC
of	O
positions	O
142	O
to	O
136	O
with	O
68	O
to	O
74	O
and	O
nucleotides	O
96	O
to	O
99	O
with	O
116	O
to	O
113	O
largely	O
ameliorated	O
defects	O
in	O
replication	O
ability	O
,	O
restoring	O
DI	O
RNA	O
replication	O
to	O
levels	O
comparable	O
to	O
that	O
of	O
wild	O
-	O
type	O
DIssE	O
RNA	O
,	O
suggesting	O
that	O
these	O
secondary	O
structures	O
are	O
important	O
for	O
efficient	O
MHV	O
replication	O
.	O

Patients	O
with	O
major	O
trauma	O
underwent	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
levels	O
were	O
measured	O
in	O
BAL	O
fluid	O
by	O
ELISA	O
.	O

Hypoxia	O
increased	O
DNA	B-FUNC
binding	I-FUNC
activity	O
of	O
AP	O
-	O
1	O
and	O
C	O
/	O
EBP	O
but	O
not	O
NF	O
-	O
kappaB	O
.	O
Hypoxia	O
induced	O
HIF	O
-	O
1	O
expression	O
,	O
but	O
cobaltous	O
ions	O
and	O
desferrioxamine	O
did	O
not	O
mimic	O
hypoxic	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
induction	O
.	O

Acute	O
hypoxia	O
,	O
a	O
clinically	O
relevant	O
stimulus	O
,	O
rapidly	O
and	O
selectively	O
upregulates	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
in	O
macrophages	O
associated	O
with	O
a	O
novel	O
pattern	O
of	O
transcription	O
factor	O
activation	O
.	O

RESULTS	O
:	O
In	O
patients	O
with	O
major	O
trauma	O
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
levels	O
were	O
significantly	O
higher	O
in	O
patients	O
that	O
progressed	O
to	O
ARDS	O
compared	O
to	O
those	O
that	O
did	O
not	O
(	O
n	O
=	O
56	O
,	O
P	O
=	O
0	O
.	O
0001	O
).	O

By	O
analogy	O
to	O
other	O
coronavirus	O
replicase	O
gene	O
products	O
,	O
three	O
protease	O
and	O
one	O
growth	O
factor	O
-	O
like	O
motif	O
were	O
seen	O
in	O
ORF1a	O
,	O
and	O
one	O
polymerase	O
domain	O
,	O
one	O
metal	O
ion	O
-	O
binding	B-FUNC
domain	O
,	O
and	O
one	O
helicase	O
motif	O
could	O
be	O
assigned	O
within	O
ORF1b	O
.	O

Immunity	O
was	O
assessed	O
as	O
antibody	B-FUNC
production	O
to	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
),	O
SRBC	O
,	O
and	O
Brucella	O
abortus	O
(	O
BA	O
)	O
antigens	O
,	O
mitogenic	O
response	O
to	O
phytohemagglutinin	O
A	O
(	O
PHA	O
)	O
and	O
concanavalin	O
A	O
(	O
Con	O
A	O
),	O
cutaneous	O
basophil	O
hypersensitivity	O
(	O
CBH	O
)	O
to	O
PHA	O
,	O
and	O
lipopolysaccharide	O
induction	O
of	O
acute	O
-	O
phase	O
proteins	O
(	O
APP	O
)	O
and	O
heterophilia	O
.	O

Antibody	B-FUNC
production	O
in	O
response	O
to	O
BA	O
antigens	O
was	O
not	O
influenced	O
by	O
VE	O
.	O

The	O
PTD	B-FUNC
sequence	O
was	O
constructed	O
upon	O
a	O
solid	O
support	O
,	O
from	O
C	O
-	O
terminus	O
to	O
N	O
-	O
terminus	O
,	O
followed	O
by	O
extension	O
with	O
four	O
glycine	O
residues	O
,	O
leaving	O
the	O
amino	O
chain	O
end	O
for	O
subsequent	O
coupling	O
with	O
remaining	O
acrylic	O
acid	O
functionalities	O
present	O
on	O
the	O
surface	O
of	O
the	O
SCK	O
.	O

CHO	B-FUNC
cells	O
bound	O
with	O
fluorescent	O
PTD	B-FUNC
-	O
nanocage	O
bioconjugates	O
were	O
analyzed	O
using	O
flow	O
cytometry	O
and	O
fluorescence	O
activated	O
cell	O
sorting	O
(	O
FACS	O
).	O

Because	O
of	O
the	O
role	O
of	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
in	O
initiating	O
cell	O
-	O
mediated	O
immunity	O
,	O
the	O
effects	O
of	O
co	O
-	O
delivery	O
of	O
plasmids	O
encoding	O
the	O
feline	O
cytokine	O
were	O
studied	O
.	O

TITLE	O
:	O
Effect	O
of	O
methylprednisolone	O
on	O
phospholipase	B-FUNC
A	I-FUNC
(	O
2	O
)	O
activity	O
and	O
lung	O
surfactant	O
degradation	O
in	O
acute	O
lung	O
injury	O
in	O
rabbits	O
.	O

Serum	O
antibody	B-FUNC
prevalence	O
averaged	O
70	O
%	O
(	O
167	O
/	O
240	O
)	O
during	O
the	O
spring	O
collection	O
period	O
and	O
25	O
%	O
(	O
46	O
/	O
185	O
)	O
during	O
the	O
autumn	O
collection	O
period	O
.	O

No	O
evidence	O
of	O
CV	O
circulation	O
by	O
antigen	O
or	O
antibody	B-FUNC
analysis	O
was	O
observed	O
.	O

ABSTRACT	O
:	O
A	O
serodiagnostic	O
ELISA	O
utilizing	O
the	O
recombinant	O
nucleoprotein	O
(	O
rN	O
protein	O
)	O
of	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
was	O
developed	O
,	O
and	O
evaluated	O
by	O
examining	O
a	O
panel	O
of	O
141	O
virus	O
neutralization	O
(	O
VN	O
)	O
positive	O
and	O
101	O
negative	O
sera	B-FUNC
.	O

Other	O
mediator	O
-	O
targeted	O
therapies	O
,	O
such	O
as	O
prostaglandin	O
E1	O
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
and	O
platelet	O
activating	O
factor	O
antagonists	O
,	O
have	O
not	O
been	O
found	O
efficacious	O
in	O
large	O
clinical	O
trials	O
of	O
ARDS	O
.	O

BHK	O
cells	O
were	O
either	O
cotransfected	O
with	O
TGEV	O
-	O
Rep	B-FUNC
(	O
AvrII	O
)	O
(	O
E	O
gene	O
deletion	O
)	O
and	O
VEE	O
-	O
TGEV	O
(	O
E	O
)	O
RNA	O
transcripts	O
or	O
transfected	O
with	O
TGEV	O
-	O
Rep	B-FUNC
(	O
AvrII	O
)	O
RNA	O
transcripts	O
and	O
subsequently	O
infected	O
with	O
VEE	O
VRPs	O
carrying	O
the	O
TGEV	O
E	O
gene	O
.	O

TITLE	O
:	O
Mechanisms	O
of	O
central	O
nervous	O
system	O
viral	O
persistence	O
:	O
the	O
critical	O
role	O
of	O
antibody	B-FUNC
and	O
B	O
cells	O
.	O

At	O
different	O
postinoculation	O
day	O
(	O
PID	O
)	O
and	O
postchallenge	O
day	O
(	O
PCD	O
)	O
virus	O
-	O
specific	O
antibody	B-FUNC
-	O
secreting	O
cells	O
(	O
ASC	O
)	O
in	O
gut	O
associated	O
lymphoid	O
tissues	O
(	O
duodenum	O
and	O
ileum	O
lamina	O
propria	O
and	O
mesenteric	O
lymph	O
nodes	O
)	O
and	O
systemic	O
locations	O
(	O
blood	O
and	O
spleen	O
)	O
were	O
assessed	O
by	O
enzyme	O
-	O
linked	O
immunospot	O
(	O
ELISPOT	O
).	O

A	O
strong	O
positive	O
correlation	O
was	O
established	O
between	O
protection	O
and	O
the	O
ASC	O
responses	O
detected	O
in	O
gut	O
associated	O
lymphoid	O
tissues	O
and	O
blood	O
at	O
the	O
challenge	O
day	O
and	O
also	O
between	O
protection	O
and	O
serum	O
isotype	O
-	O
specific	O
antibody	B-FUNC
titers	O
on	O
that	O
day	O
.	O

TITLE	O
:	O
Antibody	B-FUNC
responses	O
and	O
morbidity	O
following	O
infection	O
with	O
infectious	O
bronchitis	O
virus	O
and	O
challenge	O
with	O
Escherichia	O
coli	O
,	O
in	O
lines	O
divergently	O
selected	O
on	O
antibody	B-FUNC
response	O
.	O

ABSTRACT	O
:	O
Blood	O
was	O
collected	O
from	O
55	O
cats	O
with	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
)	O
and	O
from	O
50	O
control	O
cats	O
in	O
order	O
to	O
define	O
whether	O
differences	O
in	O
pathological	O
findings	O
and	O
in	O
distribution	O
of	O
feline	O
coronaviruses	O
(	O
FCoV	O
)	O
can	O
be	O
associated	O
with	O
changes	O
in	O
haemograms	O
,	O
serum	O
protein	O
electrophoresis	O
,	O
and	O
antibody	B-FUNC
titres	O
.	O

Activation	O
of	O
cells	O
by	O
endotoxins	O
may	O
result	O
in	O
elevated	O
secretion	O
of	O
phospholipase	B-FUNC
A	I-FUNC
(	O
2	O
)	O
(	O
sPLA	O
(	O
2	O
))	O
which	O
is	O
thought	O
to	O
contribute	O
to	O
tissue	O
damage	O
.	O

Thirty	O
of	O
these	O
commercial	O
herds	O
had	O
a	O
clinical	O
history	O
of	O
TGEV	O
infection	O
and	O
a	O
positive	O
TGEV	O
fluorescent	O
antibody	B-FUNC
test	O
recorded	O
at	O
necropsy	O
within	O
the	O
last	O
35	O
months	O
,	O
while	O
70	O
herds	O
had	O
no	O
history	O
of	O
clinical	O
TGEV	O
infection	O
.	O

The	O
blocking	O
ELISA	O
and	O
the	O
VN	O
showed	O
good	O
agreement	O
(	O
kappa	O
0	O
.	O
84	O
)	O
for	O
the	O
detection	O
of	O
porcine	O
coronavirus	O
antibody	B-FUNC
(	O
TGEV	O
or	O
PRCV	O
).	O

TITLE	O
:	O
Congenital	O
Guillain	O
-	O
Barré	O
syndrome	O
associated	O
with	O
maternal	O
inflammatory	O
bowel	O
disease	O
is	O
responsive	O
to	O
intravenous	O
immunoglobulin	B-FUNC
.	O

Experiments	O
with	O
a	O
specific	O
inhibitor	O
of	O
p38	B-FUNC
MAPK	B-FUNC
,	O
SB	O
203580	O
,	O
demonstrated	O
that	O
MHV	O
-	O
induced	O
p38	B-FUNC
MAPK	B-FUNC
activation	O
resulted	O
in	O
the	O
accumulation	O
of	O
interleukin	O
-	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
)	O
mRNAs	O
and	O
an	O
increase	O
in	O
the	O
production	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
regardless	O
of	O
MHV	O
-	O
induced	O
general	O
host	O
protein	O
synthesis	O
inhibition	O
.	O

Our	O
data	O
suggested	O
that	O
host	O
cells	O
,	O
in	O
response	O
to	O
MHV	O
replication	O
,	O
activated	O
p38	B-FUNC
MAPK	B-FUNC
,	O
which	O
subsequently	O
phosphorylated	O
eIF4E	O
to	O
efficiently	O
translate	O
certain	O
host	O
proteins	O
,	O
including	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
during	O
virus	O
-	O
induced	O
severe	O
host	O
protein	O
synthesis	O
inhibition	O
.	O

In	O
virus	O
overlay	O
binding	B-FUNC
assays	O
with	O
immobilized	O
cell	O
surface	O
proteins	O
,	O
the	O
mutant	O
virus	O
only	O
recognized	O
pAPN	O
.	O

TITLE	O
:	O
Detection	O
of	O
rodent	O
coronaviruses	O
by	O
use	O
of	O
fluorogenic	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
analysis	O
.	O

Percutaneous	O
decompression	O
is	O
a	O
safe	O
and	O
effective	O
method	O
of	O
decreasing	O
IAH	B-FUNC
and	O
preventing	O
ACS	B-FUNC
in	O
patients	O
with	O
less	O
than	O
80	O
%	O
TBSA	O
thermal	O
injury	O
.	O

In	O
addition	O
to	O
the	O
amino	O
acid	O
change	O
at	O
position	O
1114	O
that	O
stemmed	O
from	O
parental	O
srr7	O
,	O
srr7A	O
and	O
srr7B	O
had	O
mutations	O
around	O
position	O
280	O
,	O
corresponding	O
to	O
the	O
third	O
region	O
of	O
the	O
S1N330	O
receptor	O
-	O
binding	B-FUNC
site	O
(	O
S1N330	O
-	O
III	O
)	O
common	O
to	O
all	O
MHV	O
strains	O
examined	O
thus	O
far	O
.	O

The	O
best	O
predictors	O
were	O
LOV	O
for	O
LOS	O
,	O
and	O
a	O
combination	O
of	O
SNAP	B-FUNC
and	O
the	O
reason	O
for	O
ventilation	O
for	O
LOV	O
.	O

CONCLUSIONS	O
:	O
SNAP	B-FUNC
is	O
a	O
useful	O
measure	O
of	O
severity	O
of	O
illness	O
in	O
sick	O
term	O
neonates	O
admitted	O
to	O
a	O
tertiary	O
NICU	O
.	O

TITLE	O
:	O
Antibody	B-FUNC
responses	O
of	O
cattle	O
with	O
respiratory	O
coronavirus	O
infections	O
during	O
pathogenesis	O
of	O
shipping	O
fever	O
pneumonia	O
are	O
lower	O
with	O
antigens	O
of	O
enteric	O
strains	O
than	O
with	O
those	O
of	O
a	O
respiratory	O
strain	O
.	O

ABSTRACT	O
:	O
The	O
serum	O
antibody	B-FUNC
responses	O
of	O
cattle	O
with	O
respiratory	O
coronavirus	O
infections	O
during	O
the	O
pathogenesis	O
of	O
shipping	O
fever	O
pneumonia	O
were	O
analyzed	O
with	O
different	O
bovine	O
coronavirus	O
antigens	O
,	O
including	O
those	O
from	O
a	O
wild	O
-	O
type	O
respiratory	O
bovine	O
coronavirus	O
(	O
RBCV	O
)	O
strain	O
(	O
97TXSF	O
-	O
Lu	O
15	O
-	O
2	O
)	O
directly	O
isolated	O
from	O
lung	O
tissue	O
from	O
a	O
fatally	O
infected	O
bovine	O
,	O
a	O
wild	O
-	O
type	O
enteropathogenic	O
bovine	O
coronavirus	O
(	O
EBCV	O
)	O
strain	O
(	O
Ly	O
138	O
-	O
3	O
),	O
and	O
the	O
highly	O
cell	O
culture	O
-	O
adapted	O
,	O
enteric	O
prototype	O
strain	O
(	O
EBCV	O
L9	O
-	O
81	O
).	O

The	O
IN	O
and	O
HAI	O
antibody	B-FUNC
responses	O
against	O
the	O
two	O
EBCV	O
strains	O
did	O
not	O
differ	O
significantly	O
,	O
but	O
the	O
lowest	O
titers	O
were	O
detected	O
with	O
EBCV	O
strain	O
L9	O
-	O
81	O
.	O

The	O
digoxigenin	O
-	O
labeled	O
antisense	O
S1	O
riboprobe	O
detected	O
viral	O
mRNA	O
in	O
the	O
cytoplasm	O
of	O
respiratory	O
epithelial	O
cells	O
in	O
the	O
primary	O
bronchus	O
at	O
24	O
,	O
48	O
,	O
and	O
72	O
HPI	B-FUNC
.	O

At	O
baseline	O
the	O
patients	O
had	O
severe	O
ARDS	O
as	O
noted	O
by	O
a	O
mean	O
lung	O
injury	O
score	O
(	O
LIS	B-FUNC
)	O
of	O
3	O
.	O
2	O
(	O
SD	O
0	O
.	O
3	O
)	O
and	O
Pao2	O
/	O
FIo2	O
ratio	O
12	O
.	O
2	O
(	O
SD	O
3	O
.	O
2	O
)	O
kPa	O
.	O

Examination	O
of	O
postmortem	O
lungs	O
among	O
cases	O
clinically	O
diagnosed	O
as	O
ARDS	O
identified	O
a	O
cohort	O
that	O
showed	O
a	O
consistent	O
morphology	O
at	O
the	O
light	O
and	O
electron	O
microscope	O
levels	O
,	O
and	O
featured	O
pathognomonic	O
structures	O
which	O
we	O
termed	O
elastin	B-FUNC
-	O
staining	O
laminar	O
structures	O
(	O
ELS	O
).	O

All	O
patients	O
developed	O
neurologic	O
complications	O
resulting	O
from	O
ACS	B-FUNC
episodes	O
,	O
including	O
seizures	O
(	O
n	O
=	O
2	O
),	O
silent	O
cerebral	O
infarcts	O
(	O
n	O
=	O
3	O
),	O
cerebral	O
hemorrhage	O
(	O
n	O
=	O
2	O
),	O
and	O
reversible	O
posterior	O
leukoencephalopathy	O
syndrome	O
(	O
n	O
=	O
3	O
).	O

ABSTRACT	O
:	O
To	O
improve	O
the	O
detection	O
and	O
molecular	O
identification	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
avian	O
coronavirus	O
),	O
two	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
assays	O
were	O
developed	O
.	O

We	O
detected	O
TdT	B-FUNC
-	O
mediated	O
dUTP	O
nick	O
-	O
end	O
labeling	O
(	O
TUNEL	O
)	O
staining	O
in	O
the	O
livers	O
and	O
meninges	O
of	O
MHV	O
-	O
A59	O
-,	O
MHV	O
-	O
2	O
-,	O
and	O
Penn98	O
-	O
1	O
-	O
infected	O
mice	O
.	O

An	O
ELISA	O
was	O
used	O
to	O
test	O
for	O
the	O
presence	O
of	O
MHV	O
-	O
specific	O
antibody	B-FUNC
,	O
and	O
TaqMan	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
analysis	O
was	O
used	O
to	O
detect	O
MHV	O
in	O
the	O
feces	O
.	O

The	O
appearance	O
of	O
the	O
proteinase	B-FUNC
-	O
resistant	O
fragment	O
was	O
dependent	O
on	O
the	O
temperature	O
and	O
time	O
of	O
srr7	O
incubation	O
with	O
soMHVR	O
and	O
also	O
on	O
the	O
concentration	O
of	O
soMHVR	O
.	O

soMHVR	O
induced	O
conformational	O
changes	O
of	O
the	O
S	O
proteins	O
of	O
wild	O
-	O
type	O
(	O
wt	O
)	O
JHMV	O
cl	O
-	O
2	O
,	O
as	O
well	O
as	O
revertants	O
from	O
srr7	O
,	O
srr7A	O
and	O
srr7B	O
;	O
however	O
,	O
a	O
major	O
proportion	O
of	O
these	O
S	O
proteins	O
were	O
resistant	O
to	O
proteinase	B-FUNC
K	O
even	O
without	O
soMHVR	O
treatment	O
.	O

Under	O
physiological	O
circumstances	O
,	O
secretory	O
phospholipase	B-FUNC
A	I-FUNC
(	O
2	O
)	O
type	O
I	O
(	O
sPLA	O
(	O
2	O
)-	O
I	O
)	O
is	O
activated	O
by	O
trypsinogen	O
,	O
but	O
the	O
extent	O
of	O
this	O
activation	O
in	O
acute	O
pancreatitis	O
is	O
unclear	O
.	O

TITLE	O
:	O
Efficient	O
induction	O
of	O
primary	O
and	O
secondary	O
T	O
cell	O
-	O
dependent	O
immune	O
responses	O
in	O
vivo	O
in	O
the	O
absence	O
of	O
functional	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
15	I-FUNC
receptors	O
.	O

ABSTRACT	O
:	O
Using	O
isogenic	O
recombinant	O
murine	O
coronaviruses	O
expressing	O
wild	O
-	O
type	O
murine	O
hepatitis	O
virus	O
strain	O
4	O
(	O
MHV	O
-	O
4	O
)	O
or	O
MHV	O
-	O
A59	O
spike	O
glycoproteins	O
or	O
chimeric	O
MHV	O
-	O
4	O
/	O
MHV	O
-	O
A59	O
spike	O
glycoproteins	O
,	O
we	O
have	O
demonstrated	O
the	O
biological	O
functionality	O
of	O
the	O
N	O
-	O
terminus	O
of	O
the	O
spike	O
,	O
encompassing	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
).	O

The	O
study	O
revealed	O
that	O
the	O
GAV	O
and	O
potyvirus	O
3CL	O
(	O
pro	O
)	O
s	O
possess	O
similar	O
substrate	O
specificities	O
which	O
correlate	O
with	O
structural	O
similarities	O
in	O
their	O
respective	O
substrate	O
-	O
binding	B-FUNC
sites	O
,	O
identified	O
in	O
sequence	O
comparisons	O
.	O

The	O
properties	O
of	O
the	O
GAV	O
3CL	O
(	O
pro	O
)	O
define	O
a	O
novel	O
RNA	O
virus	O
proteinase	B-FUNC
variant	O
that	O
bridges	O
the	O
gap	O
between	O
the	O
distantly	O
related	O
chymotrypsin	O
-	O
like	O
cysteine	O
proteinases	O
of	O
coronaviruses	O
and	O
potyviruses	O
.	O

TITLE	O
:	O
PDGF	B-FUNC
and	O
FGF2	O
regulate	O
oligodendrocyte	O
progenitor	O
responses	O
to	O
demyelination	O
.	O

We	O
identify	O
PDGF	B-FUNC
and	O
FGF2	O
as	O
significant	O
mitogens	O
regulating	O
this	O
proliferative	O
response	O
.	O

TITLE	O
:	O
Identification	O
of	O
a	O
receptor	O
-	O
binding	B-FUNC
domain	O
of	O
the	O
spike	O
glycoprotein	O
of	O
human	O
coronavirus	O
HCoV	O
-	O
229E	O
.	O

TITLE	O
:	O
Design	O
,	O
synthesis	O
,	O
SAR	O
,	O
and	O
molecular	O
modeling	O
studies	O
of	O
acylthiocarbamates	O
:	O
a	O
novel	O
series	O
of	O
potent	O
non	O
-	O
nucleoside	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
inhibitors	O
structurally	O
related	O
to	O
phenethylthiazolylthiourea	O
derivatives	O
.	O

Patients	O
with	O
more	O
severe	O
appendicitis	O
had	O
higher	O
plasma	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
and	O
lower	O
plasma	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
and	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
than	O
did	O
those	O
with	O
uncomplicated	O
disease	O
.	O

RESULTS	O
:	O
Of	O
the	O
proinflammatory	O
cytokines	O
,	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
was	O
present	O
in	O
PF	O
but	O
not	O
in	O
plasma	O
,	O
interleukin	O
(	O
IL	O
)-	O
1beta	O
and	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
were	O
found	O
in	O
low	O
concentrations	O
in	O
both	O
PF	O
and	O
plasma	O
,	O
and	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
(	O
p70	O
)	O
was	O
detectable	O
in	O
plasma	O
but	O
not	O
PF	O
.	O

TITLE	O
:	O
Serum	O
levels	O
of	O
mannan	O
-	O
binding	B-FUNC
lectin	O
in	O
chickens	O
prior	O
to	O
and	O
during	O
experimental	O
infection	O
with	O
avian	O
infectious	O
bronchitis	O
virus	O
.	O

Extension	O
of	O
the	O
complementarity	O
between	O
the	O
TRS	B-FUNC
and	O
sequences	O
at	O
the	O
3	O
'	O
end	O
of	O
the	O
viral	O
leader	O
was	O
associated	O
with	O
transcriptional	O
activation	O
of	O
noncanonical	O
core	O
sequences	O
.	O

Soluble	O
hAPN	O
neutralized	O
the	O
infectivity	O
of	O
HCoV	O
-	O
229E	O
virions	O
at	O
37	O
degrees	O
C	O
,	O
but	O
not	O
4	O
degrees	O
C	O
.	O
Binding	B-FUNC
of	O
hAPN	O
may	O
therefore	O
trigger	O
conformational	O
changes	O
in	O
the	O
viral	O
spike	O
protein	O
at	O
37	O
degrees	O
C	O
that	O
facilitate	O
virus	O
entry	O
.	O

To	O
examine	O
the	O
basis	O
of	O
the	O
strain	O
difference	O
against	O
MHV	O
infection	O
in	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
-	O
deficient	O
mice	O
,	O
viral	O
replication	O
in	O
primary	O
hepatocyte	O
cultures	O
from	O
BALB	O
/	O
c	O
and	O
B6	O
mice	O
with	O
or	O
without	O
the	O
IFN	O
-	O
gamma	O
gene	O
was	O
compared	O
in	O
vitro	O
.	O

ABSTRACT	O
:	O
Vascular	B-FUNC
endothelial	I-FUNC
growth	I-FUNC
factor	I-FUNC
(	O
VEGF	O
),	O
an	O
angiogenic	O
and	O
chemotactic	O
peptide	O
,	O
is	O
abundantly	O
expressed	O
in	O
normal	O
lung	O
tissue	O
,	O
especially	O
in	O
alveolar	O
and	O
bronchial	O
epithelium	O
,	O
glandular	O
cells	O
of	O
the	O
bronchi	O
,	O
and	O
activated	O
alveolar	O
macrophages	O
.	O

We	O
evaluated	O
pulmonary	O
VEGF	O
expression	O
in	O
lung	O
autopsy	O
material	O
from	O
septic	O
patients	O
who	O
had	O
been	O
cared	O
for	O
by	O
intensive	O
care	O
medicine	O
using	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
),	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
and	O
immunohistochemical	O
methods	O
.	O

Viral	O
recrudescence	O
is	O
prevented	O
by	O
the	O
transfer	O
of	O
antiviral	O
antibody	B-FUNC
(	O
Ab	O
).	O

DNA	O
fragments	O
of	O
228	O
and	O
400	O
base	B-FUNC
pairs	I-FUNC
in	O
length	O
were	O
amplified	O
among	O
IBV	O
isolates	O
in	O
multiplex	O
PCR	O
,	O
suggesting	O
that	O
there	O
were	O
no	O
apparent	O
deletions	O
or	O
insertions	O
in	O
these	O
regions	O
.	O

The	O
diagnosis	O
was	O
determined	O
by	O
confirming	O
an	O
increase	O
of	O
specific	O
antibody	B-FUNC
.	O

MHV	O
-	O
2	O
was	O
injected	O
intraperitoneally	O
into	O
4	O
-	O
week	O
-	O
old	O
ICR	O
mice	O
,	O
IFN	O
or	O
the	O
vehicle	O
was	O
administered	O
intramuscularly	O
for	O
5	O
days	O
,	O
and	O
the	O
antiviral	O
effect	O
was	O
evaluated	O
based	O
on	O
survival	O
periods	O
,	O
liver	O
histology	O
,	O
serum	O
alanine	O
transaminase	O
(	O
ALT	B-FUNC
)	O
levels	O
,	O
and	O
MHV	O
-	O
2	O
virus	O
titers	O
in	O
the	O
liver	O
tissues	O
.	O

Calves	O
that	O
were	O
seronegative	O
or	O
had	O
low	O
antibody	B-FUNC
titers	O
against	O
BoTV	O
(<	O
or	O
=	O
1	O
:	O
10	O
hemagglutination	O
inhibition	O
units	O
)	O
at	O
arrival	O
seroconverted	O
to	O
BoTV	O
(>	O
4	O
-	O
fold	O
increase	O
in	O
titer	O
);	O
these	O
calves	O
were	O
more	O
likely	O
to	O
shed	O
virus	O
than	O
calves	O
that	O
were	O
seropositive	O
against	O
BoTV	O
at	O
arrival	O
.	O

Frozen	O
sections	O
of	O
the	O
thrombotic	O
coronary	O
segment	O
,	O
analysed	O
for	O
different	O
infective	O
agents	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
reverse	O
transcriptase	B-FUNC
(	O
RT	O
)-	O
PCR	O
,	O
showed	O
positive	O
amplification	O
for	O
an	O
enteroviral	O
genome	O
.	O

0	O
.	O
06	O
mL	O
/	O
kPa	O
;	O
and	O
bleomycin	O
+	O
granulocyte	B-FUNC
colony	I-FUNC
-	I-FUNC
stimulating	I-FUNC
factor	I-FUNC
,	O
0	O
.	O
65	O
+/-	O

Lung	O
morphology	O
with	O
bleomycin	O
+	O
granulocyte	B-FUNC
colony	I-FUNC
-	I-FUNC
stimulating	I-FUNC
factor	I-FUNC
showed	O
,	O
in	O
addition	O
to	O
the	O
changes	O
observed	O
with	O
bleomycin	O
alone	O
,	O
four	O
patterns	O
indicating	O
more	O
severe	O
disease	O
:	O
honeycomb	O
foci	O
,	O
pleural	O
thickening	O
with	O
hyaline	O
fibrosis	O
,	O
interstitial	O
granuloma	O
with	O
increased	O
number	O
of	O
macrophages	O
but	O
not	O
neutrophils	O
,	O
and	O
established	O
interstitial	O
fibrosis	O
.	O

Lidocaine	O
,	O
which	O
prevents	O
neutrophil	O
adhesion	O
to	O
endothelial	O
cells	O
,	O
inhibited	O
granulocyte	B-FUNC
colony	I-FUNC
-	I-FUNC
stimulating	I-FUNC
factor	I-FUNC
-	O
related	O
exacerbation	O
of	O
acute	O
lung	O
injury	O
(	O
bronchoalveolar	O
lavage	O
fluid	O
cells	O
and	O
pulmonary	O
edema	O
)	O
and	O
pulmonary	O
fibrosis	O
(	O
lung	O
static	O
compliance	O
and	O
morphologic	O
changes	O
).	O

The	O
binding	B-FUNC
for	O
one	O
protein	O
-	O
protein	O
interaction	O
pair	O
(	O
D757	O
-	O
R761	O
motif	O
of	O
the	O
SARS	O
-	O
CoV	O
S	O
protein	O
to	O
P585	O
-	O
A653	O
domain	O
of	O
CD13	O
)	O
has	O
been	O
simulated	O
by	O
molecular	O
modeling	O
and	O
docking	O
simulation	O
methods	O
.	O

Either	O
the	O
3D	O
model	O
of	O
the	O
SARS	O
-	O
CoV	O
3CL	O
proteinase	B-FUNC
or	O
the	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
the	O
TGEV	O
Mpro	O
may	O
be	O
used	O
as	O
a	O
starting	O
point	O
for	O
design	O
anti	O
-	O
SARS	O
drugs	O
.	O

TITLE	O
:	O
Identification	O
of	O
the	O
murine	O
coronavirus	O
MP1	O
cleavage	O
site	O
recognized	O
by	O
papain	O
-	O
like	O
proteinase	B-FUNC
2	O
.	O

TITLE	O
:	O
[	O
Antibody	B-FUNC
response	O
of	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
to	O
nucleocapsid	O
antigen	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
].	O

ABSTRACT	O
:	O
To	O
assess	O
serum	O
antibody	B-FUNC
responses	O
of	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
to	O
nucleocapsid	O
(	O
N	O
)	O
antigen	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
.	O

Isolated	O
retinas	O
were	O
analyzed	O
for	O
IFN	O
-	O
gamma	O
mRNA	O
by	O
RT	O
-	O
PCR	O
,	O
and	O
sera	B-FUNC
were	O
evaluated	O
for	O
IFN	O
-	O
gamma	O
protein	O
by	O
ELISA	O
assays	O
.	O

GMSA	O
and	O
competition	O
experiments	O
demonstrated	O
binding	B-FUNC
to	O
both	O
HNF4	O
and	O
IE1	O
.	O
2	O
fragments	O
could	O
be	O
competed	O
with	O
the	O
cold	O
specific	O
oligonucleotides	O
but	O
not	O
with	O
the	O
same	O
amount	O
of	O
non	O
-	O
specific	O
oligos	O
nucleotides	O
.	O

All	O
patients	O
received	O
standard	O
treatment	O
:	O
ribavirin	O
1000	O
mg	O
orally	O
daily	O
for	O
10	O
days	O
,	O
Levofloxacin	O
500	O
mg	O
orally	O
daily	O
for	O
7	O
days	O
,	O
and	O
intravenous	O
immunoglobulin	B-FUNC
(	O
IVIG	O
)	O
1	O
g	O
/	O
kg	O
/	O
day	O
for	O
2	O
day	O
after	O
the	O
onset	O
of	O
symptoms	O
.	O

The	O
level	O
of	O
serum	O
IL	O
was	O
increased	O
to	O
a	O
great	O
extent	O
in	O
the	O
35	O
SARS	O
patients	O
,	O
and	O
the	O
levels	O
of	O
serum	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
were	O
242	O
.	O
53	O
(	O
92	O
.	O
69	O
)	O
pg	O
/	O
ml	O
,	O
77	O
.	O
43	O
(	O
63	O
.	O
37	O
)	O
pg	O
/	O
ml	O
and	O
65	O
.	O
94	O
(	O
43	O
.	O
21	O
)	O
pg	O
/	O
ml	O
,	O
respectively	O
.	O

The	O
level	O
of	O
serum	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
increased	O
markedly	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

Among	O
them	O
,	O
18	O
patients	O
who	O
presented	O
with	O
SpO	O
(	O
2	O
)	O
of	O
90	O
%	O
-	O
93	O
%	O
at	O
rest	B-FUNC
under	O
O	O
(	O
2	O
)	O
inhalation	O
5	O
L	O
/	O
min	O
were	O
further	O
recorded	O
for	O
their	O
SpO	O
(	O
2	O
)	O
during	O
slight	O
physical	O
movement	O
and	O
CPAP	O
.	O

1	O
.	O
8	O
)	O
mmol	O
/	O
L	O
]	O
[(	O
196	O
+/-	O
70	O
)	O
mg	O
/	O
dl	O
vs	O
(	O
110	O
+/-	O
21	O
)	O
mg	O
/	O
dl	O
]	O
(	O
P	O
=	O
0	O
.	O
0002	O
),	O
and	O
the	O
abnormally	O
high	O
ALT	B-FUNC
levels	O
presented	O
in	O
some	O
of	O
the	O
patients	O
decreased	O
but	O
not	O
significantly	O
(	O
81	O
.	O
0	O
%	O
vs	O
57	O
.	O
1	O
%)	O
(	O
P	O
=	O
0	O
.	O
18	O
).	O

The	O
specific	O
IgG	O
antibody	B-FUNC
didn	O
'	O
t	O
emerge	O
in	O
some	O
patients	O
in	O
the	O
early	O
stage	O
of	O
the	O
disease	O
,	O
and	O
the	O
negative	O
results	O
didn	O
'	O
t	O
indicate	O
that	O
they	O
were	O
not	O
infected	O
.	O

it	O
'	O
s	O
possible	O
in	O
Río	O
Cuarto	O
to	O
made	O
a	O
fast	B-FUNC
and	O
direct	O
virology	O
diagnostic	O
using	O
an	O
electron	O
microscopy	O
.	O

Subsequently	O
,	O
because	O
of	O
passive	O
antibody	B-FUNC
transfer	O
,	O
the	O
offspring	O
of	O
these	O
primed	O
gilts	O
were	O
more	O
efficient	O
in	O
surviving	O
a	O
lethal	O
TGEV	O
challenge	O
.	O

RESULTS	O
:	O
When	O
being	O
admitted	O
to	O
hospital	O
,	O
serum	O
ALT	B-FUNC
and	O
(	O
or	O
)	O
AST	O
levels	O
were	O
elevated	O
in	O
37	O
.	O
7	O
%	O
SARS	O
patients	O
.	O

Mortality	O
rates	O
of	O
the	O
F1	O
(	O
H	O
x	O
L	O
)	O
hybrids	O
and	O
F2	O
and	O
backcross	O
segregants	O
reflected	O
co	O
-	O
dominance	O
of	O
both	O
characters	O
and	O
the	O
survivors	O
had	O
higher	O
preexisting	O
anti	O
-	O
MHV	O
antibody	B-FUNC
titers	O
.	O

ABSTRACT	O
:	O
Reductive	O
metabolism	O
of	O
carbon	O
tetrachloride	O
(	O
CCl	B-FUNC
(	O
4	O
))	O
is	O
thought	O
to	O
cause	O
lipid	O
peroxidation	O
which	O
results	O
in	O
hepatic	O
injury	O
.	O

CCl	B-FUNC
(	O
4	O
)	O
treatment	O
(	O
1	O
mL	O
/	O
kg	O
,	O
intraperitoneally	O
)	O
produced	O
severe	O
hepatic	O
injury	O
in	O
rats	O
as	O
revealed	O
by	O
significant	O
increases	O
in	O
serum	O
alanine	O
transaminase	O
(	O
ALT	B-FUNC
)	O
(	O
EC	O
2	O
.	O
6	O
.	O
1	O
.	O
2	O
)	O
activity	O
and	O
hepatic	O
malondialdehyde	O
(	O
MDA	O
)	O
content	O
,	O
severe	O
liver	O
cell	O
injury	O
,	O
and	O
increases	O
in	O
hepatic	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
mRNA	O
expression	O
and	O
DNA	B-FUNC
binding	I-FUNC
activity	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
).	O

EBC	O
was	O
collected	O
and	O
analyzed	O
for	O
NO	O
(	O
2	O
)(-),	O
interleukin	O
(	O
IL	O
)-	O
6	O
,	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
.	O

All	O
of	O
these	O
proteins	O
contain	O
amino	O
acid	O
sequences	O
with	O
strong	O
similarity	O
to	O
the	O
RNA	O
-	O
binding	B-FUNC
domains	O
of	O
hnRNP	O
A1	O
.	O

The	O
clinic	O
symptoms	O
,	O
chest	O
film	O
and	O
tongue	O
figure	O
of	O
40	O
uncertain	O
SARS	O
patients	O
treated	O
with	O
ICWM	O
were	O
observed	O
and	O
T	O
-	O
lymphocyte	O
subsets	O
,	O
serum	O
coronavirus	O
nucleic	O
acid	O
and	O
antibody	B-FUNC
in	O
20	O
patients	O
were	O
tested	O
dynamically	O
.	O

Serum	O
coronavirus	O
nucleic	O
acid	O
was	O
positive	O
in	O
3	O
patients	O
,	O
coronavirus	O
antibody	B-FUNC
positive	O
in	O
two	O
and	O
both	O
were	O
positive	O
in	O
one	O
.	O

All	O
SARS	O
patients	O
had	O
remarkably	O
increased	O
plasma	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
concentrations	O
(	O
median	O
31	O
.	O
23	O
ng	O
/	O
L	O
)	O
at	O
the	O
onset	O
of	O
disease	O
compared	O
with	O
those	O
of	O
normal	O
controls	O
(	O
6	O
.	O
28	O
ng	O
/	O
L	O
,	O
P	O
<	O
0	O
.	O
01	O
).	O

The	O
mean	O
concentration	O
of	O
serum	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
in	O
SARS	O
patients	O
did	O
not	O
differ	O
from	O
that	O
in	O
the	O
control	O
group	O
in	O
initial	O
and	O
peak	O
stages	O
,	O
but	O
became	O
significantly	O
higher	O
in	O
remission	O
and	O
recovery	O
stage	O
compared	O
with	O
the	O
control	O
group	O
,	O
initial	O
and	O
peak	O
stages	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

The	O
mean	O
concentration	O
of	O
serum	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
in	O
SARS	O
patients	O
did	O
not	O
differ	O
from	O
that	O
of	O
the	O
control	O
group	O
in	O
initial	O
stage	O
,	O
but	O
was	O
significantly	O
higher	O
than	O
control	O
group	O
in	O
peak	O
stage	O
and	O
remission	O
and	O
recovery	O
stage	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Concurrently	O
,	O
the	O
mean	O
concentration	O
of	O
serum	O
IL	B-FUNC
-	I-FUNC
13	I-FUNC
decreased	O
gradually	O
,	O
and	O
the	O
mean	O
concentration	O
of	O
serum	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
level	O
in	O
SARS	O
patients	O
was	O
lower	O
than	O
that	O
of	O
the	O
control	O
group	O
during	O
all	O
the	O
courses	O
of	O
SARS	O
,	O
suggesting	O
that	O
the	O
immune	O
state	O
of	O
the	O
patients	O
with	O
SARS	O
was	O
obviously	O
abnormal	O
.	O

These	O
caveolin	O
-	O
binding	B-FUNC
sites	O
located	O
in	O
replicase	O
1AB	O
,	O
spike	O
protein	O
,	O
orf3	O
protein	O
,	O
and	O
M	O
protein	O
,	O
respectively	O
.	O

The	O
enterotropism	O
of	O
TGEV	O
is	O
connected	O
with	O
the	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
activity	O
of	O
the	O
viral	O
surface	O
protein	O
S	O
.	O
Here	O
we	O
show	O
that	O
,	O
among	O
porcine	O
intestinal	O
brush	O
border	O
membrane	O
proteins	O
,	O
TGEV	O
recognizes	O
a	O
mucin	O
-	O
type	O
glycoprotein	O
designated	O
MGP	O
in	O
a	O
sialic	O
acid	O
-	O
dependent	O
fashion	O
.	O

Virus	O
binding	B-FUNC
assays	O
with	O
cryosections	O
of	O
the	O
small	O
intestine	O
from	O
a	O
suckling	O
piglet	O
revealed	O
the	O
binding	B-FUNC
of	O
TGEV	O
to	O
mucin	O
-	O
producing	O
goblet	O
cells	O
.	O

CONCLUSIONS	O
:	O
No	O
SARS	O
coronavirus	O
-	O
specific	O
antibody	B-FUNC
are	O
present	O
in	O
the	O
sera	B-FUNC
of	O
non	O
-	O
SARS	O
children	O
.	O

TITLE	O
:	O
Biosynthesis	O
,	O
purification	O
,	O
and	O
substrate	O
specificity	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
3C	O
-	O
like	O
proteinase	B-FUNC
.	O

The	O
results	O
indicated	O
that	O
13	O
%	O
of	O
the	O
animal	O
traders	O
,	O
none	O
of	O
whom	O
had	O
SARS	O
diagnosed	O
,	O
had	O
IgG	O
antibody	B-FUNC
to	O
SARS	O
-	O
CoV	O
,	O
compared	O
with	O
1	O
%-	O
3	O
%	O
of	O
persons	O
in	O
three	O
control	O
groups	O
.	O

Recombinant	O
viruses	O
replicated	O
as	O
efficiently	O
as	O
WT	O
virus	O
and	O
both	O
were	O
inhibited	O
by	O
treatment	O
with	O
the	O
cysteine	O
proteinase	B-FUNC
inhibitor	I-FUNC
(	O
2S	O
,	O
3S	O
)-	O
transepoxysuccinyl	O
-	O
L	O
-	O
leucylamido	O
-	O
3	O
-	O
methylbutane	O
ethyl	O
ester	O
.	O

The	O
model	O
indicates	O
that	O
SARS	O
can	O
spread	O
very	O
fast	B-FUNC
when	O
there	O
are	O
no	O
interventions	O
.	O

TITLE	O
:	O
[	O
Analysis	O
of	O
false	O
-	O
positive	O
associated	O
with	O
antibody	B-FUNC
tests	O
for	O
SARS	O
-	O
CoV	O
in	O
SLE	O
patients	O
].	O

All	O
samples	O
of	O
positive	O
SARS	O
-	O
CoV	O
-	O
IgG	O
and	O
IgM	O
antibody	B-FUNC
were	O
negative	O
by	O
RT	O
-	O
PCR	O
.	O

TITLE	O
:	O
[	O
Detection	O
of	O
the	O
anti	O
-	O
SARS	O
-	O
coronavirus	O
specific	O
antibody	B-FUNC
levels	O
in	O
156	O
SARS	O
patients	O
].	O

All	O
were	O
having	O
positive	O
results	O
for	O
SARS	O
-	O
associated	O
coronavirus	O
ribonucleic	O
acid	O
by	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
performed	O
on	O
their	O
nasopharyngeal	O
aspirates	O
or	O
stool	O
samples	O
.	O

The	O
antibody	B-FUNC
titers	O
of	O
pigs	O
experimentally	O
immunized	O
with	O
commercial	O
live	O
vaccine	O
and	O
two	O
types	O
of	O
inactivated	O
vaccines	O
clearly	O
increased	O
after	O
immunization	O
,	O
and	O
all	O
pigs	O
were	O
completely	O
protected	O
against	O
challenge	O
with	O
virulent	O
strains	O
.	O

IL	B-FUNC
-	I-FUNC
1	I-FUNC
beta	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
,	O
TNF	O
-	O
alpha	O
,	O
macrophage	O
inhibitory	O
protein	O
(	O
MIP	O
)-	O
1	O
alpha	O
,	O
and	O
RANTES	O
showed	O
no	O
upregulation	O
in	O
the	O
brains	O
of	O
control	O
cats	O
,	O
moderate	O
upregulation	O
in	O
neurological	O
FIP	O
cats	O
,	O
and	O
very	O
high	O
upregulation	O
in	O
generalized	O
FIP	O
cats	O
.	O

We	O
found	O
that	O
the	O
amount	O
of	O
transcription	O
factors	O
binding	B-FUNC
to	O
promoter	O
sequences	O
of	O
c	O
-	O
Fos	O
,	O
ATF2	O
,	O
CREB	O
-	O
1	O
,	O
and	O
FosB	O
was	O
increased	O
by	O
the	O
expression	O
of	O
SARS	O
-	O
CoV	O
N	O
.	O
Since	O
these	O
factors	O
are	O
related	O
to	O
AP	O
-	O
1	O
signal	O
transduction	O
pathway	O
,	O
we	O
investigated	O
whether	O
the	O
AP	O
-	O
1	O
pathway	O
was	O
activated	O
by	O
SARS	O
-	O
CoV	O
N	O
protein	O
using	O
the	O
PathDetect	O
system	O
.	O

Immunohistochemistry	O
identified	O
positive	O
monoclonal	O
antibody	B-FUNC
against	O
SARS	O
-	O
CoV	O
nuceeocapsid	O
(	O
N	O
)	O
protein	O
in	O
the	O
alveolar	O
epithelium	O
and	O
the	O
infiltrating	O
monocytes	O
or	O
macrophages	O
in	O
the	O
lung	O
,	O
spleen	O
and	O
lymph	O
nodes	O
;	O
the	O
presence	O
of	O
the	O
antibody	B-FUNC
was	O
also	O
detected	O
in	O
the	O
serous	O
gland	O
epithelium	O
of	O
the	O
trachea	O
/	O
bronchus	O
,	O
squamous	O
epithelium	O
of	O
the	O
esophagus	O
,	O
the	O
gastric	O
parietal	O
cells	O
,	O
the	O
epithelium	O
of	O
the	O
intestinal	O
tract	O
,	O
acidophilic	O
cells	O
in	O
the	O
parathyroids	O
and	O
pituitary	O
,	O
acinus	O
cells	O
in	O
the	O
pancreas	O
,	O
adrenal	O
cortical	O
cells	O
,	O
sweat	O
gland	O
cells	O
,	O
small	O
vessel	O
endothelium	O
,	O
bone	O
marrow	O
promyelocytes	O
,	O
epithelial	O
cells	O
of	O
the	O
distal	O
convoluted	O
tubule	O
of	O
the	O
kidney	O
,	O
brain	O
neurons	O
,	O
and	O
the	O
hepatocytes	O
near	O
the	O
central	O
vein	O
.	O

RESULTS	O
:	O
Immunohistochemistry	O
identified	O
positive	O
monoclonal	O
antibody	B-FUNC
against	O
SARS	O
-	O
CoV	O
nuceeocapsid	O
(	O
N	O
)	O
protein	O
in	O
the	O
alveolar	O
epithelium	O
and	O
the	O
infiltrating	O
monocytes	O
or	O
macrophages	O
in	O
the	O
lung	O
,	O
spleen	O
and	O
lymph	O
nodes	O
;	O
the	O
presence	O
of	O
the	O
antibody	B-FUNC
was	O
also	O
detected	O
in	O
the	O
serous	O
gland	O
epithelium	O
of	O
the	O
trachea	O
/	O
bronchus	O
,	O
squamous	O
epithelium	O
of	O
the	O
esophagus	O
,	O
the	O
gastric	O
parietal	O
cells	O
,	O
the	O
epithelium	O
of	O
the	O
intestinal	O
tract	O
,	O
acidophilic	O
cells	O
in	O
the	O
parathyroids	O
and	O
pituitary	O
,	O
acinus	O
cells	O
in	O
the	O
pancreas	O
,	O
adrenal	O
cortical	O
cells	O
,	O
sweat	O
gland	O
cells	O
,	O
small	O
vessel	O
endothelium	O
,	O
bone	O
marrow	O
promyelocytes	O
,	O
epithelial	O
cells	O
of	O
the	O
distal	O
convoluted	O
tubule	O
of	O
the	O
kidney	O
,	O
brain	O
neurons	O
,	O
and	O
the	O
hepatocytes	O
near	O
the	O
central	O
vein	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
serum	O
anti	O
-	O
coronavirus	O
antibody	B-FUNC
titer	O
in	O
medical	O
personnel	O
who	O
had	O
closely	O
contacted	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
patients	O
.	O

The	O
serum	O
anti	O
-	O
coronavirus	O
IgG	O
antibody	B-FUNC
titer	O
in	O
medical	O
personnel	O
who	O
had	O
closely	O
contacted	O
with	O
SARS	O
patients	O
,	O
healthy	O
individuals	O
,	O
patients	O
with	O
community	O
acquired	O
pneumonia	O
and	O
patients	O
recovered	O
from	O
SARS	O
was	O
detected	O
by	O
using	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
method	O
.	O

The	O
mean	O
concentration	O
of	O
serum	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
in	O
SARS	O
patients	O
did	O
not	O
differ	O
from	O
the	O
control	O
group	O
in	O
3	O
-	O
7	O
day	O
group	O
and	O
8	O
-	O
14	O
day	O
group	O
,	O
but	O
became	O
significantly	O
higher	O
in	O
over	O
14	O
day	O
group	O
as	O
compared	O
to	O
the	O
control	O
group	O
,	O
3	O
-	O
7	O
day	O
group	O
and	O
8	O
-	O
14	O
day	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

Although	O
TGF	O
-	O
beta1	O
in	O
sera	B-FUNC
decreased	O
in	O
over	O
14	O
day	O
group	O
,	O
the	O
average	O
was	O
still	O
higher	O
than	O
that	O
of	O
the	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

Notably	O
,	O
N371	O
and	O
N385	O
,	O
located	O
at	O
the	O
COOH	O
terminus	O
of	O
the	O
N	O
protein	O
,	O
inhibited	O
binding	B-FUNC
of	O
antibodies	O
to	O
SARS	O
-	O
coronavirus	O
lysate	O
and	O
bound	O
to	O
antibodies	O
in	O
>	O
94	O
%	O
of	O
samples	O
from	O
SARS	O
study	O
patients	O
.	O

Here	O
we	O
identify	O
a	O
metallopeptidase	O
,	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
isolated	O
from	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)-	O
permissive	O
Vero	O
E6	O
cells	O
,	O
that	O
efficiently	O
binds	B-FUNC
the	O
S1	O
domain	O
of	O
the	O
SARS	O
-	O
CoV	O
S	O
protein	O
.	O

Using	O
SARS	O
-	O
CoV	O
ELISA	O
kit	B-FUNC
to	O
detect	O
relevant	O
antibody	B-FUNC
in	O
fresh	O
serum	O
of	O
healthy	O
,	O
fever	O
,	O
probable	O
,	O
and	O
suspect	O
cases	O
.	O

It	O
is	O
reliable	O
to	O
detect	O
SARS	O
-	O
CoV	O
antibody	B-FUNC
in	O
late	O
suspect	O
patients	O
,	O
but	O
there	O
will	O
be	O
high	O
false	O
-	O
positive	O
result	O
in	O
ordinary	O
fever	O
cases	O
.	O

We	O
propose	O
that	O
the	O
clinically	O
observed	O
resistance	O
of	O
SARS	O
to	O
ribavirin	O
is	O
probably	O
due	O
to	O
perturbation	O
of	O
the	O
conserved	O
motif	O
A	O
that	O
controls	O
rNTP	O
binding	B-FUNC
and	O
fidelity	O
of	O
polymerization	O
.	O

In	O
addition	O
N	O
protein	O
binds	B-FUNC
the	O
intracellular	O
form	O
of	O
the	O
genomic	O
RNA	O
,	O
all	O
of	O
the	O
MHV	O
subgenomic	O
mRNAs	O
,	O
and	O
expressed	O
non	O
-	O
MHV	O
RNA	O
transcripts	O
to	O
form	O
ribonucleoprotein	O
(	O
RNP	O
)	O
complexes	O
in	O
infected	O
cells	O
.	O

This	O
increases	O
protection	O
of	O
the	O
laying	O
birds	O
against	O
egg	O
production	O
losses	O
and	O
induces	O
a	O
sustained	O
level	O
of	O
serum	O
antibody	B-FUNC
,	O
which	O
is	O
passed	O
to	O
progeny	O
.	O

ABSTRACT	O
:	O
Tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
has	O
a	O
central	O
role	O
in	O
the	O
pathogenesis	O
of	O
acute	O
pancreatitis	O
and	O
related	O
systemic	O
complications	O
.	O

RESULTS	O
:	O
Infliximab	O
treatment	O
significantly	O
decreased	O
serum	O
amylase	B-FUNC
activity	I-FUNC
(	O
11939	O
+/-	O

TITLE	O
:	O
Fecal	O
immunoglobulin	B-FUNC
A	O
antibodies	O
in	O
dogs	O
infected	O
or	O
vaccinated	O
with	O
canine	O
coronavirus	O
.	O

Early	O
diagnosis	O
can	O
be	O
made	O
with	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
of	O
nasopharyngeal	O
aspirate	O
samples	O
.	O

None	O
of	O
these	O
healthcare	O
workers	O
had	O
antibody	B-FUNC
to	O
SARS	O
CoV	O
,	O
indicating	O
that	O
subclinical	O
or	O
mild	O
infection	O
attributable	O
to	O
SARS	O
-	O
CoV	O
in	O
adults	O
is	O
rare	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
mAbs	O
produced	O
against	O
S	O
-	O
protein	O
receptor	O
-	O
binding	B-FUNC
domain	O
of	O
SARS	O
-	O
CoV	O
.	O
The	O
3	O
S1	O
-	O
specific	O
mAbs	O
may	O
be	O
useful	O
for	O
further	O
study	O
of	O
the	O
function	O
of	O
the	O
S	O
protein	O
and	O
for	O
diagnosis	O
of	O
SARS	O
-	O
CoV	O
infection	O
.	O

All	O
the	O
animals	O
were	O
treated	O
with	O
PSV	O
for	O
6	O
h	O
.	O
iNO	O
levels	O
at	O
different	O
input	O
and	O
sampling	O
sites	O
in	O
the	O
NO	O
and	O
SNO	B-FUNC
groups	O
were	O
detected	O
by	O
on	O
-	O
line	O
chemiluminescent	O
technique	O
.	O

Goiter	O
with	O
hypervascularization	O
was	O
noticed	O
,	O
associated	O
with	O
pure	B-FUNC
T3	O
hyperthyroidism	O
(	O
T3l	O
=	O
26	O
pg	O
/	O
ml	O
;	O
N	O
<	O
3	O
.	O
8	O
).	O

Levels	O
of	O
tryptase	O
were	O
significantly	O
higher	O
in	O
acute	O
sera	B-FUNC
(	O
26	O
.	O
6	O
+/-	O

TITLE	O
:	O
Bystander	O
CD8	O
T	O
-	O
cell	O
-	O
mediated	O
demyelination	O
is	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
-	O
dependent	O
in	O
a	O
coronavirus	O
model	O
of	O
multiple	O
sclerosis	O
.	O

This	O
review	O
summarizes	O
recent	O
studies	O
that	O
demonstrate	O
the	O
critical	O
role	O
played	O
by	O
inflammatory	O
mediators	O
such	O
as	O
tumour	O
necrosis	O
factor	O
(	O
TNF	O
)-	O
alpha	O
,	O
interleukin	O
(	O
IL	O
)-	O
1beta	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
platelet	O
activating	O
factor	O
(	O
PAF	O
),	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
granulocyte	O
macrophage	O
-	O
colony	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
),	O
C5a	O
,	O
intercellular	O
adhesion	O
molecule	O
(	O
ICAM	O
)-	O
1	O
,	O
substance	O
P	O
,	O
chemokines	O
,	O
VEGF	O
,	O
IGF	O
-	O
I	O
,	O
KGF	O
,	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
),	O
and	O
reactive	O
nitrogen	O
species	O
(	O
RNS	O
)	O
in	O
the	O
pathogenesis	O
of	O
ARDS	O
.	O

TITLE	O
:	O
Antibody	B-FUNC
detection	O
of	O
SARS	O
-	O
CoV	O
spike	O
and	O
nucleocapsid	O
protein	O
.	O

The	O
potent	O
inhibitor	O
MLN	O
-	O
4760	O
((	O
S	O
,	O
S	O
)-	O
2	O
-[	O
1	O
-	O
carboxy	O
-	O
2	O
-[	O
3	O
-(	O
3	O
,	O
5	O
-	O
dichlorobenzyl	O
)-	O
3H	O
-	O
imidazol4	O
-	O
yl	O
]-	O
ethylamino	O
]-	O
4	O
-	O
methylpentanoic	O
acid	O
)	O
makes	O
key	O
binding	B-FUNC
interactions	O
within	O
the	O
active	O
site	O
and	O
offers	O
insights	O
regarding	O
the	O
action	O
of	O
residues	O
involved	O
in	O
catalysis	O
and	O
substrate	O
specificity	O
.	O

Interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
inducible	O
protein	O
-	O
10	O
kDa	O
(	O
IP	O
-	O
10	O
)	O
is	O
a	O
CXC	O
chemokine	O
and	O
a	O
chemoattractant	O
for	O
CXCR3	O
+	O
T	O
cells	O
.	O

With	O
this	O
soluble	O
S	O
protein	O
fragment	O
as	O
an	O
affinity	O
ligand	B-FUNC
,	O
we	O
screened	O
HeLa	O
cells	O
transduced	O
with	O
retroviral	O
cDNA	O
library	O
from	O
Vero	O
E6	O
cells	O
and	O
obtained	O
a	O
HeLa	O
cell	O
clone	O
which	O
could	O
bind	B-FUNC
with	O
the	O
S	O
protein	O
.	O

Reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
using	O
enhanced	O
real	O
-	O
time	O
PCR	O
was	O
applied	O
to	O
look	O
for	O
evidence	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
infection	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
usefulness	O
of	O
ascites	O
as	O
a	O
material	O
for	O
viral	O
tests	O
in	O
cats	O
with	O
effusive	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
),	O
we	O
attempted	O
to	O
detect	O
anti	O
-	O
feline	O
coronavirus	O
antibody	B-FUNC
,	O
anti	O
-	O
feline	O
immunodeficiency	O
virus	O
antibody	B-FUNC
,	O
and	O
feline	O
leukemia	O
virus	O
antigen	O
in	O
ascites	O
from	O
88	O
cats	O
clinically	O
suspected	O
with	O
effusive	O
FIP	O
.	O

In	O
each	O
of	O
these	O
three	O
viral	O
tests	O
,	O
all	O
cats	O
positive	O
for	O
serum	O
antibody	B-FUNC
/	O
antigen	O
were	O
also	O
positive	O
for	O
ascitic	O
antibody	B-FUNC
/	O
antigen	O
,	O
while	O
cats	O
negative	O
for	O
serum	O
antibody	B-FUNC
/	O
antigen	O
were	O
also	O
negative	O
for	O
ascitic	O
antibody	B-FUNC
/	O
antigen	O
.	O

MHV	O
-	O
JHM	O
infection	O
also	O
induced	O
sustained	O
mRNA	O
accumulation	O
of	O
the	O
innate	O
immune	O
response	O
products	O
interleukin	O
(	O
IL	O
)-	O
6	O
and	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
.	O

Thus	O
,	O
the	O
enzymatic	O
activity	O
of	O
the	O
hemagglutinin	O
-	O
esterase	O
of	O
ISAV	O
is	O
comparable	O
to	O
that	O
of	O
the	O
sialate	O
-	O
4	O
-	O
O	O
-	O
esterases	B-FUNC
of	O
murine	O
coronaviruses	O
and	O
related	O
group	O
2	O
coronaviruses	O
.	O

About	O
90	O
%	O
of	O
the	O
probable	O
cases	O
were	O
positive	O
for	O
IgG	O
antibody	B-FUNC
.	O

Four	O
canine	O
sera	B-FUNC
-	O
positive	O
for	O
CCoV	O
type	O
II	O
,	O
four	O
sera	B-FUNC
-	O
positive	O
for	O
CCoV	O
type	O
I	O
and	O
10	O
negative	O
control	O
sera	B-FUNC
were	O
examined	O
.	O

These	O
expression	O
vectors	O
induced	O
robust	O
immune	O
responses	O
mediated	O
by	O
CD4	O
and	O
CD8	O
cells	O
,	O
as	O
well	O
as	O
significant	O
antibody	B-FUNC
titres	O
,	O
measured	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

The	O
specificity	O
of	O
the	O
IgG	O
antibody	B-FUNC
test	O
(	O
ELISA	O
with	O
positive	O
samples	O
confirmed	O
by	O
the	O
two	O
western	O
-	O
blot	O
assays	O
)	O
was	O
100	O
%,	O
and	O
the	O
sensitivity	O
was	O
94	O
.	O
3	O
%.	O

Detection	O
of	O
antibody	B-FUNC
to	O
SARS	O
CoV	O
is	O
useful	O
in	O
the	O
diagnosis	O
of	O
SARS	O
;	O
however	O
,	O
at	O
the	O
incubation	O
and	O
initial	O
phases	O
of	O
the	O
illness	O
,	O
serological	O
assay	O
is	O
of	O
little	O
value	O
,	O
because	O
of	O
late	O
seroconversion	O
in	O
most	O
patients	O
.	O

TITLE	O
:	O
Protective	O
effects	O
of	O
preischemic	O
treatment	O
with	O
pioglitazone	O
,	O
a	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
-	O
gamma	O
ligand	B-FUNC
,	O
on	O
lung	O
ischemia	O
-	O
reperfusion	O
injury	O
in	O
rats	O
.	O

Secretory	O
phospholipase	O
A2	O
(	O
sPLA2	O
),	O
a	O
potent	O
inflammatory	O
mediator	O
,	O
is	O
elevated	O
in	O
ACS	B-FUNC
,	O
and	O
sPLA2	O
levels	O
in	O
serum	O
or	O
plasma	O
predict	O
impending	O
ACS	B-FUNC
.	O

EP3	O
and	O
EP4	O
also	O
formed	O
conformational	O
epitopes	O
,	O
and	O
antibodies	O
against	O
these	O
epitopes	O
existed	O
in	O
all	O
52	O
of	O
the	O
sera	B-FUNC
tested	O
.	O

Serum	O
antibody	B-FUNC
against	O
SARS	O
-	O
CoV	O
IgG	O
was	O
determined	O
cross	O
-	O
sectionally	O
and	O
symptoms	O
of	O
respiratory	O
infection	O
were	O
investigated	O
retrospectively	O
for	O
part	O
of	O
traders	O
of	O
three	O
wholesale	O
markets	O
for	O
wild	O
animals	O
in	O
Guangzhou	O
.	O

Prevalence	O
of	O
symptoms	O
of	O
acute	O
upper	O
respiratory	O
infection	O
in	O
people	O
with	O
positive	O
antibody	B-FUNC
against	O
SARS	O
-	O
CoV	O
was	O
higher	O
(	O
49	O
.	O
28	O
%)	O
than	O
that	O
in	O
those	O
with	O
negative	O
antibody	B-FUNC
(	O
30	O
.	O
35	O
%).	O

Two	O
calpain	O
inhibitors	O
,	O
Val	O
-	O
Leu	O
-	O
CHO	B-FUNC
(	O
calpain	O
inhibitor	O
VI	O
)	O
and	O
Z	O
-	O
Val	O
-	O
Phe	O
-	O
Ala	O
-	O
CHO	B-FUNC
(	O
calpain	O
inhibitor	O
III	O
),	O
were	O
the	O
most	O
potent	O
inhibitors	O
of	O
SARSCoV	O
.	O
By	O
virus	O
yield	O
reduction	O
assay	O
,	O
calpain	O
inhibitor	O
VI	O
had	O
a	O
90	O
%	O
effective	O
concentration	O
(	O
EC90	O
)	O
of	O
3	O
microM	O
and	O
calpain	O
inhibitor	O
III	O
had	O
an	O
EC90	O
of	O
15	O
microM	O
.	O
Beta	O
-	O
D	O
-	O
N4	O
-	O
hydroxycytidine	O
was	O
the	O
most	O
selective	O
nucleoside	O
analogue	O
inhibitor	O
with	O
an	O
EC90	O
of	O
6	O
microM	O
by	O
virus	O
yield	O
reduction	O
assay	O
.	O

Continuing	O
the	O
improvement	O
requires	O
continuing	O
the	O
intravenous	O
immunoglobulin	B-FUNC
-	O
G	O
treatment	O
,	O
indicating	O
both	O
intravenous	O
immunoglobulin	B-FUNC
-	O
G	O
responsiveness	O
and	O
dependency	O
.	O

The	O
intravenous	O
immunoglobulin	B-FUNC
-	O
G	O
responsive	O
type	O
-	O
2	O
diabetes	O
polyneuropathy	O
usually	O
is	O
dysschwannian	O
,	O
sometimes	O
mainly	O
dysneuronal	O
intravenous	O
immunoglobulin	B-FUNC
-	O
G	O
,	O
the	O
most	O
beneficial	O
and	O
safest	O
treatment	O
,	O
is	O
costly	O
,	O
but	O
if	O
intravenous	O
immunoglobulin	B-FUNC
-	O
G	O
-	O
treatability	O
of	O
a	O
dysimmune	O
component	O
of	O
type	O
-	O
2	O
diabetes	O
neuropathy	O
is	O
overlooked	O
,	O
dismissed	O
or	O
rejected	O
,	O
as	O
commonly	O
happens	O
,	O
other	O
costs	O
are	O
high	O
regarding	O
the	O
patient	O
'	O
s	O
worsening	O
morbidity	O
and	O
disability	O
,	O
and	O
resultant	O
need	O
for	O
increased	O
medical	O
care	O
.	O

The	O
genetic	O
-	O
metabolic	O
milieu	O
(	O
but	O
not	O
necessarily	O
glucose	O
dysmetabolism	O
per	O
se	O
.)	O
of	O
type	O
-	O
2	O
diabetes	O
putatively	O
predisposes	O
to	O
the	O
presumably	O
-	O
dysimmune	O
intravenous	O
immunoglobulin	B-FUNC
-	O
G	O
-	O
responsive	O
polyneuropathy	O
.	O

In	O
some	O
of	O
our	O
patients	O
,	O
especially	O
ones	O
having	O
a	O
strong	O
type	O
-	O
2	O
diabetes	O
genetic	O
background	O
,	O
the	O
intravenous	O
immunoglobulin	B-FUNC
-	O
G	O
-	O
responsive	O
neuropathy	O
preceded	O
the	O
diagnosis	O
of	O
type	O
-	O
2	O
diabetes	O
by	O
5	O
-	O
10	O
years	O
.	O

ABSTRACT	O
:	O
To	O
understand	O
the	O
time	O
-	O
course	O
of	O
viraemia	O
and	O
antibody	B-FUNC
responses	O
to	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
RT	O
-	O
PCR	O
and	O
ELISA	O
were	O
used	O
to	O
assay	O
376	O
blood	O
samples	O
from	O
135	O
SARS	O
patients	O
at	O
various	O
stages	O
of	O
the	O
illness	O
,	O
including	O
samples	O
from	O
patients	O
who	O
were	O
in	O
their	O
early	O
convalescent	O
phase	O
.	O

Our	O
results	O
showed	O
that	O
IL	O
-	O
1beta	O
induced	O
an	O
11	O
-	O
fold	O
increase	O
in	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
production	O
in	O
pediatric	O
PMs	O
(	O
659	O
+/-	O
103	O
vs	O
.	O
60	O
+/-	O
25	O
control	O
,	O
P	O
<	O
0	O
.	O
05	O
).	O

Furthermore	O
,	O
pediatric	O
PMs	O
had	O
an	O
11	O
-	O
fold	O
increase	O
in	O
IL	O
-	O
1beta	O
-	O
induced	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
production	O
,	O
while	O
adult	O
PMs	O
did	O
not	O
produce	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
.	O

We	O
suggest	O
that	O
immunobioinformatics	O
may	O
become	O
a	O
fast	B-FUNC
and	O
valuable	O
tool	O
in	O
rational	O
vaccine	O
design	O
.	O

ABSTRACT	O
:	O
A	O
36	O
-	O
year	O
-	O
old	O
male	O
with	O
a	O
known	O
history	O
of	O
sickle	O
cell	O
disease	O
(	O
SCD	O
)	O
and	O
acute	O
chest	O
syndrome	O
(	O
ACS	B-FUNC
)	O
was	O
treated	O
in	O
our	O
hospital	O
.	O

Binding	B-FUNC
analysis	O
of	O
SARS	O
coronavirus	O
main	O
proteinase	B-FUNC
with	O
HIV	O
,	O
psychotic	O
and	O
parasite	O
drugs	O
.	O

All	O
positive	O
results	O
obtained	O
using	O
the	O
in	O
-	O
practice	O
kit	B-FUNC
should	O
be	O
confirmed	O
and	O
titrated	O
by	O
IFA	O
.	O

Early	O
attempts	O
at	O
vaccination	O
have	O
been	O
unsuccessful	O
,	O
some	O
even	O
serving	O
to	O
exacerbate	O
the	O
disease	O
through	O
antibody	B-FUNC
-	O
dependent	O
enhancement	O
.	O

TITLE	O
:	O
Reverse	O
transcriptase	B-FUNC
PCR	O
diagnostic	O
assay	O
for	O
the	O
coronavirus	O
associated	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

Direct	O
reaction	O
bilirubin	O
(	O
DBil	O
),	O
total	O
bile	O
acid	O
(	O
TBA	O
),	O
gamma	O
-	O
glutamyltransferase	O
(	O
GGT	O
)	O
and	O
alkaline	O
phosphatase	B-FUNC
(	O
ALP	O
)	O
showed	O
no	O
marked	O
difference	O
between	O
SARS	O
patients	O
and	O
controls	O
,	O
all	O
P	O
>	O
0	O
.	O
05	O
.	O

RESULTS	O
:	O
Alanine	O
aminotransferase	O
(	O
ALT	B-FUNC
),	O
aspartate	O
aminotransferase	O
(	O
AST	O
),	O
lactate	O
dehydrogenase	O
(	O
LDH	O
),	O
total	O
bilirubin	O
(	O
TBil	O
)	O
of	O
patients	O
with	O
SARS	O
were	O
higher	O
than	O
those	O
of	O
controls	O
,	O
they	O
were	O
(	O
91	O
.	O
61	O
+/-	O
50	O
.	O
53	O
)	O
U	O
/	O
L	O
vs	O
.	O
(	O
32	O
.	O
91	O
+/-	O
10	O
.	O
56	O
)	O
U	O
/	O
L	O
,	O
(	O
78	O
.	O
68	O
+/-	O
33	O
.	O
32	O
)	O
U	O
/	O
L	O
vs	O
.	O
(	O
29	O
.	O
43	O
+/-	O
8	O
.	O
89	O
)	O
U	O
/	O
L	O
,	O
(	O
429	O
.	O
95	O
+/-	O
188	O
.	O
94	O
)	O
U	O
/	O
L	O
vs	O
.	O
(	O
200	O
.	O
83	O
+/-	O
44	O
.	O
86	O
)	O
U	O
/	O
L	O
,	O
(	O
11	O
.	O
67	O
+/-	O
4	O
.	O
26	O
)	O
micromol	O
/	O
L	O
vs	O
.	O
(	O
8	O
.	O
44	O
+/-	O
3	O
.	O
86	O
)	O
micromol	O
/	O
L	O
,	O
all	O
P	O
<	O
0	O
.	O
001	O
.	O

ABSTRACT	O
:	O
To	O
accelerate	O
the	O
development	O
of	O
drugs	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
we	O
constructed	O
a	O
homology	O
model	O
of	O
the	O
SARS	O
coronavirus	O
main	O
protease	O
using	O
our	O
modeling	O
software	O
,	O
FAMS	O
Ligand	B-FUNC
&	O
Complex	O
,	O
and	O
released	O
it	O
before	O
the	O
X	O
-	O
ray	O
structure	O
was	O
solved	O
.	O

TITLE	O
:	O
Development	O
of	O
reverse	O
transcriptase	B-FUNC
PCR	O
and	O
nested	O
PCR	O
to	O
detect	O
porcine	O
hemagglutinating	O
encephalomyelitis	O
virus	O
.	O

Canine	O
(	O
distemper	O
virus	O
and	O
FECV	O
/	O
FIPV	O
antibody	B-FUNC
prevalence	O
varied	O
considerably	O
over	O
time	O
,	O
whereas	O
FIV	O
,	O
FPLV	O
/	O
CPV	O
,	O
and	O
FCV	O
had	O
a	O
stable	O
,	O
apparently	O
endemic	O
temporal	O
pattern	O
.	O

The	O
tropism	O
of	O
this	O
reporter	O
virus	O
was	O
similar	O
to	O
that	O
of	O
wild	O
-	O
type	O
,	O
replication	O
-	O
competent	O
SARS	O
-	O
CoV	O
,	O
and	O
binding	B-FUNC
of	O
purified	O
S	O
to	O
susceptible	O
target	O
cells	O
was	O
demonstrated	O
by	O
flow	O
cytometry	O
.	O

While	O
the	O
amounts	O
of	O
the	O
cellular	O
cyclin	B-FUNC
-	O
dependent	O
kinase	O
(	O
Cdk	B-FUNC
)	O
inhibitors	O
p21	O
(	O
Cip1	O
),	O
p27	O
(	O
Kip1	O
),	O
and	O
p16	O
(	O
INK4a	O
)	O
did	O
not	O
change	O
in	O
infected	O
cells	O
,	O
MHV	O
infection	O
in	O
asynchronous	O
cultures	O
induced	O
a	O
clear	O
reduction	O
in	O
the	O
amounts	O
of	O
Cdk4	O
and	O
G	O
(	O
1	O
)	O
cyclins	O
(	O
cyclins	O
D1	O
,	O
D2	O
,	O
D3	O
,	O
and	O
E	O
)	O
in	O
both	O
DBT	O
and	O
17Cl	O
-	O
1	O
cells	O
and	O
a	O
reduction	O
in	O
Cdk6	O
levels	O
in	O
17Cl	O
-	O
1	O
cells	O
.	O

To	O
stimulate	O
the	O
structure	O
-	O
based	O
drug	O
design	O
against	O
SARS	O
(	O
severe	O
acute	O
respiratory	O
syndrome	O
),	O
a	O
pharmacophore	O
search	O
was	O
conducted	O
over	O
3	O
.	O
6	O
millions	O
of	O
compounds	O
based	O
on	O
the	O
atomic	O
coordinates	O
of	O
the	O
complex	O
obtained	O
by	O
docking	O
KZ7088	O
(	O
a	O
derivative	O
of	O
AG7088	O
)	O
to	O
SARS	O
CoV	O
M	O
(	O
pro	O
)	O
(	O
coronavirus	O
main	O
proteinase	B-FUNC
),	O
as	O
reportedly	O
recently	O
(	O
Chou	O
,	O
K	O
.	O
C	O
.;	O
Wei	O
,	O
D	O
.	O
Q	O
.;	O
Zhong	O
,	O
W	O
.	O
Z	O
.	O
Biochem	O
.	O

IgM	O
antibody	B-FUNC
was	O
negative	O
in	O
all	O
the	O
samples	O
.	O

ABSTRACT	O
:	O
A	O
protocol	O
for	O
obtaining	O
small	O
amounts	O
of	O
highly	O
pure	B-FUNC
virus	O
preparations	O
starting	O
from	O
reduced	O
volumes	O
(<	O
5	O
ml	O
)	O
of	O
infected	O
tissue	O
culture	O
supernatants	O
is	O
described	O
.	O

TITLE	O
:	O
Glycan	O
arrays	O
lead	O
to	O
the	O
discovery	O
of	O
autoimmunogenic	O
activity	O
of	O
SARS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
Using	O
carbohydrate	O
microarrays	O
,	O
we	O
characterized	O
the	O
carbohydrate	B-FUNC
binding	I-FUNC
activity	O
of	O
SARS	O
-	O
CoV	O
neutralizing	O
antibodies	O
elicited	O
by	O
an	O
inactivated	O
SARS	O
-	O
CoV	O
vaccine	O
.	O

Purified	O
N	O
protein	O
was	O
used	O
to	O
measure	O
the	O
SARS	O
-	O
CoV	O
specific	O
IgG	O
antibodies	O
from	O
16	O
SARS	O
-	O
CoV	O
infected	O
patients	O
'	O
sera	B-FUNC
and	O
from	O
131	O
control	O
subjects	O
using	O
ELISA	O
assay	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
make	O
differential	O
diagnosis	O
between	O
Pneumoniae	O
associated	O
with	O
SIRS	O
and	O
Coagulopathy	O
(	O
PASC	O
)	O
and	O
Simple	O
Pneumoniae	O
(	O
SP	O
)	O
by	O
using	O
a	O
newly	O
developed	O
SF	O
test	O
utilizing	O
an	O
SF	O
specific	O
monoclonal	O
antibody	B-FUNC
(	O
IF	O
-	O
43	O
).	O

RESULTS	O
:	O
The	O
specificity	O
of	O
the	O
kit	B-FUNC
was	O
determined	O
using	O
animal	O
coronaviruses	O
and	O
other	O
bacterial	O
and	O
viral	O
strains	O
,	O
causing	O
acute	O
respiratory	O
and	O
intestinal	O
infections	O
,	O
and	O
was	O
shown	O
to	O
be	O
100	O
%.	O

CONCLUSIONS	O
:	O
The	O
kit	B-FUNC
""""	O
AmpliSens	O
SARS	O
""""	O
for	O
qualitative	O
detection	O
of	O
SARS	O
-	O
related	O
coronavirus	O
RNA	O
by	O
reverse	O
transcription	O
and	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
in	O
nasopharyngeal	O
wash	O
/	O
aspirates	O
,	O
naso	O
/	O
oropharyngeal	O
swabs	O
,	O
plasma	O
,	O
and	O
extract	O
from	O
feces	O
has	O
been	O
developed	O
in	O
the	O
Central	O
Research	O
Institute	O
for	O
Epidemiology	O
of	O
the	O
RF	O
Ministry	O
of	O
Health	O
.	O

The	O
binding	B-FUNC
strength	O
of	O
each	O
of	O
the	O
X	O
(	O
j	O
)	O
reagents	O
to	O
each	O
other	O
is	O
measured	O
,	O
for	O
example	O
by	O
an	O
ELISA	O
assay	O
,	O
giving	O
an	O
N	O
x	O
N	O
matrix	O
K	O
.	O
The	O
matrix	O
K	O
is	O
used	O
to	O
define	O
another	O
set	O
of	O
N	O
reagents	O
called	O
Y	O
(	O
j	O
),	O
with	O
j	O
=	O
1	O
to	O
N	O
,	O
each	O
of	O
which	O
is	O
a	O
linear	O
combination	O
of	O
the	O
X	O
(	O
j	O
)	O
reagents	O
and	O
each	O
of	O
which	O
is	O
tailored	O
to	O
be	O
complementary	O
to	O
one	O
of	O
the	O
X	O
(	O
j	O
)	O
reagents	O
.	O

Cleavage	O
sites	O
were	O
predicted	O
in	O
proteins	O
such	O
as	O
the	O
cystic	B-FUNC
fibrosis	I-FUNC
transmembrane	I-FUNC
conductance	I-FUNC
regulator	I-FUNC
(	O
CFTR	O
),	O
transcription	O
factors	O
CREB	O
-	O
RP	O
and	O
OCT	O
-	O
1	O
,	O
and	O
components	O
of	O
the	O
ubiquitin	B-FUNC
pathway	O
.	O

Here	O
,	O
we	O
show	O
that	O
this	O
vaccine	O
,	O
when	O
administered	O
to	O
previously	O
sensitized	O
gilts	O
,	O
can	O
boost	O
neutralizing	O
antibody	B-FUNC
levels	O
in	O
the	O
animals	O
'	O
serum	O
,	O
colostrum	O
and	O
milk	O
.	O

Pneumonia	O
developed	O
in	O
six	O
workers	O
,	O
and	O
assays	O
showed	O
anti	O
-	O
SARS	O
immunoglobulin	B-FUNC
(	O
Ig	O
)	O
M	O
and	O
IgG	O
.	O
The	O
other	O
three	O
workers	O
were	O
IgM	O
-	O
positive	O
and	O
had	O
lower	O
IgG	O
titers	O
;	O
in	O
two	O
,	O
mild	O
illness	O
developed	O
,	O
and	O
one	O
remained	O
asymptomatic	O
.	O

Western	O
blot	O
analysis	O
showed	O
that	O
the	O
reaction	O
of	O
GST	O
-	O
N	O
to	O
anti	O
-	O
SARS	O
-	O
CoV	O
sera	B-FUNC
was	O
positive	O
.	O

ABSTRACT	O
:	O
In	O
this	O
study	O
,	O
two	O
homology	O
models	O
(	O
denoted	O
as	O
MproST	O
and	O
MproSH	O
)	O
of	O
main	O
proteinase	B-FUNC
(	O
Mpro	B-FUNC
)	O
from	O
the	O
novel	O
coronavirus	O
associated	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
-	O
CoV	O
)	O
were	O
constructed	O
based	O
on	O
the	O
crystal	O
structures	O
of	O
Mpro	B-FUNC
from	O
transmissible	O
gastroenteritis	O
coronavirus	O
(	O
TGEV	O
)	O
(	O
MproT	O
)	O
and	O
human	O
coronavirus	O
HcoV	O
-	O
229E	O
(	O
MproH	O
),	O
respectively	O
.	O

We	O
found	O
a	O
highly	O
restricted	O
,	O
immunoglobulin	B-FUNC
G	O
-	O
dominated	O
antibody	B-FUNC
response	O
in	O
patients	O
with	O
SARS	O
,	O
directed	O
most	O
frequently	O
(	O
89	O
%	O
by	O
ELISA	O
)	O
and	O
predominantly	O
at	O
the	O
nucleocapsid	O
.	O

TITLE	O
:	O
Human	O
monoclonal	O
antibody	B-FUNC
as	O
prophylaxis	O
for	O
SARS	O
coronavirus	O
infection	O
in	O
ferrets	O
.	O

Using	O
the	O
NTPase	O
active	O
site	O
,	O
HCoV	O
-	O
229E	O
nsp13	O
also	O
mediates	O
RNA	O
5	O
'-	O
triphosphatase	B-FUNC
activity	I-FUNC
,	O
which	O
may	O
be	O
involved	O
in	O
the	O
capping	O
of	O
viral	O
RNAs	O
.	O

ABSTRACT	O
:	O
An	O
immunocomb	O
-	O
based	O
dot	O
-	O
ELISA	O
,	O
employing	O
specially	O
designed	O
apparatus	O
,	O
was	O
used	O
to	O
measure	O
the	O
antibody	B-FUNC
status	O
for	O
the	O
three	O
major	O
poultry	O
diseases	O
--	O
Newcastle	O
disease	O
,	O
infectious	O
bursal	O
disease	O
and	O
infectious	O
bronchitis	O
--	O
in	O
single	O
test	O
sera	B-FUNC
.	O

An	O
assay	O
for	O
determining	O
neutralizing	O
antibody	B-FUNC
titers	O
was	O
developed	O
.	O

TITLE	O
:	O
Development	O
and	O
characterisation	O
of	O
neutralising	O
monoclonal	O
antibody	B-FUNC
to	O
the	O
SARS	O
-	O
coronavirus	O
.	O

SARS	O
-	O
CoV	O
immunoglobulin	B-FUNC
G	O
(	O
IgG	O
)	O
antibody	B-FUNC
was	O
determined	O
by	O
enzyme	O
linked	O
immunoadsorbent	O
assay	O
(	O
ELISA	O
).	O

The	O
absorbance	O
(	O
A	O
)	O
value	O
of	O
SARS	O
-	O
CoV	O
IgG	O
antibody	B-FUNC
ranged	O
from	O
0	O
.	O
81	O
to	O
2	O
.	O
06	O
in	O
patients	O
after	O
half	O
an	O
year	O
of	O
SARS	O
onset	O
,	O
and	O
form	O
0	O
.	O
79	O
to	O
2	O
.	O
01	O
in	O
patients	O
before	O
half	O
an	O
year	O
of	O
SARS	O
onset	O
.	O

SARS	O
-	O
CoV	O
IgG	O
antibody	B-FUNC
could	O
inhibit	O
SARS	O
-	O
CoV	O
-	O
mediated	O
cytopathic	O
response	O
,	O
indicating	O
it	O
might	O
be	O
one	O
of	O
protective	O
antibodies	O
.	O

At	O
day	O
240	O
,	O
all	O
patients	O
were	O
still	O
positive	O
for	O
anti	O
-	O
nucleocapsid	O
protein	O
IgG	O
antibody	B-FUNC
.	O

The	O
appearance	O
and	O
persistence	O
of	O
SARS	O
-	O
CoV	O
-	O
specific	O
antibodies	O
were	O
assessed	O
,	O
with	O
immunoglobulin	B-FUNC
G	O
detected	O
in	O
59	O
%	O
of	O
samples	O
collected	O
within	O
14	O
days	O
and	O
persisting	O
for	O
60	O
to	O
95	O
days	O
after	O
the	O
onset	O
of	O
illness	O
.	O

Evaluation	O
of	O
cells	O
permissive	O
to	O
other	O
coronaviruses	O
indicated	O
that	O
these	O
cell	O
types	O
are	O
not	O
infected	O
by	O
SARS	O
-	O
CoV	O
,	O
providing	O
additional	O
evidence	O
that	O
SARS	O
-	O
CoV	O
binds	B-FUNC
an	O
alternative	O
receptor	O
.	O

Totally	O
531	O
samples	O
(	O
including	O
urine	O
,	O
stool	O
,	O
and	O
OWF	O
)	O
were	O
collected	O
from	O
177	O
convalescence	O
patients	O
with	O
positive	O
SARS	O
antibody	B-FUNC
which	O
were	O
confirmed	O
by	O
ELISA	O
method	O
.	O

The	O
concentrations	O
of	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
and	O
TNF	O
-	O
alpha	O
were	O
not	O
significantly	O
different	O
in	O
different	O
groups	O
.	O

Phylogenetic	O
analysis	O
revealed	O
maximum	O
similarity	O
between	O
strain	O
SoD	B-FUNC
genome	O
and	O
Frankfurt	O
1	O
strain	O
genome	O
.	O

The	O
spectrum	O
of	O
SARS	O
-	O
specific	O
antibody	B-FUNC
profiles	O
in	O
SARS	O
patients	O
was	O
investigated	O
from	O
7	O
to	O
210	O
days	O
after	O
the	O
onset	O
of	O
the	O
symptoms	O
.	O

Commercial	O
antiviral	O
agents	O
and	O
pure	B-FUNC
chemical	O
compounds	O
extracted	O
from	O
traditional	O
Chinese	O
medicinal	O
herbs	O
were	O
screened	O
against	O
10	O
clinical	O
isolates	O
of	O
SARS	O
coronavirus	O
by	O
neutralisation	O
tests	O
with	O
confirmation	O
by	O
plaque	O
reduction	O
assays	O
.	O

TITLE	O
:	O
Mouse	O
antibody	B-FUNC
production	O
test	O
:	O
can	O
we	O
do	O
without	O
it	O
?	O

Analysis	O
of	O
serial	O
tenfold	O
dilutions	O
of	O
virus	O
stocks	O
revealed	O
that	O
the	O
sensitivity	O
of	O
the	O
mouse	O
antibody	B-FUNC
production	O
test	O
on	O
day	O
28	O
(	O
10	O
(-	O
10	O
)	O
dilution	O
)	O
was	O
at	O
least	O
10	O
times	O
higher	O
than	O
that	O
of	O
the	O
viral	O
plaque	O
assay	O
(	O
10	O
(-	O
9	O
)	O
dilution	O
)	O
and	O
10	O
(	O
4	O
)	O
times	O
more	O
than	O
that	O
of	O
the	O
RT	O
-	O
PCR	O
(	O
10	O
(-	O
6	O
)	O
dilution	O
)	O
for	O
detection	O
of	O
MHV	O
-	O
A59	O
.	O

In	O
the	O
present	O
paper	O
,	O
we	O
show	O
that	O
SARS	O
-	O
CoV	O
N	O
is	O
capable	O
of	O
inducing	O
apoptosis	O
of	O
COS	O
-	O
1	O
monkey	O
kidney	O
cells	O
in	O
the	O
absence	O
of	O
growth	O
factors	O
by	O
down	O
-	O
regulating	O
ERK	B-FUNC
(	O
extracellular	O
-	O
signal	O
-	O
regulated	O
kinase	O
),	O
up	O
-	O
regulating	O
JNK	B-FUNC
(	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
)	O
and	O
p38	B-FUNC
MAPK	B-FUNC
(	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
)	O
pathways	O
,	O
and	O
affecting	O
their	O
downstream	O
effectors	O
.	O

Furthermore	O
,	O
activation	O
of	O
the	O
p38	B-FUNC
MAPK	B-FUNC
pathway	O
was	O
found	O
to	O
induce	O
actin	O
reorganization	O
in	O
cells	O
devoid	O
of	O
growth	O
factors	O
.	O

Replication	O
of	O
the	O
approximately	O
30	O
-	O
kb	O
positive	O
-	O
strand	O
RNA	O
genome	O
of	O
coronaviruses	O
and	O
discontinuous	O
synthesis	O
of	O
an	O
extensive	O
set	O
of	O
subgenome	O
-	O
length	O
RNAs	O
(	O
transcription	O
)	O
are	O
mediated	O
by	O
the	O
replicase	O
-	O
transcriptase	B-FUNC
,	O
a	O
barely	O
characterized	O
protein	O
complex	O
that	O
comprises	O
several	O
cellular	O
proteins	O
and	O
up	O
to	O
16	O
viral	O
subunits	O
.	O

The	O
coronavirus	O
replicase	O
-	O
transcriptase	B-FUNC
was	O
recently	O
predicted	O
to	O
contain	O
RNA	O
-	O
processing	O
enzymes	O
that	O
are	O
extremely	O
rare	O
or	O
absent	O
in	O
other	O
RNA	O
viruses	O
.	O

With	O
descending	O
in	O
infectious	O
generation	O
,	O
cases	O
treated	O
with	O
methylprednisolone	O
,	O
human	O
gamma	O
-	O
immunoglobulin	B-FUNC
,	O
interferon	O
-	O
alpha	O
,	O
and	O
antiviral	O
drugs	O
(	O
oral	O
ribavirin	O
or	O
oseltamivir	O
)	O
increased	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
the	O
duration	O
of	O
their	O
use	O
also	O
increased	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

277	O
(	O
2002	O
)	O
19727	O
]	O
that	O
the	O
SU	O
of	O
a	O
murine	O
hepatitis	O
coronavirus	O
(	O
MHV	O
)	O
forms	O
dimers	O
,	O
the	O
dimerization	O
domain	O
overlaps	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
and	O
that	O
this	O
dimeric	O
state	O
is	O
important	O
for	O
binding	B-FUNC
to	O
receptor	O
molecules	O
that	O
initiates	O
entry	O
into	O
cells	O
.	O

RESULTS	O
:	O
We	O
found	O
that	O
85	O
.	O
9	O
%	O
of	O
serum	O
samples	O
contained	O
NAbs	O
against	O
SARS	O
-	O
CoV	O
and	O
that	O
most	O
of	O
the	O
NAb	O
activities	O
could	O
be	O
attributed	O
to	O
immunoglobulin	B-FUNC
G	O
.	O
The	O
NAbs	O
became	O
detectable	O
first	O
at	O
5	O
-	O
10	O
days	O
after	O
the	O
onset	O
of	O
symptoms	O
,	O
and	O
their	O
levels	O
peaked	O
at	O
20	O
-	O
30	O
days	O
and	O
then	O
were	O
sustained	O
for	O
>	O
150	O
days	O
.	O

All	O
sera	B-FUNC
tested	O
contained	O
Ab	O
to	O
cryptic	O
FAH	O
epitopes	O
according	O
with	O
results	O
from	O
western	O
-	O
blot	O
tests	O
,	O
whereas	O
ELISA	O
data	O
indicated	O
that	O
some	O
of	O
these	O
same	O
sera	B-FUNC
did	O
recognize	O
native	O
epitopes	O
of	O
the	O
autoantigen	O
(	O
autoAg	O
).	O

ABSTRACT	O
:	O
To	O
find	O
out	O
the	O
timing	O
of	O
serologic	O
responses	O
after	O
illness	O
onset	O
and	O
distribution	O
of	O
IgG	O
antibody	B-FUNC
to	O
SARS	O
-	O
CoV	O
in	O
SARS	O
cases	O
of	O
transmission	O
chain	O
or	O
non	O
-	O
transmission	O
chain	O
.	O

The	O
sensitivity	O
of	O
the	O
SARS	O
specific	O
IgG	O
kit	B-FUNC
utilized	O
needs	O
to	O
be	O
further	O
improved	O
.	O

Total	O
RNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
lymphocytes	O
of	O
a	O
patient	O
with	O
SARS	O
virus	O
-	O
specific	O
IgG	O
antibody	B-FUNC
and	O
was	O
transcribed	O
reversely	O
into	O
cDNA	O
.	O

The	O
neutralizing	O
ability	O
of	O
antisera	O
directed	O
against	O
the	O
expressed	O
structural	O
proteins	O
was	O
greater	O
than	O
that	O
of	O
convalescent	O
patient	O
antisera	O
,	O
confirming	O
that	O
,	O
as	O
immunogens	O
,	O
the	O
former	O
induce	O
strong	O
,	O
SARS	O
-	O
CoV	O
-	O
specific	O
neutralizing	O
antibody	B-FUNC
responses	O
.	O

Our	O
results	O
showed	O
that	O
the	O
antibodies	O
could	O
efficiently	O
and	O
specifically	O
bind	B-FUNC
to	O
their	O
corresponding	O
proteins	O
from	O
E	O
.	O
coli	O
expressed	O
or	O
lysate	O
of	O
SARS	O
-	O
CoV	O
infected	O
Vero	O
-	O
E6	O
cells	O
by	O
Western	O
blot	O
analysis	O
.	O

TITLE	O
:	O
Specific	O
antibody	B-FUNC
secreting	O
cells	O
from	O
chickens	O
can	O
be	O
detected	O
by	O
three	O
days	O
and	O
memory	O
B	O
cells	O
by	O
three	O
weeks	O
post	O
-	O
infection	O
with	O
the	O
avian	O
respiratory	O
coronavirus	O
.	O

A	O
discrepancy	O
between	O
the	O
ELISA	O
and	O
S2	O
WB	O
arose	O
when	O
evaluating	O
per	O
-	O
2003	O
sera	B-FUNC
from	O
individuals	O
(	O
n	O
=	O
10	O
)	O
with	O
SARS	O
-	O
like	O
symptoms	O
(	O
ELISA	O
--	O
100	O
%	O
positive	O
,	O
S2	O
WB	O
--	O
30	O
%	O
positive	O
).	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
CoV	O
),	O
a	O
type	O
I	O
transmembrane	O
envelope	O
glycoprotein	O
,	O
consists	O
of	O
S1	O
and	O
S2	O
domains	O
responsible	O
for	O
virus	O
binding	B-FUNC
and	O
fusion	O
,	O
respectively	O
.	O

Intravenous	O
immunoglobulin	B-FUNC
was	O
given	O
to	O
three	O
patients	O
.	O

Conjunctival	O
,	O
throat	O
,	O
stool	O
,	O
and	O
urine	O
specimens	O
were	O
collected	O
weekly	O
from	O
64	O
patients	O
and	O
tested	O
for	O
SARS	O
-	O
CoV	O
RNA	O
by	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
;	O
serum	O
samples	O
were	O
collected	O
weekly	O
and	O
tested	O
for	O
SARS	O
-	O
CoV	O
antibody	B-FUNC
with	O
indirect	O
enzyme	O
immunoassay	O
and	O
immunofluorescence	O
assay	O
.	O

ABSTRACT	O
:	O
Many	O
viruses	O
achieve	O
reversible	O
attachment	O
to	O
sialic	O
acid	O
(	O
Sia	O
)	O
by	O
encoding	O
envelope	O
glycoproteins	O
with	O
receptor	O
-	O
binding	B-FUNC
and	O
receptor	O
-	O
destroying	O
activities	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
3C	O
-	O
like	O
proteinase	B-FUNC
N	O
terminus	O
is	O
indispensable	O
for	O
proteolytic	O
activity	O
but	O
not	O
for	O
enzyme	O
dimerization	O
.	O

This	O
conclusion	O
is	O
verified	O
by	O
the	O
surface	O
plasmon	O
resonance	O
biosensor	O
determination	O
,	O
indicating	O
that	O
the	O
model	O
substrate	O
cannot	O
bind	B-FUNC
to	O
the	O
N	O
-	O
terminal	O
deleted	O
proteinase	B-FUNC
.	O

These	O
results	O
suggest	O
the	O
N	O
terminus	O
is	O
not	O
indispensable	O
for	O
the	O
proteinase	B-FUNC
dimerization	O
but	O
may	O
fix	O
the	O
dimer	O
at	O
the	O
active	O
state	O
and	O
is	O
therefore	O
vital	O
to	O
enzymatic	O
activity	O
.	O

ABSTRACT	O
:	O
Nonstructural	O
protein	O
15	O
(	O
Nsp15	O
)	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
produced	O
in	O
Escherichia	O
coli	O
has	O
endoribonuclease	B-FUNC
activity	I-FUNC
that	O
preferentially	O
cleaved	O
5	O
'	O
of	O
uridylates	O
of	O
RNAs	O
.	O

Concentrations	O
of	O
Mn	O
(	O
2	O
+)	O
needed	O
for	O
endoribonuclease	B-FUNC
activity	I-FUNC
induced	O
significant	O
conformation	O
change	O
(	O
s	O
)	O
in	O
the	O
protein	O
,	O
as	O
measured	O
by	O
changes	O
in	O
tryptophan	O
fluorescence	O
.	O

Immunized	O
ferrets	O
developed	O
a	O
more	O
rapid	O
and	O
vigorous	O
neutralizing	O
antibody	B-FUNC
response	O
than	O
control	O
animals	O
after	O
challenge	O
with	O
SARS	O
-	O
CoV	O
;	O
however	O
,	O
they	O
also	O
exhibited	O
strong	O
inflammatory	O
responses	O
in	O
liver	O
tissue	O
.	O

Although	O
inhibitors	O
of	O
ERK1	B-FUNC
/	O
2	O
and	O
JNK	B-FUNC
(	O
PD98059	O
and	O
SP600125	O
)	O
had	O
no	O
effect	O
on	O
phosphorylation	O
status	O
of	O
STAT3	O
,	O
inhibitors	O
of	O
p38	B-FUNC
MAPK	B-FUNC
(	O
SB203580	O
and	O
SB202190	O
)	O
partially	O
inhibited	O
dephosphorylation	O
of	O
STAT3	O
at	O
Tyr	O
-	O
705	O
.	O

We	O
report	O
that	O
,	O
in	O
planar	O
lipid	O
bilayers	O
,	O
synthetic	O
peptides	O
corresponding	O
to	O
the	O
SARS	O
-	O
CoV	O
E	O
protein	O
forms	O
ion	B-FUNC
channels	I-FUNC
that	O
are	O
more	O
permeable	O
to	O
monovalent	O
cations	O
than	O
to	O
monovalent	O
anions	O
.	O

Several	O
minor	O
immunodominant	O
epitopes	O
were	O
reactive	O
with	O
about	O
50	O
%	O
of	O
the	O
SARS	O
sera	B-FUNC
.	O

Antisera	O
from	O
mice	O
immunized	O
with	O
inactivated	O
SARS	O
-	O
CoV	O
recognized	O
the	O
two	O
major	O
immunodominant	O
epitopes	O
and	O
one	O
antigenic	O
site	O
located	O
adjacent	O
to	O
the	O
N	O
-	O
terminal	O
region	O
(	O
aa	O
76	O
to	O
101	O
),	O
which	O
did	O
not	O
react	O
with	O
the	O
sera	B-FUNC
from	O
SARS	O
patients	O
.	O

The	O
virus	O
was	O
first	O
identified	O
by	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
and	O
showed	O
a	O
distinct	O
restriction	O
fragment	O
length	O
polymorphism	O
pattern	O
from	O
previously	O
described	O
Israeli	O
isolates	O
.	O

Serum	O
of	O
60	O
SARS	O
patients	O
,	O
20	O
samples	O
of	O
serum	O
and	O
20	O
samples	O
of	O
gargling	O
fluid	O
of	O
medical	O
staff	O
of	O
the	O
""""	O
Fever	O
Clinic	O
""","	O
and	O
one	O
cDNA	O
specimen	O
obtained	O
from	O
one	O
SARS	O
suspect	O
patient	O
were	O
examined	O
with	O
F	O
-	O
PCR	O
diagnosis	O
kit	B-FUNC
and	O
gene	O
-	O
chip	O
technique	O
for	O
SARS	O
coronavirus	O
.	O

Their	O
blood	O
sera	B-FUNC
and	O
secretions	O
of	O
the	O
nasal	O
cavity	O
were	O
examined	O
in	O
the	O
indirect	O
hemagglutination	O
(	O
IHA	O
)	O
test	O
with	O
dried	O
standard	O
erythrocyte	O
diagnostic	O
preparations	O
.	O

The	O
up	O
-	O
regulation	O
of	O
LIX	O
,	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
,	O
and	O
macrophage	O
inflammatory	O
protein	O
2	O
was	O
confirmed	O
at	O
the	O
protein	O
level	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
.	O

Specimens	O
from	O
the	O
first	O
day	O
of	O
his	O
admission	O
were	O
among	O
the	O
first	O
to	O
demonstrate	O
the	O
novel	O
coronavirus	O
,	O
by	O
culture	O
,	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
and	O
rising	O
of	O
specific	O
antibody	B-FUNC
,	O
but	O
proper	O
protective	O
measures	O
remained	O
unknown	O
.	O

TITLE	O
:	O
[	O
Dynamic	O
changes	O
of	O
immunoglobulin	B-FUNC
G	O
in	O
convalescents	O
who	O
have	O
suffered	O
from	O
severe	O
acute	O
respiratory	O
syndrome	O
patients	O
].	O

After	O
that	O
,	O
serum	O
antibody	B-FUNC
levels	O
remained	O
at	O
a	O
plateau	O
or	O
had	O
a	O
slight	O
decrease	O
,	O
though	O
two	O
boosters	O
were	O
given	O
in	O
the	O
succedent	O
4	O
to	O
5	O
weeks	O
.	O

In	O
this	O
study	O
,	O
the	O
N	O
protein	O
of	O
SARS	O
-	O
CoV	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
DH5alpha	O
and	O
identified	O
with	O
pooled	O
sera	B-FUNC
from	O
patients	O
in	O
the	O
convalescence	O
phase	O
of	O
SARS	O
.	O

The	O
major	O
immunoglobulin	B-FUNC
G	O
subclass	O
recognizing	O
N	O
protein	O
was	O
immunoglobulin	B-FUNC
G2a	O
,	O
and	O
stimulated	O
splenocytes	O
secreted	O
high	O
levels	O
of	O
gamma	O
interferon	O
and	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
in	O
response	O
to	O
N	O
protein	O
.	O

Mutation	O
of	O
the	O
AP	O
-	O
1	O
,	O
not	O
the	O
kappaB	O
site	O
,	O
abolished	O
the	O
SARS	O
-	O
CoV	O
S	O
protein	O
-	O
induced	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
promoter	O
activity	O
.	O

These	O
results	O
suggested	O
that	O
the	O
S	O
protein	O
of	O
SARS	O
-	O
CoV	O
could	O
induce	O
release	O
of	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
in	O
the	O
lung	O
cells	O
via	O
activations	O
of	O
MAPKs	O
and	O
AP	O
-	O
1	O
.	O

ABSTRACT	O
:	O
The	O
ubiquitin	B-FUNC
-	O
proteasome	O
system	O
is	O
involved	O
in	O
cellular	O
endocytosis	O
and	O
maturation	O
of	O
some	O
viruses	O
.	O

In	O
the	O
presence	O
of	O
MG132	O
,	O
the	O
entering	O
viruses	O
accumulated	O
in	O
both	O
the	O
endosome	O
and	O
denser	O
lysosome	O
,	O
suggesting	O
that	O
the	O
ubiquitin	B-FUNC
-	O
proteasome	O
system	O
is	O
involved	O
in	O
the	O
release	O
of	O
virus	O
from	O
the	O
endosome	O
to	O
the	O
cytosol	O
during	O
the	O
virus	O
entry	O
step	O
.	O

For	O
the	O
survival	O
group	O
,	O
IFN	O
-	O
gamma	O
and	O
MCP	B-FUNC
-	O
1	O
were	O
inversely	O
associated	O
with	O
circulating	O
lymphocytes	O
count	O
and	O
monocytes	O
count	O
,	O
but	O
positively	O
associated	O
with	O
circulating	O
neutrophils	O
count	O
.	O

The	O
kinetics	O
of	O
neutralisation	O
antibodies	O
obtained	O
with	O
100x	O
the	O
tissue	O
culture	O
infective	O
dose	O
(	O
TCID50	O
)	O
of	O
the	O
SARS	O
-	O
CoV	O
TW1	O
strain	O
in	O
five	O
patients	O
with	O
SARS	O
nearly	O
paralleled	O
those	O
for	O
IgG	O
.	O
There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
kinetics	O
of	O
the	O
IgG	O
,	O
IgM	O
and	O
IgA	O
responses	O
between	O
patients	O
with	O
or	O
without	O
underlying	O
medical	O
disease	O
,	O
steroid	O
or	O
intravenous	O
immunoglobulin	B-FUNC
therapy	O
,	O
or	O
mechanical	O
ventilation	O
.	O

ABSTRACT	O
:	O
Nidoviruses	O
(	O
Coronaviridae	O
,	O
Arteriviridae	O
,	O
and	O
Roniviridae	O
)	O
encode	O
a	O
nonstructural	O
protein	O
,	O
called	O
nsp10	O
in	O
arteriviruses	O
and	O
nsp13	O
in	O
coronaviruses	O
,	O
that	O
is	O
comprised	O
of	O
a	O
C	O
-	O
terminal	O
superfamily	O
1	O
helicase	O
domain	O
and	O
an	O
N	O
-	O
terminal	O
,	O
putative	O
zinc	O
-	O
binding	B-FUNC
domain	O
(	O
ZBD	O
).	O

Taken	O
together	O
,	O
the	O
data	O
strongly	O
support	O
the	O
zinc	O
-	O
binding	B-FUNC
function	O
of	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
nidovirus	O
helicases	O
.	O

However	O
,	O
phosphorylated	O
N	O
protein	O
bound	O
to	O
viral	O
RNA	O
with	O
a	O
higher	O
binding	B-FUNC
affinity	O
than	O
nonviral	O
RNA	O
,	O
suggesting	O
that	O
phosphorylation	O
of	O
N	O
protein	O
determined	O
the	O
recognition	O
of	O
virus	O
RNA	O
.	O

TITLE	O
:	O
Effect	O
of	O
soluble	O
porcine	O
aminopeptidase	O
N	O
on	O
antibody	B-FUNC
production	O
against	O
porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

Antibody	B-FUNC
production	O
against	O
PEDV	O
was	O
compared	O
among	O
groups	O
at	O
regular	O
intervals	O
.	O

The	O
entire	O
ORF	O
(	O
open	O
-	O
reading	O
frame	O
)	O
encodes	O
for	O
two	O
major	O
enzyme	O
activities	O
,	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
and	O
proteinase	B-FUNC
activities	O
.	O

Using	O
Enzyme	O
-	O
Linked	O
Immunosorbent	O
Assay	O
(	O
ELISA	O
),	O
these	O
peptides	O
were	O
screened	O
in	O
the	O
sera	B-FUNC
from	O
SARS	O
patients	O
.	O

These	O
recombinant	O
S	O
fragments	O
were	O
confirmed	O
to	O
have	O
positive	O
cross	O
-	O
reactions	O
with	O
SARS	O
sera	B-FUNC
,	O
either	O
by	O
Western	O
blot	O
or	O
by	O
ELISA	O
.	O

We	O
have	O
also	O
annotated	O
non	O
-	O
coding	O
regions	O
and	O
identified	O
the	O
transcription	O
regulating	O
sequences	O
(	O
TRS	B-FUNC
)	O
in	O
the	O
intergenic	O
regions	O
.	O

The	O
binding	B-FUNC
specificity	O
of	O
phage	O
antibody	B-FUNC
to	O
SARS	O
virus	O
was	O
detected	O
by	O
ELISA	O
.	O

A	O
human	O
phage	O
antibody	B-FUNC
library	O
consisting	O
of	O
1	O
.	O
3	O
x	O
10	O
(	O
6	O
)	O
clones	O
was	O
constructed	O
by	O
electrotransformation	O
and	O
60	O
percent	O
of	O
the	O
clones	O
contained	O
Fab	O
genes	O
.	O

(	O
3	O
)	O
The	O
IgG	O
antibody	B-FUNC
emerged	O
in	O
one	O
of	O
24	O
children	O
,	O
whose	O
mother	O
,	O
a	O
nurse	O
,	O
had	O
suffered	O
from	O
SARS	O
(	O
4	O
%).	O

IgM	O
-	O
capture	O
,	O
indirect	O
and	O
antigen	O
-	O
sandwiched	O
enzyme	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
were	O
used	O
to	O
detect	O
the	O
SARS	O
-	O
CoV	O
specific	O
IgM	O
,	O
IgG	O
and	O
total	O
antibodies	O
in	O
sera	B-FUNC
of	O
clinical	O
SARS	O
patients	O
or	O
non	O
-	O
SARS	O
individuals	O
.	O

Synergistic	O
activation	O
by	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
/	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
induced	O
the	O
expression	O
of	O
the	O
IFNgamma	O
gene	O
in	O
Mphi	O
from	O
both	O
mouse	O
strains	O
.	O

CONCLUSIONS	O
:	O
S1	O
domain	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
,	O
which	O
is	O
responsible	O
for	O
receptor	B-FUNC
binding	I-FUNC
,	O
can	O
efficiently	O
and	O
sufficiently	O
induce	O
highly	O
potent	O
neutralizing	O
antibody	B-FUNC
in	O
mice	O
.	O

S450	O
-	O
650	O
-	O
based	O
ELISA	O
system	O
was	O
able	O
to	O
detect	O
anti	O
-	O
SARS	O
-	O
CoV	O
IgG	O
Abs	O
in	O
patient	O
sera	B-FUNC
.	O

TITLE	O
:	O
Molecular	O
and	O
biological	O
characterization	O
of	O
human	O
monoclonal	O
antibodies	O
binding	B-FUNC
to	O
the	O
spike	O
and	O
nucleocapsid	O
proteins	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

The	O
MAb	O
ability	O
to	O
block	O
S1	O
-	O
receptor	B-FUNC
binding	I-FUNC
and	O
the	O
level	O
of	O
neutralization	O
of	O
the	O
two	O
strongly	O
neutralizing	O
S1	O
MAbs	O
correlated	O
with	O
the	O
binding	B-FUNC
affinity	O
to	O
the	O
S1	O
domain	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
levels	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
IgG	O
antibody	B-FUNC
of	O
SARS	O
patients	O
,	O
people	O
who	O
closely	O
contacted	O
SARS	O
patients	O
and	O
normal	O
subjects	O
in	O
Gansu	O
province	O
.	O

Serological	O
examination	O
using	O
blood	O
samples	O
collected	O
on	O
the	O
12th	O
and	O
28th	O
hospital	O
days	O
revealed	O
elevation	O
of	O
anti	O
-	O
L	O
.	O
pneumophila	O
serogroup	O
I	O
antibody	B-FUNC
.	O

TITLE	O
:	O
Development	O
and	O
characterization	O
of	O
a	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
-	O
neutralizing	O
human	O
monoclonal	O
antibody	B-FUNC
that	O
provides	O
effective	O
immunoprophylaxis	O
in	O
mice	O
.	O

Immunoprecipitation	O
analysis	O
revealed	O
2	O
antibody	B-FUNC
-	O
binding	B-FUNC
epitopes	O
:	O
one	O
MAb	O
(	O
201	O
)	O
bound	O
within	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
at	O
aa	O
490	O
-	O
510	O
,	O
and	O
the	O
other	O
MAb	O
(	O
68	O
)	O
bound	O
externally	O
to	O
the	O
domain	O
at	O
aa	O
130	O
-	O
150	O
.	O

RESULTS	O
:	O
Both	O
MAbs	O
bound	O
to	O
S	O
glycoprotein	O
expressed	O
on	O
transfected	O
cells	O
but	O
differed	O
in	O
their	O
ability	O
to	O
block	O
binding	B-FUNC
of	O
S	O
glycoprotein	O
to	O
Vero	O
E6	O
cells	O
.	O

This	O
recombinant	O
N	O
protein	O
(	O
hGST	O
-	O
N	O
)	O
was	O
purified	O
and	O
used	O
to	O
measure	O
the	O
SARS	O
-	O
CoV	O
N	O
-	O
specific	O
antibody	B-FUNC
in	O
the	O
sera	B-FUNC
of	O
eight	O
SARS	O
patients	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

Forty	O
compounds	O
were	O
purchased	O
and	O
tested	O
by	O
HPLC	O
and	O
colorimetric	O
assay	O
against	O
SARS	O
3C	O
-	O
like	O
proteinase	B-FUNC
.	O

(	O
2	O
)	O
The	O
evidence	O
for	O
immune	O
implication	O
in	O
distress	O
strongly	O
supports	O
immunomodulators	O
for	O
therapy	O
:	O
phosphodiesterase	B-FUNC
inhibitors	O
(	O
due	O
to	O
their	O
down	O
-	O
modulating	O
activity	O
on	O
proinflammatory	O
cytokines	O
);	O
inhaled	O
corticoids	O
(	O
aimed	O
at	O
producing	O
a	O
local	O
immunomodulation	O
);	O
teophylline	O
or	O
nedocromil	O
sodium	O
(	O
which	O
prevents	O
inflammatory	O
cell	O
recruitment	O
into	O
the	O
airway	O
wall	O
).	O

In	O
situ	O
hybridization	O
was	O
used	O
to	O
identify	O
sites	O
of	O
virus	O
replication	O
,	O
and	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
analysis	O
was	O
used	O
to	O
detect	O
viral	O
RNA	O
in	O
feces	O
and	O
blood	O
.	O

Our	O
Spike	O
protein	O
-	O
based	O
immunoflourescence	O
assay	O
(	O
IFA	O
)	O
based	O
on	O
this	O
recombinant	O
baculovirus	O
-	O
Sf	O
-	O
9	O
system	O
was	O
further	O
assessed	O
with	O
a	O
panel	O
of	O
163	O
clinical	O
samples	O
collected	O
during	O
the	O
SARS	O
epidemic	O
in	O
Singapore	O
,	O
which	O
include	O
samples	O
from	O
21	O
clinically	O
confirmed	O
SARS	O
,	O
42	O
non	O
-	O
SARS	O
patient	O
sera	B-FUNC
,	O
and	O
100	O
normal	O
sera	B-FUNC
.	O

The	O
presence	O
of	O
a	O
canonical	O
CS	O
was	O
not	O
sufficient	O
to	O
drive	O
transcription	O
,	O
but	O
subgenomic	O
synthesis	O
requires	O
a	O
minimum	O
base	B-FUNC
pairing	I-FUNC
between	O
the	O
leader	O
TRS	B-FUNC
(	O
TRS	B-FUNC
-	O
L	O
)	O
and	O
the	O
complement	O
of	O
the	O
body	O
TRS	B-FUNC
(	O
cTRS	O
-	O
B	O
)	O
provided	O
by	O
the	O
CS	O
and	O
its	O
adjacent	O
nucleotides	O
.	O

The	O
immunological	O
effect	O
of	O
anti	O
-	O
SARS	O
-	O
CoV	O
antibody	B-FUNC
was	O
tested	O
with	O
purified	O
rS	O
(	O
a	O
)	O
and	O
rS	O
(	O
b	O
)	O
proteins	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
).	O

The	O
binding	B-FUNC
mechanism	O
was	O
also	O
analyzed	O
between	O
the	O
best	O
screening	O
compound	O
and	O
the	O
SARS	O
protein	O
.	O

One	O
fourth	O
of	O
patients	O
with	O
SARS	O
developed	O
hypouricemia	O
,	O
which	O
might	O
result	O
from	O
a	O
defect	O
in	O
renal	O
UA	O
handling	O
and	O
was	O
associated	O
with	O
a	O
high	O
serum	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
level	O
.	O

The	O
detection	O
rates	O
were	O
comparable	O
to	O
those	O
obtained	O
with	O
a	O
commercial	O
SARS	O
-	O
CoV	O
IFA	O
kit	B-FUNC
(	O
EUROIMMUN	O
,	O
Gross	O
Groenau	O
,	O
Germany	O
)	O
and	O
a	O
conventional	O
IFA	O
performed	O
at	O
the	O
Singapore	O
General	O
Hospital	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
the	O
prevalence	O
of	O
inapparent	O
infection	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
among	O
healthcare	O
workers	O
,	O
we	O
performed	O
a	O
serosurvey	O
to	O
test	O
for	O
immunoglobulin	B-FUNC
(	O
Ig	O
)	O
G	O
antibodies	O
to	O
the	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
among	O
1	O
,	O
147	O
healthcare	O
workers	O
in	O
3	O
hospitals	O
that	O
admitted	O
SARS	O
patients	O
in	O
mid	O
-	O
May	O
2003	O
.	O

Using	O
fragmented	O
S	O
genes	O
as	O
immunogens	O
,	O
we	O
also	O
mapped	O
a	O
neutralizing	O
epitope	O
in	O
the	O
region	O
of	O
N	O
-	O
terminal	O
400	O
to	O
600	O
amino	O
acids	O
of	O
the	O
S	O
glycoprotein	O
(	O
S400	O
-	O
600	O
),	O
which	O
overlaps	O
with	O
the	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
receptor	O
-	O
binding	B-FUNC
region	O
(	O
RBR	O
;	O
S318	O
-	O
510	O
).	O

Liver	O
damage	O
of	O
patients	O
with	O
SARS	O
usually	O
occurs	O
in	O
the	O
early	O
stage	O
of	O
the	O
disease	O
with	O
a	O
high	O
occurrence	O
rate	O
and	O
a	O
prolonged	O
profile	O
,	O
which	O
can	O
be	O
characterized	O
by	O
early	O
,	O
obvious	O
decrease	O
of	O
albumin	O
levels	O
and	O
slightly	O
abnormal	O
levels	O
of	O
ALT	B-FUNC
.	O

When	O
the	O
antibodies	O
were	O
tested	O
for	O
their	O
ability	O
to	O
inhibit	O
SARS	O
-	O
CoV	O
propagation	O
in	O
Vero	O
E6	O
culture	O
,	O
it	O
was	O
found	O
that	O
the	O
anti	O
-	O
SDelta10	O
antibody	B-FUNC
,	O
which	O
was	O
targeted	O
to	O
amino	O
acid	O
residues	O
1029	O
to	O
1192	O
of	O
S	O
,	O
which	O
include	O
heptad	O
repeat	O
2	O
,	O
has	O
strong	O
neutralizing	O
activities	O
,	O
suggesting	O
that	O
this	O
region	O
of	O
S	O
carries	O
neutralizing	O
epitopes	O
and	O
is	O
very	O
important	O
for	O
virus	O
entry	O
into	O
cells	O
.	O

Monoclonal	O
antibodies	O
(	O
Mabs	O
)	O
and	O
established	O
drugs	O
,	O
such	O
as	O
interferons	O
and	O
HIV	O
proteinase	B-FUNC
inhibitors	O
,	O
are	O
also	O
discussed	O
in	O
relation	O
to	O
anti	O
-	O
SARS	O
clinical	O
use	O
.	O

Depletion	O
of	O
RBD	O
-	O
specific	O
antibodies	O
from	O
patient	O
or	O
rabbit	O
immune	O
sera	B-FUNC
by	O
immunoadsorption	O
significantly	O
reduced	O
serum	O
-	O
mediated	O
neutralizing	O
activity	O
,	O
while	O
affinity	O
-	O
purified	O
anti	O
-	O
RBD	O
antibodies	O
had	O
relatively	O
higher	O
potency	O
neutralizing	O
infectivity	O
of	O
SARS	O
pseudovirus	O
,	O
indicating	O
that	O
the	O
RBD	O
of	O
S	O
protein	O
is	O
a	O
critical	O
neutralization	O
determinant	O
of	O
SARS	O
-	O
CoV	O
during	O
viral	O
infection	O
and	O
immunization	O
.	O

We	O
further	O
demonstrated	O
that	O
2C5	O
,	O
but	O
not	O
1A5	O
,	O
was	O
able	O
to	O
block	O
binding	B-FUNC
of	O
the	O
RBD	O
to	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
the	O
functional	O
receptor	O
on	O
targeted	O
cells	O
.	O

TITLE	O
:	O
The	O
substrate	O
specificity	O
of	O
SARS	O
coronavirus	O
3C	O
-	O
like	O
proteinase	B-FUNC
.	O

Residues	O
at	O
position	O
P4	O
,	O
P3	O
,	O
and	O
P3	O
'	O
are	O
critical	O
for	O
substrate	O
recognition	O
and	O
binding	B-FUNC
,	O
and	O
increment	O
of	O
beta	O
-	O
sheet	O
conformation	O
tendency	O
is	O
also	O
helpful	O
.	O

And	O
the	O
antibody	B-FUNC
detective	O
rate	O
was	O
decreased	O
by	O
the	O
month	O
.	O

In	O
contrast	O
,	O
only	O
1	O
of	O
278	O
healthy	O
subjects	O
enrolled	O
in	O
the	O
study	O
was	O
found	O
to	O
be	O
positive	O
for	O
the	O
IgG	O
antibody	B-FUNC
.	O

To	O
develop	O
and	O
evaluate	O
an	O
ELISA	O
system	O
for	O
detection	O
of	O
anti	O
-	O
S	O
Abs	O
in	O
patient	O
sera	B-FUNC
.	O

Previous	O
data	O
suggested	O
that	O
CD4	O
(+)	O
T	O
cells	O
may	O
support	O
CD8	O
(+)	O
T	O
cells	O
through	O
secretion	O
of	O
interleukin	O
-	O
2	O
(	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
).	O

ABSTRACT	O
:	O
Elevation	O
of	O
alanine	O
aminotransferase	O
(	O
ALT	B-FUNC
)	O
level	O
is	O
commonly	O
seen	O
among	O
patients	O
suffering	O
from	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

Serial	O
assay	O
of	O
serum	O
ALT	B-FUNC
was	O
followed	O
in	O
patients	O
who	O
fulfilled	O
the	O
WHO	O
criteria	O
of	O
SARS	O
.	O

We	O
studied	O
the	O
pathologic	O
specimens	O
from	O
6	O
SARS	O
patients	O
by	O
immunohistochemical	O
staining	O
using	O
a	O
specific	O
antibody	B-FUNC
against	O
SARS	O
-	O
CoV	O
.	O
Positive	O
viral	O
staining	O
was	O
only	O
found	O
in	O
the	O
lung	O
tissue	O
taken	O
from	O
the	O
patients	O
who	O
died	O
in	O
the	O
early	O
stage	O
of	O
the	O
disease	O
,	O
usually	O
less	O
than	O
10	O
days	O
after	O
symptom	O
onset	O
.	O

For	O
the	O
two	O
novel	O
sgRNAs	O
,	O
each	O
used	O
a	O
variant	O
of	O
the	O
TRS	B-FUNC
that	O
has	O
one	O
nucleotide	O
mismatch	O
in	O
the	O
conserved	O
hexanucleotide	O
core	O
(	O
ACGAAC	O
)	O
in	O
the	O
TRS	B-FUNC
.	O

A	O
single	O
inoculation	O
with	O
the	O
RV	O
-	O
based	O
vaccine	O
expressing	O
SARS	O
-	O
CoV	O
S	O
protein	O
induced	O
a	O
strong	O
SARS	O
-	O
CoV	O
-	O
neutralizing	O
antibody	B-FUNC
response	O
.	O

We	O
report	O
here	O
the	O
cloning	O
,	O
expression	O
,	O
and	O
purification	O
of	O
the	O
N	O
-	O
terminal	O
GST	O
-	O
fused	O
SARS	O
-	O
CoV	O
RdRp	B-FUNC
and	O
its	O
polymerase	O
catalytic	O
domain	O
in	O
Escherichia	O
coli	O
.	O

TITLE	O
:	O
Targeting	O
non	O
-	O
human	O
coronaviruses	O
to	O
human	O
cancer	O
cells	O
using	O
a	O
bispecific	O
single	O
-	O
chain	O
antibody	B-FUNC
.	O

Furthermore	O
,	O
in	O
the	O
presence	O
of	O
the	O
targeting	O
antibody	B-FUNC
,	O
infected	O
cancer	O
cells	O
formed	O
syncytia	O
typical	O
of	O
productive	O
coronavirus	O
infection	O
.	O

The	O
Puumala	O
virus	O
is	O
responsible	O
for	O
a	O
minor	O
form	O
of	O
the	O
disease	O
that	O
is	O
observed	O
in	O
areas	O
of	O
the	O
Occidental	O
sector	O
of	O
the	O
ex	O
-	O
URSS	O
,	O
in	O
Scandinavia	O
and	O
in	O
the	O
rest	B-FUNC
of	O
Europe	O
,	O
notably	O
in	O
the	O
North	O
-	O
East	O
of	O
France	O
.	O

GST	O
pull	O
-	O
down	O
results	O
clearly	O
demonstrated	O
that	O
SARS_N	O
protein	O
could	O
directly	O
and	O
specifically	O
bind	B-FUNC
to	O
human	O
hnRNP	O
A1	O
in	O
vitro	O
.	O

In	O
addition	O
,	O
the	O
determined	O
results	O
showed	O
that	O
SARS_N	O
protein	O
has	O
only	O
one	O
binding	B-FUNC
domain	O
for	O
interacting	O
with	O
human	O
hnRNP	O
A1	O
,	O
which	O
is	O
different	O
from	O
the	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
binding	B-FUNC
case	O
where	O
the	O
nucleocapsid	O
protein	O
of	O
MHV	O
(	O
MHV_N	O
)	O
was	O
found	O
to	O
have	O
two	O
binding	B-FUNC
domains	O
involved	O
in	O
the	O
MHV_N	O
/	O
hnRNP	O
A1	O
interaction	O
,	O
thereby	O
suggesting	O
that	O
SARS_N	O
protein	O
might	O
carry	O
out	O
a	O
different	O
binding	B-FUNC
mode	O
to	O
bind	B-FUNC
to	O
human	O
hnRNP	O
A1	O
for	O
its	O
further	O
function	O
performance	O
in	O
comparison	O
with	O
MHV_N	O
.	O

Expression	O
levels	O
for	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
IFN	O
-	O
gamma	O
and	O
CXCL10	O
consistently	O
peaked	O
within	O
4	O
days	O
of	O
peak	O
viral	O
load	O
.	O

TITLE	O
:	O
Antibody	B-FUNC
responses	O
to	O
individual	O
proteins	O
of	O
SARS	O
coronavirus	O
and	O
their	O
neutralization	O
activities	O
.	O

In	O
the	O
detectable	O
specific	O
antibodies	O
,	O
anti	O
-	O
S	O
and	O
anti	O
-	O
N	O
were	O
dominant	O
and	O
could	O
persist	O
in	O
the	O
sera	B-FUNC
of	O
SARS	O
patients	O
until	O
week	O
30	O
.	O

The	O
results	O
suggest	O
(	O
1	O
)	O
that	O
anti	O
-	O
S	O
and	O
anti	O
-	O
N	O
antibodies	O
are	O
diagnostic	O
markers	O
and	O
in	O
particular	O
that	O
S3	O
is	O
immunogenic	O
and	O
therefore	O
is	O
a	O
good	O
candidate	O
as	O
a	O
subunit	O
vaccine	O
antigen	O
;	O
and	O
(	O
2	O
)	O
that	O
,	O
from	O
a	O
virus	O
structure	O
viewpoint	O
,	O
the	O
presence	O
in	O
some	O
human	O
sera	B-FUNC
of	O
antibodies	O
reacting	O
with	O
two	O
recombinant	O
polypeptides	O
,	O
3a	O
and	O
9b	O
,	O
supports	O
the	O
hypothesis	O
that	O
they	O
are	O
synthesized	O
during	O
the	O
virus	O
cycle	O
.	O

In	O
addition	O
to	O
its	O
structural	O
role	O
,	O
it	O
has	O
been	O
described	O
as	O
an	O
RNA	O
-	O
binding	B-FUNC
protein	O
that	O
might	O
be	O
involved	O
in	O
coronavirus	O
RNA	O
synthesis	O
.	O

The	O
level	O
of	O
virus	O
RNA	O
and	O
infectious	O
particles	O
was	O
reduced	O
by	O
up	O
to	O
4	O
log	O
units	O
,	O
with	O
IC50	O
values	O
ranging	O
from	O
19	O
to	O
34	O
microM	O
.	O
These	O
findings	O
demonstrate	O
that	O
the	O
old	O
drug	O
cinanserin	O
is	O
an	O
inhibitor	O
of	O
SARS	O
-	O
CoV	O
replication	O
,	O
acting	O
most	O
likely	O
via	O
inhibition	O
of	O
the	O
3CL	O
proteinase	B-FUNC
.	O

Firstly	O
,	O
SARS	O
-	O
CoV	O
-	O
specific	O
IgGs	O
were	O
detected	O
in	O
the	O
sera	B-FUNC
of	O
macaques	O
from	O
11	O
to	O
60	O
days	O
after	O
inoculation	O
.	O

ABSTRACT	O
:	O
Accurate	O
assessment	O
of	O
neutralizing	O
antibody	B-FUNC
activities	O
is	O
important	O
either	O
for	O
patients	O
infected	O
with	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
)	O
or	O
for	O
animals	O
and	O
volunteers	O
immunized	O
with	O
the	O
experimental	O
vaccines	O
against	O
the	O
SARS	O
associated	O
coronavirus	O
(	O
SCV	O
).	O

In	O
this	O
report	O
,	O
we	O
described	O
the	O
utility	O
of	O
these	O
two	O
new	O
neutralization	O
assays	O
in	O
measuring	O
the	O
neutralizing	O
activities	O
against	O
SCV	O
infection	O
from	O
rabbit	O
sera	B-FUNC
immunized	O
with	O
various	O
forms	O
of	O
spike	O
protein	O
of	O
SCV	O
.	O

Potent	O
neutralizing	O
activity	O
directed	O
against	O
NL63	O
-	O
but	O
not	O
229E	O
-	O
S	O
protein	O
was	O
detected	O
in	O
virtually	O
all	O
sera	B-FUNC
from	O
patients	O
8	O
years	O
of	O
age	O
or	O
older	O
,	O
suggesting	O
that	O
HCoV	O
-	O
NL63	O
infection	O
of	O
humans	O
is	O
common	O
and	O
usually	O
acquired	O
during	O
childhood	O
.	O

The	O
current	O
study	O
was	O
undertaken	O
to	O
clarify	O
whether	O
furosemide	O
attenuates	O
the	O
inflammatory	O
response	O
by	O
changing	O
the	O
epidermal	B-FUNC
growth	I-FUNC
factor	I-FUNC
level	O
in	O
patients	O
with	O
acute	O
lung	O
injury	O
.	O

The	O
interaction	O
between	O
SARS	O
coronavirus	O
3C	O
-	O
like	O
(	O
3CL	O
)	O
proteinase	B-FUNC
and	O
an	O
octapeptide	O
interface	O
inhibitor	O
was	O
studied	O
by	O
affinity	O
capillary	O
electrophoresis	O
(	O
ACE	O
).	O

The	O
results	O
showed	O
that	O
SARS	O
3CL	O
proteinase	B-FUNC
was	O
able	O
to	O
complex	O
with	O
the	O
octapeptide	O
competitively	O
,	O
with	O
binding	B-FUNC
constants	O
of	O
2	O
.	O
44	O
x	O
10	O
(	O
4	O
)	O
M	O
(-	O
1	O
)	O
at	O
20	O
degrees	O
C	O
and	O
2	O
.	O
11	O
x	O
10	O
(	O
4	O
)	O
M	O
(-	O
1	O
)	O
at	O
37	O
degrees	O
C	O
.	O
In	O
addition	O
,	O
the	O
thermodynamic	O
parameters	O
deduced	O
reveal	O
that	O
hydrophobic	O
interaction	O
might	O
play	O
major	O
roles	O
,	O
along	O
with	O
electrostatic	O
force	O
,	O
in	O
the	O
binding	B-FUNC
process	O
.	O

TITLE	O
:	O
Inhibition	O
of	O
SARS	O
-	O
CoV	O
3C	O
-	O
like	O
Protease	B-FUNC
Activity	I-FUNC
by	O
Theaflavin	O
-	O
3	O
,	O
3	O
'-	O
digallate	O
(	O
TF3	O
).	O

A	O
case	O
control	O
study	O
involving	O
44	O
SARS	O
cases	O
,	O
16	O
anti	O
-	O
SARS	O
-	O
CoV	O
antibody	B-FUNC
-	O
positive	O
contacts	O
,	O
87	O
antibody	B-FUNC
-	O
negative	O
contacts	O
,	O
and	O
50	O
non	O
-	O
contacts	O
in	O
Vietnam	O
,	O
failed	O
to	O
obtain	O
any	O
evidence	O
that	O
the	O
ACE2	O
gene	O
polymorphisms	O
are	O
involved	O
in	O
the	O
disease	O
process	O
in	O
the	O
population	O
.	O

To	O
prevent	O
further	O
antibody	B-FUNC
-	O
mediated	O
cases	O
,	O
the	O
evaluation	O
of	O
TRALI	O
should	O
include	O
leucocyte	O
antibody	B-FUNC
testing	O
of	O
implicated	O
donors	O
.	O

In	O
this	O
study	O
we	O
evaluated	O
the	O
manufacturing	O
process	O
of	O
an	O
immunoglobulin	B-FUNC
preparation	O
(	O
OCTAGAM	O
,	O
manufactured	O
by	O
Octapharma	O
Pharmazeutika	O
Produktionsges	O
.	O
m	O
.	O
b	O
.	O

Positive	O
SARS	O
-	O
Co	O
virus	O
IgG	O
antibody	B-FUNC
results	O
were	O
seen	O
in	O
208	O
of	O
258	O
patients	O
,	O
with	O
21	O
.	O
3	O
%	O
(	O
55	O
of	O
258	O
patients	O
)	O
still	O
having	O
a	O
pulmonary	O
diffusion	O
abnormality	O
(	O
D	O
(	O
LCO	O
)	O
<	O
80	O
%	O
of	O
predicted	O
).	O

By	O
comparing	O
the	O
155	O
survivors	O
with	O
positive	O
SARS	O
-	O
CoV	O
IgG	O
antibody	B-FUNC
results	O
and	O
D	O
(	O
LCO	O
)	O
>	O
or	O
=	O
80	O
%	O
predicted	O
with	O
the	O
50	O
patients	O
with	O
negative	O
SARS	O
-	O
CoV	O
IgG	O
results	O
,	O
we	O
found	O
that	O
53	O
patients	O
with	O
positive	O
SARS	O
-	O
CoV	O
IgG	O
results	O
and	O
a	O
lung	O
diffusion	O
abnormality	O
had	O
endured	O
a	O
much	O
longer	O
course	O
of	O
fever	O
and	O
received	O
larger	O
doses	O
of	O
glucocorticoid	O
,	O
as	O
well	O
as	O
higher	O
ratios	O
of	O
oxygen	O
inhalation	O
and	O
noninvasive	O
ventilation	O
treatment	O
.	O

RESULTS	O
:	O
Positive	O
SARS	O
-	O
Co	O
virus	O
IgG	O
antibody	B-FUNC
results	O
were	O
seen	O
in	O
208	O
of	O
258	O
patients	O
,	O
with	O
21	O
.	O
3	O
%	O
(	O
55	O
of	O
258	O
patients	O
)	O
still	O
having	O
a	O
pulmonary	O
diffusion	O
abnormality	O
(	O
D	O
(	O
LCO	O
)	O
<	O
80	O
%	O
of	O
predicted	O
).	O

RESULTS	O
:	O
The	O
recombinant	O
SARS	O
-	O
specific	O
antigen	O
reacted	O
only	O
with	O
SARS	O
positive	O
sera	B-FUNC
but	O
not	O
with	O
normal	O
sera	B-FUNC
.	O

RdRp	B-FUNC
,	O
spike	O
and	O
nucleocapsid	O
DNA	O
fragments	O
were	O
inserted	O
into	O
the	O
plasmid	O
pGL3	O
-	O
Control	O
,	O
obtained	O
plasmids	O
pGL	B-FUNC
-	O
R	O
,	O
pGL	B-FUNC
-	O
S	O
and	O
pGL	B-FUNC
-	O
N	O
can	O
express	O
hybrid	O
mRNAs	O
luciferase	O
-	O
RdRp	B-FUNC
,	O
spike	O
and	O
-	O
nucleocapsid	O
in	O
cells	O
.	O

Firefly	O
luciferase	O
expression	O
of	O
pGL	B-FUNC
-	O
R	O
was	O
reduced	O
to	O
13	O
%	O
by	O
esiRNA	O
-	O
R	O
.	O
Expression	O
of	O
pGLS	O
was	O
reduced	O
to	O
11	O
%	O
by	O
esiRNA	O
-	O
S	O
.	O
Expression	O
of	O
pGL	B-FUNC
-	O
N	O
was	O
reduced	O
to	O
40	O
%	O
by	O
esiRNA	O
-	O
N	O
.	O
Control	O
esiRNAs	O
didn	O
'	O
t	O
affect	O
luciferase	O
expression	O
;	O
Hybrid	O
mRNAs	O
'	O
abundance	O
was	O
dramatically	O
reduced	O
by	O
corresponding	O
esiRNAs	O
.	O

The	O
change	O
in	O
laboratory	O
findings	O
is	O
less	O
than	O
that	O
,	O
which	O
might	O
be	O
attributable	O
to	O
milder	O
virulence	O
of	O
the	O
SARS	O
-	O
CoV	O
.	O
The	O
antibody	B-FUNC
appears	O
earlier	O
in	O
these	O
patients	O
.	O

TITLE	O
:	O
Comprehensive	O
antibody	B-FUNC
epitope	O
mapping	O
of	O
the	O
nucleocapsid	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
:	O
insight	O
into	O
the	O
humoral	O
immunity	O
of	O
SARS	O
.	O

The	O
antigenic	O
structures	O
identified	O
for	O
the	O
SARS	O
-	O
CoV	O
N	O
protein	O
,	O
the	O
epitope	O
-	O
specific	O
mAbs	O
,	O
and	O
the	O
serum	O
antibody	B-FUNC
profile	O
in	O
SARS	O
patients	O
have	O
potential	O
use	O
in	O
the	O
clinical	O
diagnosis	O
and	O
understanding	O
of	O
the	O
protective	O
immunity	O
to	O
SARS	O
-	O
CoV	O
.	O
RESULTS	O
:	O
We	O
identified	O
5	O
conformational	O
and	O
3	O
linear	O
epitopes	O
within	O
the	O
entire	O
N	O
protein	O
;	O
3	O
conformational	O
and	O
3	O
linear	O
epitopes	O
were	O
immunodominant	O
.	O

ABSTRACT	O
:	O
The	O
use	O
of	O
recombinant	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
nucleocapsid	O
protein	O
(	O
N	O
)	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)-	O
based	O
antibody	B-FUNC
and	O
antigen	O
tests	O
for	O
diagnosis	O
of	O
SARS	O
-	O
CoV	O
infections	O
have	O
been	O
widely	O
reported	O
.	O

When	O
only	O
the	O
lung	O
was	O
perfused	O
,	O
endotoxin	O
caused	O
pulmonary	O
hypertension	O
and	O
neutropenia	O
;	O
but	O
oxygenation	O
was	O
maintained	O
;	O
TNF	O
-	O
alpha	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
and	O
8	O
-	O
isoprostane	O
levels	O
were	O
minimally	O
elevated	O
;	O
and	O
there	O
was	O
no	O
lung	O
edema	O
.	O

The	O
difference	O
in	O
chloride	O
sensitivity	O
between	O
ACE2	O
and	O
ACE	O
was	O
investigated	O
,	O
and	O
the	O
absence	O
of	O
a	O
second	O
chloride	O
-	O
binding	B-FUNC
site	O
(	O
CL2	O
)	O
in	O
ACE2	O
confirmed	O
.	O

After	O
several	O
viral	O
passages	O
in	O
the	O
presence	O
of	O
a	O
TRS	B-FUNC
-	O
targeted	O
P	O
-	O
PMO	O
,	O
partially	O
drug	O
-	O
resistant	O
SARS	O
-	O
CoV	O
mutants	O
arose	O
which	O
contained	O
three	O
contiguous	O
base	O
point	O
mutations	O
at	O
the	O
binding	B-FUNC
site	O
of	O
a	O
TRS	B-FUNC
-	O
targeted	O
P	O
-	O
PMO	O
.	O

We	O
showed	O
that	O
cholesterol	O
depletion	O
by	O
methyl	O
beta	O
-	O
cyclodextrin	O
or	O
filipin	O
did	O
not	O
affect	O
virus	O
binding	B-FUNC
but	O
reduced	O
virus	O
entry	O
.	O

Thus	O
,	O
the	O
lipid	O
raft	O
involvement	O
in	O
MHV	O
entry	O
occurs	O
at	O
a	O
step	O
following	O
virus	O
binding	B-FUNC
.	O

ABSTRACT	O
:	O
Using	O
clinical	O
samples	O
from	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
we	O
showed	O
that	O
the	O
sensitivities	O
of	O
a	O
quantitative	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
80	O
%	O
for	O
fecal	O
samples	O
and	O
25	O
%	O
for	O
urine	O
samples	O
)	O
were	O
higher	O
than	O
those	O
of	O
the	O
polyclonal	O
(	O
50	O
%	O
and	O
5	O
%)	O
and	O
monoclonal	O
(	O
35	O
%	O
and	O
8	O
%)	O
antibody	B-FUNC
-	O
based	O
nucleocapsid	O
antigen	O
capture	O
enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
.	O

In	O
18	O
healthy	O
control	O
sera	B-FUNC
,	O
one	O
ANA	O
and	O
one	O
AMA	O
were	O
positive	O
.	O

It	O
is	O
conserved	O
in	O
all	O
known	O
isolates	O
of	O
SARS	O
-	O
CoV	O
and	O
has	O
been	O
verified	O
by	O
in	O
vitro	O
peptide	O
-	O
binding	B-FUNC
studies	O
to	O
be	O
a	O
good	O
to	O
intermediate	O
binder	O
to	O
HLA	O
-	O
A	O
*	O
0301	O
and	O
HLA	O
-	O
A	O
*	O
1101	O
,	O
with	O
IC50	O
values	O
of	O
70	O
and	O
186	O
nM	O
,	O
respectively	O
[	O
Sylvester	O
-	O
Hvid	O
et	O
al	O
.	O
(	O
2004	O
),	O
Tissue	O
Antigens	O
,	O
63	O
,	O
395	O
-	O
400	O
].	O

In	O
terms	O
of	O
the	O
residues	O
lining	O
the	O
peptide	O
-	O
binding	B-FUNC
groove	O
,	O
the	O
HLA	O
-	O
A	O
*	O
1101	O
-	O
SNP362	O
-	O
370	O
complex	O
is	O
very	O
similar	O
to	O
other	O
known	O
structures	O
of	O
HLA	O
-	O
A	O
*	O
1101	O
and	O
HLA	O
-	O
A	O
*	O
6801	O
.	O

We	O
also	O
demonstrated	O
,	O
by	O
passive	O
antibody	B-FUNC
transfer	O
,	O
that	O
the	O
antibody	B-FUNC
response	O
induced	O
by	O
the	O
vaccine	O
was	O
sufficient	O
for	O
controlling	O
SARS	O
-	O
CoV	O
infection	O
.	O

Extraction	O
of	O
total	O
RNA	O
followed	O
by	O
RT	O
-	O
PCR	O
produced	O
cDNA	O
of	O
597	O
base	B-FUNC
pairs	I-FUNC
.	O

Moreover	O
,	O
we	O
provide	O
an	O
evidence	O
that	O
12	O
amino	O
acids	O
domain	O
(	O
194	O
-	O
205	O
)	O
in	O
the	O
M	O
protein	O
is	O
responsible	O
for	O
binding	B-FUNC
to	O
N	O
protein	O
.	O

Synthetic	O
peptides	O
M1	O
-	O
31	O
derived	O
from	O
the	O
N	O
-	O
terminal	O
epitope	O
and	O
M132	O
-	O
161	O
derived	O
from	O
the	O
C	O
-	O
terminal	O
epitope	O
were	O
highly	O
reactive	O
with	O
all	O
of	O
the	O
convalescent	O
-	O
phase	O
sera	B-FUNC
from	O
40	O
SARS	O
patients	O
but	O
not	O
with	O
30	O
control	O
serum	O
samples	O
from	O
healthy	O
blood	O
donors	O
,	O
suggesting	O
their	O
potential	O
application	O
for	O
serologic	O
diagnosis	O
of	O
SARS	O
.	O

We	O
showed	O
that	O
both	O
peptides	O
(	O
M1	O
-	O
31	O
and	O
M132	O
-	O
161	O
)	O
were	O
able	O
to	O
induce	O
high	O
titers	O
of	O
antibody	B-FUNC
responses	O
in	O
the	O
immunized	O
rabbits	O
,	O
highlighting	O
their	O
antigenicity	O
and	O
immunogenicity	O
.	O

In	O
contrast	O
,	O
only	O
4	O
/	O
13	O
laboratories	O
detected	O
most	O
of	O
the	O
anti	O
-	O
SARS	O
antibody	B-FUNC
positive	O
samples	O
without	O
false	O
positive	O
results	O
using	O
enzyme	O
immunoassays	O
(	O
EIA	O
)	O
and	O
/	O
or	O
immunoblot	O
.	O

Antibody	B-FUNC
titers	O
against	O
the	O
reovirus	O
injected	O
by	O
the	O
intravenous	O
route	O
occurred	O
in	O
higher	O
number	O
than	O
those	O
in	O
the	O
nasal	O
cavity	O
.	O

ABSTRACT	O
:	O
The	O
entry	O
of	O
the	O
SARS	O
coronavirus	O
(	O
SCV	O
)	O
into	O
cells	O
is	O
initiated	O
by	O
binding	B-FUNC
of	O
its	O
spike	O
envelope	O
glycoprotein	O
(	O
S	O
)	O
to	O
a	O
receptor	O
,	O
ACE2	O
.	O

The	O
shortest	O
of	O
these	O
fragments	O
still	O
able	O
to	O
bind	B-FUNC
the	O
receptor	O
ACE2	O
did	O
not	O
include	O
residue	O
318	O
(	O
which	O
is	O
a	O
potential	O
glycosylation	O
site	O
),	O
but	O
started	O
at	O
residue	O
319	O
,	O
and	O
has	O
only	O
two	O
potential	O
glycosylation	O
sites	O
(	O
residues	O
330	O
and	O
357	O
).	O

IAH	B-FUNC
is	O
a	O
frequent	O
finding	O
in	O
patients	O
admitted	O
to	O
the	O
ICU	O
because	O
of	O
SAP	O
,	O
and	O
is	O
associated	O
with	O
a	O
high	O
occurrence	O
rate	O
of	O
organ	O
dysfunction	O
.	O

Mortality	O
is	O
high	O
in	O
patients	O
with	O
IAH	B-FUNC
,	O
and	O
because	O
the	O
direct	O
causal	O
relationship	O
between	O
IAH	B-FUNC
and	O
organ	O
dysfunction	O
is	O
not	O
proven	O
in	O
patients	O
with	O
SAP	O
,	O
surgical	O
decompression	O
should	O
not	O
routinely	O
be	O
performed	O
.	O

The	O
results	O
indicated	O
that	O
apart	O
from	O
the	O
two	O
subunits	O
of	O
cellular	O
RNA	O
polymerase	O
complex	O
,	O
BTF3	O
and	O
ATF5	O
,	O
this	O
nsp10	O
protein	O
was	O
also	O
able	O
to	O
interact	O
specifically	O
with	O
the	O
NADH	O
4L	O
subunit	O
and	O
cytochrome	B-FUNC
oxidase	O
II	O
.	O

Further	O
study	O
revealed	O
that	O
the	O
activity	O
of	O
the	O
NADH	O
-	O
cytochrome	B-FUNC
was	O
altered	O
and	O
the	O
inner	O
mitochondrial	O
membrane	O
was	O
depolarized	O
in	O
the	O
transfected	O
human	O
embryo	O
lung	O
fibroblast	O
by	O
the	O
nsp10	O
protein	O
gene	O
.	O

Here	O
,	O
we	O
describe	O
evidence	O
that	O
stem	O
-	O
loop	O
IV	O
,	O
a	O
bulged	O
stem	O
-	O
loop	O
mapping	O
at	O
nt	O
186	O
through	O
215	O
,	O
(	O
i	O
)	O
is	O
phylogenetically	O
conserved	O
among	O
group	O
2	O
coronaviruses	O
and	O
may	O
have	O
a	O
homolog	O
in	O
groups	O
1	O
and	O
3	O
,	O
(	O
ii	O
)	O
exists	O
as	O
a	O
higher	O
-	O
order	O
structure	O
on	O
the	O
basis	O
of	O
enzyme	O
probing	O
,	O
(	O
iii	O
)	O
is	O
required	O
as	O
a	O
higher	O
-	O
order	O
element	O
for	O
replication	O
of	O
a	O
BCoV	O
defective	O
interfering	O
(	O
DI	O
)	O
RNA	O
in	O
the	O
positive	O
but	O
not	O
the	O
negative	O
strand	O
,	O
and	O
(	O
iv	O
)	O
as	O
a	O
higher	O
-	O
order	O
structure	O
in	O
wild	O
-	O
type	O
(	O
wt	O
)	O
and	O
mutant	O
molecules	O
that	O
replicate	O
,	O
specifically	O
binds	B-FUNC
six	O
cellular	O
proteins	O
in	O
the	O
molecular	O
mass	O
range	O
of	O
25	O
to	O
58	O
kDa	O
as	O
determined	O
by	O
electrophoretic	O
mobility	O
shift	O
and	O
UV	O
cross	O
-	O
linking	O
assays	O
;	O
binding	B-FUNC
to	O
viral	O
proteins	O
was	O
not	O
detected	O
.	O

TITLE	O
:	O
Association	O
between	O
mannose	O
-	O
binding	B-FUNC
lectin	O
gene	O
polymorphisms	O
and	O
susceptibility	O
to	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
infection	O
.	O

The	O
human	O
synthetic	O
single	O
-	O
chain	O
fragment	O
variable	O
(	O
scFv	O
)	O
ETH	O
-	O
2	O
phage	O
antibody	B-FUNC
library	O
was	O
used	O
for	O
the	O
isolation	O
of	O
scFvs	O
against	O
the	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
of	O
SARS	O
-	O
CoV	O
using	O
a	O
bio	O
panning	O
-	O
based	O
strategy	O
.	O

Cross	O
-	O
reactivity	O
was	O
found	O
when	O
testing	O
for	O
antibody	B-FUNC
against	O
human	O
T	O
-	O
cell	O
lymphotropic	O
virus	O
(	O
HTLV	O
)	O
in	O
one	O
patient	O
with	O
SARS	O
.	O

Soluble	O
vascular	O
cell	O
adhesion	O
molecule	O
-	O
1	O
(	O
sVCAM	O
-	O
1	O
)	O
and	O
soluble	O
Fas	O
ligand	B-FUNC
(	O
sFasL	O
)	O
in	O
plasma	O
were	O
measured	O
by	O
ELISA	O
,	O
and	O
intracellular	O
activated	O
caspase	O
-	O
3	O
fragment	O
in	O
different	O
leukocytes	O
was	O
determined	O
by	O
flow	O
cytometry	O
.	O

In	O
addition	O
,	O
the	O
expression	O
of	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
within	O
the	O
inflammatory	O
lesions	O
was	O
examined	O
by	O
RT	O
-	O
PCR	O
.	O

Bacterially	O
expressed	O
forms	O
of	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
)	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
X	O
domains	O
were	O
shown	O
to	O
dephosphorylate	O
Appr	O
-	O
1	O
"""-"	O
p	O
,	O
a	O
side	O
product	O
of	O
cellular	O
tRNA	B-FUNC
splicing	O
,	O
to	O
ADP	O
-	O
ribose	O
in	O
a	O
highly	O
specific	O
manner	O
.	O

Using	O
the	O
exon	O
splicing	O
enhancers	O
,	O
including	O
a	O
bidirectional	O
splicing	O
enhancer	O
(	O
BSE	O
)	O
or	O
an	O
exon	O
splicing	O
enhancer	O
derived	O
from	O
the	O
EDA	O
alternative	O
exon	O
of	O
the	O
fibronectin	O
gene	O
(	O
EDA	O
ESE	O
),	O
were	O
also	O
found	O
to	O
increase	O
STR2	O
protein	O
expression	O
in	O
CHO	B-FUNC
/	O
dhFr	B-FUNC
-	O
cells	O
by	O
1	O
.	O
7	O
-	O
and	O
2	O
.	O
6	O
-	O
fold	O
.	O

Screening	O
for	O
viral	O
contamination	O
is	O
done	O
by	O
the	O
mouse	O
antibody	B-FUNC
production	O
(	O
MAP	O
)	O
test	O
,	O
by	O
cell	O
culture	O
,	O
or	O
alternatively	O
by	O
direct	O
detection	O
of	O
the	O
viral	O
agents	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
).	O

There	O
was	O
a	O
significant	O
relationship	O
between	O
antibody	B-FUNC
titers	O
against	O
TGEV	O
,	O
FCoV	O
1	O
,	O
and	O
FCoV	O
2	O
and	O
TGEV	O
antigen	O
detected	O
the	O
highest	O
proportion	O
of	O
seropositive	O
cats	O
.	O

A	O
mutant	O
in	O
the	O
N	O
terminus	O
of	O
Nsp15	O
was	O
impaired	O
in	O
hexamer	O
formation	O
and	O
had	O
low	O
endoribonuclease	B-FUNC
activity	I-FUNC
,	O
suggesting	O
that	O
oligomerization	O
is	O
required	O
for	O
endoribonuclease	B-FUNC
activity	I-FUNC
.	O

Indirect	O
Immunofluorescence	O
assay	O
indicated	O
that	O
they	O
could	O
specifically	O
bind	B-FUNC
to	O
protein	O
X4	O
expressed	O
in	O
SARS	O
-	O
CoV	O
infected	O
Vero	O
E6	O
cells	O
.	O

The	O
results	O
of	O
ELISA	O
showed	O
that	O
among	O
114	O
sera	B-FUNC
from	O
healthy	O
controls	O
,	O
4	O
(	O
3	O
.	O
5	O
%)	O
were	O
positive	O
of	O
SARS	O
-	O
CoV	O
-	O
IgG	O
antibody	B-FUNC
and	O
114	O
(	O
100	O
%)	O
were	O
all	O
negative	O
of	O
SARS	O
-	O
CoV	O
-	O
IgM	O
antibody	B-FUNC
;	O
the	O
specificity	O
of	O
SARS	O
-	O
CoV	O
-	O
IgG	O
antibody	B-FUNC
for	O
SARS	O
patients	O
was	O
96	O
.	O
5	O
%,	O
but	O
the	O
specificity	O
of	O
both	O
SARS	O
-	O
CoV	O
-	O
IgG	O
and	O
-	O
IgM	O
antibodies	O
for	O
SARS	O
patients	O
was	O
100	O
%.	O

All	O
sera	B-FUNC
for	O
negative	O
or	O
positive	O
ELISA	O
results	O
were	O
also	O
negative	O
or	O
positive	O
results	O
using	O
ELISA	O
with	O
Vero	O
E6	O
cells	O
lysates	O
.	O

No	O
induction	O
of	O
cytokine	O
genes	O
(	O
alpha	O
interferon	O
[	O
IFN	O
-	O
alpha	O
],	O
IFN	O
-	O
beta	O
,	O
interleukin	O
-	O
28A	O
/	O
B	O
[	O
IL	O
-	O
28A	O
/	O
B	O
],	O
IL	O
-	O
29	O
,	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
,	O
CCL5	O
,	O
or	O
CXCL10	O
)	O
or	O
IFN	O
-	O
alpha	O
/	O
beta	O
-	O
induced	O
MxA	O
gene	O
was	O
seen	O
in	O
SCV	O
-	O
infected	O
A549	O
cells	O
,	O
macrophages	O
,	O
or	O
DCs	O
.	O

With	O
an	O
internal	O
diameter	O
of	O
approximately	O
30	O
angstroms	O
,	O
the	O
central	O
channel	O
has	O
dimensions	O
and	O
positive	O
electrostatic	O
properties	O
favorable	O
for	O
nucleic	B-FUNC
acid	I-FUNC
binding	I-FUNC
,	O
implying	O
that	O
its	O
role	O
is	O
to	O
confer	O
processivity	O
on	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
.	O

ABSTRACT	O
:	O
The	O
mannose	B-FUNC
binding	I-FUNC
proteins	O
on	O
the	O
surface	O
of	O
the	O
dendritic	O
cells	O
are	O
responsible	O
for	O
capture	O
of	O
pathogens	O
in	O
the	O
early	O
stages	O
of	O
immune	O
response	O
.	O

Docking	O
studies	O
suggested	O
a	O
binding	B-FUNC
mode	O
in	O
which	O
the	O
phenyl	O
ring	O
acts	O
as	O
a	O
spacer	O
bridging	O
the	O
inhibitor	O
'	O
s	O
activated	O
double	O
bond	O
and	O
its	O
hydrophobic	O
tert	O
-	O
butyl	O
moiety	O
.	O

RESULTS	O
:	O
Recombinant	O
N	O
protein	O
reacted	O
strongly	O
and	O
specifically	O
with	O
the	O
sera	B-FUNC
from	O
immunized	O
mice	O
and	O
SARS	O
patients	O
.	O

We	O
previously	O
reported	O
that	O
concanavalin	O
A	O
-	O
immobilized	O
polystyrene	O
nanospheres	O
(	O
Con	O
A	O
-	O
NS	O
)	O
could	O
efficiently	O
capture	O
HIV	O
-	O
1	O
particles	O
and	O
intranasal	O
immunization	O
with	O
inactivated	O
HIV	O
-	O
1	O
-	O
capturing	O
nanospheres	O
(	O
HIV	O
-	O
NS	O
)	O
induced	O
vaginal	O
anti	O
-	O
HIV	O
-	O
1	O
IgA	O
antibody	B-FUNC
responses	O
in	O
mice	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
mucosal	O
antibody	B-FUNC
response	O
in	O
mice	O
after	O
the	O
intravaginal	O
or	O
intranasal	O
immunization	O
in	O
detail	O
with	O
using	O
different	O
sized	O
(	O
360	O
,	O
660	O
,	O
940	O
and	O
1230	O
nm	O
)	O
HIV	O
-	O
NS	O
.	O

Commercially	O
available	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
tests	O
for	O
SARS	O
have	O
recently	O
appeared	O
;	O
however	O
,	O
meaningful	O
evaluations	O
of	O
these	O
assays	O
have	O
not	O
yet	O
been	O
performed	O
and	O
their	O
true	O
performance	O
has	O
not	O
been	O
determined	O
.	O

ELISA	O
,	O
Western	O
-	O
blotting	O
and	O
neutralization	O
assay	O
detected	O
specific	O
antibody	B-FUNC
against	O
SARS	O
coronavirus	O
.	O

AGP	O
was	O
purified	O
by	O
perchloric	O
acid	O
precipitation	O
and	O
ion	O
-	O
exchange	O
chromatography	O
from	O
a	O
pool	O
of	O
peritoneal	O
fluid	O
obtained	O
from	O
cats	O
with	O
FIP	O
,	O
as	O
determined	O
by	O
a	O
panel	O
of	O
laboratory	O
tests	O
,	O
including	O
serum	O
AGP	O
concentration	O
,	O
albumin	O
:	O
globulin	O
ratio	O
,	O
and	O
total	O
protein	O
concentration	O
,	O
anti	O
-	O
coronavirus	O
antibody	B-FUNC
titers	O
,	O
and	O
effusion	O
analysis	O
.	O

The	O
ELISA	O
data	O
showed	O
that	O
GST	O
/	O
RBD	O
antigen	O
had	O
positive	O
reaction	O
with	O
anti	O
-	O
RBD	O
mouse	O
monoclonal	O
antibody	B-FUNC
1A5	O
.	O

ABSTRACT	O
:	O
The	O
serological	O
response	O
profile	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
CoV	O
)	O
infection	O
was	O
defined	O
by	O
neutralization	O
tests	O
and	O
subclass	O
-	O
specific	O
immunofluorescent	O
(	O
IF	O
)	O
tests	O
using	O
serial	O
sera	B-FUNC
from	O
20	O
patients	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
43	O
-	O
year	O
-	O
old	O
man	O
with	O
ITP	O
refractory	O
to	O
steroids	O
and	O
intravenous	O
immunoglobulin	B-FUNC
who	O
developed	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
after	O
a	O
single	O
infusion	O
of	O
rituximab	O
.	O

TITLE	O
:	O
Antibody	B-FUNC
responses	O
against	O
SARS	O
coronavirus	O
are	O
correlated	O
with	O
disease	O
outcome	O
of	O
infected	O
individuals	O
.	O

This	O
position	O
is	O
predicted	O
to	O
map	O
in	O
the	O
N	O
-	O
terminal	O
polyprotein	O
papain	O
-	O
like	O
proteinase	B-FUNC
(	O
PLP	O
-	O
1	O
)	O
cleavage	O
site	O
at	O
the	O
p9	O
/	O
p87	O
junction	O
.	O

The	O
spike	O
glycoprotein	O
,	O
S	O
,	O
which	O
mediates	O
receptor	B-FUNC
binding	I-FUNC
and	O
membrane	O
fusion	O
,	O
plays	O
a	O
critical	O
role	O
in	O
MHV	O
pathogenesis	O
.	O

Our	O
findings	O
suggest	O
that	O
the	O
properties	O
of	O
S	O
receptor	O
utilization	O
and	O
/	O
or	O
fusogenicity	O
mainly	O
determine	O
organ	O
and	O
host	O
cell	O
tropism	O
but	O
that	O
HE	O
enhances	O
the	O
efficiency	O
of	O
infection	O
and	O
promotes	O
viral	O
dissemination	O
,	O
at	O
least	O
in	O
some	O
tissues	O
,	O
presumably	O
by	O
serving	O
as	O
a	O
second	O
receptor	O
-	O
binding	B-FUNC
protein	O
.	O

SARS	O
CoV	O
-	O
PLpro	O
hydrolyzed	O
both	O
diubiquitin	O
and	O
ubiquitin	B-FUNC
-	O
7	O
-	O
amino	O
-	O
4	O
-	O
methylcoumarin	O
(	O
AMC	O
)	O
substrates	O
,	O
and	O
hydrolysis	O
of	O
ubiquitin	B-FUNC
-	O
AMC	O
is	O
approximately	O
180	O
-	O
fold	O
more	O
efficient	O
than	O
hydrolysis	O
of	O
a	O
peptide	O
substrate	O
that	O
mimics	O
the	O
PLpro	O
replicase	O
recognition	O
sequence	O
.	O

TITLE	O
:	O
The	O
papain	O
-	O
like	O
protease	O
from	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
is	O
a	O
deubiquitinating	B-FUNC
enzyme	I-FUNC
.	O

These	O
results	O
clearly	O
establish	O
that	O
SARS	O
-	O
CoV	O
PLpro	O
is	O
a	O
deubiquitinating	B-FUNC
enzyme	I-FUNC
,	O
thereby	O
confirming	O
our	O
earlier	O
prediction	O
.	O

Significant	O
features	O
of	O
this	O
study	O
that	O
unique	O
to	O
the	O
contemporary	O
literature	O
are	O
i	O
)	O
the	O
over	O
-	O
representation	O
of	O
certain	O
breeds	O
(	O
Burmese	O
,	O
Australian	O
Mist	O
,	O
British	O
Shorthaired	O
,	O
and	O
Cornish	O
Rex	B-FUNC
)	O
and	O
the	O
under	O
-	O
representation	O
of	O
other	O
breeds	O
(	O
Domestic	O
Shorthaired	O
,	O
Persian	O
);	O
ii	O
)	O
the	O
overrepresentation	O
of	O
males	O
;	O
iii	O
)	O
the	O
tendency	O
for	O
effusive	O
disease	O
in	O
Australian	O
Mist	O
cats	O
and	O
non	O
-	O
effusive	O
disease	O
in	O
Burmese	O
;	O
iv	O
)	O
the	O
even	O
age	O
distribution	O
of	O
disease	O
seen	O
in	O
cats	O
older	O
than	O
2	O
years	O
-	O
of	O
-	O
age	O
;	O
and	O
v	O
)	O
the	O
presence	O
of	O
fulminant	O
immune	O
-	O
mediated	O
haemolytic	O
anaemia	O
in	O
two	O
cats	O
in	O
this	O
study	O
.	O

Significant	O
features	O
of	O
this	O
study	O
that	O
unique	O
to	O
the	O
contemporary	O
literature	O
are	O
i	O
)	O
the	O
over	O
-	O
representation	O
of	O
certain	O
breeds	O
(	O
Burmese	O
,	O
Australian	O
Mist	O
,	O
British	O
Shorthaired	O
,	O
and	O
Cornish	O
Rex	B-FUNC
)	O
and	O
the	O
under	O
-	O
representation	O
of	O
other	O
breeds	O
(	O
Domestic	O
Shorthaired	O
,	O
Persian	O
);	O
ii	O
)	O
the	O
overrepresentation	O
of	O
males	O
;	O
iii	O
)	O
the	O
tendency	O
for	O
effusive	O
disease	O
in	O
Australian	O
Mist	O
cats	O
and	O
non	O
-	O
effusive	O
disease	O
in	O
Burmese	O
;	O
iv	O
)	O
the	O
even	O
age	O
distribution	O
of	O
disease	O
seen	O
in	O
cats	O
older	O
than	O
2	O
years	O
-	O
of	O
-	O
age	O
;	O
and	O
v	O
)	O
the	O
presence	O
of	O
fulminant	O
immune	O
-	O
mediated	O
haemolytic	O
anaemia	O
in	O
two	O
cats	O
in	O
this	O
study	O
.	O

ABSTRACT	O
:	O
To	O
develop	O
a	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
to	O
detect	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
from	O
commercially	O
-	O
raised	O
poultry	O
in	O
New	O
Zealand	O
and	O
compare	O
results	O
with	O
those	O
from	O
virus	O
isolation	O
.	O

TITLE	O
:	O
Solution	O
structure	O
of	O
the	O
X4	O
protein	O
coded	O
by	O
the	O
SARS	O
related	O
coronavirus	O
reveals	O
an	O
immunoglobulin	B-FUNC
like	O
fold	O
and	O
suggests	O
a	O
binding	B-FUNC
activity	O
to	O
integrin	O
I	O
domains	O
.	O

Peptide	O
scanning	O
suggested	O
the	O
region	O
spanning	O
residues	O
660	O
-	O
683	O
might	O
act	O
as	O
a	O
receptor	O
-	O
binding	B-FUNC
domain	O
.	O

The	O
serum	O
IgM	O
antibody	B-FUNC
of	O
most	O
patients	O
became	O
undetectable	O
within	O
6	O
months	O
after	O
the	O
onset	O
of	O
SARS	O
.	O

In	O
an	O
effort	O
to	O
develop	O
a	O
novel	O
microfluidic	O
based	O
drug	O
screening	O
platform	O
,	O
systematic	O
studies	O
on	O
the	O
interaction	O
between	O
granulocyte	B-FUNC
colony	I-FUNC
-	I-FUNC
stimulating	I-FUNC
factor	I-FUNC
(	O
G	O
-	O
CSF	O
)	O
and	O
sulfated	O
oligosaccharides	O
were	O
carried	O
out	O
at	O
both	O
molecular	O
and	O
cellular	O
levels	O
.	O

Concentrations	O
of	O
plasma	O
glucose	O
,	O
urea	O
N	O
,	O
and	O
insulin	B-FUNC
-	I-FUNC
like	I-FUNC
growth	I-FUNC
factor	I-FUNC
-	O
I	O
were	O
increased	O
when	O
calves	O
were	O
fed	O
variable	O
amount	O
of	O
milk	O
replacer	O
.	O

Plasma	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
was	O
highest	O
in	O
calves	O
with	O
the	O
highest	O
plasma	O
IgG	O
concentrations	O
on	O
the	O
day	O
of	O
arrival	O
and	O
might	O
be	O
related	O
to	O
the	O
calf	O
'	O
s	O
ability	O
to	O
identify	O
pathogens	O
in	O
the	O
environment	O
.	O

The	O
remaining	O
PL1pros	O
from	O
some	O
of	O
the	O
coronaviruses	O
form	O
the	O
other	O
group	O
,	O
featuring	O
a	O
more	O
open	O
papain	O
-	O
like	O
binding	B-FUNC
site	O
,	O
and	O
is	O
referred	O
to	O
as	O
the	O
O	O
-	O
group	O
.	O

Serum	O
,	O
peripheral	O
-	O
blood	O
mononuclear	O
cells	O
,	O
nasopharyngeal	O
aspirates	O
,	O
throat	O
swabs	O
,	O
and	O
rectal	O
swabs	O
from	O
these	O
patients	O
were	O
assayed	O
for	O
HCoV	O
-	O
NL63	O
by	O
real	O
-	O
time	O
reverse	O
-	O
transcriptase	B-FUNC
(	O
RT	B-FUNC
)	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
),	O
and	O
the	O
throat	O
swabs	O
,	O
nasopharyngeal	O
aspirates	O
,	O
and	O
rectal	O
swabs	O
were	O
also	O
assayed	O
for	O
HCoV	O
-	O
NH	O
by	O
RT	B-FUNC
-	O
PCR	O
.	O

Following	O
a	O
review	O
of	O
the	O
function	O
of	O
immunoglobulin	B-FUNC
A	O
in	O
defence	O
against	O
infection	O
,	O
a	O
group	O
of	O
articles	O
considers	O
vaccination	O
and	O
gene	O
therapy	O
approaches	O
,	O
the	O
latter	O
involving	O
consideration	O
of	O
both	O
viral	O
and	O
bacterial	O
strategies	O
.	O

Binding	B-FUNC
sites	O
of	O
these	O
MAbs	O
were	O
mapped	O
to	O
four	O
linear	O
epitopes	O
.	O

In	O
contrast	O
,	O
N	O
-	O
GST	O
elicited	O
strong	O
T	O
cell	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
but	O
minimal	O
IFN	O
-	O
gamma	O
responses	O
and	O
a	O
much	O
greater	O
antibody	B-FUNC
response	O
.	O

The	O
purified	O
inactivated	O
SARS	O
vaccine	O
could	O
induce	O
high	O
levels	O
of	O
neutralizing	O
antibody	B-FUNC
,	O
and	O
protect	O
the	O
monkeys	O
from	O
the	O
challenge	O
of	O
SARS	O
-	O
CoV	O
.	O
The	O
SARS	O
vaccine	O
prepared	O
in	O
the	O
study	O
appeared	O
to	O
be	O
safe	O
in	O
monkeys	O
.	O

There	O
were	O
no	O
biologically	O
significant	O
differences	O
between	O
control	O
and	O
vector	O
groups	O
for	O
complete	O
blood	O
count	O
,	O
serum	O
chemistry	O
,	O
and	O
neutralizing	O
anti	O
-	O
AAV2	O
antibody	B-FUNC
levels	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
GeneChip	O
-	O
based	O
genome	O
characterization	O
is	O
fast	B-FUNC
and	O
reproducible	O
.	O

Cytokines	O
and	O
chemokines	O
that	O
best	O
predicted	O
the	O
combination	O
of	O
acid	O
and	O
small	O
gastric	O
particles	O
were	O
cytokine	O
-	O
induced	O
neutrophil	O
chemoattractant	O
1	O
(	O
6	O
h	O
)	O
and	O
MCP	B-FUNC
-	O
1	O
(	O
24	O
h	O
)	O
in	O
rats	O
,	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
/	O
macrophage	O
inflammatory	O
protein	O
2	O
(	O
5	O
h	O
)	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
/	O
MCP	B-FUNC
-	O
1	O
(	O
24	O
h	O
)	O
in	O
wild	O
-	O
type	O
mice	O
,	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
/	O
macrophage	O
inflammatory	O
protein	O
2	O
(	O
5	O
h	O
)	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
/	O
keratinocyte	O
-	O
derived	O
cytokine	O
(	O
24	O
h	O
)	O
in	O
MCP	B-FUNC
-	O
1	O
(-/-)	O
mice	O
.	O

The	O
interleukin	O
(	O
IL	O
)-	O
6	O
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
and	O
transforming	O
growth	O
factor	O
-	O
beta1	O
(	O
TGF	O
-	O
beta1	O
)	O
of	O
serum	O
and	O
BALF	O
were	O
measured	O
by	O
ELISA	O
.	O

TITLE	O
:	O
[	O
Receptor	O
-	O
binding	B-FUNC
ability	O
of	O
fragments	O
260	O
-	O
600	O
and	O
397	O
-	O
796	O
of	O
SARS	O
-	O
associated	O
coronavirus	O
spike	O
protein	O
].	O

The	O
appropriate	O
expression	O
of	O
the	O
proteins	O
was	O
confirmed	O
by	O
Western	O
blotting	O
using	O
both	O
SARS	O
patients	O
'	O
sera	B-FUNC
and	O
anti	O
-	O
6	O
x	O
histidine	O
antibody	B-FUNC
.	O

Both	O
S260	O
-	O
600	O
and	O
S397	O
-	O
796	O
exhibited	O
different	O
receptor	B-FUNC
binding	I-FUNC
activity	O
.	O

In	O
contrast	O
,	O
the	O
S260	O
-	O
600	O
protein	O
did	O
not	O
bind	B-FUNC
NIH3T3	O
cells	O
.	O

Immunoglobulin	B-FUNC
kappa	O
light	O
chain	O
(	O
m	O
/	O
z	O
24	O
505	O
)	O
positively	O
correlated	O
with	O
viral	O
load	O
.	O

TITLE	O
:	O
The	O
nucleocapsid	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
inhibits	O
the	O
activity	O
of	O
cyclin	B-FUNC
-	O
cyclin	B-FUNC
-	O
dependent	O
kinase	O
complex	O
and	O
blocks	O
S	O
phase	O
progression	O
in	O
mammalian	O
cells	O
.	O

Whereas	O
N	O
protein	O
could	O
directly	O
bind	B-FUNC
to	O
cyclin	B-FUNC
D	O
and	O
inhibit	O
the	O
activity	O
of	O
CDK4	O
-	O
cyclin	B-FUNC
D	O
complex	O
;	O
inhibition	O
of	O
CDK2	O
activity	O
appeared	O
to	O
be	O
achieved	O
in	O
two	O
different	O
ways	O
:	O
indirectly	O
by	O
down	O
-	O
regulation	O
of	O
protein	O
levels	O
of	O
CDK2	O
,	O
cyclin	B-FUNC
E	O
,	O
and	O
cyclin	B-FUNC
A	O
and	O
by	O
direct	O
binding	B-FUNC
of	O
N	O
protein	O
to	O
CDK2	O
-	O
cyclin	B-FUNC
complex	O
.	O

Alanine	O
aminotransferase	O
(	O
ALT	B-FUNC
)	O
and	O
total	O
bilirubin	O
(	O
TBil	O
)	O
in	O
serum	O
were	O
measured	O
to	O
assess	O
the	O
severity	O
of	O
liver	O
injury	O
.	O

In	O
association	O
with	O
changes	O
in	O
liver	O
histology	O
,	O
marked	O
elevations	O
in	O
serum	O
ALT	B-FUNC
and	O
TBil	O
were	O
observed	O
.	O

Using	O
a	O
newly	O
established	O
human	O
monoclonal	O
anti	O
-	O
M	O
antibody	B-FUNC
we	O
detected	O
glycosylated	O
and	O
nonglycosylated	O
membrane	O
-	O
associated	O
M	O
in	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
infected	O
cells	O
and	O
in	O
purified	O
virions	O
.	O

Ranked	O
by	O
the	O
luciferase	B-FUNC
activity	I-FUNC
from	O
the	O
highest	O
to	O
the	O
lowest	O
,	O
the	O
order	O
is	O
A549	O
,	O
HepG2	O
,	O
ECV304	O
,	O
HeLa	O
and	O
Vero	O
E6	O
.	O

ABSTRACT	O
:	O
Interferon	O
(	O
IFN	O
)-	O
alphas	O
bind	B-FUNC
to	O
and	O
activate	O
their	O
cognate	O
cell	O
surface	O
receptor	O
to	O
invoke	O
an	O
antiviral	O
response	O
in	O
target	O
cells	O
.	O

ABSTRACT	O
:	O
In	O
a	O
cohort	O
study	O
of	O
56	O
convalescent	O
patients	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
titers	O
of	O
immunoglobulin	B-FUNC
G	O
(	O
IgG	O
)	O
antibodies	O
and	O
neutralizing	O
antibodies	O
(	O
NAbs	O
)	O
against	O
SARS	O
-	O
associated	O
coronavirus	O
were	O
assessed	O
at	O
regular	O
intervals	O
(	O
at	O
1	O
,	O
4	O
,	O
7	O
,	O
10	O
,	O
16	O
,	O
and	O
24	O
months	O
after	O
the	O
onset	O
of	O
disease	O
)	O
by	O
use	O
of	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
and	O
neutralization	O
assay	O
.	O

IgG	O
antibody	B-FUNC
and	O
NAb	O
titers	O
were	O
highly	O
correlated	O
,	O
peaking	O
at	O
month	O
4	O
after	O
the	O
onset	O
of	O
disease	O
and	O
decreasing	O
thereafter	O
.	O

SARS	O
-	O
CoV	O
and	O
RSV	O
induced	O
high	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
RANTES	O
compared	O
with	O
FluAV	O
and	O
hPIV2	O
.	O

Neutralizing	O
antibody	B-FUNC
titers	O
correlated	O
closely	O
with	O
standard	O
ELISA	O
reactivity	O
against	O
the	O
S	O
glycoprotein	O
.	O

TITLE	O
:	O
The	O
relationship	O
between	O
the	O
feline	O
coronavirus	O
antibody	B-FUNC
titre	O
and	O
the	O
age	O
,	O
breed	O
,	O
gender	O
and	O
health	O
status	O
of	O
Australian	O
cats	O
.	O

RESULTS	O
:	O
Results	O
from	O
637	O
Coronase	O
and	O
191	O
7B	O
FIP	O
antibody	B-FUNC
tests	O
were	O
recorded	O
.	O

There	O
was	O
no	O
statistical	O
relationship	O
between	O
the	O
Coronase	O
or	O
7B	O
FIP	O
antibody	B-FUNC
titres	O
and	O
age	O
,	O
gender	O
or	O
overall	O
health	O
status	O
,	O
even	O
when	O
considering	O
only	O
those	O
cats	O
in	O
which	O
clinical	O
signs	O
suggestive	O
of	O
FIP	O
were	O
present	O
.	O

TITLE	O
:	O
Mouse	O
hepatitis	O
virus	O
pathogenesis	O
in	O
the	O
central	O
nervous	O
system	O
is	O
independent	O
of	O
IL	B-FUNC
-	I-FUNC
15	I-FUNC
and	O
natural	O
killer	O
cells	O
.	O

The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
this	O
virus	O
is	O
a	O
type	O
I	O
surface	O
glycoprotein	O
that	O
mediates	O
binding	B-FUNC
of	O
the	O
virus	O
to	O
the	O
host	O
receptor	O
and	O
the	O
subsequent	O
fusion	O
between	O
the	O
viral	O
and	O
host	O
membranes	O
.	O

After	O
four	O
rounds	O
of	O
the	O
panning	O
,	O
a	O
number	O
of	O
SARS	O
-	O
CoV	O
virus	O
-	O
targeted	O
human	O
recombinant	O
Fab	O
antibodies	O
were	O
isolated	O
from	O
the	O
SARS	O
patient	O
antibody	B-FUNC
library	O
.	O

These	O
results	O
suggested	O
that	O
the	O
S	O
and	O
M	O
protein	O
-	O
specific	O
neutralizing	O
antibodies	O
could	O
recognize	O
conformational	O
epitopes	O
which	O
might	O
be	O
involved	O
in	O
the	O
binding	B-FUNC
of	O
virions	O
to	O
cellular	O
receptors	O
and	O
the	O
fusion	O
activity	O
of	O
the	O
virus	O
.	O

A	O
sequence	O
of	O
68	O
residuals	O
was	O
identified	O
as	O
a	O
potential	O
DNA	O
-	O
binding	B-FUNC
domain	O
essential	O
for	O
activating	O
COX	O
-	O
2	O
expression	O
.	O

We	O
propose	O
that	O
SARS	O
-	O
CoV	O
N	O
protein	O
causes	O
inflammation	O
of	O
the	O
lungs	O
by	O
activating	O
COX	O
-	O
2	O
gene	O
expression	O
by	O
binding	B-FUNC
directly	O
to	O
the	O
promoter	O
resulting	O
in	O
inflammation	O
through	O
multiple	O
COX	O
-	O
2	O
signaling	O
cascades	O
.	O

The	O
median	O
Immunocomb	O
scores	O
of	O
DSH	O
,	O
Persian	O
,	O
Siamese	O
and	O
Devon	O
Rex	B-FUNC
cats	O
were	O
significantly	O
lower	O
than	O
that	O
of	O
Burmese	O
,	O
BSH	O
,	O
Abyssinian	O
,	O
Birman	O
,	O
Ragdoll	O
and	O
Russian	O
Blue	O
.	O

ABSTRACT	O
:	O
The	O
Vaccine	O
Research	O
Center	O
has	O
developed	O
a	O
number	O
of	O
vaccine	O
candidates	O
for	O
different	O
diseases	O
/	O
infectious	O
agents	O
(	O
HIV	O
-	O
1	O
,	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
virus	O
,	O
West	O
Nile	O
virus	O
,	O
and	O
Ebola	O
virus	O
,	O
plus	O
a	O
plasmid	O
cytokine	O
adjuvant	O
-	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
/	O
Ig	O
)	O
based	O
on	O
a	O
DNA	O
plasmid	O
vaccine	O
platform	O
.	O

In	O
particular	O
,	O
SARS	O
-	O
CoV	O
did	O
not	O
activate	O
significant	O
transcription	O
of	O
the	O
interferons	O
IFN	O
-	O
alpha	O
,	O
IFN	O
-	O
beta	O
,	O
IFN	O
-	O
lambda1	O
,	O
IFN	O
-	O
lambda2	O
/	O
3	O
,	O
as	O
well	O
as	O
of	O
the	O
interferon	O
-	O
induced	O
antiviral	O
genes	O
ISG56	O
and	O
MxA	O
,	O
the	O
chemokine	O
RANTES	O
and	O
the	O
interleukine	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
.	O

However	O
,	O
binding	B-FUNC
to	O
sialic	O
acids	O
is	O
required	O
for	O
the	O
enteropathogenicity	O
of	O
TGEV	O
.	O

The	O
expansion	O
of	O
the	O
V	O
gamma	O
9V	O
delta	O
2	O
T	O
cell	O
population	O
was	O
associated	O
with	O
higher	O
anti	O
-	O
SARS	O
-	O
CoV	O
immunoglobulin	B-FUNC
G	O
titers	O
.	O

This	O
was	O
confirmed	O
using	O
a	O
pan	O
-	O
coronavirus	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
that	O
amplified	O
part	O
of	O
gene	O
1	O
that	O
encodes	O
the	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
.	O

The	O
antibody	B-FUNC
-	O
bound	O
RBD	O
structure	O
is	O
completely	O
defined	O
,	O
revealing	O
two	O
previously	O
unresolved	O
segments	O
(	O
residues	O
376	O
-	O
381	O
and	O
503	O
-	O
512	O
)	O
and	O
a	O
new	O
disulfide	O
bond	O
(	O
between	O
residues	O
378	O
and	O
511	O
).	O

The	O
hydrophobic	O
pocket	O
in	O
the	O
P2	O
position	O
at	O
the	O
protease	O
cleavage	O
site	O
is	O
crucial	O
to	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	O
)-	O
specific	O
binding	B-FUNC
,	O
which	O
is	O
limited	O
to	O
substitution	O
by	O
hydrophobic	O
residue	O
.	O

The	O
binding	B-FUNC
interface	O
of	O
SARS	O
-	O
CoV	O
3CL	O
(	O
pro	O
)	O
that	O
is	O
facing	O
the	O
P1	O
'	O
position	O
is	O
suggested	O
to	O
be	O
occupied	O
by	O
acidic	O
amino	O
acids	O
,	O
thus	O
the	O
P1	O
'	O
position	O
is	O
intolerant	O
to	O
acidic	O
residue	O
substitution	O
,	O
owing	O
to	O
electrostatic	O
repulsion	O
.	O

Here	O
,	O
it	O
is	O
discussed	O
that	O
binding	B-FUNC
to	O
sialic	O
acid	O
may	O
be	O
used	O
by	O
IBV	O
for	O
primary	O
attachment	O
to	O
the	O
cell	O
surface	O
;	O
tighter	O
binding	B-FUNC
and	O
subsequent	O
fusion	O
between	O
the	O
viral	O
and	O
the	O
cellular	O
membrane	O
may	O
require	O
interaction	O
with	O
a	O
second	O
receptor	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
the	O
prevalence	O
of	O
pulmonary	O
hypertension	O
associated	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
to	O
asses	O
the	O
value	O
of	O
pulmonary	O
artery	O
trunk	O
diameter	O
(	O
PAT	B-FUNC
)	O
to	O
predict	O
pulmonary	O
hypertension	O
.	O

Torovirus	O
-	O
specific	O
nucleic	O
acid	O
confirmed	O
by	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
was	O
found	O
in	O
12	O
of	O
230	O
calves	O
(	O
5	O
.	O
2	O
%).	O

ABSTRACT	O
:	O
Rapid	O
elucidation	O
of	O
neutralizing	O
antibody	B-FUNC
epitopes	O
on	O
emerging	O
viral	O
pathogens	O
like	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
CoV	O
)	O
or	O
highly	O
pathogenic	O
avian	O
influenza	O
H5N1	O
virus	O
is	O
of	O
great	O
importance	O
for	O
rational	O
design	O
of	O
vaccines	O
against	O
these	O
viruses	O
.	O

This	O
study	O
demonstrates	O
that	O
by	O
using	O
this	O
novel	O
strategy	O
one	O
can	O
rapidly	O
predict	O
and	O
identify	O
a	O
neutralizing	O
antibody	B-FUNC
epitope	O
,	O
even	O
in	O
the	O
absence	O
of	O
the	O
crystal	O
structure	O
of	O
its	O
target	O
protein	O
.	O

TITLE	O
:	O
Cross	O
-	O
neutralization	O
of	O
human	O
and	O
palm	O
civet	O
severe	O
acute	O
respiratory	O
syndrome	O
coronaviruses	O
by	O
antibodies	O
targeting	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
of	O
spike	O
protein	O
.	O

2	O
positive	O
clones	O
that	O
having	O
specific	O
affinity	O
to	O
SARS	O
sera	B-FUNC
were	O
obtained	O
.	O

Extracorporeal	O
lung	O
assist	O
(	O
ECLA	O
)	O
or	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
using	O
capillary	O
membrane	O
oxygenators	O
can	O
provide	O
sufficient	O
gas	O
exchange	O
and	O
lung	O
rest	B-FUNC
.	O

In	O
addition	O
,	O
differential	O
expression	O
of	O
cytokines	O
within	O
these	O
pulmonary	O
tissues	O
were	O
observed	O
,	O
including	O
notable	O
genes	O
involved	O
in	O
the	O
interferon	O
(	O
IFN	O
)	O
pathway	O
,	O
such	O
as	O
Stat1	O
,	O
IFN	O
regulatory	O
factor	O
-	O
1	O
(	O
IRF	O
-	O
1	O
),	O
interleukin	O
-	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
),	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
and	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
,	O
that	O
are	O
often	O
characterized	O
as	O
elevated	O
in	O
ARDS	O
patients	O
.	O

ABSTRACT	O
:	O
The	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
is	O
a	O
structural	O
component	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
can	O
induce	O
antibody	B-FUNC
responses	O
in	O
SARS	O
patients	O
during	O
infection	O
.	O

Apparently	O
,	O
major	O
mechanistic	O
differences	O
must	O
exist	O
between	O
nidoviruses	O
,	O
which	O
raises	O
questions	O
about	O
the	O
functions	O
of	O
the	O
common	O
leader	O
sequence	O
and	O
nidovirus	O
transcriptase	B-FUNC
proteins	O
and	O
the	O
evolution	O
of	O
nidovirus	O
transcription	O
.	O

A	O
similarity	O
search	O
using	O
SARS	O
M	O
(	O
pro	O
)	O
protease	O
subpockets	O
as	O
queries	O
retrieved	O
ligands	O
and	O
ligand	B-FUNC
fragments	O
accommodated	O
in	O
a	O
physicochemical	O
environment	O
similar	O
to	O
that	O
of	O
the	O
query	O
.	O

Furthermore	O
,	O
this	O
information	O
can	O
be	O
used	O
to	O
identify	O
possible	O
cross	O
-	O
reactivities	O
among	O
proteins	O
due	O
to	O
similarities	O
in	O
their	O
binding	B-FUNC
sites	O
.	O

In	O
in	O
vitro	O
viral	O
infectivity	O
assays	O
,	O
no	O
inhibition	O
was	O
observed	O
for	O
either	O
HRN1	O
or	O
HRN2	O
anti	O
-	O
serum	O
,	O
whereas	O
both	O
HRC1	O
and	O
HRC2	O
anti	O
-	O
sera	B-FUNC
could	O
inhibit	O
SARS	O
-	O
CoV	O
infection	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Two	O
of	O
the	O
siRNA	O
expression	O
cassettes	O
for	O
RDRP	B-FUNC
successfully	O
inhibited	O
the	O
expression	O
of	O
the	O
gene	O
,	O
whereas	O
both	O
of	O
the	O
siRNA	O
expression	O
cassettes	O
for	O
envelope	O
E	O
decreased	O
approx	O
90	O
%	O
of	O
the	O
envelope	O
E	O
gene	O
expression	O
.	O

The	O
value	O
of	O
some	O
approved	O
diagnostic	O
kit	B-FUNC
at	O
least	O
in	O
children	O
for	O
SARS	O
etiological	O
diagnosis	O
needs	O
to	O
be	O
analyzed	O
further	O
.	O

The	O
FIP1	O
-	O
like	O
1	O
(	O
FIP1L1	O
)-	O
platelet	B-FUNC
-	I-FUNC
derived	I-FUNC
growth	I-FUNC
factor	I-FUNC
receptor	O
alpha	O
(	O
PDGFRalpha	O
)	O
fusion	O
transcript	O
was	O
found	O
with	O
the	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
analysis	O
.	O

Coinfections	O
with	O
PEDV	O
and	O
porcine	O
GAR	B-FUNC
were	O
identified	O
in	O
16	O
farms	O
(	O
43	O
.	O
2	O
%).	O

PEDV	O
,	O
porcine	O
GAR	B-FUNC
,	O
and	O
TGEV	O
infection	O
were	O
26	O
.	O
3	O
%,	O
13	O
.	O
2	O
%,	O
and	O
2	O
.	O
7	O
%	O
respectively	O
.	O

The	O
results	O
demonstrated	O
that	O
(	O
1	O
)	O
a	O
single	O
dose	O
of	O
RBD	O
-	O
rAAV	O
vaccination	O
could	O
induce	O
sufficient	O
neutralizing	O
antibody	B-FUNC
against	O
SARS	O
-	O
CoV	O
infection	O
;	O
(	O
2	O
)	O
two	O
more	O
repeated	O
doses	O
of	O
the	O
vaccination	O
boosted	O
the	O
neutralizing	O
antibody	B-FUNC
to	O
about	O
5	O
times	O
of	O
the	O
level	O
achieved	O
by	O
a	O
single	O
dose	O
of	O
the	O
immunization	O
and	O
(	O
3	O
)	O
the	O
level	O
of	O
the	O
antibody	B-FUNC
continued	O
to	O
increase	O
for	O
the	O
entire	O
duration	O
of	O
the	O
experiment	O
of	O
5	O
.	O
5	O
months	O
.	O

The	O
positive	O
rate	O
of	O
the	O
poliovirus	O
antibody	B-FUNC
in	O
the	O
serum	O
of	O
SARS	O
patients	O
2	O
years	O
after	O
recovery	O
was	O
significantly	O
different	O
from	O
that	O
of	O
the	O
normal	O
controls	O
,	O
and	O
the	O
positive	O
rate	O
of	O
poliovirus	O
in	O
the	O
fecal	O
specimens	O
was	O
still	O
very	O
high	O
,	O
and	O
more	O
importantly	O
back	O
mutations	O
have	O
occurred	O
in	O
the	O
attenuating	O
mutation	O
sites	O
at	O
nucleotide	O
position	O
which	O
plays	O
an	O
important	O
role	O
in	O
the	O
poliomyelitis	O
.	O

No	O
positive	O
results	O
for	O
antibody	B-FUNC
to	O
SARS	O
-	O
CoV	O
were	O
detected	O
in	O
the	O
25	O
healthy	O
persons	O
.	O

CONCLUSIONS	O
:	O
The	O
positive	O
rate	O
of	O
the	O
poliovirus	O
antibody	B-FUNC
in	O
the	O
serum	O
of	O
SARS	O
patients	O
2	O
years	O
after	O
recovery	O
was	O
significantly	O
different	O
from	O
that	O
of	O
the	O
normal	O
controls	O
,	O
and	O
the	O
positive	O
rate	O
of	O
poliovirus	O
in	O
the	O
fecal	O
specimens	O
was	O
still	O
very	O
high	O
,	O
and	O
more	O
importantly	O
back	O
mutations	O
have	O
occurred	O
in	O
the	O
attenuating	O
mutation	O
sites	O
at	O
nucleotide	O
position	O
which	O
plays	O
an	O
important	O
role	O
in	O
the	O
poliomyelitis	O
.	O

TITLE	O
:	O
Peptides	O
derived	O
from	O
HIV	O
-	O
1	O
,	O
HIV	O
-	O
2	O
,	O
Ebola	O
virus	O
,	O
SARS	O
coronavirus	O
and	O
coronavirus	O
229E	O
exhibit	O
high	O
affinity	O
binding	B-FUNC
to	O
the	O
formyl	O
peptide	O
receptor	O
.	O

ETYIKPWWVWL	O
did	O
not	O
stimulate	O
GTPgammaS	O
binding	B-FUNC
but	O
inhibited	O
the	O
stimulation	O
by	O
formyl	O
-	O
NleLeuPhe	O
.	O

Consistent	O
with	O
these	O
observations	O
,	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
and	O
IFN	O
-	O
gamma	O
downregulated	O
cell	O
surface	O
expression	O
of	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
the	O
SARS	O
-	O
CoV	O
receptor	O
.	O

Totally	O
927	O
bats	O
of	O
9	O
species	O
(	O
Cynopterus	O
sphinx	O
,	O
Rousettus	O
leschenaulti	O
,	O
Miniopterus	O
schreibersi	O
,	O
Hipposideros	O
pratti	O
,	O
Rhinolophusasinicus	O
,	O
Scotophilusakuhlii	O
,	O
Hipposideros	O
Pomona	O
,	O
Rhinolophus	O
affinis	O
,	O
and	O
Rhinolophus	O
pusillus	O
)	O
captured	O
in	O
Guangzhou	O
and	O
its	O
vicinity	O
from	O
September	O
2004	O
to	O
November	O
2005	O
were	O
available	O
for	O
this	O
investigation	O
,	O
from	O
which	O
3	O
,	O
043	O
samples	O
(	O
813	O
throat	O
swasb	O
,	O
524	O
sera	B-FUNC
,	O
853	O
lung	O
tissues	O
and	O
853	O
colorectal	O
tissue	O
specimens	O
)	O
were	O
obtained	O
.	O

The	O
second	O
Zn	O
finger	O
,	O
with	O
four	O
cysteines	O
,	O
is	O
a	O
distant	O
member	O
of	O
the	O
""""	O
gag	O
-	O
knuckle	O
fold	O
group	O
""""	O
of	O
Zn2	O
+-	O
binding	B-FUNC
domains	O
and	O
appears	O
to	O
maintain	O
the	O
structural	O
integrity	O
of	O
the	O
C	O
-	O
terminal	O
tail	O
.	O

A	O
distinct	O
clustering	O
of	O
basic	O
residues	O
on	O
the	O
protein	O
surface	O
suggests	O
a	O
nucleic	O
acid	O
-	O
binding	B-FUNC
function	O
.	O

Gel	O
shift	O
assays	O
indicate	O
that	O
in	O
isolation	O
,	O
nsp10	O
binds	B-FUNC
single	O
-	O
and	O
double	O
-	O
stranded	O
RNA	O
and	O
DNA	O
with	O
high	O
-	O
micromolar	O
affinity	O
and	O
without	O
obvious	O
sequence	O
specificity	O
.	O

NM	O
calves	O
had	O
a	O
high	O
geometric	O
mean	O
titer	O
for	O
BCV	O
antibody	B-FUNC
at	O
arrival	O
(	O
GMT	O
,	O
1	O
,	O
928	O
);	O
only	O
2	O
%	O
shed	O
BCV	O
in	O
nasal	O
secretions	O
and	O
1	O
%	O
in	O
feces	O
.	O

RESULTS	O
:	O
NM	O
calves	O
had	O
a	O
high	O
geometric	O
mean	O
titer	O
for	O
BCV	O
antibody	B-FUNC
at	O
arrival	O
(	O
GMT	O
,	O
1	O
,	O
928	O
);	O
only	O
2	O
%	O
shed	O
BCV	O
in	O
nasal	O
secretions	O
and	O
1	O
%	O
in	O
feces	O
.	O

We	O
conducted	O
a	O
multicenter	O
evaluation	O
of	O
four	O
automated	O
and	O
four	O
manual	O
extraction	O
methods	O
using	O
dilutions	O
of	O
viral	O
lysate	O
in	O
replicate	O
mock	O
stool	O
samples	O
,	O
followed	O
by	O
quantitation	O
of	O
SARS	O
CoV	O
RNA	O
using	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
PCR	O
.	O

Additionally	O
,	O
ventilator	O
settings	O
are	O
reduced	O
to	O
""""	O
rest	B-FUNC
""""	O
settings	O
,	O
avoiding	O
the	O
consequences	O
of	O
ventilator	O
-	O
induced	O
lung	O
injury	O
that	O
can	O
contribute	O
to	O
a	O
worse	O
outcome	O
.	O

Viruses	O
are	O
known	O
to	O
target	O
ubiquitin	B-FUNC
and	O
ubiquitin	B-FUNC
-	O
like	O
modifier	O
pathways	O
using	O
various	O
strategies	O
,	O
including	O
the	O
recruitment	O
of	O
host	O
deubiquitinating	O
enzymes	O
.	O

Our	O
data	O
showed	O
that	O
H5N1	O
viral	O
infection	O
in	O
mice	O
resulted	O
in	O
typical	O
ARDS	O
,	O
which	O
was	O
characterized	O
by	O
the	O
following	O
features	O
:	O
(	O
1	O
)	O
about	O
80	O
%	O
of	O
mice	O
(	O
13	O
of	O
16	O
)	O
dead	O
on	O
Days	O
6	O
to	O
8	O
postinoculation	O
;	O
(	O
2	O
)	O
highly	O
edematous	O
lungs	O
and	O
dramatically	O
increased	O
lung	O
wet	O
:	O
dry	O
weight	O
ratios	O
and	O
lung	O
wet	O
weight	O
:	O
body	O
weight	O
ratios	O
;	O
(	O
3	O
)	O
inflammatory	O
cellular	O
infiltration	O
,	O
alveolar	O
and	O
interstitial	O
edema	O
,	O
and	O
hemorrhage	O
in	O
lungs	O
;	O
(	O
4	O
)	O
progressive	O
and	O
severe	O
hypoxemia	O
;	O
and	O
(	O
5	O
)	O
significant	O
increase	O
in	O
neutrophils	O
,	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
,	O
and	O
interleukin	O
-	O
6	O
in	O
BALF	O
.	O

Mice	O
immunized	O
with	O
the	O
adjuvanted	O
antigen	O
elicited	O
strong	O
antibody	B-FUNC
and	O
cellular	O
immune	O
responses	O
;	O
furthermore	O
,	O
adding	O
the	O
CpG	O
ODN	O
to	O
the	O
alum	O
resulted	O
in	O
increased	O
IgG2a	O
antibody	B-FUNC
titers	O
and	O
a	O
higher	O
number	O
of	O
INF	O
-	O
gamma	O
-	O
secreting	O
murine	O
splenocytes	O
.	O

Replacing	O
the	O
SCoV	O
TRS	B-FUNC
with	O
the	O
MHV	O
TRS	B-FUNC
in	O
the	O
MHV	O
/	O
5	O
'	O
UTR	O
SCoV	O
chimera	O
permitted	O
the	O
synthesis	O
of	O
minus	O
-	O
sense	O
genome	O
-	O
sized	O
RNA	O
but	O
did	O
not	O
support	O
the	O
production	O
of	O
positive	O
-	O
or	O
minus	O
-	O
sense	O
subgenomic	O
RNA7	O
.	O

These	O
results	O
suggest	O
a	O
role	O
for	O
the	O
TRS	B-FUNC
in	O
the	O
replication	O
of	O
minus	O
-	O
sense	O
genomic	O
RNA	O
in	O
addition	O
to	O
its	O
known	O
function	O
in	O
subgenomic	O
RNA	O
synthesis	O
.	O

Particularly	O
,	O
it	O
induces	O
GRP78	O
/	O
94	O
through	O
PKR	O
-	O
like	O
ER	O
kinase	O
but	O
has	O
no	O
influence	O
on	O
activating	O
transcription	O
factor	O
6	O
or	O
X	O
box	O
-	O
binding	B-FUNC
protein	O
1	O
.	O

TITLE	O
:	O
Cooperative	O
involvement	O
of	O
the	O
S1	O
and	O
S2	O
subunits	O
of	O
the	O
murine	O
coronavirus	O
spike	O
protein	O
in	O
receptor	B-FUNC
binding	I-FUNC
and	O
extended	O
host	O
range	O
.	O

In	O
addition	O
,	O
these	O
viruses	O
showed	O
a	O
decreased	O
binding	B-FUNC
to	O
and	O
inhibition	O
by	O
soluble	O
CEACAM1a	O
.	O

Recent	O
guidelines	O
for	O
the	O
conduct	O
of	O
CEAs	B-FUNC
in	O
critical	O
care	O
may	O
increase	O
the	O
number	O
and	O
improve	O
the	O
quality	O
of	O
future	O
CEAs	B-FUNC
.	O

In	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
),	O
nsps	O
1	O
,	O
2	O
,	O
and	O
3	O
are	O
processed	O
by	O
two	O
papain	O
-	O
like	O
proteinase	B-FUNC
activities	O
within	O
nsp3	O
(	O
PLP1	O
and	O
PLP2	O
)	O
to	O
yield	O
nsp1	O
,	O
an	O
nsp2	O
-	O
3	O
intermediate	O
,	O
and	O
mature	O
nsp2	O
and	O
nsp3	O
.	O

At	O
postchallenge	O
day	O
7	O
,	O
serum	O
IgG	O
and	O
fecal	O
IgA	O
antibody	B-FUNC
titers	O
remained	O
the	O
same	O
or	O
increased	O
only	O
twofold	O
compared	O
to	O
prechallenge	O
titers	O
.	O

Based	O
on	O
its	O
3D	O
structure	O
,	O
we	O
used	O
site	O
-	O
directed	O
mutagenesis	O
to	O
identify	O
residues	O
essential	O
for	O
the	O
RNA	O
-	O
binding	B-FUNC
activity	O
of	O
the	O
IBV	O
N	O
protein	O
and	O
viral	O
infectivity	O
.	O

TITLE	O
:	O
Identification	O
of	O
a	O
B	O
-	O
cell	O
antigenic	O
epitope	O
at	O
the	O
N	O
-	O
terminus	O
of	O
SARS	O
-	O
CoV	O
M	O
protein	O
and	O
characterization	O
of	O
monoclonal	O
antibody	B-FUNC
against	O
the	O
protein	O
.	O

ABSTRACT	O
:	O
To	O
identify	O
the	O
potential	O
B	O
-	O
cell	O
antigenic	O
epitopes	O
within	O
the	O
N	O
-	O
terminus	O
of	O
SARS	O
-	O
CoV	O
(	O
SARS	O
-	O
associated	O
coronavirus	O
,	O
SARS	O
-	O
CoV	O
)	O
M	O
protein	O
and	O
characterize	O
monoclonal	O
antibody	B-FUNC
(	O
MAb	O
)	O
against	O
the	O
protein	O
as	O
well	O
as	O
its	O
recognizing	O
region	O
,	O
we	O
expressed	O
and	O
purified	O
a	O
portion	O
of	O
SARS	O
-	O
CoV	O
M	O
protein	O
(	O
amino	O
acid	O
1	O
-	O
43	O
)	O
in	O
Escherichia	O
coli	O
(	O
E	O
.	O
coli	O
).	O

In	O
contrast	O
,	O
another	O
RNA	O
-	O
binding	B-FUNC
protein	O
,	O
PTB	O
,	O
did	O
not	O
show	O
these	O
activities	O
.	O

N	O
protein	O
chaperone	B-FUNC
activity	I-FUNC
was	O
blocked	O
by	O
specific	O
monoclonal	O
antibodies	O
.	O

We	O
investigated	O
whether	O
genetically	O
determined	O
differences	O
in	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
(	O
TNF	O
)-	O
alpha	O
production	O
can	O
influence	O
the	O
severity	O
of	O
Hantavirus	O
disease	O
.	O

hUbc9	O
,	O
a	O
ubiquitin	B-FUNC
conjugating	O
enzyme	O
of	O
sumoylation	O
system	O
,	O
was	O
found	O
to	O
interact	O
specifically	O
with	O
the	O
N	O
protein	O
,	O
implying	O
the	O
post	O
-	O
translational	O
sumoylation	O
of	O
the	O
N	O
protein	O
.	O

Gel	O
shift	O
assay	O
results	O
revealed	O
that	O
the	O
SARS	O
-	O
CoV	O
N	O
protein	O
C	O
-	O
terminus	O
is	O
also	O
able	O
to	O
associate	O
with	O
nucleic	O
acids	O
and	O
residues	O
363	O
-	O
382	O
are	O
the	O
responsible	O
interaction	O
partner	O
,	O
demonstrating	O
that	O
this	O
fragment	O
might	O
involve	O
genomic	O
RNA	B-FUNC
binding	I-FUNC
sites	O
.	O

Oral	O
administration	O
of	O
crude	O
extracts	O
from	O
antibody	B-FUNC
-	O
expressing	O
plant	O
tissue	O
to	O
2	O
-	O
day	O
-	O
old	O
piglets	O
showed	O
that	O
both	O
the	O
alphaSIP	O
and	O
full	O
-	O
length	O
IgA	O
molecules	O
can	O
provide	O
in	O
vivo	O
protection	O
against	O
TGEV	O
.	O

ABSTRACT	O
:	O
To	O
identify	O
the	O
epitope	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
specific	O
neutralizing	O
monoclonal	O
antibody	B-FUNC
(	O
MAb	O
)	O
2C5	O
.	O

Specific	O
immobilization	O
of	O
GBP	O
-	O
EGFP	O
fusion	O
protein	O
and	O
its	O
interaction	O
with	O
the	O
antibody	B-FUNC
in	O
the	O
microchannels	O
could	O
be	O
demonstrated	O
.	O

TITLE	O
:	O
Identifying	O
epitopes	O
responsible	O
for	O
neutralizing	O
antibody	B-FUNC
and	O
DC	O
-	O
SIGN	O
binding	B-FUNC
on	O
the	O
spike	O
glycoprotein	O
of	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

Thereafter	O
,	O
nitric	O
oxide	O
levels	O
decreased	O
but	O
remained	O
detectable	O
in	O
blood	O
up	O
to	O
96	O
hpi	B-FUNC
.	O

The	O
results	O
show	O
that	O
POMs	O
bind	B-FUNC
with	O
3CL	O
(	O
pro	O
)	O
in	O
the	O
active	O
site	O
region	O
with	O
high	O
affinity	O
;	O
POMs	O
are	O
more	O
prone	O
to	O
bind	B-FUNC
with	O
3CL	O
(	O
pro	O
)	O
than	O
with	O
some	O
organic	O
compounds	O
;	O
for	O
the	O
POMs	O
/	O
3CL	O
(	O
pro	O
)	O
complex	O
,	O
the	O
OTi	O
(	O
2	O
)	O
in	O
POMs	O
is	O
the	O
vital	O
element	O
for	O
electrostatic	O
interaction	O
,	O
and	O
the	O
electrostatic	O
binding	B-FUNC
energy	O
is	O
strong	O
enough	O
to	O
keep	O
the	O
complex	O
stable	O
.	O

The	O
early	O
induction	O
of	O
IP	O
-	O
10	O
and	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
,	O
as	O
well	O
as	O
the	O
subsequent	O
over	O
-	O
production	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
lack	O
of	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
production	O
,	O
probably	O
contribute	O
to	O
the	O
main	O
immuno	O
-	O
pathological	O
processes	O
involved	O
in	O
lung	O
injury	O
in	O
SARS	O
.	O

The	O
mean	O
ratio	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
to	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
in	O
SARS	O
patients	O
(	O
4	O
.	O
84	O
;	O
range	O
0	O
.	O
41	O
-	O
21	O
)	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
CAP	O
patients	O
(	O
2	O
.	O
95	O
;	O
range	O
0	O
.	O
02	O
-	O
10	O
.	O
57	O
)	O
(	O
P	O
=	O
0	O
.	O
04	O
).	O

N	O
protein	O
underwent	O
a	O
conformational	O
change	O
upon	O
binding	B-FUNC
viral	O
RNA	O
and	O
the	O
data	O
indicated	O
electrostatic	O
interactions	O
were	O
involved	O
in	O
the	O
binding	B-FUNC
of	O
the	O
protein	O
to	O
RNA	O
.	O

Using	O
the	O
phage	O
-	O
displayed	O
peptide	O
library	O
screening	O
method	O
and	O
purified	O
Fab	O
fragments	O
of	O
immunoglobulin	B-FUNC
G	O
(	O
IgG	O
Fab	O
)	O
from	O
normal	O
human	O
sera	B-FUNC
and	O
convalescent	O
sera	B-FUNC
from	O
SARS	O
-	O
CoV	O
-	O
infected	O
patients	O
as	O
targets	O
,	O
11	O
B	O
cell	O
epitopes	O
of	O
SARS	O
-	O
CoV	O
spike	O
glycoprotein	O
(	O
S	O
protein	O
)	O
and	O
membrane	O
protein	O
(	O
M	O
protein	O
)	O
were	O
screened	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
fragment	O
450	O
-	O
650	O
of	O
the	O
S	O
protein	O
(	O
S450	O
-	O
650	O
)	O
is	O
predominantly	O
recognized	O
by	O
convalescent	O
sera	B-FUNC
of	O
SARS	O
patients	O
.	O

Sera	B-FUNC
were	O
analyzed	O
for	O
antibodies	O
against	O
feline	O
immunodeficiency	O
virus	O
(	O
FIV	O
),	O
feline	O
calicivirus	O
(	O
FCV	O
),	O
feline	O
herpesvirus	O
1	O
(	O
feline	O
rhinotracheitis	O
:	O
FHV1	O
),	O
feline	O
/	O
canine	O
parvovirus	O
(	O
FPV	O
/	O
CPV	O
),	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
feline	O
coronavirus	O
:	O
FIPV	O
),	O
and	O
canine	O
distemper	O
virus	O
(	O
CDV	O
)	O
or	O
for	O
the	O
presence	O
of	O
feline	O
leukemia	O
virus	O
(	O
FeLV	O
)	O
antigens	O
.	O

A	O
conservative	O
T742V	O
substitution	O
or	O
a	O
T742R	O
substitution	O
in	O
fAPN	O
destroyed	O
receptor	B-FUNC
activity	I-FUNC
for	O
the	O
pig	O
,	O
dog	O
,	O
and	O
cat	O
coronaviruses	O
,	O
while	O
a	O
T742S	O
substitution	O
retained	O
these	O
receptor	O
activities	O
.	O

Thus	O
,	O
the	O
hydroxyl	O
on	O
T742	O
is	O
required	O
for	O
the	O
coronavirus	O
receptor	B-FUNC
activity	I-FUNC
of	O
fAPN	O
.	O

The	O
preferentially	O
type	O
2	O
cell	O
expressed	O
genes	O
involved	O
in	O
critical	O
functions	O
(	O
such	O
as	O
ATP	B-FUNC
-	I-FUNC
binding	I-FUNC
cassette	I-FUNC
transporter	I-FUNC
,	O
ABCA3	O
),	O
those	O
involved	O
in	O
susceptibility	O
to	O
acute	O
lung	O
damage	O
,	O
and	O
those	O
with	O
known	O
susceptibility	O
to	O
other	O
severe	O
lung	O
diseases	O
(	O
such	O
as	O
G	O
protein	O
-	O
coupled	O
receptor	O
for	O
asthma	O
susceptibility	O
,	O
GPR154	O
alias	O
GPRA	O
)	O
will	O
possibly	O
serve	O
as	O
candidate	O
genes	O
in	O
future	O
studies	O
.	O

Interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
inducible	O
protein	O
10	O
(	O
IP	O
-	O
10	O
)	O
was	O
markedly	O
elevated	O
in	O
the	O
blood	O
during	O
the	O
early	O
stage	O
of	O
SARS	O
[(	O
7	O
,	O
600	O
+/-	O
2	O
,	O
400	O
)	O
ng	O
/	O
L	O
,	O
P	O
<	O
0	O
.	O
01	O
],	O
and	O
remained	O
at	O
a	O
high	O
level	O
in	O
the	O
progressive	O
stage	O
[(	O
8	O
,	O
100	O
+/-	O

The	O
effects	O
of	O
adenovirus	O
-	O
delivered	O
small	O
hairpin	O
RNA	O
on	O
SARS	O
-	O
CoV	O
gene	O
expression	O
were	O
determined	O
by	O
RT	O
-	O
PCR	O
,	O
Western	O
blot	O
,	O
and	O
luciferase	B-FUNC
activity	I-FUNC
assays	O
.	O

Here	O
,	O
we	O
demonstrated	O
that	O
,	O
among	O
five	O
accessory	O
proteins	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
tested	O
,	O
3a	O
/	O
X1	O
and	O
7a	O
/	O
X4	O
were	O
capable	O
of	O
activating	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappaB	O
)	O
and	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	B-FUNC
),	O
and	O
significantly	O
enhanced	O
interleukin	O
8	O
(	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
)	O
promoter	O
activity	O
.	O

ABSTRACT	O
:	O
Chemical	O
denaturant	O
sensitivity	O
of	O
the	O
dimeric	O
main	O
protease	O
from	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
to	O
guanidinium	O
chloride	O
was	O
examined	O
in	O
terms	O
of	O
fluorescence	O
spectroscopy	O
,	O
circular	O
dichroism	O
,	O
analytical	O
ultracentrifuge	O
,	O
and	O
enzyme	B-FUNC
activity	I-FUNC
change	O
.	O

The	O
rat	O
-	O
passaged	O
virus	O
more	O
efficiently	O
infected	O
CHO	B-FUNC
cells	O
expressing	O
rat	O
ACE2	O
than	O
did	O
the	O
original	O
isolate	O
.	O

Mutation	O
of	O
any	O
of	O
these	O
serine	O
residues	O
to	O
alanine	O
had	O
a	O
debilitating	O
effect	O
on	O
the	O
catalytic	B-FUNC
activity	I-FUNC
of	O
3CLpro	O
.	O

TITLE	O
:	O
Generation	O
and	O
characterization	O
of	O
human	O
monoclonal	O
neutralizing	O
antibodies	O
with	O
distinct	O
binding	B-FUNC
and	O
sequence	O
features	O
against	O
SARS	O
coronavirus	O
using	O
XenoMouse	O
.	O

Immuno	O
-	O
EM	O
revealed	O
that	O
budding	O
occurred	O
at	O
membranes	O
of	O
the	O
ERGIC	O
(	O
ER	O
-	O
Golgi	O
intermediate	O
compartment	O
)	O
and	O
the	O
Golgi	O
region	O
as	O
early	O
as	O
3	O
h	O
post	O
infection	O
,	O
demonstrating	O
that	O
SARS	O
-	O
CoV	O
replicates	O
surprisingly	O
fast	B-FUNC
.	O

Proteinase	B-FUNC
K	O
digestion	O
experiments	O
indicate	O
that	O
the	O
TM	O
domain	O
of	O
nsp3	O
has	O
4	O
membrane	O
-	O
spanning	O
helices	O
.	O

We	O
tested	O
two	O
preventive	O
strategies	O
,	O
vaccination	O
and	O
passive	O
transfer	O
of	O
serum	O
antibody	B-FUNC
,	O
to	O
determine	O
the	O
extent	O
of	O
protection	O
achieved	O
against	O
SARS	O
-	O
CoV	O
challenge	O
in	O
this	O
model	O
.	O

It	O
was	O
recently	O
demonstrated	O
that	O
the	O
protein	O
forms	O
ion	B-FUNC
channels	I-FUNC
.	O

Pro	O
-	O
inflammatory	O
cytokines	O
and	O
chemokines	O
,	O
particularly	O
IP	O
-	O
10	O
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
and	O
MCP	B-FUNC
-	O
1	O
,	O
are	O
elevated	O
in	O
the	O
lungs	O
and	O
peripheral	O
blood	O
,	O
but	O
there	O
is	O
an	O
unusual	O
lack	O
of	O
an	O
antiviral	O
interferon	O
(	O
IFN	O
)	O
response	O
.	O

After	O
humoral	O
and	O
cellular	O
immune	O
response	O
detection	O
,	O
different	O
levels	O
of	O
SARS	O
-	O
CoV	O
N	O
protein	O
specific	O
antibodies	O
and	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
(	O
IFN	O
-	O
gamma	O
)	O
secretion	O
are	O
shown	O
compared	O
to	O
controls	O
.	O

Among	O
the	O
three	O
heterogeneous	O
combinations	O
,	O
pcDNA3	O
.	O
1	O
-	O
N	O
/	O
pcDNA3	O
.	O
1	O
-	O
N	O
/	O
pcDNA3	O
.	O
1	O
-	O
N	O
/	O
rAd	O
-	O
N	O
induced	O
the	O
strongest	O
antibody	B-FUNC
response	O
.	O

We	O
also	O
demonstrated	O
that	O
another	O
unusual	O
pathway	O
,	O
the	O
calcium	O
-	O
independent	O
PI3K	B-FUNC
/	O
PKC	B-FUNC
epsilon	O
/	O
JNK	B-FUNC
/	O
CREB	O
pathway	O
,	O
functioned	O
in	O
cooperation	O
with	O
the	O
calcium	O
-	O
dependent	O
pathway	O
to	O
induce	O
COX	O
-	O
2	O
expression	O
upon	O
stimulation	O
by	O
spike	O
protein	O
.	O

The	O
performance	O
consists	O
of	O
three	O
parts	O
:	O
a	O
surface	O
modification	O
for	O
ligand	B-FUNC
immobilization	O
/	O
surface	O
,	O
a	O
protein	O
array	O
fabrication	O
with	O
an	O
integrated	O
microfluidic	O
system	O
for	O
patterning	O
,	O
packaging	O
and	O
liquid	O
handling	O
,	O
and	O
a	O
protein	O
array	O
reader	O
of	O
imaging	O
ellipsometer	O
.	O

A	O
sustained	O
increase	O
of	O
adhesion	O
molecules	O
occurs	O
during	O
acute	O
stress	O
in	O
children	O
which	O
may	O
contribute	O
to	O
morbidity	O
in	O
patients	O
with	O
sepsis	O
(	O
sE	O
-	O
Selectin	B-FUNC
)	O
or	O
traumatic	O
brain	O
injury	O
(	O
sICAM	O
-	O
1	O
).	O

Unexpectedly	O
,	O
we	O
found	O
that	O
INDO	O
has	O
a	O
potent	O
direct	O
antiviral	O
activity	O
against	O
the	O
coronaviruses	O
SARS	O
-	O
CoV	O
and	O
CCoV	O
.	O
INDO	O
does	O
not	O
affect	O
coronavirus	O
binding	B-FUNC
or	O
entry	O
into	O
host	O
cells	O
,	O
but	O
acts	O
by	O
blocking	O
viral	O
RNA	O
synthesis	O
at	O
cytoprotective	O
doses	O
.	O

So	O
it	O
is	O
speculated	O
that	O
the	O
total	O
IgG	O
antibody	B-FUNC
may	O
be	O
positive	O
3	O
to	O
5	O
years	O
after	O
infection	O
,	O
but	O
it	O
seems	O
that	O
N	O
-	O
IgG	O
and	O
S	O
-	O
IgG	O
keep	O
positive	O
shorter	O
in	O
time	O
than	O
total	O
IgG	O
antibody	B-FUNC
.	O

ABSTRACT	O
:	O
Myelin	O
transcription	O
factor	O
1	O
(	O
Myt1	O
)	O
is	O
a	O
zinc	O
-	O
finger	O
DNA	B-FUNC
binding	I-FUNC
protein	O
that	O
influences	O
developing	O
oligodendrocyte	O
progenitor	O
(	O
OP	O
)	O
cell	O
proliferation	O
,	O
differentiation	O
,	O
and	O
myelin	O
gene	O
transcription	O
in	O
vitro	O
.	O

And	O
the	O
calculations	O
predict	O
a	O
number	O
of	O
single	O
substitutions	O
on	O
RBD	O
,	O
receptor	O
or	O
antibody	B-FUNC
that	O
could	O
remarkably	O
elevate	O
the	O
binding	B-FUNC
affinities	O
of	O
those	O
complexes	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
TNF	O
-	O
alpha	O
production	O
was	O
increased	O
with	O
viral	O
replication	O
in	O
macrophages	O
inoculated	O
with	O
a	O
mixture	O
of	O
FIPV	O
and	O
anti	O
-	O
S	O
antibody	B-FUNC
,	O
and	O
demonstrated	O
that	O
this	O
culture	O
supernatant	O
had	O
feline	O
PBMC	O
apoptosis	O
-	O
inducing	O
activity	O
.	O

Reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
was	O
used	O
to	O
detect	O
and	O
quantify	O
SARS	O
-	O
CoV	O
in	O
934	O
sera	B-FUNC
and	O
self	O
-	O
collected	O
throat	O
washes	O
and	O
fecal	O
samples	O
from	O
271	O
patients	O
with	O
laboratory	O
-	O
confirmed	O
SARS	O
managed	O
at	O
a	O
single	O
institution	O
.	O

Thirty	O
-	O
six	O
percent	O
of	O
identified	O
up	O
-	O
regulated	O
proteins	O
were	O
located	O
in	O
the	O
mitochondria	O
,	O
including	O
apoptosis	O
-	O
inducing	O
factor	O
,	O
ATP	O
synthase	O
beta	O
chain	O
and	O
cytochrome	B-FUNC
c	I-FUNC
oxidase	O
.	O

TITLE	O
:	O
G1	O
phase	O
cell	O
cycle	O
arrest	O
induced	O
by	O
SARS	O
-	O
CoV	O
3a	O
protein	O
via	O
the	O
cyclin	B-FUNC
D3	O
/	O
pRb	O
pathway	O
.	O

However	O
,	O
before	O
potential	O
clinical	O
application	O
,	O
the	O
antibody	B-FUNC
needs	O
to	O
be	O
tested	O
in	O
as	O
many	O
animal	O
models	O
as	O
possible	O
to	O
ensure	O
its	O
safety	O
and	O
efficiency	O
.	O

ABSTRACT	O
:	O
The	O
genetic	O
diversity	O
of	O
2	O
pairs	O
(	O
AH65	O
and	O
AH187	O
)	O
of	O
wild	O
type	O
bovine	O
coronaviruses	O
(	O
BCoV	O
)	O
sequenced	O
directly	O
from	O
nasal	O
(	O
respiratory	O
)	O
and	O
rectal	O
(	O
enteric	O
)	O
swabs	O
of	O
two	O
feedlot	O
calves	O
with	O
respiratory	O
and	O
enteric	O
symptoms	O
[	O
Hasoksuz	O
,	O
M	O
.,	O
Sreevatsan	O
,	O
S	O
.,	O
Cho	B-FUNC
,	O
K	O
.	O
O	O
.,	O
Hoet	O
,	O
A	O
.	O
E	O
.,	O
Saif	O
,	O
L	O
.	O
J	O
.,	O
2002b	O
.	O

Early	O
detection	O
of	O
increases	O
in	O
plasma	O
levels	O
of	O
soluble	O
E	O
selectin	B-FUNC
by	O
a	O
rapid	O
assay	O
system	O
,	O
developed	O
by	O
the	O
authors	O
,	O
enables	O
early	O
effective	O
treatment	O
of	O
patients	O
with	O
sepsis	O
.	O

TITLE	O
:	O
Identification	O
of	O
antibody	B-FUNC
against	O
porcine	O
coronavirus	O
in	O
human	O
milk	O
.	O

Our	O
results	O
indicate	O
that	O
HS	O
plays	O
a	O
role	O
as	O
an	O
attachment	O
factor	O
for	O
IBV	O
,	O
working	O
in	O
concert	O
with	O
other	O
factors	O
like	O
sialic	O
acid	O
to	O
mediate	O
virus	O
binding	B-FUNC
to	O
cells	O
,	O
and	O
may	O
explain	O
in	O
part	O
the	O
extended	O
tropism	O
of	O
IBV	O
Beaudette	O
.	O

To	O
compare	O
the	O
immunoglobulin	B-FUNC
G	O
(	O
IgG	O
)	O
responses	O
to	O
the	O
S	O
and	O
N	O
proteins	O
of	O
SARS	O
-	O
CoV	O
in	O
SARS	O
patients	O
during	O
the	O
manifestation	O
/	O
convalescent	O
period	O
with	O
those	O
during	O
the	O
postinfection	O
period	O
,	O
serum	O
samples	O
were	O
collected	O
from	O
hospitalized	O
SARS	O
patients	O
within	O
6	O
weeks	O
after	O
the	O
onset	O
of	O
illness	O
(	O
set	O
1	O
;	O
57	O
sequential	O
samples	O
from	O
19	O
patients	O
)	O
or	O
2	O
to	O
3	O
months	O
after	O
their	O
recovery	O
(	O
set	O
2	O
;	O
33	O
postinfection	O
samples	O
from	O
33	O
subjects	O
).	O

In	O
order	O
to	O
further	O
characterize	O
the	O
functional	O
properties	O
of	O
this	O
protein	O
,	O
we	O
initiated	O
studies	O
to	O
check	O
its	O
RNA	B-FUNC
binding	I-FUNC
activity	O
.	O

However	O
,	O
intramuscular	O
immunization	O
evoked	O
a	O
vigorous	O
antibody	B-FUNC
response	O
and	O
a	O
weak	O
T	O
-	O
cell	O
response	O
,	O
and	O
vaccination	O
by	O
electroporation	O
evoked	O
a	O
vigorous	O
response	O
with	O
a	O
predominant	O
subclass	O
IgG1	O
antibody	B-FUNC
response	O
and	O
a	O
moderate	O
T	O
-	O
cell	O
response	O
.	O

Our	O
findings	O
show	O
that	O
the	O
spike	O
DNA	O
vaccine	O
has	O
good	O
immunogenicity	O
and	O
can	O
induce	O
specific	O
humoral	O
and	O
cellular	O
immunities	O
in	O
BALB	O
/	O
c	O
mice	O
,	O
while	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
plays	O
an	O
immunoadjuvant	O
role	O
and	O
enhances	O
the	O
humoral	O
and	O
cellular	O
immune	O
responses	O
.	O

In	O
further	O
analysis	O
to	O
determine	O
the	O
correlation	O
between	O
the	O
phosphorylation	O
and	O
the	O
antigenicity	O
of	O
SARS	O
-	O
N	O
protein	O
,	O
dephosphorylated	O
SARS	O
-	O
N	O
protein	O
treated	O
with	O
protein	O
phosphatase	B-FUNC
1	O
(	O
PP1	O
)	O
remarkably	O
enhanced	O
the	O
cross	O
-	O
reactivity	O
against	O
SARS	O
negative	O
serum	O
and	O
considerably	O
reduced	O
immunoreactivity	O
with	O
SARS	O
-	O
N	O
mAb	O
.	O

We	O
also	O
provide	O
new	O
comparative	O
data	O
on	O
viral	O
replication	O
and	O
associated	O
pathology	O
following	O
infection	O
of	O
golden	O
Syrian	O
hamsters	O
with	O
various	O
SARS	O
-	O
CoV	O
strains	O
and	O
report	O
the	O
levels	O
of	O
neutralizing	O
antibody	B-FUNC
titers	O
following	O
these	O
infections	O
and	O
the	O
cross	O
-	O
protective	O
efficacy	O
of	O
infection	O
with	O
these	O
strains	O
in	O
protecting	O
against	O
heterologous	O
challenge	O
.	O

TITLE	O
:	O
Expression	O
,	O
glycosylation	O
,	O
and	O
modification	O
of	O
the	O
spike	O
(	O
S	O
)	O
glycoprotein	O
of	O
SARS	O
CoV	O
.	O
ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
glycoprotein	O
of	O
coronaviruses	O
is	O
known	O
to	O
be	O
essential	O
in	O
the	O
binding	B-FUNC
of	O
the	O
virus	O
to	O
the	O
host	O
cell	O
at	O
the	O
advent	O
of	O
the	O
infection	O
process	O
.	O

Analysis	O
of	O
the	O
immunogenicity	O
of	O
the	O
UV	O
-	O
F	O
-	O
V	O
+	O
alum	O
vaccine	O
in	O
mice	O
revealed	O
that	O
it	O
generated	O
comparable	O
neutralizing	O
serum	O
anti	O
-	O
SARS	O
-	O
CoV	O
IgG	O
antibody	B-FUNC
levels	O
as	O
the	O
UV	O
-	O
V	O
+	O
alum	O
vaccine	O
.	O

TITLE	O
:	O
The	O
use	O
of	O
hepatitis	O
C	O
virus	O
NS3	O
/	O
4A	O
and	O
secreted	O
alkaline	O
phosphatase	B-FUNC
to	O
quantitate	O
cell	O
-	O
cell	O
membrane	O
fusion	O
mediated	O
by	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
S	O
protein	O
and	O
the	O
receptor	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
.	O

ABSTRACT	O
:	O
The	O
membrane	O
fusion	O
process	O
mediated	O
by	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
S	O
protein	O
and	O
its	O
cellular	O
receptor	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
had	O
been	O
reconstituted	O
using	O
two	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	B-FUNC
)	O
cell	O
lines	O
that	O
constitutively	O
express	O
these	O
recombinant	O
proteins	O
separately	O
.	O

This	O
study	O
investigated	O
increased	O
susceptibility	O
to	O
multiple	O
organ	O
dysfunction	O
syndrome	O
(	O
MODS	O
)	O
in	O
extensively	O
burned	O
patients	O
with	O
ACS	B-FUNC
.	O

Two	O
groups	O
of	O
12	O
conventional	O
,	O
colostrum	O
-	O
deprived	O
,	O
1	O
-	O
day	O
-	O
old	O
,	O
large	O
White	O
-	O
Duroc	O
cross	O
breed	O
piglets	O
were	O
inoculated	O
orally	O
with	O
PEDV	O
(	O
3	O
x	O
10	O
(	O
5	O
)	O
50	O
%	O
tissue	O
culture	O
infective	O
doses	O
),	O
with	O
or	O
without	O
EGF	B-FUNC
(	O
10	O
microg	O
/	O
kg	O
/	O
day	O
,	O
intraperitoneally	O
once	O
daily	O
for	O
4	O
days	O
after	O
infection	O
)	O
and	O
compared	O
to	O
12	O
uninfected	O
,	O
untreated	O
control	O
piglets	O
.	O

PEDV	B-FUNC
+	I-FUNC
EGF	I-FUNC
piglets	O
had	O
less	O
severe	O
clinical	O
signs	O
than	O
PEDV	O
only	O
piglets	O
at	O
48	O
and	O
60	O
h	O
post	O
-	O
infection	O
(	O
hpi	B-FUNC
).	O

Blood	O
samples	O
were	O
obtained	O
for	O
the	O
determination	O
of	O
amylase	O
,	O
lipase	O
,	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
(	O
TNF	O
)-	O
alpha	O
,	O
interleukin	O
(	O
IL	O
)-	O
1beta	O
,	O
macrophage	O
inflammatory	O
peptide	O
(	O
MIP	O
)-	O
2	O
and	O
soluble	O
intercellular	O
adhesion	O
molecule	O
(	O
sICAM	O
)-	O
1	O
levels	O
,	O
while	O
pancreatic	O
and	O
lung	O
tissues	O
were	O
removed	O
for	O
myeloperoxidase	O
(	O
MPO	B-FUNC
)	O
activity	O
,	O
nitric	O
oxide	O
(	O
NOx	O
)	O
level	O
,	O
CD40	O
expression	O
and	O
histological	O
evaluation	O
.	O

Results	O
showed	O
that	O
the	O
intranasal	O
route	O
caused	O
the	O
highest	O
production	O
of	O
specific	O
immunoglobulin	B-FUNC
G	O
(	O
IgG	O
),	O
IgG2a	O
,	O
and	O
secretory	O
IgA	O
,	O
where	O
IgG2a	O
was	O
imprinted	O
as	O
a	O
Th1	O
cell	O
bias	O
.	O

Pathological	O
findings	O
and	O
immunohistochemical	O
identification	O
using	O
a	O
monoclonal	O
anti	O
-	O
canine	O
Coronavirus	O
antibody	B-FUNC
are	O
included	O
.	O

Trypsin	O
was	O
not	O
the	O
determinant	O
for	O
the	O
viral	O
replication	O
,	O
suggesting	O
that	O
the	O
restriction	O
of	O
IBV	O
replication	O
in	O
HeLa	O
cells	O
is	O
the	O
result	O
of	O
intracellular	O
events	O
rather	O
than	O
the	O
binding	B-FUNC
to	O
or	O
fusion	O
with	O
host	O
cells	O
.	O

The	O
serological	O
antibody	B-FUNC
response	O
to	O
the	O
aMPV	O
vaccine	O
given	O
with	O
the	O
IBV	O
and	O
NDV	O
vaccine	O
was	O
significantly	O
lower	O
than	O
when	O
the	O
aMPV	O
vaccine	O
was	O
given	O
alone	O
.	O

TITLE	O
:	O
Intratracheally	O
administered	O
pathogen	O
-	O
associated	O
molecular	O
patterns	O
affect	O
antibody	B-FUNC
responses	O
of	O
poultry	O
.	O

The	O
N	O
-	O
protein	O
peptide	O
N220	O
shows	O
a	O
high	O
binding	B-FUNC
affinity	O
towards	O
human	O
MHC	O
class	O
I	O
in	O
T2	O
-	O
cells	O
,	O
and	O
is	O
capable	O
of	O
activating	O
cytotoxic	O
T	O
-	O
cells	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
).	O

Predictors	O
of	O
death	O
at	O
the	O
onset	O
of	O
ARDS	O
were	O
advanced	O
age	O
,	O
MODS	O
>	O
or	O
=	O
to	O
8	O
,	O
and	O
LIS	B-FUNC
>	O
or	O
=	O
2	O
.	O
76	O
.	O

It	O
begins	O
with	O
the	O
release	O
of	O
interleukin	O
(	O
IL	O
)-	O
1	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
tumour	O
necrosis	O
factor	O
(	O
TNF	O
)-	O
alpha	O
from	O
inflammatory	O
cells	O
.	O

Expression	O
of	O
M	O
suppressed	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
induced	O
NF	O
-	O
kappaB	O
activation	O
using	O
a	O
luciferase	O
reporter	O
assay	O
.	O

The	O
distribution	O
of	O
ACS	B-FUNC
during	O
the	O
year	O
was	O
bimodal	O
,	O
peaking	O
in	O
May	O
and	O
September	O
and	O
at	O
its	O
lowest	O
in	O
June	O
and	O
December	O
/	O
January	O
.	O

RESULTS	O
:	O
Of	O
240	O
patients	O
registered	O
with	O
SCD	O
,	O
52	O
(	O
22	O
%)	O
developed	O
55	O
episodes	O
of	O
ACS	B-FUNC
.	O

The	O
evolution	O
was	O
complicated	O
:	O
pneumothorax	O
(	O
3	O
cases	O
),	O
hypokaliemia	O
(	O
3	O
cases	O
),	O
inappropriate	O
secretion	O
of	O
ADH	B-FUNC
syndrome	O
(	O
1	O
case	O
).	O

Passive	O
immunisation	O
with	O
sera	B-FUNC
from	O
surviving	O
patients	O
leads	O
to	O
partial	O
success	O
.	O

We	O
hypothesized	O
that	O
mesenchymal	O
stem	O
cells	O
(	O
MSCs	B-FUNC
),	O
with	O
or	O
without	O
transfection	O
with	O
the	O
vasculoprotective	O
gene	O
angiopoietin	O
1	O
(	O
ANGPT1	O
)	O
would	O
have	O
beneficial	O
effects	O
in	O
experimental	O
ALI	O
in	O
mice	O
.	O

Syngeneic	O
MSCs	B-FUNC
with	O
or	O
without	O
transfection	O
with	O
plasmid	O
containing	O
the	O
human	O
ANGPT1	O
gene	O
(	O
pANGPT1	O
)	O
were	O
delivered	O
through	O
the	O
right	O
jugular	O
vein	O
of	O
mice	O
30	O
min	O
after	O
intratracheal	O
instillation	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
to	O
induce	O
lung	O
injury	O
.	O

Furthermore	O
,	O
administration	O
of	O
MSCs	B-FUNC
transfected	O
with	O
pANGPT1	O
resulted	O
in	O
nearly	O
complete	O
reversal	O
of	O
LPS	O
-	O
induced	O
increases	O
in	O
lung	O
permeability	O
as	O
assessed	O
by	O
reductions	O
in	O
IgM	O
and	O
albumin	O
levels	O
in	O
BAL	O
(	O
96	O
%,	O
CI	O
6	O
%-	O
185	O
%;	O
and	O
74	O
%,	O
CI	O
23	O
%-	O
126	O
%,	O
respectively	O
).	O

These	O
multiplex	O
nested	O
PCRs	O
adopted	O
fast	B-FUNC
PCR	O
technology	O
.	O

The	O
high	O
speed	O
of	O
fast	B-FUNC
PCR	O
(	O
within	O
35	O
min	O
)	O
greatly	O
improved	O
the	O
efficiency	O
of	O
these	O
assays	O
.	O

TITLE	O
:	O
[	O
A	O
three	O
-	O
year	O
follow	O
-	O
up	O
study	O
on	O
sera	B-FUNC
specific	O
antibody	B-FUNC
in	O
severe	O
acute	O
respiratory	O
syndrome	O
cases	O
after	O
the	O
onset	O
of	O
illness	O
].	O

13	O
,	O
17	O
and	O
13	O
sera	B-FUNC
samples	O
were	O
collected	O
in	O
the	O
5th	O
,	O
20th	O
and	O
35th	O
month	O
after	O
onset	O
.	O

The	O
average	O
neutralizing	O
antibody	B-FUNC
titers	O
were	O
1	O
:	O
43	O
(	O
1	O
:	O
16	O
-	O
1	O
:	O
203	O
),	O
1	O
:	O
36	O
(	O
1	O
:	O
17	O
-	O
1	O
:	O
59	O
)	O
and	O
1	O
:	O
21	O
(	O
1	O
:	O
10	O
-	O
1	O
:	O
39	O
)	O
on	O
the	O
5th	O
,	O
20th	O
and	O
35th	O
month	O
after	O
onset	O
,	O
and	O
the	O
differences	O
were	O
statistically	O
significant	O
(	O
F	O
=	O
60	O
.	O
419	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

Therefore	O
,	O
the	O
p38	B-FUNC
MAPK	B-FUNC
and	O
NF	O
-	O
kappaB	O
pathways	O
are	O
potential	O
therapeutic	O
targets	O
for	O
reducing	O
the	O
inflammatory	O
consequences	O
of	O
ricin	B-FUNC
poisoning	O
.	O

As	O
a	O
consequence	O
,	O
IgG	O
antibody	B-FUNC
avidity	O
assays	O
gave	O
better	O
discrimination	O
between	O
acute	O
-	O
phase	O
and	O
late	O
-	O
convalescent	O
-	O
phase	O
serum	O
samples	O
than	O
IgM	O
,	O
IgA	O
,	O
or	O
IgGAM	O
assays	O
.	O

The	O
results	O
showed	O
that	O
assays	O
to	O
detect	O
low	O
-	O
avidity	O
antibody	B-FUNC
may	O
be	O
useful	O
for	O
discriminating	O
early	O
from	O
late	O
antibody	B-FUNC
responses	O
and	O
also	O
for	O
distinguishing	O
anamnestic	O
cross	O
-	O
reactive	O
antibody	B-FUNC
responses	O
from	O
primary	O
specific	O
responses	O
.	O

The	O
goal	O
of	O
this	O
project	O
was	O
to	O
better	O
define	O
the	O
relationship	O
between	O
the	O
endoribonuclease	B-FUNC
activity	I-FUNC
of	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
Nsp15	O
(	O
mNsp15	O
)	O
and	O
its	O
role	O
in	O
virus	O
infection	O
.	O

PRONE	O
also	O
influenced	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
expression	O
in	O
patients	O
with	O
severe	O
CAP	O
.	O

Further	O
,	O
when	O
used	O
therapeutically	O
this	O
antibody	B-FUNC
led	O
to	O
an	O
approximately	O
4	O
-	O
log	O
(	O
10	O
)	O
decrease	O
in	O
viral	O
burden	O
in	O
infected	O
animal	O
lungs	O
.	O

Kinetic	O
analysis	O
of	O
RNA	B-FUNC
binding	I-FUNC
indicated	O
that	O
the	O
C	O
-	O
terminal	O
phosphorylation	O
cluster	O
was	O
involved	O
in	O
the	O
recognition	O
of	O
viral	O
RNA	O
from	O
non	O
-	O
viral	O
RNA	O
.	O

Furthermore	O
,	O
our	O
results	O
show	O
that	O
receptor	B-FUNC
binding	I-FUNC
and	O
subsequent	O
membrane	O
fusion	O
are	O
distinct	O
steps	O
,	O
and	O
that	O
each	O
spike	O
can	O
bind	B-FUNC
up	O
to	O
three	O
ACE2	O
molecules	O
.	O

Dot	O
blot	O
analysis	O
showed	O
that	O
SARS	O
-	O
CoV	O
spike	O
protein	O
,	O
which	O
was	O
expressed	O
and	O
purified	O
from	O
mammal	O
cells	O
,	O
can	O
be	O
detected	O
by	O
anti	O
-	O
Z	O
sera	B-FUNC
from	O
rabbit	O
.	O

The	O
antibody	B-FUNC
titring	O
from	O
1	O
:	O
100	O
to	O
400	O
against	O
the	O
equine	O
anti	O
-	O
SARS	O
-	O
CoV	O
F	O
(	O
ab	O
')(	O
2	O
)	O
in	O
the	O
inoculated	O
hosts	O
could	O
be	O
detected	O
at	O
week	O
2	O
during	O
the	O
successive	O
injections	O
of	O
the	O
equine	O
F	O
(	O
ab	O
')(	O
2	O
).	O

We	O
demonstrate	O
that	O
the	O
SARS	O
-	O
CoV	O
PTM	O
peptide	O
binds	B-FUNC
to	O
and	O
interacts	O
with	O
phospholipid	O
model	O
membranes	O
,	O
and	O
,	O
at	O
the	O
same	O
time	O
,	O
it	O
adopts	O
different	O
conformations	O
when	O
bound	O
to	O
membranes	O
of	O
different	O
compositions	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
protein	O
7a	O
binds	B-FUNC
directly	O
and	O
specifically	O
to	O
human	O
lymphocyte	O
function	O
-	O
associated	O
antigen	O
1	O
(	O
LFA	O
-	O
1	O
)	O
on	O
the	O
cell	O
surface	O
of	O
Jurkat	O
cells	O
.	O

One	O
cell	O
type	O
was	O
type	O
II	O
cells	O
,	O
which	O
were	O
positive	O
for	O
SP	O
-	O
A	O
,	O
SP	O
-	O
C	O
,	O
cytokeratin	O
,	O
a	O
type	O
II	O
cell	O
-	O
specific	O
monoclonal	O
antibody	B-FUNC
,	O
and	O
Ep	O
-	O
CAM	O
.	O

The	O
results	O
showed	O
that	O
astragalus	O
polysaccharide	O
and	O
isatis	O
root	O
polysaccharide	O
at	O
low	O
dosages	O
,	O
and	O
achyranthes	O
root	O
polysaccharide	O
and	O
Chinese	O
yam	O
polysaccharide	O
at	O
high	O
dosages	O
significantly	O
enhanced	O
the	O
ND	O
antibody	B-FUNC
titers	O
,	O
concanavalin	O
A	O
-	O
induced	O
proliferation	O
of	O
peripheral	O
blood	O
lymphocytes	O
,	O
and	O
ratio	O
of	O
CD4	O
(+)	O
to	O
CD8	O
(+)	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
In	O
this	O
report	O
,	O
for	O
surface	O
display	O
of	O
viral	O
antigen	O
on	O
lactobacilli	O
,	O
we	O
have	O
developed	O
a	O
surface	O
antigen	O
display	O
system	O
using	O
the	O
poly	O
-	O
gamma	O
-	O
glutamate	O
synthetase	O
A	O
protein	O
(	O
pgsA	O
)	O
of	O
Bacillus	O
subtilis	O
as	O
an	O
anchoring	B-FUNC
matrix	O
.	O

Absorbance	O
of	O
IgG	O
in	O
pregnant	O
sow	O
sera	B-FUNC
highly	O
increased	O
duration	O
of	O
the	O
experiment	O
.	O

Furthermore	O
,	O
p38	B-FUNC
MAPK	B-FUNC
inhibitor	O
,	O
SB203580	O
,	O
inhibits	O
CPE	O
induced	O
by	O
HCoV	O
-	O
229E	O
infection	O
and	O
viral	O
replication	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
relationship	O
between	O
antibodies	O
detected	O
in	O
patients	O
'	O
and	O
/	O
or	O
donors	O
'	O
sera	B-FUNC
and	O
the	O
clinical	O
features	O
of	O
acute	O
non	O
-	O
haemolytic	O
transfusion	O
reactions	O
(	O
ANHTRs	O
),	O
and	O
to	O
determine	O
any	O
gender	O
-	O
related	O
difference	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
role	O
of	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
(	O
TNFalpha	O
)	O
in	O
the	O
pathogenesis	O
of	O
acute	O
viral	O
encephalitis	O
,	O
TNFalpha	O
-	O
deficient	O
mice	O
were	O
infected	O
with	O
a	O
highly	O
neurovirulent	O
strain	O
of	O
mouse	O
hepatitis	O
virus	O
,	O
JHM	O
,	O
and	O
compared	O
with	O
JHM	O
-	O
infected	O
C57BL	O
/	O
6	O
mice	O
as	O
controls	O
.	O

SL	O
-	O
CoVs	O
and	O
SARS	O
-	O
CoVs	O
share	O
identical	O
genome	O
organizations	O
and	O
high	O
sequence	O
identities	O
,	O
with	O
the	O
main	O
exception	O
of	O
the	O
N	O
terminus	O
of	O
the	O
spike	O
protein	O
(	O
S	O
),	O
known	O
to	O
be	O
responsible	O
for	O
receptor	B-FUNC
binding	I-FUNC
in	O
CoVs	O
.	O

It	O
inhibits	O
mitochondrial	O
cytochrome	B-FUNC
c	I-FUNC
oxidase	O
and	O
leads	O
to	O
pulmonary	O
and	O
cardiac	O
toxicity	O
.	O

ABSTRACT	O
:	O
Infection	O
of	O
SCID	O
mice	O
with	O
a	O
recombinant	O
murine	O
coronavirus	O
(	O
mouse	O
hepatitis	O
virus	O
[	O
MHV	O
])	O
expressing	O
the	O
T	O
-	O
cell	O
chemoattractant	O
CXC	O
chemokine	O
ligand	B-FUNC
10	O
(	O
CXCL10	O
)	O
resulted	O
in	O
increased	O
survival	O
and	O
reduced	O
viral	O
burden	O
within	O
the	O
brain	O
and	O
liver	O
compared	O
to	O
those	O
of	O
mice	O
infected	O
with	O
an	O
isogenic	O
control	O
virus	O
(	O
MHV	O
),	O
supporting	O
an	O
important	O
role	O
for	O
CXCL10	O
in	O
innate	O
immune	O
responses	O
following	O
viral	O
infection	O
.	O

After	O
introducing	O
a	O
K479N	O
mutation	O
within	O
the	O
S	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
)	O
of	O
SZ16	O
,	O
the	O
recombinant	O
virus	O
(	O
icSZ16	O
-	O
S	O
K479N	O
)	O
replicated	O
in	O
Vero	O
cells	O
but	O
was	O
severely	O
debilitated	O
in	O
growth	O
.	O

These	O
data	O
suggest	O
that	O
the	O
human	O
adaptation	O
of	O
zoonotic	O
SARS	O
-	O
CoV	O
strains	O
may	O
select	O
for	O
some	O
variants	O
that	O
are	O
highly	O
susceptible	O
to	O
select	O
MAbs	O
that	O
bind	B-FUNC
to	O
RBDs	O
.	O

In	O
the	O
absence	O
of	O
tissue	O
hypoperfusion	O
,	O
coronary	O
artery	O
disease	O
,	O
or	O
acute	O
hemorrhage	O
,	O
target	O
a	O
hemoglobin	O
of	O
7	O
-	O
9	O
g	O
/	O
dL	O
(	O
1B	O
);	O
a	O
low	O
tidal	O
volume	O
(	O
1B	O
)	O
and	O
limitation	O
of	O
inspiratory	O
plateau	O
pressure	O
strategy	O
(	O
1C	O
)	O
for	O
acute	O
lung	O
injury	O
(	O
ALI	O
)/	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
);	O
application	O
of	O
at	O
least	O
a	O
minimal	O
amount	O
of	O
positive	O
end	O
-	O
expiratory	O
pressure	O
in	O
acute	O
lung	O
injury	O
(	O
1C	O
);	O
head	O
of	O
bed	O
elevation	O
in	O
mechanically	O
ventilated	O
patients	O
unless	O
contraindicated	O
(	O
1B	O
);	O
avoiding	O
routine	O
use	O
of	O
pulmonary	O
artery	O
catheters	O
in	O
ALI	O
/	O
ARDS	O
(	O
1A	O
);	O
to	O
decrease	O
days	O
of	O
mechanical	O
ventilation	O
and	O
ICU	O
length	O
of	O
stay	O
,	O
a	O
conservative	O
fluid	O
strategy	O
for	O
patients	O
with	O
established	O
ALI	O
/	O
ARDS	O
who	O
are	O
not	O
in	O
shock	O
(	O
1C	O
);	O
protocols	O
for	O
weaning	O
and	O
sedation	O
/	O
analgesia	O
(	O
1B	O
);	O
using	O
either	O
intermittent	O
bolus	O
sedation	O
or	O
continuous	O
infusion	O
sedation	O
with	O
daily	O
interruptions	O
or	O
lightening	O
(	O
1B	O
);	O
avoidance	O
of	O
neuromuscular	O
blockers	O
,	O
if	O
at	O
all	O
possible	O
(	O
1B	O
);	O
institution	O
of	O
glycemic	O
control	O
(	O
1B	O
),	O
targeting	O
a	O
blood	O
glucose	O
<	O
150	O
mg	O
/	O
dL	O
after	O
initial	O
stabilization	O
(	O
2C	O
);	O
equivalency	O
of	O
continuous	O
veno	O
-	O
veno	O
hemofiltration	O
or	O
intermittent	O
hemodialysis	O
(	O
2B	O
);	O
prophylaxis	O
for	O
deep	O
vein	O
thrombosis	O
(	O
1A	O
);	O
use	O
of	O
stress	O
ulcer	O
prophylaxis	O
to	O
prevent	O
upper	O
gastrointestinal	O
bleeding	O
using	O
H2	O
blockers	O
(	O
1A	O
)	O
or	O
proton	B-FUNC
pump	I-FUNC
inhibitors	O
(	O
1B	O
);	O
and	O
consideration	O
of	O
limitation	O
of	O
support	O
where	O
appropriate	O
(	O
1D	O
).	O

TITLE	O
:	O
Mannan	O
-	O
binding	B-FUNC
lectin	O
(	O
MBL	O
)	O
serum	O
concentration	O
in	O
relation	O
to	O
propagation	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
in	O
chickens	O
.	O

TITLE	O
:	O
Detection	O
of	O
12	O
respiratory	O
viruses	O
with	O
two	O
-	O
set	O
multiplex	O
reverse	O
transcriptase	B-FUNC
-	O
PCR	O
assay	O
using	O
a	O
dual	O
priming	O
oligonucleotide	O
system	O
.	O

TITLE	O
:	O
Intranasal	O
vaccination	O
of	O
recombinant	O
adeno	O
-	O
associated	O
virus	O
encoding	O
receptor	O
-	O
binding	B-FUNC
domain	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
protein	O
induces	O
strong	O
mucosal	O
immune	O
responses	O
and	O
provides	O
long	O
-	O
term	O
protection	O
against	O
SARS	O
-	O
CoV	O
infection	O
.	O

These	O
residues	O
are	O
involved	O
in	O
dimerization	O
through	O
hydrogen	O
bonding	O
and	O
broadly	O
located	O
in	O
the	O
N	O
-	O
terminal	O
finger	O
,	O
the	O
alpha	O
-	O
helix	O
A	O
'	O
of	O
domain	O
I	O
,	O
and	O
the	O
oxyanion	O
loop	O
near	O
the	O
S1	O
substrate	O
-	O
binding	B-FUNC
subsite	O
in	O
domain	O
II	O
.	O

One	O
hundred	O
twenty	O
sera	B-FUNC
collected	O
from	O
cats	O
belonging	O
to	O
catteries	O
or	O
community	O
shelters	O
and	O
to	O
households	O
were	O
tested	O
for	O
FCoV	O
type	O
I	O
and	O
II	O
antibodies	O
.	O

Ninety	O
-	O
six	O
sera	B-FUNC
tested	O
positive	O
for	O
FCoV	O
antibodies	O
by	O
VN	O
and	O
ELISA	O
.	O

Coexpression	O
of	O
SCoV	O
S	O
protein	O
and	O
E	O
,	O
M	O
and	O
N	O
proteins	O
of	O
mouse	O
hepatitis	O
virus	O
in	O
293T	O
or	O
CHO	B-FUNC
cells	O
resulted	O
in	O
the	O
efficient	O
production	O
of	O
chimeric	O
VLPs	O
carrying	O
SCoV	O
S	O
protein	O
.	O

Antibodies	O
raised	O
against	O
the	O
S3	O
fragment	O
were	O
able	O
to	O
block	O
the	O
binding	B-FUNC
of	O
a	O
panel	O
of	O
S	O
-	O
specific	O
monoclonal	O
antibodies	O
(	O
mAb	O
)	O
to	O
SARS	O
-	O
CoV	O
in	O
ELISA	O
,	O
further	O
demonstrating	O
the	O
immunodominance	O
of	O
this	O
region	O
.	O

However	O
,	O
the	O
potential	O
of	O
this	O
assay	O
could	O
clearly	O
be	O
demonstrated	O
employing	O
SARS	O
-	O
positive	O
serum	O
samples	O
,	O
where	O
nonspecific	O
binding	B-FUNC
to	O
nucleocapsids	O
of	O
other	O
HCoVs	O
was	O
not	O
observed	O
.	O

Elevation	O
of	O
serum	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
was	O
observed	O
before	O
treatment	O
with	O
antibiotics	O
and	O
glucocorticoids	O
,	O
but	O
the	O
elevation	O
of	O
transforming	O
growth	O
factor	O
-	O
beta	O
(	O
1	O
)	O
was	O
delayed	O
for	O
2	O
to	O
4	O
weeks	O
after	O
the	O
accident	O
.	O

TITLE	O
:	O
Structural	O
basis	O
for	O
potent	O
cross	O
-	O
neutralizing	O
human	O
monoclonal	O
antibody	B-FUNC
protection	O
against	O
lethal	O
human	O
and	O
zoonotic	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
challenge	O
.	O

Positive	O
antibody	B-FUNC
titers	O
against	O
T	O
.	O
gondii	O
were	O
found	O
in	O
seven	O
of	O
the	O
19	O
giant	O
pandas	O
.	O

Transverse	O
subcostal	O
laparostomy	O
is	O
a	O
promising	O
alternative	O
decompression	O
technique	O
for	O
ACS	B-FUNC
in	O
SAP	O
.	O

Acute	O
respiratory	O
failure	O
frequency	O
differed	O
significantly	O
with	O
the	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
-	O
1082	O
genotype	O
(	O
P	O
=	O
.	O
007	O
;	O
P	O
corrected	O
,	O
.	O
03	O
),	O
whereas	O
there	O
was	O
no	O
significant	O
relation	O
to	O
any	O
other	O
cytokine	O
genotype	O
after	O
Bonferroni	O
correction	O
for	O
multiple	O
testing	O
.	O

TITLE	O
:	O
Duration	O
of	O
antibody	B-FUNC
responses	O
after	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

ABSTRACT	O
:	O
Among	O
176	O
patients	O
who	O
had	O
had	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
SARS	O
-	O
specific	O
antibodies	O
were	O
maintained	O
for	O
an	O
average	O
of	O
2	O
years	O
,	O
and	O
significant	O
reduction	O
of	O
immunoglobulin	B-FUNC
G	O
-	O
positive	O
percentage	O
and	O
titers	O
occurred	O
in	O
the	O
third	O
year	O
.	O

The	O
resulting	O
cell	O
secretes	O
not	O
only	O
the	O
immunoglobulins	O
of	O
both	O
parents	O
but	O
also	O
hybrid	O
molecules	O
manifesting	O
the	O
binding	B-FUNC
characteristics	O
of	O
the	O
individual	O
fusion	O
partners	O
.	O

TITLE	O
:	O
[	O
Potent	O
immune	O
responses	O
elicited	O
by	O
a	O
bicistronic	O
IBV	O
DNA	O
vaccine	O
expressing	O
S1	O
and	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
gene	O
].	O

SI	O
gene	O
of	O
avian	O
infectious	O
bronchitis	O
virus	O
and	O
interleukin	O
-	O
2	O
(	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
)	O
gene	O
from	O
chicken	O
were	O
inserted	O
into	O
the	O
bicistronic	O
pIRES	O
-	O
EGFP	O
/	O
DsRed	O
plasmid	O
.	O

However	O
,	O
immunization	O
with	O
the	O
bicistronic	O
plasmid	O
pIRES	O
-	O
Sl	O
/	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
that	O
co	O
-	O
expressing	O
S1	O
and	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
under	O
control	O
of	O
a	O
single	O
promoter	O
led	O
to	O
a	O
dramatic	O
augmentation	O
of	O
humoral	O
and	O
T	O
cell	O
responses	O
.	O

In	O
fact	O
,	O
in	O
transmissible	O
gastroenteritis	O
CoV	O
,	O
a	O
good	O
correlation	O
has	O
been	O
observed	O
between	O
subgenomic	O
mRNA	O
(	O
sg	O
mRNA	O
)	O
levels	O
and	O
the	O
free	O
energy	O
(	O
DeltaG	O
)	O
of	O
TRS	B-FUNC
-	O
L	O
and	O
cTRS	O
-	O
B	O
duplex	O
formation	O
.	O

We	O
postulated	O
that	O
additional	O
factors	O
should	O
regulate	O
transcription	O
of	O
sg	O
mRNA	O
N	O
.	O
In	O
this	O
report	O
,	O
we	O
have	O
described	O
a	O
novel	O
transcription	O
regulation	O
mechanism	O
operating	O
in	O
CoV	O
by	O
which	O
a	O
9	O
-	O
nucleotide	O
(	O
nt	O
)	O
sequence	O
located	O
449	O
nt	O
upstream	O
of	O
the	O
N	O
gene	O
TRS	B-FUNC
core	O
sequence	O
(	O
CS	O
-	O
N	O
)	O
interacts	O
with	O
a	O
complementary	O
sequence	O
just	O
upstream	O
of	O
CS	O
-	O
N	O
,	O
specifically	O
increasing	O
the	O
accumulation	O
of	O
sg	O
mRNA	O
N	O
.	O
Alteration	O
of	O
this	O
complementarity	O
in	O
mutant	O
replicon	O
genomes	O
showed	O
a	O
correlation	O
between	O
the	O
predicted	O
stability	O
of	O
the	O
base	B-FUNC
pairing	I-FUNC
between	O
9	O
-	O
nt	O
sequences	O
and	O
the	O
accumulation	O
of	O
sg	O
mRNA	O
N	O
.	O
This	O
interaction	O
is	O
exclusively	O
conserved	O
in	O
group	O
1a	O
CoVs	O
,	O
the	O
only	O
CoV	O
subgroup	O
in	O
which	O
the	O
N	O
gene	O
is	O
not	O
the	O
most	O
3	O
'	O
gene	O
in	O
the	O
viral	O
genome	O
.	O

However	O
,	O
further	O
deletion	O
of	O
Gln	O
-	O
299	O
or	O
Arg	O
-	O
298	O
drastically	O
decreased	O
the	O
enzyme	B-FUNC
activity	I-FUNC
to	O
1	O
-	O
2	O
%	O
of	O
wild	O
type	O
(	O
WT	O
),	O
and	O
the	O
major	O
form	O
was	O
a	O
monomeric	O
one	O
.	O

Detailed	O
analysis	O
of	O
the	O
point	O
mutants	O
of	O
these	O
two	O
amino	O
acid	O
residues	O
and	O
their	O
nearby	O
hydrogen	O
bond	O
partner	O
Ser	O
-	O
123	O
and	O
Ser	O
-	O
139	O
revealed	O
a	O
strong	O
correlation	O
between	O
the	O
enzyme	B-FUNC
activity	I-FUNC
loss	O
and	O
dimer	O
dissociation	O
.	O

Feline	O
leukemia	O
virus	O
antigen	O
,	O
feline	O
immunodeficiency	O
virus	O
antibody	B-FUNC
,	O
or	O
coronavirus	O
antibodies	O
were	O
not	O
detected	O
.	O

Compared	O
with	O
the	O
RBD	O
-	O
rAAV	O
prime	O
/	O
boost	O
vaccination	O
,	O
RBD	O
-	O
rAAV	O
prime	O
/	O
RBD	O
-	O
peptide	O
(	O
RBD	O
-	O
Pep	O
)	O
boost	O
induced	O
similar	O
levels	O
of	O
Th1	O
and	O
neutralizing	O
antibody	B-FUNC
responses	O
that	O
protected	O
the	O
vaccinated	O
mice	O
from	O
subsequent	O
SARS	O
-	O
CoV	O
challenge	O
,	O
but	O
stronger	O
Th2	O
and	O
CTL	O
responses	O
.	O

Murine	O
hyperimmune	O
sera	B-FUNC
against	O
these	O
peptides	O
bound	O
to	O
proteins	O
of	O
human	O
lung	O
epithelial	O
cells	O
A549	O
.	O

Mimicyp	O
adopts	O
a	O
typical	O
cyclophilin	B-FUNC
-	O
fold	O
,	O
yet	O
it	O
also	O
forms	O
trimers	O
unlike	O
any	O
previously	O
characterized	O
homologue	O
.	O

To	O
identify	O
residues	O
in	O
the	O
spike	O
protein	O
of	O
NL63	O
that	O
are	O
important	O
for	O
hACE2	O
binding	B-FUNC
,	O
this	O
study	O
first	O
generated	O
a	O
series	O
of	O
S1	O
-	O
truncated	O
variants	O
,	O
examined	O
their	O
associations	O
with	O
the	O
hACE2	O
receptor	O
and	O
subsequently	O
mapped	O
a	O
minimal	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
that	O
consisted	O
of	O
141	O
residues	O
(	O
aa	O
476	O
-	O
616	O
)	O
towards	O
the	O
C	O
terminus	O
of	O
the	O
S1	O
domain	O
.	O

Only	O
initial	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
was	O
associated	O
with	O
increased	O
Pao2	O
/	O
Fio2	O
(	O
P	O
=	O
.	O
013	O
)	O
and	O
with	O
a	O
minimum	O
Pao2	O
/	O
Fio2	O
>	O
200	O
(	O
P	O
=	O
.	O
042	O
)	O
during	O
72	O
hours	O
.	O

Three	O
biomarkers	O
-	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
intercellular	O
adhesion	O
molecule	O
1	O
and	O
protein	O
C	O
-	O
remained	O
significantly	O
different	O
by	O
multivariate	O
analysis	O
that	O
included	O
age	O
,	O
gender	O
,	O
Simplified	O
Acute	O
Physiology	O
Score	O
II	O
and	O
all	O
biomarkers	O
that	O
were	O
significant	O
on	O
bivariate	O
analysis	O
.	O

Findings	O
on	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
assays	O
for	O
SARS	O
-	O
CoV	O
at	O
a	O
national	O
reference	O
laboratory	O
were	O
suspected	O
to	O
represent	O
false	O
positives	O
,	O
but	O
this	O
was	O
confounded	O
by	O
concurrent	O
identification	O
of	O
antibody	B-FUNC
to	O
N	O
protein	O
on	O
serology	O
.	O

Notably	O
,	O
sera	B-FUNC
demonstrated	O
cross	O
-	O
reactivity	O
against	O
nucleocapsid	O
peptide	O
sequences	O
common	O
to	O
HCoV	O
-	O
OC43	O
and	O
SARS	O
-	O
CoV	O
.	O
These	O
findings	O
underscore	O
the	O
virulence	O
of	O
human	O
CoV	O
-	O
OC43	O
in	O
elderly	O
populations	O
and	O
confirm	O
that	O
cross	O
-	O
reactivity	O
to	O
antibody	B-FUNC
against	O
nucleocapsid	O
proteins	O
from	O
these	O
viruses	O
must	O
be	O
considered	O
when	O
interpreting	O
serological	O
tests	O
for	O
SARS	O
-	O
CoV	O
.	O
RESULTS	O
:	O
Ninety	O
-	O
five	O
of	O
142	O
residents	O
(	O
67	O
%)	O
and	O
53	O
of	O
160	O
staff	O
members	O
(	O
33	O
%)	O
experienced	O
symptoms	O
of	O
respiratory	O
infection	O
.	O

After	O
five	O
cycles	O
of	O
screening	O
,	O
a	O
dodecapeptide	O
KKKKYRNIRRPG	O
(	O
DP	O
)	O
was	O
identified	O
to	O
possess	O
the	O
highest	O
binding	B-FUNC
affinity	O
to	O
the	O
immobilized	O
sense	O
peptide	O
.	O

Modeling	O
of	O
the	O
nsp5	O
structure	O
of	O
Alb	O
/	O
ts	O
/	O
nsp5	O
/	O
V148A	O
predicted	O
that	O
the	O
Val148Ala	O
mutation	O
alters	O
residue	O
148	O
interactions	O
with	O
residues	O
of	O
the	O
substrate	O
binding	B-FUNC
S1	O
subsite	O
of	O
the	O
nsp5	O
active	O
-	O
site	O
cavity	O
.	O

This	O
study	O
identifies	O
novel	O
residues	O
in	O
nsp5	O
that	O
may	O
be	O
important	O
for	O
regulating	O
substrate	O
specificity	O
and	O
nsp5	O
proteinase	B-FUNC
activity	I-FUNC
.	O

TITLE	O
:	O
Characterization	O
of	O
ubiquitin	B-FUNC
and	O
ubiquitin	B-FUNC
-	O
like	O
-	O
protein	O
isopeptidase	O
activities	O
.	O

Herein	O
is	O
described	O
a	O
readily	O
quantifiable	O
novel	O
isopeptidase	O
assay	O
platform	O
consisting	O
of	O
Ub	O
or	O
UBL	O
fused	O
to	O
the	O
reporter	O
enzyme	O
phospholipase	B-FUNC
A	I-FUNC
(	O
2	O
)	O
(	O
PLA	O
(	O
2	O
)).	O

TITLE	O
:	O
[	O
Evaluation	O
of	O
Seeplex	O
RV	O
detection	O
kit	B-FUNC
for	O
detecting	O
rhinovirus	O
,	O
human	O
metapneumovirus	O
,	O
and	O
coronavirus	O
].	O

Anti	O
-	O
EN	O
antibody	B-FUNC
was	O
positive	O
in	O
the	O
sera	B-FUNC
of	O
40	O
.	O
9	O
%	O
of	O
SARS	O
patients	O
.	O

TITLE	O
:	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
RB1	O
genetic	O
variants	O
contribute	O
to	O
human	O
susceptibility	O
to	O
severe	O
acute	O
respiratory	O
syndrome	O
infection	O
among	O
Chinese	O
.	O

The	O
distribution	O
of	O
aquaporin	B-FUNC
-	O
4	O
(	O
AQP	O
-	O
4	O
)	O
on	O
the	O
cell	O
membrane	O
was	O
observed	O
with	O
immunohistochemistry	O
,	O
and	O
the	O
expression	O
of	O
AQP	O
-	O
4	O
mRNA	O
was	O
detected	O
with	O
RT	O
-	O
PCR	O
.	O

The	O
sera	B-FUNC
of	O
55	O
fulvous	O
fruit	O
bats	O
(	O
Rousettus	O
dasymallus	O
)	O
were	O
tested	O
using	O
the	O
SPA	O
-	O
ELISA	O
.	O

Coronavirus	O
antibody	B-FUNC
was	O
detected	O
in	O
2	O
out	O
of	O
the	O
55	O
bat	O
serum	O
samples	O
.	O

To	O
evaluate	O
the	O
utility	O
of	O
this	O
system	O
we	O
constructed	O
DeltaE1	O
/	O
DeltaE2	O
vector	O
carrying	O
different	O
classes	O
of	O
protein	O
,	O
that	O
is	O
,	O
the	O
gene	O
coding	O
for	O
spike	O
protein	O
derived	O
from	O
the	O
Coronavirus	O
causing	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
-	O
CoV	O
),	O
a	O
gene	O
coding	O
for	O
the	O
SARS	O
-	O
CoV	O
receptor	O
or	O
the	O
genes	O
coding	O
for	O
an	O
antibody	B-FUNC
shown	O
to	O
bind	B-FUNC
and	O
neutralize	O
SARS	O
-	O
CoV	O
(	O
SARS	O
-	O
AB	O
).	O

The	O
lung	O
MPO	B-FUNC
,	O
malondialdehyde	O
(	O
MDA	O
),	O
protein	O
carbonyl	O
and	O
NO	O
levels	O
were	O
higher	O
in	O
the	O
sepsis	O
group	O
when	O
compared	O
to	O
group	O
control	O
,	O
sham	O
,	O
leflunomide	O
and	O
sepsis	O
+	O
leflunomide	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
and	O
MPO	B-FUNC
,	O
MDA	O
and	O
NO	O
levels	O
were	O
higher	O
in	O
the	O
sepsis	O
+	O
leflunomide	O
group	O
than	O
in	O
the	O
sham	O
,	O
control	O
and	O
leflunomide	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Twenty	O
-	O
nine	O
of	O
these	O
cats	O
were	O
FECV	O
naïve	O
before	O
infection	O
and	O
followed	O
sequentially	O
for	O
fecal	O
virus	O
shedding	O
and	O
antibody	B-FUNC
responses	O
over	O
a	O
period	O
of	O
8	O
-	O
48	O
months	O
.	O

ABSTRACT	O
:	O
The	O
human	O
leukocyte	O
antigen	O
(	O
HLA	O
)	O
class	O
I	O
system	O
comprises	O
a	O
highly	O
polymorphic	O
set	O
of	O
molecules	O
that	O
specifically	O
bind	B-FUNC
and	O
present	O
peptides	O
to	O
cytotoxic	O
T	O
cells	O
.	O

The	O
GBP	O
-	O
fusion	O
method	O
allows	O
immobilization	O
of	O
proteins	O
in	O
bioactive	O
forms	O
onto	O
the	O
gold	O
surface	O
without	O
surface	O
modification	O
suitable	O
for	O
studying	O
antigen	O
-	O
antibody	B-FUNC
interaction	O
.	O

Viral	O
antibody	B-FUNC
titers	O
to	O
eight	O
respiratory	O
viruses	O
(	O
influenza	O
A	O
and	O
B	O
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
parainfluenza	O
virus	O
serotype	O
three	O
(	O
PIV	O
-	O
3	O
),	O
PIV	O
-	O
2	O
,	O
human	O
metapneumovirus	O
(	O
hMPV	O
),	O
and	O
coronaviruses	O
229E	O
and	O
OC43	O
)	O
were	O
measured	O
using	O
enzyme	O
immunoassay	O
at	O
baseline	O
and	O
53	O
weeks	O
.	O

In	O
one	O
of	O
the	O
structures	O
,	O
the	O
thioester	O
product	O
has	O
been	O
hydrolyzed	O
and	O
benzoic	O
acid	O
is	O
observed	O
to	O
bind	B-FUNC
to	O
the	O
hydrophobic	O
S2	O
pocket	O
.	O

RESULTS	O
:	O
Significantly	O
altered	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
7	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
and	O
IL	B-FUNC
-	I-FUNC
13	I-FUNC
were	O
detected	O
within	O
the	O
first	O
7	O
days	O
after	O
admission	O
in	O
serum	O
from	O
burn	O
pediatric	O
patients	O
with	O
concomitant	O
inhalation	O
injury	O
who	O
did	O
not	O
survive	O
when	O
compared	O
with	O
similar	O
patients	O
who	O
did	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

In	O
contrast	O
,	O
treatment	O
of	O
mice	O
with	O
anti	O
-	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
/	O
23p40	O
or	O
anti	O
-	O
IL	O
-	O
23p19	O
resulted	O
in	O
inhibition	O
of	O
the	O
autoimmune	O
model	O
of	O
demyelination	O
,	O
experimental	O
autoimmune	O
encephalomyelitis	O
(	O
EAE	O
).	O

ABSTRACT	O
:	O
Complement	O
staining	O
as	O
a	O
predictor	O
of	O
antibody	B-FUNC
-	O
mediated	O
rejection	O
(	O
AMR	O
)	O
after	O
lung	O
transplantation	O
continues	O
to	O
be	O
debated	O
.	O

Mannose	O
-	O
binding	B-FUNC
lectin	O
(	O
MBL	O
)	O
and	O
MBL	O
-	O
associated	O
serine	O
protease	O
2	O
(	O
MASP	O
-	O
2	O
)	O
deficiencies	O
are	O
common	O
primary	O
immunodeficiencies	O
the	O
clinical	O
penetrance	O
of	O
which	O
remains	O
controversial	O
.	O

DUB	O
activity	O
is	O
usually	O
assayed	O
using	O
full	O
-	O
length	O
ubiquitin	B-FUNC
,	O
and	O
these	O
enzymes	O
generally	O
show	O
low	O
activity	O
towards	O
small	O
substrates	O
that	O
constitute	O
the	O
P4	O
-	O
P1	O
LRGG	O
(	O
Lys	O
-	O
Arg	O
-	O
Gly	O
-	O
Gly	O
)	O
C	O
-	O
terminal	O
motif	O
of	O
ubiquitin	B-FUNC
.	O

As	O
part	O
of	O
such	O
efforts	O
,	O
a	O
simple	O
,	O
easy	O
to	O
use	O
immunoswab	O
method	O
was	O
developed	O
by	O
generating	O
a	O
panel	O
of	O
monoclonal	O
antibodies	O
(	O
MAbs	O
),	O
Bispecific	O
MAbs	O
and	O
chicken	O
polyclonal	O
IgY	O
antibody	B-FUNC
against	O
the	O
SARS	O
-	O
CoV	O
nucleocapsid	O
protein	O
(	O
NP	O
).	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
3a	O
protein	O
activates	O
the	O
mitochondrial	O
death	O
pathway	O
through	O
p38	B-FUNC
MAP	O
kinase	O
activation	O
.	O

In	O
the	O
intrinsic	O
pathway	O
,	O
there	O
was	O
activation	O
of	O
caspase	O
-	O
9	O
and	O
cytochrome	B-FUNC
c	I-FUNC
release	O
from	O
the	O
mitochondria	O
.	O

This	O
was	O
the	O
result	O
of	O
increased	O
Bax	O
oligomerization	O
and	O
higher	O
levels	O
of	O
p53	O
in	O
3a	O
protein	O
-	O
expressing	O
cells	O
,	O
which	O
depended	O
on	O
the	O
activation	O
of	O
p38	B-FUNC
MAP	O
kinase	O
(	O
MAPK	B-FUNC
)	O
in	O
these	O
cells	O
.	O

In	O
direct	O
Annexin	O
V	O
staining	O
assays	O
,	O
the	O
3a	O
protein	O
-	O
expressing	O
cells	O
showed	O
increased	O
apoptosis	O
that	O
was	O
attenuated	O
with	O
the	O
p38	B-FUNC
MAPK	B-FUNC
inhibitor	O
SB203580	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
3C	O
-	O
like	O
proteinase	B-FUNC
(	O
3CLpro	O
)	O
plays	O
important	O
roles	O
in	O
viral	O
life	O
cycle	O
through	O
extensive	O
processing	O
of	O
the	O
polyproteins	O
1a	O
and	O
1ab	O
into	O
12	O
mature	O
,	O
non	O
-	O
structural	O
proteins	O
(	O
nsp5	O
-	O
nsp16	O
).	O

We	O
tested	O
sera	B-FUNC
collected	O
from	O
12	O
ocelots	O
(	O
Leopardus	O
pardalis	O
)	O
native	O
to	O
Barro	O
Colorado	O
Island	O
,	O
Panama	O
,	O
which	O
is	O
free	O
of	O
domestic	O
animals	O
,	O
for	O
antibodies	O
to	O
feline	O
herpes	O
virus	O
,	O
feline	O
calicivirus	O
,	O
feline	O
corona	O
virus	O
,	O
feline	O
panleukopenia	O
virus	O
,	O
canine	O
distemper	O
virus	O
,	O
and	O
feline	O
immunodeficiency	O
virus	O
(	O
FIV	O
),	O
typically	O
a	O
species	O
-	O
specific	O
infection	O
.	O

Later	O
,	O
we	O
screened	O
his	O
sera	B-FUNC
for	O
antibodies	O
to	O
anti	O
-	O
aminoacyl	O
tRNA	B-FUNC
synthetase	O
to	O
diagnose	O
anti	O
-	O
aminoacyl	O
tRNA	B-FUNC
synthetase	O
syndrome	O
because	O
anti	O
-	O
PL	O
-	O
12	O
antibodies	O
were	O
positive	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
overexpression	O
of	O
ORF	O
-	O
6	O
also	O
induces	O
apoptosis	O
and	O
that	O
Caspase	O
-	O
3	O
inhibitor	O
and	O
JNK	B-FUNC
inhibitor	O
block	O
ORF	O
-	O
6	O
induced	O
apoptosis	O
.	O

Additional	O
doses	O
of	O
vaccine	O
increased	O
the	O
production	O
of	O
neutralising	O
antibody	B-FUNC
5	O
-	O
fold	O
compared	O
with	O
a	O
single	O
dose	O
.	O

The	O
S1	O
domain	O
mediates	O
the	O
binding	B-FUNC
of	O
the	O
virus	O
to	O
its	O
receptor	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
,	O
which	O
is	O
abundantly	O
distributed	O
on	O
the	O
surface	O
of	O
human	O
lung	O
cells	O
.	O

Here	O
we	O
describe	O
a	O
discovery	O
platform	O
that	O
utilizes	O
self	O
-	O
inactivating	O
(	O
SIN	O
)	O
lentiviral	O
vectors	O
for	O
the	O
surface	O
display	O
of	O
high	O
-	O
affinity	O
single	O
-	O
chain	O
variable	O
region	O
(	O
scFv	O
)	O
antibody	B-FUNC
fragments	O
on	O
human	O
cells	O
and	O
lentivirus	O
particles	O
.	O

Bivalent	O
scFvFc	O
human	O
antibodies	O
were	O
fused	O
in	O
frame	O
with	O
different	O
transmembrane	O
(	O
TM	O
)	O
anchoring	B-FUNC
moieties	O
to	O
allow	O
efficient	O
high	O
-	O
level	O
expression	O
on	O
human	O
cells	O
and	O
the	O
optimal	O
TM	O
was	O
identified	O
.	O

This	O
antibody	B-FUNC
display	O
platform	O
will	O
complement	O
existing	O
technologies	O
by	O
virtue	O
of	O
providing	O
properties	O
unique	O
to	O
lentiviruses	O
and	O
antibody	B-FUNC
expression	O
in	O
human	O
cells	O
,	O
which	O
,	O
in	O
turn	O
,	O
may	O
aid	O
the	O
discovery	O
of	O
novel	O
therapeutic	O
human	O
mAbs	O
.	O

ACS	B-FUNC
was	O
discussed	O
followed	O
by	O
a	O
short	O
review	O
of	O
the	O
literature	O
.	O

Depletion	O
of	O
cholesterol	O
from	O
the	O
ACE2	O
-	O
expressing	O
cells	O
reduced	O
the	O
binding	B-FUNC
of	O
S	O
-	O
expressing	O
cells	O
by	O
50	O
%	O
whereas	O
the	O
binding	B-FUNC
of	O
soluble	O
S	O
protein	O
was	O
not	O
affected	O
.	O

Animal	O
age	O
was	O
significantly	O
associated	O
with	O
increased	O
antibody	B-FUNC
prevalence	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

How	O
these	O
structures	O
are	O
assembled	O
is	O
still	O
largely	O
unknown	O
,	O
but	O
it	O
is	O
likely	O
that	O
the	O
membrane	O
-	O
spanning	O
members	O
of	O
these	O
nonstructural	O
proteins	O
(	O
nsps	O
)	O
are	O
responsible	O
for	O
the	O
induction	O
of	O
the	O
double	O
-	O
membrane	O
vesicles	O
and	O
for	O
anchoring	B-FUNC
the	O
replication	O
complexes	O
to	O
these	O
membranes	O
.	O

TITLE	O
:	O
Neuroprotective	O
effect	O
of	O
apolipoprotein	B-FUNC
D	O
against	O
human	O
coronavirus	O
OC43	O
-	O
induced	O
encephalitis	O
in	O
mice	O
.	O

Novel	O
peptide	O
-	O
aldehyde	O
derivatives	O
containing	O
a	O
side	O
-	O
chain	O
-	O
protected	O
C	O
-	O
terminal	O
Gln	O
efficiently	O
inhibited	O
the	O
catalytic	B-FUNC
activity	I-FUNC
of	O
the	O
R188I	O
mutant	O
.	O

While	O
normal	O
DPD	B-FUNC
enzyme	B-FUNC
activity	I-FUNC
is	O
rate	O
limiting	O
in	O
5	O
-	O
FU	O
catabolism	O
,	O
its	O
deficiency	O
could	O
increase	O
concentrations	O
of	O
bioavailable	O
5	O
-	O
FU	O
anabolic	O
products	O
leading	O
to	O
5	O
-	O
FU	O
related	O
toxicity	O
syndrome	O
.	O

Screening	O
patients	O
for	O
DPD	B-FUNC
deficiency	O
prior	O
to	O
administration	O
of	O
5	O
-	O
FU	O
or	O
capecitabine	O
using	O
UraBT	O
could	O
potentially	O
lower	O
risk	O
of	O
toxicity	O
.	O

As	O
the	O
cell	O
surface	O
is	O
cleared	O
from	O
viral	O
proteins	O
,	O
internalization	O
might	O
offer	O
protection	O
against	O
antibody	B-FUNC
-	O
dependent	O
cell	O
lysis	O
.	O

Taken	O
together	O
,	O
pure	B-FUNC
and	O
biological	O
active	O
RBD	O
of	O
the	O
S	O
protein	O
could	O
be	O
expressed	O
in	O
P	O
.	O
pastoris	O
,	O
and	O
the	O
P	O
.	O
pastoris	O
expression	O
platform	O
will	O
be	O
a	O
good	O
alternative	O
for	O
the	O
expression	O
of	O
viral	O
proteins	O
,	O
in	O
particular	O
,	O
the	O
highly	O
glycosylated	O
surface	O
proteins	O
that	O
mediate	O
the	O
tissue	O
tropism	O
and	O
viral	O
entry	O
.	O

We	O
found	O
that	O
cathepsin	O
L	O
(	O
CPL	B-FUNC
)	O
inhibitors	O
blocked	O
229E	O
infection	O
the	O
most	O
remarkably	O
among	O
a	O
variety	O
of	O
protease	O
inhibitors	O
tested	O
.	O

The	O
active	O
-	O
site	O
residues	O
responsible	O
for	O
mediating	O
ADRP	O
activity	O
were	O
found	O
to	O
be	O
highly	O
conserved	O
in	O
terms	O
of	O
both	O
sequence	O
alignment	O
and	O
structural	O
superposition	O
,	O
whereas	O
the	O
substrate	O
binding	B-FUNC
pocket	O
exhibited	O
variations	O
in	O
structure	O
but	O
not	O
in	O
sequence	O
.	O

Of	O
interest	O
,	O
the	O
frequency	O
of	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
-	O
positive	O
cells	O
elicited	O
by	O
the	O
SARS	O
-	O
CoV	O
3a	O
DNA	O
vaccine	O
was	O
significantly	O
higher	O
than	O
that	O
elicited	O
by	O
the	O
SL	O
-	O
CoV	O
3a	O
DNA	O
vaccine	O
.	O

A	O
detailed	O
examination	O
of	O
SARS	O
-	O
CoV	O
infected	O
animal	O
and	O
human	O
convalescent	O
sera	B-FUNC
could	O
provide	O
evidence	O
of	O
nAb	O
pressure	O
which	O
,	O
if	O
found	O
,	O
may	O
lead	O
to	O
strategies	O
to	O
effectively	O
block	O
virus	O
evolution	O
pathways	O
by	O
broadening	O
the	O
activity	O
of	O
nAbs	O
.	O

In	O
the	O
airsacs	O
,	O
a	O
few	O
bacteria	O
were	O
found	O
from	O
0	O
.	O
5	O
hpi	B-FUNC
up	O
to	O
4	O
dpi	O
in	O
E	O
.	O
coli	O
and	O
IBV	O
-	O
E	O
.	O
coli	O
inoculated	O
birds	O
.	O

Within	O
two	O
hours	O
of	O
iLA	O
treatment	O
,	O
arterial	O
oxygen	O
partial	O
pressure	O
/	O
inspired	O
oxygen	O
fraction	O
ratio	O
increased	O
significantly	O
and	O
a	O
fast	B-FUNC
improvement	O
in	O
arterial	O
carbon	O
dioxide	O
partial	O
pressure	O
and	O
pH	O
was	O
observed	O
.	O

ABSTRACT	O
:	O
Propagation	O
of	O
new	O
human	O
respiratory	O
virus	O
pathogens	O
in	O
established	O
cell	O
lines	O
is	O
hampered	O
by	O
a	O
lack	O
of	O
predictability	O
regarding	O
cell	O
line	O
permissivity	O
and	O
by	O
availability	O
of	O
suitable	O
antibody	B-FUNC
reagents	O
to	O
detect	O
infection	O
in	O
cell	O
lines	O
that	O
do	O
not	O
exhibit	O
significant	O
cytopathic	O
effect	O
.	O

Compared	O
to	O
healthy	O
group	O
and	O
SARS	O
non	O
-	O
AVNFH	O
group	O
,	O
transthyretin	O
,	O
C4B3	O
,	O
fibrinogen	O
gamma	O
,	O
apolipoprotein	B-FUNC
L	O
,	O
apolipoprotein	B-FUNC
A	O
-	O
IV	O
precursor	O
,	O
albumin	O
and	O
prealbumin	O
showed	O
lower	O
expression	O
,	O
inversely	O
serpin	O
peptidase	O
inhibitor	O
,	O
alpha	O
-	O
1	O
-	O
antitrypsin	O
precursor	O
and	O
serum	O
amyloid	O
P	O
components	O
showed	O
higher	O
expression	O
in	O
serum	O
in	O
the	O
SARS	O
AVNFH	O
necrosis	O
group	O
.	O

This	O
polypeptide	O
cocktail	O
was	O
also	O
used	O
to	O
set	O
up	O
an	O
ELISA	O
-	O
based	O
IgG	O
-	O
plus	O
-	O
IgM	O
antibody	B-FUNC
detection	O
test	O
,	O
which	O
showed	O
99	O
%	O
specificity	O
and	O
90	O
%	O
sensitivity	O
upon	O
evaluation	O
using	O
sera	B-FUNC
from	O
100	O
healthy	O
negative	O
controls	O
and	O
20	O
SARS	O
patients	O
.	O

Furthermore	O
,	O
the	O
epitope	O
-	O
specific	O
T	O
cells	O
from	O
naive	O
donors	O
secreted	O
IFN	O
-	O
gamma	O
and	O
IL	B-FUNC
-	I-FUNC
13	I-FUNC
upon	O
re	O
-	O
stimulation	O
with	O
corresponding	O
tetramers	O
.	O

Here	O
we	O
show	O
that	O
all	O
disordered	O
regions	O
are	O
also	O
capable	O
of	O
binding	B-FUNC
to	O
RNA	O
.	O

Patients	O
with	O
positive	O
results	O
of	O
either	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
or	O
antibody	B-FUNC
to	O
SARS	O
coronavirus	O
were	O
defined	O
as	O
SARS	O
cases	O
and	O
others	O
with	O
negative	O
results	O
as	O
control	O
cases	O
.	O

Thus	O
,	O
VSV	O
pseudotyped	O
with	O
SARS	O
-	O
CoV	O
S	O
protein	O
is	O
useful	O
for	O
developing	O
a	O
rapid	O
detection	O
system	O
for	O
neutralizing	O
antibody	B-FUNC
specific	O
for	O
SARS	O
-	O
CoV	O
infection	O
as	O
well	O
as	O
studying	O
the	O
S	O
-	O
mediated	O
cell	O
entry	O
of	O
SARS	O
-	O
CoV	O
.	O

TITLE	O
:	O
Identification	O
of	O
sugar	O
residues	O
involved	O
in	O
the	O
binding	B-FUNC
of	O
TGEV	O
to	O
porcine	O
brush	O
border	O
membranes	O
.	O

Here	O
we	O
show	O
that	O
infection	O
of	O
primary	O
blood	O
-	O
derived	O
feline	O
mononuclear	O
cells	O
by	O
FIPV	O
WSU	O
79	O
-	O
1146	O
and	O
FIPV	O
-	O
DF2	O
leads	O
to	O
rapid	O
activation	O
of	O
the	O
p38	B-FUNC
MAPK	B-FUNC
pathway	O
and	O
that	O
this	O
activation	O
regulates	O
production	O
of	O
the	O
pro	O
-	O
inflammatory	O
cytokine	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
and	O
interleukin	O
-	O
1	O
beta	O
(	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
beta	O
).	O

FIPV	O
-	O
induced	O
p38	B-FUNC
MAPK	B-FUNC
activation	O
and	O
pro	O
-	O
inflammatory	O
cytokine	O
production	O
was	O
inhibited	O
by	O
the	O
pyridinyl	O
imidazole	O
inhibitors	O
SB	O
203580	O
and	O
SC	O
409	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

FIPV	O
-	O
induced	O
p38	B-FUNC
MAPK	B-FUNC
activation	O
was	O
observed	O
in	O
primary	O
feline	O
blood	O
-	O
derived	O
mononuclear	O
cells	O
individually	O
purified	O
from	O
multiple	O
SPF	O
cats	O
,	O
as	O
was	O
the	O
inhibition	O
of	O
TNF	O
-	O
alpha	O
production	O
by	O
pyridinyl	O
imidazole	O
inhibitors	O
.	O

TITLE	O
:	O
Parallel	O
synthesis	O
,	O
molecular	O
modelling	O
and	O
further	O
structure	O
-	O
activity	O
relationship	O
studies	O
of	O
new	O
acylthiocarbamates	O
as	O
potent	O
non	O
-	O
nucleoside	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
inhibitors	O
.	O

Here	O
,	O
we	O
report	O
that	O
mice	O
deficient	O
in	O
MyD88	O
(	O
MyD88	O
(-/-)),	O
an	O
adapter	O
protein	O
that	O
mediates	O
Toll	O
-	O
like	O
receptor	O
(	O
TLR	O
),	O
IL	B-FUNC
-	I-FUNC
1R	I-FUNC
,	O
and	O
IL	B-FUNC
-	I-FUNC
18R	I-FUNC
signaling	O
,	O
are	O
far	O
more	O
susceptible	O
to	O
rMA15	O
infection	O
.	O

Similar	O
numbers	O
of	O
virus	O
-	O
specific	O
CD8	O
(+)	O
T	O
cells	O
were	O
retained	O
in	O
the	O
CNS	O
of	O
IL	B-FUNC
-	I-FUNC
15	I-FUNC
(-/-)	O
and	O
wt	O
mice	O
,	O
consistent	O
with	O
loss	O
of	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
/	O
15	O
receptor	O
(	O
CD122	O
)	O
expression	O
.	O

Mass	O
spectrometric	O
analysis	O
and	O
deletion	O
mapping	O
showed	O
that	O
the	O
major	O
phosphorylation	O
sites	O
were	O
located	O
at	O
the	O
central	O
serine	O
-	O
arginine	O
(	O
SR	O
)-	O
rich	O
motif	O
that	O
contains	O
several	O
glycogen	O
synthase	O
kinase	O
(	O
GSK	B-FUNC
)-	O
3	O
substrate	O
consensus	O
sequences	O
.	O

Mutation	O
of	O
the	O
two	O
priming	O
sites	O
critical	O
for	O
GSK	B-FUNC
-	O
3	O
phosphorylation	O
in	O
the	O
SR	O
-	O
rich	O
motif	O
abolished	O
N	O
protein	O
phosphorylation	O
.	O

Instead	O
,	O
the	O
downregulation	O
of	O
ENaC	O
activity	O
by	O
SARS	O
proteins	O
was	O
partially	O
or	O
completely	O
restored	O
by	O
administration	O
of	O
inhibitors	O
of	O
PKCalpha	B-FUNC
/	O
beta1	O
and	O
PKCzeta	B-FUNC
.	O

ABSTRACT	O
:	O
The	O
hyperinduction	O
of	O
proinflammatory	O
cytokines	O
and	O
chemokines	O
such	O
as	O
TNF	O
-	O
alpha	O
,	O
IFN	O
-	O
beta	O
,	O
and	O
CCL2	O
/	O
MCP	B-FUNC
-	O
1	O
in	O
primary	O
human	O
macrophages	O
and	O
respiratory	O
epithelial	O
cells	O
by	O
the	O
highly	O
pathogenic	O
avian	O
influenza	O
H5N1	O
is	O
believed	O
to	O
contribute	O
to	O
the	O
unusual	O
severity	O
of	O
human	O
H5N1	O
disease	O
.	O

We	O
conclude	O
that	O
IRF3	O
and	O
p38	B-FUNC
kinase	O
separately	O
and	O
predominantly	O
contribute	O
to	O
H5N1	O
-	O
mediated	O
induction	O
of	O
IFN	O
-	O
beta	O
,	O
IFN	O
-	O
lambda1	O
,	O
and	O
MCP	B-FUNC
-	O
1	O
but	O
only	O
partly	O
control	O
TNF	O
-	O
alpha	O
induction	O
.	O

Here	O
we	O
compared	O
the	O
IBV	O
strains	O
Beaudette	O
,	O
4	O
/	O
91	O
,	O
Italy02	O
,	O
and	O
QX	O
for	O
their	O
sialic	O
acid	O
-	O
binding	B-FUNC
properties	O
.	O

Also	O
,	O
titration	O
of	O
S	O
protein	O
-	O
specific	O
production	O
and	O
secretion	O
of	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
by	O
ELISA	O
showed	O
that	O
the	O
dose	O
of	O
5	O
.	O
6nM	O
of	O
S	O
produced	O
a	O
significant	O
increase	O
in	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
(	O
p	O
=	O
0	O
.	O
003	O
)	O
compared	O
to	O
mock	O
-	O
treated	O
controls	O
.	O

TITLE	O
:	O
A	O
computational	O
analysis	O
of	O
SARS	O
cysteine	O
proteinase	B-FUNC
-	O
octapeptide	O
substrate	O
interaction	O
:	O
implication	O
for	O
structure	O
and	O
active	O
site	O
binding	B-FUNC
mechanism	O
.	O

The	O
hypothesis	O
proposed	O
that	O
Glu47	O
of	O
SARS	O
CoVMpro	O
is	O
an	O
important	O
residue	O
in	O
the	O
S3	O
subsite	O
and	O
is	O
involved	O
in	O
binding	B-FUNC
with	O
P3Lys	O
of	O
the	O
octapeptide	O
.	O

The	O
secreted	O
SQ	O
protein	O
in	O
which	O
the	O
transmembrane	O
domain	O
was	O
deleted	O
,	O
as	O
well	O
as	O
the	O
full	O
-	O
length	O
spike	O
protein	O
,	O
showed	O
the	O
most	O
potential	O
to	O
induce	O
the	O
production	O
of	O
neutralizing	O
antibody	B-FUNC
(	O
nAb	O
)	O
in	O
mice	O
.	O

In	O
addition	O
,	O
the	O
S	O
proteins	O
were	O
recognized	O
specifically	O
by	O
the	O
sera	B-FUNC
of	O
convalescent	O
patients	O
with	O
SARS	O
,	O
and	O
that	O
of	O
mice	O
immunized	O
with	O
inactivated	O
SARS	O
-	O
CoV	O
,	O
but	O
did	O
not	O
react	O
with	O
anti	O
-	O
sera	B-FUNC
of	O
HCoV	O
-	O
OC43	O
or	O
HCoV	O
-	O
229E	O
,	O
or	O
sera	B-FUNC
from	O
healthy	O
donors	O
(	O
although	O
RBD	O
showed	O
a	O
false	O
-	O
positive	O
in	O
1	O
of	O
55	O
control	O
samples	O
of	O
human	O
sera	B-FUNC
).	O

Serum	O
or	O
lung	O
homogenate	O
levels	O
of	O
some	O
cytokines	O
such	O
as	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
and	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
(	O
IFN	O
-	O
gamma	O
)	O
along	O
with	O
acute	O
injury	O
lung	O
index	O
and	O
histology	O
were	O
also	O
analyzed	O
.	O

Most	O
of	O
these	O
more	O
recently	O
developed	O
antiviral	O
mAbs	O
have	O
come	O
from	O
the	O
use	O
of	O
antibody	B-FUNC
phage	O
-	O
display	O
technologies	O
and	O
the	O
implementation	O
of	O
simplified	O
,	O
inexpensive	O
yet	O
efficient	O
methods	O
,	O
for	O
expressing	O
and	O
purifying	O
the	O
initially	O
selected	O
fragment	O
antibodies	O
is	O
of	O
prime	O
importance	O
in	O
further	O
facilitating	O
this	O
area	O
of	O
research	O
.	O

ABSTRACT	O
:	O
Differential	O
scanning	O
calorimetry	O
,	O
circular	O
dichroism	O
spectroscopy	O
,	O
nuclear	O
magnetic	O
resonance	O
spectroscopy	O
,	O
and	O
numerical	O
simulations	O
were	O
used	O
to	O
study	O
the	O
thermostability	O
of	O
the	O
N	O
-	O
terminal	O
RNA	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
the	O
SARS	O
-	O
CoV	O
nucleocapsid	O
protein	O
.	O

The	O
high	O
mortality	O
of	O
SARS	O
,	O
the	O
identification	O
of	O
a	O
natural	O
reservoir	O
,	O
and	O
the	O
well	O
-	O
founded	O
fear	O
of	O
provoking	O
antibody	B-FUNC
-	O
enhanced	O
disease	O
as	O
a	O
result	O
of	O
vaccination	O
fueled	O
the	O
ongoing	O
efforts	O
in	O
anti	O
-	O
coronavirus	O
drug	O
discovery	O
.	O

TITLE	O
:	O
Neutralizing	O
antibody	B-FUNC
against	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
coronavirus	O
spike	O
is	O
highly	O
effective	O
for	O
the	O
protection	O
of	O
mice	O
in	O
the	O
murine	O
SARS	O
model	O
.	O

Symptoms	O
did	O
not	O
improve	O
with	O
steroid	O
or	O
immunoglobulin	B-FUNC
treatment	O
,	O
but	O
improvement	O
in	O
symptoms	O
was	O
observed	O
after	O
plasmapheresis	O
.	O

In	O
the	O
present	O
work	O
,	O
the	O
method	O
for	O
purification	O
of	O
duck	O
immunoglobulin	B-FUNC
A	O
was	O
developed	O
,	O
and	O
the	O
induction	O
of	O
intestinal	O
mucosal	O
immune	O
responses	O
against	O
DEV	O
was	O
studied	O
by	O
orally	O
infected	O
ducklings	O
with	O
virulent	O
DEV	O
.	O

The	O
results	O
indicate	O
that	O
the	O
DVE	O
infection	O
can	O
stimulate	O
both	O
IgA	O
-	O
dominated	O
antibody	B-FUNC
immune	O
responses	O
in	O
the	O
intestinal	O
tract	O
,	O
and	O
IgG	O
-	O
dominated	O
antibody	B-FUNC
systemic	O
immunity	O
in	O
the	O
serum	O
of	O
ducklings	O
orally	O
inoculated	O
with	O
virulent	O
DEV	O
.	O

Finally	O
,	O
we	O
showed	O
that	O
8ab	O
binds	B-FUNC
to	O
the	O
luminal	O
domain	O
of	O
ATF6	O
.	O

Factors	O
independently	O
associated	O
with	O
multiple	O
-	O
type	O
HPV	O
were	O
Hispanic	O
ethnicity	O
[	O
adjusted	O
odds	O
ratio	O
(	O
AOR	B-FUNC
),	O
2	O
.	O
45	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
95	O
%	O
CI	O
),	O
1	O
.	O
05	O
-	O
5	O
.	O
67	O
],	O
concurrent	O
detection	O
of	O
genital	O
warts	O
(	O
AOR	B-FUNC
,	O
10	O
.	O
40	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
12	O
-	O
96	O
.	O
6	O
),	O
smoking	O
>	O
or	O
=	O
10	O
cigarettes	O
/	O
d	O
(	O
AOR	B-FUNC
,	O
3	O
.	O
00	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
07	O
-	O
8	O
.	O
43	O
),	O
greater	O
lifetime	O
number	O
of	O
female	O
sexual	O
partners	O
(	O
AOR	B-FUNC
,	O
13	O
.	O
73	O
for	O
>	O
or	O
=	O
21	O
versus	O
1	O
-	O
5	O
;	O
95	O
%	O
CI	O
,	O
5	O
.	O
34	O
-	O
35	O
.	O
3	O
),	O
and	O
condom	O
use	O
less	O
than	O
half	O
the	O
time	O
(	O
AOR	B-FUNC
,	O
2	O
.	O
03	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
07	O
-	O
3	O
.	O
84	O
).	O

ABSTRACT	O
:	O
The	O
coronavirus	O
spike	O
protein	O
(	O
S	O
)	O
plays	O
a	O
key	O
role	O
in	O
the	O
early	O
steps	O
of	O
viral	O
infection	O
,	O
with	O
the	O
S1	O
domain	O
responsible	O
for	O
receptor	B-FUNC
binding	I-FUNC
and	O
the	O
S2	O
domain	O
mediating	O
membrane	O
fusion	O
.	O

The	O
protection	O
was	O
associated	O
with	O
measurable	O
serum	O
antibody	B-FUNC
responses	O
to	O
both	O
the	O
nucleocapsid	O
and	O
S1	O
structural	O
proteins	O
of	O
TCoV	O
that	O
were	O
detectable	O
as	O
early	O
as	O
1	O
week	O
post	O
-	O
infection	O
.	O

Neutrophil	O
adhesion	O
to	O
,	O
surface	O
expression	O
of	O
ICAM	O
-	O
1	O
and	O
VCAM	O
-	O
1	O
on	O
,	O
and	O
release	O
of	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
G	O
-	O
CSF	O
from	O
A549	O
cells	O
were	O
measured	O
by	O
ELISA	O
after	O
stimulation	O
with	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
beta	O
or	O
TNFalpha	O
.	O

The	O
generation	O
of	O
cytokines	O
of	O
significance	O
for	O
adhesive	O
and	O
proliferative	O
events	O
in	O
host	O
defense	O
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
G	O
-	O
CSF	O
,	O
was	O
also	O
potently	O
impaired	O
by	O
EtP	O
.	O
Exposure	O
of	O
lung	O
epithelial	O
cells	O
to	O
2	O
.	O
5	O
-	O
10	O
mM	O
EtP	O
inhibited	O
the	O
generation	O
of	O
inflammatory	O
-	O
regulating	O
cytokines	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
G	O
-	O
CSF	O
,	O
reduced	O
ICAM	O
-	O
1	O
and	O
VCAM	O
-	O
1	O
expression	O
and	O
impeded	O
the	O
adhesiveness	O
of	O
neutrophils	O
to	O
lung	O
epithelial	O
cells	O
.	O

This	O
review	O
examines	O
dsRNA	O
including	O
Poly	O
ICLC	O
and	O
liposome	O
-	O
encapsulated	O
Poly	O
ICLC	O
(	O
LE	O
Poly	O
ICLC	O
)	O
as	O
TLR	O
-	O
3	O
agonists	O
for	O
their	O
antiviral	O
activity	O
against	O
seasonal	O
and	O
highly	O
pathogenic	O
avian	O
influenza	O
(	O
HPAI	B-FUNC
)	O
viruses	O
.	O

In	O
order	O
to	O
assess	O
the	O
role	O
of	O
activated	O
neutrophils	O
,	O
pro	O
-	O
and	O
anti	O
-	O
inflammatory	O
cytokines	O
and	O
adhesion	O
molecules	O
at	O
the	O
onset	O
and	O
development	O
of	O
respiratory	O
complications	O
and	O
respiratory	O
failure	O
,	O
we	O
measured	O
the	O
serum	O
levels	O
of	O
pro	O
-	O
inflammatory	O
(	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
beta	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
,	O
TNF	O
-	O
alpha	O
)	O
and	O
anti	O
-	O
inflammatory	O
(	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
ra	O
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
)	O
cytokines	O
in	O
51	O
AP	O
patients	O
who	O
had	O
been	O
diagnosed	O
with	O
pancreatitis	O
-	O
associated	O
lung	O
injury	O
with	O
and	O
without	O
the	O
development	O
of	O
organ	O
dysfunction	O
.	O

TITLE	O
:	O
[	O
Scleroedema	O
adultorum	O
Buschke	O
in	O
a	O
diabetic	O
subject	O
:	O
intravenous	O
immunoglobulin	B-FUNC
therapy	O
].	O

Both	O
a	O
rapid	O
viral	O
culture	O
with	O
direct	O
fluorescence	O
antibody	B-FUNC
(	O
DFA	O
)	O
staining	O
and	O
a	O
PCR	O
-	O
based	O
assay	O
(	O
MultiCode	O
-	O
PLx	O
Respiratory	O
Virus	O
Panel	O
)	O
were	O
performed	O
on	O
patients	O
with	O
hematologic	O
malignancies	O
,	O
who	O
underwent	O
collection	O
of	O
a	O
nasopharyngeal	O
swab	O
or	O
bronchoalveolar	O
lavage	O
from	O
October	O
2006	O
to	O
April	O
2007	O
.	O

The	O
best	O
docking	O
score	O
and	O
binding	B-FUNC
energy	O
for	O
6MP	O
and	O
6TG	O
is	O
against	O
ubiquitin	B-FUNC
-	O
specific	O
protease	O
(	O
USP	B-FUNC
)	O
14	O
,	O
suggesting	O
that	O
6MP	O
and	O
6TG	O
are	O
potential	O
inhibitors	O
of	O
USP14	O
.	O

Consequently	O
,	O
the	O
expression	O
of	O
M	O
protein	O
prevents	O
the	O
formation	O
of	O
TRAF3	O
.	O
TANK	O
.	O
TBK1	B-FUNC
/	O
IKKepsilon	O
complex	O
and	O
thereby	O
inhibits	O
TBK1	B-FUNC
/	O
IKKepsilon	O
-	O
dependent	O
activation	O
of	O
IRF3	O
/	O
IRF7	O
transcription	O
factors	O
.	O

We	O
found	O
that	O
RBD193	O
-	O
CHO	B-FUNC
reacted	O
strongly	O
with	O
a	O
panel	O
of	O
six	O
monoclonal	O
antibodies	O
recognizing	O
various	O
conformational	O
and	O
linear	O
epitopes	O
in	O
RBD	O
,	O
suggesting	O
that	O
this	O
recombinant	O
protein	O
maintains	O
intact	O
conformation	O
and	O
good	O
antigenicity	O
.	O

Immunization	O
of	O
mice	O
with	O
RBD193	O
-	O
CHO	B-FUNC
resulted	O
in	O
induction	O
of	O
high	O
titers	O
of	O
RBD	O
-	O
specific	O
neutralizing	O
antibodies	O
and	O
potent	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
-	O
expressing	O
T	O
cell	O
responses	O
.	O

RBD193	O
-	O
CHO	B-FUNC
induced	O
immunity	O
that	O
protected	O
a	O
majority	O
of	O
the	O
vaccinated	O
mice	O
from	O
SARS	O
-	O
CoV	O
challenge	O
.	O

Here	O
,	O
we	O
present	O
an	O
overview	O
of	O
recently	O
identified	O
substances	O
that	O
inhibit	O
and	O
/	O
or	O
reverse	O
endothelial	O
barrier	O
disruption	O
and	O
permeability	O
or	O
alveolar	O
epithelial	O
dysfunction	O
:	O
(	O
1	O
)	O
zinc	O
chelators	O
,	O
which	O
were	O
shown	O
to	O
attenuate	O
the	O
effects	O
of	O
oxidative	O
stress	O
on	O
the	O
pulmonary	O
endothelium	O
;	O
(	O
2	O
)	O
peroxisome	O
proliferator	O
activated	O
receptor	O
(	O
PPAR	O
)	O
ligands	O
,	O
which	O
have	O
been	O
shown	O
to	O
exert	O
anti	O
-	O
inflammatory	O
effects	O
,	O
by	O
decreasing	O
the	O
expression	O
of	O
pro	O
-	O
inflammatory	O
genes	O
;	O
(	O
3	O
)	O
extracellular	O
ATP	O
,	O
produced	O
during	O
inflammation	O
,	O
which	O
induces	O
a	O
rapid	O
and	O
dose	O
-	O
dependent	O
increase	O
in	O
transendothelial	O
electrical	O
resistance	O
(	O
TER	O
)	O
across	O
pulmonary	O
endothelial	O
cells	O
;	O
(	O
4	O
)	O
the	O
lectin	O
-	O
like	O
domain	O
of	O
TNF	O
,	O
which	O
is	O
spatially	O
distinct	O
from	O
the	O
receptor	B-FUNC
binding	I-FUNC
sites	O
and	O
which	O
protects	O
from	O
hydrostatic	O
and	O
permeability	O
edema	O
and	O
(	O
5	O
)	O
Hsp90	O
inhibitors	O
,	O
which	O
prevent	O
and	O
repair	O
toxin	O
-	O
induced	O
hyperpermeability	O
.	O

The	O
study	O
drugs	O
were	O
administered	O
after	O
a	O
12	O
-	O
hour	O
overnight	O
fast	B-FUNC
.	O

The	O
period	O
from	O
3	O
-	O
7	O
days	O
in	O
the	O
LPS	O
group	O
was	O
the	O
first	O
rapid	O
pulmonary	O
fibrosis	O
stage	O
,	O
whereas	O
the	O
second	O
fast	B-FUNC
fibrosis	O
stage	O
occurred	O
on	O
days	O
14	O
-	O
21	O
.	O

The	O
integrin	O
-	O
binding	B-FUNC
motif	O
Arg	O
-	O
Gly	O
-	O
Asp	O
(	O
RGD	O
)	O
was	O
incorporated	O
into	O
the	O
pcDNA	O
3	O
.	O
1	O
mammalian	O
expression	O
vector	O
expressing	O
the	O
codon	O
-	O
optimized	O
extracellular	O
domain	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
protein	O
,	O
and	O
tested	O
by	O
immunizing	O
C57BL	O
/	O
6	O
mice	O
.	O

To	O
test	O
for	O
associations	O
between	O
coronaviruses	O
and	O
serious	O
mental	O
disorders	O
,	O
we	O
utilized	O
a	O
recently	O
developed	O
assay	O
and	O
measured	O
immunoglobulin	B-FUNC
G	O
(	O
IgG	O
)	O
response	O
against	O
4	O
human	O
coronavirus	O
strains	O
(	O
229E	O
,	O
HKU1	O
,	O
NL63	O
,	O
and	O
OC43	O
)	O
in	O
106	O
patients	O
with	O
a	O
recent	O
onset	O
of	O
psychotic	O
symptoms	O
and	O
196	O
nonpsychiatric	O
controls	O
.	O

We	O
expressed	O
results	O
quantitatively	O
as	O
antibody	B-FUNC
levels	O
and	O
qualitatively	O
as	O
seroprevalence	O
relative	O
to	O
a	O
defined	O
seropositivity	O
cutoff	O
value	O
.	O

There	O
was	O
also	O
strong	O
induction	O
of	O
TNF	O
-	O
related	O
apoptosis	O
-	O
inducing	O
ligand	B-FUNC
(	O
TRAIL	O
),	O
but	O
not	O
Fas	O
ligand	B-FUNC
gene	O
expression	O
in	O
SARS	O
-	O
CoV	O
infected	O
DCs	O
.	O

RESULTS	O
:	O
Our	O
results	O
demonstrates	O
that	O
SARS	O
-	O
CoV	O
did	O
not	O
modulate	O
TLR	O
-	O
1	O
to	O
TLR	O
-	O
10	O
gene	O
expression	O
but	O
significantly	O
induced	O
the	O
expression	O
of	O
CCR	B-FUNC
-	O
1	O
,	O
CCR	B-FUNC
-	O
3	O
,	O
and	O
CCR	B-FUNC
-	O
5	O
.	O

The	O
rN	O
protein	O
-	O
specific	O
IgG	O
in	O
the	O
mouse	O
sera	B-FUNC
attained	O
a	O
titer	O
about	O
1	O
:	O
1	O
,	O
800	O
following	O
three	O
doses	O
of	O
immunization	O
,	O
which	O
suggested	O
effective	O
B	O
-	O
cell	O
maturation	O
and	O
differentiation	O
in	O
mice	O
.	O

Antibodies	O
of	O
the	O
subclasses	O
IgG1	O
and	O
IgG2a	O
were	O
abundantly	O
present	O
in	O
the	O
mouse	O
sera	B-FUNC
.	O

TITLE	O
:	O
Intragastric	O
administration	O
of	O
attenuated	O
Salmonella	O
typhimurium	O
harbouring	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
DNA	O
vaccine	O
induced	O
specific	O
antibody	B-FUNC
production	O
.	O

ABSTRACT	O
:	O
The	O
immunogenicity	O
of	O
SARS	O
-	O
CoV	O
nucleocapsid	O
DNA	O
vaccine	O
and	O
the	O
immunoregulatory	O
activity	O
of	O
interleukin	O
-	O
2	O
(	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
)	O
were	O
investigated	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
cytokine	O
expression	O
(	O
interleukin	O
[	O
IL	O
]-	O
1beta	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
[	O
TNF	O
]-	O
alpha	O
),	O
C	O
-	O
reactive	O
protein	O
,	O
and	O
endotoxins	O
on	O
the	O
first	O
day	O
of	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
admission	O
are	O
associated	O
with	O
hospital	O
mortality	O
in	O
severe	O
community	O
-	O
acquired	O
pneumonia	O
(	O
CAP	O
).	O

ABSTRACT	O
:	O
Red	O
cell	O
exchange	O
(	O
RCE	O
)	O
is	O
part	O
of	O
the	O
management	O
of	O
acute	O
chest	O
syndrome	O
(	O
ACS	B-FUNC
)	O
in	O
patients	O
with	O
sickle	O
cell	O
disease	O
.	O

We	O
retrospectively	O
reviewed	O
53	O
episodes	O
of	O
ACS	B-FUNC
in	O
44	O
patients	O
who	O
received	O
RCE	O
from	O
January	O
2003	O
to	O
October	O
2006	O
.	O

Using	O
an	O
enzyme	O
immunosorbent	O
assay	O
,	O
the	O
authors	O
compared	O
sera	B-FUNC
from	O
95	O
turkey	O
-	O
exposed	O
individuals	O
with	O
sera	B-FUNC
from	O
82	O
nonexposed	O
controls	O
for	O
serologic	O
evidence	O
of	O
infection	O
with	O
HEV	O
.	O

In	O
this	O
study	O
,	O
we	O
expressed	O
the	O
recombinant	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
rRBD	O
)	O
in	O
mammalian	O
(	O
293T	O
)	O
cells	O
,	O
insect	O
(	O
Sf9	O
)	O
cells	O
,	O
and	O
E	O
.	O
coli	O
,	O
respectively	O
,	O
and	O
compared	O
their	O
immunogenicity	O
and	O
protection	O
against	O
SARS	O
-	O
CoV	O
infection	O
in	O
an	O
established	O
mouse	O
model	O
.	O

Our	O
results	O
show	O
that	O
all	O
rRBD	O
proteins	O
expressed	O
in	O
the	O
above	O
systems	O
maintained	O
intact	O
conformation	O
,	O
being	O
able	O
to	O
induce	O
highly	O
potent	O
neutralizing	O
antibody	B-FUNC
responses	O
and	O
complete	O
protective	O
immunity	O
against	O
SARS	O
-	O
CoV	O
challenge	O
in	O
mice	O
,	O
albeit	O
the	O
rRBD	O
expressed	O
in	O
293T	O
cells	O
elicited	O
stronger	O
humoral	O
immune	O
responses	O
with	O
significantly	O
higher	O
neutralizing	O
activity	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
than	O
those	O
expressed	O
in	O
Sf9	O
and	O
E	O
.	O
coli	O
cells	O
.	O

ADCML	O
consists	O
of	O
virus	O
-	O
specific	O
antibodies	O
that	O
bind	B-FUNC
to	O
cell	O
surface	O
expressed	O
viral	O
proteins	O
which	O
result	O
in	O
complement	O
activation	O
and	O
cell	O
lysis	O
.	O

ABSTRACT	O
:	O
Hemagglutinin	O
esterases	B-FUNC
(	O
HEs	O
),	O
closely	O
related	O
envelope	O
glycoproteins	O
in	O
influenza	O
C	O
and	O
corona	O
-	O
and	O
toroviruses	O
,	O
mediate	O
reversible	O
attachment	O
to	O
O	O
-	O
acetylated	O
sialic	O
acids	O
(	O
Sias	O
).	O

Depending	O
on	O
mouse	O
strain	O
,	O
the	O
viral	O
fixation	O
to	O
heparan	O
sulfate	O
/	O
TLR2	O
stimulated	O
differently	O
the	O
p38	B-FUNC
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	B-FUNC
)	O
and	O
nuclear	O
factor	O
(	O
NF	O
)-	O
kappaB	O
in	O
the	O
induction	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
TNF	O
-	O
alpha	O
.	O

The	O
synergistic	O
IFN	O
-	O
gamma	O
production	O
involves	O
the	O
p38	B-FUNC
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	B-FUNC
)	O
rather	O
than	O
the	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
-	O
1	O
/	O
2	O
MAPK	B-FUNC
signalling	O
pathway	O
.	O

Treatment	O
with	O
PCN	O
significantly	O
increased	O
survival	O
and	O
was	O
marked	O
by	O
enhanced	O
viral	O
clearance	O
,	O
accelerated	O
induction	O
of	O
viral	O
-	O
specific	O
antibody	B-FUNC
production	O
,	O
and	O
significant	O
decreases	O
in	O
morbidity	O
and	O
lung	O
damage	O
.	O

Furthermore	O
,	O
GADD34	O
,	O
a	O
component	O
of	O
the	O
protein	O
phosphatase	B-FUNC
1	O
(	O
PP1	O
)	O
complex	O
,	O
which	O
dephosphorylates	O
eIF	O
-	O
2alpha	O
,	O
was	O
significantly	O
induced	O
in	O
IBV	O
-	O
infected	O
cells	O
.	O

of	O
IFN	O
-	O
gamma	O
and	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
contents	O
in	O
the	O
supernatant	O
of	O
spleen	O
cell	O
culture	O
in	O
immunized	O
group	O
.	O

Stoichiometric	O
NTD	O
fully	O
unwinds	O
a	O
TRS	B-FUNC
-	O
cTRS	O
duplex	O
that	O
mimics	O
a	O
transiently	O
formed	O
transcription	O
intermediate	O
in	O
viral	O
subgenomic	O
RNA	O
synthesis	O
.	O

Although	O
the	O
antibody	B-FUNC
levels	O
in	O
the	O
rFPV	O
-	O
IBVS1	O
-	O
ChIFNgamma	O
-	O
vaccinated	O
group	O
were	O
lower	O
than	O
those	O
in	O
the	O
attenuated	O
live	O
IB	O
vaccine	O
H120	O
group	O
and	O
the	O
rFPV	O
-	O
IBVS1	O
group	O
,	O
the	O
rFPV	O
-	O
IBVS1	O
-	O
ChIFNgamma	O
provided	O
the	O
strongest	O
protection	O
against	O
an	O
IBV	O
LX4	O
virus	O
challenge	O
(	O
15	O
out	O
of	O
16	O
chickens	O
immunized	O
with	O
rFPV	O
-	O
IBVS1	O
-	O
ChIFNgamma	O
were	O
protected	O
),	O
followed	O
by	O
the	O
attenuated	O
live	O
IB	O
vaccine	O
(	O
13	O
/	O
16	O
protected	O
)	O
and	O
the	O
rFPV	O
-	O
IBVS1	O
(	O
12	O
/	O
16	O
protected	O
).	O

We	O
searched	O
PubMed	O
for	O
all	O
SARS	O
antibody	B-FUNC
detection	O
papers	O
(	O
in	O
English	O
or	O
Chinese	O
language	O
)	O
using	O
the	O
keywords	O
'	O
SARS	O
'	O
and	O
'	B-FUNC
antibody	I-FUNC
'.	O

Interferon	O
gamma	O
(	O
IFN	O
gamma	O
)	O
secreting	O
peripheral	O
blood	O
mononuclear	O
cells	O
were	O
more	O
abundant	O
in	O
sows	O
but	O
not	O
specifically	O
increased	O
by	O
PRRSV	O
infection	O
in	O
any	O
age	O
group	O
,	O
and	O
interleukin	O
-	O
10	O
(	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
)	O
levels	O
in	O
blood	O
were	O
not	O
correlated	O
with	O
PRRSV	O
infection	O
status	O
.	O

To	O
understand	O
the	O
mechanism	O
by	O
which	O
a	O
virus	O
escapes	O
from	O
antibody	B-FUNC
-	O
mediated	O
neutralization	O
,	O
we	O
have	O
investigated	O
the	O
interactions	O
of	O
non	O
-	O
neutralizing	O
and	O
neutralizing	O
antibodies	O
at	O
an	O
epitope	O
cluster	O
on	O
the	O
spike	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

While	O
mAb	O
341C	O
binds	B-FUNC
to	O
a	O
mostly	O
linear	O
epitope	O
composed	O
of	O
residues	O
(	O
507	O
)	O
PAT	B-FUNC
(	O
509	O
)	O
and	O
V	O
(	O
349	O
),	O
mAb	O
240C	O
binds	B-FUNC
to	O
an	O
epitope	O
that	O
partially	O
overlaps	O
the	O
former	O
by	O
at	O
least	O
two	O
residues	O
(	O
P	O
(	O
507	O
)	O
and	O
A	O
(	O
508	O
)).	O

TITLE	O
:	O
The	O
RNA	B-FUNC
polymerase	I-FUNC
activity	I-FUNC
of	O
SARS	O
-	O
coronavirus	O
nsp12	O
is	O
primer	O
dependent	O
.	O

It	O
is	O
presumed	O
that	O
replication	O
and	O
transcription	O
of	O
the	O
approximately	O
30	O
-	O
kb	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
RNA	O
genome	O
are	O
catalyzed	O
by	O
an	O
RdRp	B-FUNC
domain	O
in	O
the	O
C	O
-	O
terminal	O
part	O
of	O
nonstructural	O
protein	O
12	O
(	O
nsp12	O
),	O
one	O
of	O
16	O
replicase	O
subunits	O
.	O

Although	O
many	O
methods	O
have	O
been	O
proposed	O
for	O
protein	O
structure	O
alignment	O
or	O
comparison	O
,	O
alternative	O
similarity	O
measures	O
are	O
still	O
strongly	O
demanded	O
due	O
to	O
the	O
requirement	O
of	O
fast	B-FUNC
screening	O
and	O
query	O
in	O
large	O
-	O
scale	O
structure	O
databases	O
.	O

Such	O
therapies	O
,	O
directed	O
at	O
host	O
-	O
cell	O
molecules	O
,	O
may	O
provide	O
alternative	O
options	O
for	O
combating	O
fast	B-FUNC
-	O
mutating	O
or	O
newly	O
emerging	O
pathogens	O
,	O
where	O
conventional	O
approaches	O
face	O
difficulties	O
.	O

We	O
determined	O
the	O
crystal	O
structure	O
of	O
NL63	O
-	O
CoV	O
spike	O
protein	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
complexed	O
with	O
human	O
ACE2	O
.	O

Airway	O
proteases	O
regulate	O
the	O
infectivity	O
of	O
SARS	O
-	O
CoV	O
in	O
a	O
fashion	O
dependent	O
on	O
previous	O
receptor	B-FUNC
binding	I-FUNC
.	O

H1N1	O
influenza	O
was	O
confirmed	O
with	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
assay	O
in	O
eight	O
patients	O
.	O

Limited	O
data	O
suggest	O
that	O
biological	O
agents	O
(	O
e	O
.	O
g	O
.	O
anti	O
-	O
TNF	O
-	O
alpha	O
,	O
anti	O
-	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
),	O
rituximab	O
or	O
intravenous	O
immunoglobulins	O
might	O
be	O
promising	O
for	O
the	O
treatment	O
of	O
severe	O
cases	O
.	O

ABSTRACT	O
:	O
The	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
spike	O
(	O
S	O
)	O
protein	O
plays	O
an	O
important	O
role	O
in	O
viral	O
infection	O
,	O
and	O
is	O
a	O
potential	O
major	O
neutralizing	O
determinant	O
.	O

Specific	O
parameters	O
assessed	O
in	O
the	O
innate	O
pulmonary	O
inflammatory	O
response	O
were	O
leukocytes	O
,	O
macrophages	O
,	O
and	O
polymorphonuclear	O
neutrophils	O
(	O
PMNs	O
)	O
in	O
BAL	O
;	O
whole	O
lung	O
myeloperoxidase	B-FUNC
activity	I-FUNC
;	O
and	O
a	O
series	O
of	O
cytokines	O
or	O
chemokines	O
present	O
in	O
BAL	O
at	O
5	O
or	O
24	O
hours	O
after	O
injury	O
:	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
alpha	O
,	O
interleukin	O
(	O
IL	O
)-	O
1beta	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
interferon	B-FUNC
-	I-FUNC
gamma	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
macrophage	O
inflammatory	O
protein	O
-	O
2	O
,	O
cytokine	O
-	O
induced	O
neutrophil	O
chemoattractant	O
-	O
1	O
,	O
and	O
monocyte	O
chemoattractant	O
protein	O
-	O
1	O
.	O

Cytokine	O
stimulation	O
increased	O
the	O
binding	B-FUNC
capability	O
of	O
anti	O
-	O
S2	O
antibodies	O
to	O
human	O
lung	O
epithelial	O
cells	O
.	O

Moreover	O
,	O
several	O
reports	O
describe	O
the	O
presence	O
of	O
autoantibodies	O
and	O
immune	O
complexes	O
[	O
anti	O
-	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
(	O
interleukin	O
-	O
8	O
)	O
autoantibody	O
/	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
complexes	O
]	O
in	O
lung	O
fluids	O
(	O
oedema	O
and	O
bronchoalveolar	O
lavage	O
fluids	O
)	O
from	O
patients	O
with	O
ALI	O
/	O
ARDS	O
.	O

The	O
7a	O
protein	O
is	O
present	O
in	O
the	O
virus	O
particle	O
and	O
has	O
been	O
shown	O
to	O
interact	O
with	O
several	O
host	O
proteins	O
;	O
thereby	O
implicating	O
it	O
as	O
being	O
involved	O
in	O
several	O
pathogenic	O
processes	O
including	O
apoptosis	O
,	O
inhibition	O
of	O
cellular	O
protein	O
synthesis	O
,	O
and	O
activation	O
of	O
p38	B-FUNC
mitogen	O
activated	O
protein	O
kinase	O
.	O

Illness	O
severity	O
was	O
measured	O
using	O
score	O
for	O
neonatal	O
acute	O
physiology	O
(	O
SNAP	B-FUNC
).	O

There	O
was	O
an	O
inverse	O
correlation	O
between	O
SNAP	B-FUNC
at	O
birth	O
and	O
fT	O
(	O
4	O
.)	O

This	O
CTF	O
is	O
able	O
to	O
heterodimerize	O
with	O
full	O
-	O
length	O
MLK3	O
,	O
and	O
interact	O
with	O
the	O
active	O
form	O
of	O
the	O
small	O
GTPase	O
Cdc42	O
,	O
resulting	O
in	O
diminished	O
activation	O
loop	O
phosphorylation	O
of	O
MLK3	O
and	O
reduced	O
signalling	O
to	O
JNK	B-FUNC
.	O

Three	O
of	O
the	O
chimeric	O
mAbs	O
retain	O
their	O
binding	B-FUNC
specificity	O
while	O
one	O
conformational	O
mAb	O
,	O
F26G19	O
,	O
lost	O
its	O
ability	O
to	O
bind	B-FUNC
the	O
S	O
protein	O
despite	O
high	O
level	O
expression	O
.	O

We	O
found	O
that	O
NL63	O
PLP2	O
deconjugated	O
ubiquitin	B-FUNC
(	O
Ub	B-FUNC
)	O
and	O
the	O
Ub	B-FUNC
-	O
line	O
molecule	O
ISG15	O
from	O
cellular	O
substrates	O
and	O
processed	O
both	O
lysine	O
-	O
48	O
-	O
and	O
lysine	O
-	O
63	O
-	O
linked	O
polyubiquitin	O
chains	O
.	O

Whereas	O
,	O
the	O
most	O
common	O
complications	O
observed	O
were	O
raised	O
Alanine	O
aminotransferases	O
(	O
ALT	B-FUNC
)	O
levels	O
(	O
51	O
.	O
9	O
%)	O
and	O
the	O
levels	O
were	O
greater	O
than	O
10	O
-	O
folds	O
of	O
normal	O
value	O
in	O
4	O
.	O
9	O
%,	O
thrombocytopenia	O
(	O
42	O
.	O
1	O
%),	O
varicella	O
pneumonia	O
(	O
28	O
.	O
4	O
%),	O
skin	O
infection	O
(	O
25	O
.	O
4	O
%),	O
septicaemia	O
(	O
10	O
.	O
7	O
%),	O
Encephalitis	O
/	O
Meningitis	O
(	O
8	O
.	O
8	O
%),	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
(	O
ARDS	O
)	O
(	O
6	O
.	O
8	O
%),	O
acute	O
renal	O
failure	O
(	O
2	O
.	O
9	O
%)	O
and	O
acute	O
hepatic	O
failure	O
(	O
1	O
.	O
9	O
%).	O

ABSTRACT	O
:	O
A	O
total	O
of	O
2	O
,	O
703	O
pig	O
sera	B-FUNC
from	O
171	O
farms	O
in	O
six	O
regions	O
in	O
Japan	O
were	O
screened	O
for	O
virus	O
-	O
neutralizing	O
(	O
VN	O
)	O
antibody	B-FUNC
against	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
).	O

Cotransfection	O
of	O
individual	O
shRNA	O
plasmids	O
and	O
pcDNA3	O
.	O
0	O
-	O
mfgl2	O
and	O
pcDNA3	O
.	O
0	O
-	O
mTNFR1	O
expression	O
constructs	O
into	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	B-FUNC
)	O
cells	O
significantly	O
inhibited	O
mfgl2	O
and	O
mTNFR1	O
gene	O
expression	O
,	O
as	O
evidenced	O
by	O
fluorescence	O
microscopy	O
,	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
,	O
and	O
Western	O
blotting	O
.	O

ABSTRACT	O
:	O
To	O
evaluate	O
murine	O
norovirus	O
(	O
MNV	O
)	O
infection	O
in	O
laboratory	O
mice	O
,	O
we	O
attempted	O
to	O
develop	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
system	O
and	O
an	O
indirect	O
immunofluorescent	O
antibody	B-FUNC
(	O
IFA	O
)	O
assay	O
for	O
detecting	O
the	O
anti	O
-	O
MNV	O
-	O
S7	O
antibody	B-FUNC
in	O
mice	O
.	O

We	O
found	O
that	O
some	O
serum	O
samples	O
were	O
negative	O
for	O
antibodies	O
to	O
mouse	O
hepatitis	O
virus	O
and	O
Mycoplasma	O
pulmonis	O
but	O
positive	O
for	O
antibody	B-FUNC
to	O
MNV	O
-	O
S7	O
.	O

The	O
sPLA2	O
activity	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
(	O
TNF	O
)-	O
α	O
were	O
significantly	O
higher	O
in	O
the	O
bronchoalveolar	O
lavage	O
of	O
ARDS	O
infants	O
.	O

TITLE	O
:	O
Plasmapheresis	O
treatment	O
in	O
Guillain	O
-	O
Barré	O
syndrome	O
:	O
potential	O
benefit	O
over	O
intravenous	O
immunoglobulin	B-FUNC
.	O

Seven	O
days	O
after	O
completion	O
of	O
immunoglobulin	B-FUNC
treatment	O
,	O
plasma	O
exchange	O
was	O
started	O
with	O
an	O
exchange	O
of	O
about	O
three	O
litres	O
of	O
plasma	O
every	O
day	O
for	O
three	O
days	O
and	O
every	O
second	O
day	O
on	O
two	O
further	O
occasions	O
.	O

Current	O
thinking	O
in	O
this	O
area	O
is	O
that	O
Mpro	O
dimerization	O
is	O
essential	O
for	O
catalysis	O
,	O
although	O
the	O
influence	O
of	O
the	O
substrate	O
binding	B-FUNC
on	O
the	O
dimer	O
formation	O
has	O
never	O
been	O
explored	O
.	O

We	O
conclude	O
that	O
protein	O
-	O
ligand	B-FUNC
and	O
protein	O
-	O
protein	O
interactions	O
are	O
closely	O
correlated	O
in	O
Mpro	O
.	O

The	O
spike	O
(	O
S	O
)	O
protein	O
,	O
especially	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
SARS	O
-	O
CoV	O
,	O
plays	O
important	O
roles	O
in	O
the	O
prevention	O
of	O
SARS	O
infection	O
,	O
and	O
is	O
thus	O
an	O
important	O
component	O
in	O
SARS	O
vaccine	O
development	O
.	O

In	O
the	O
first	O
,	O
the	O
results	O
of	O
the	O
alpha	O
-	O
IBV	O
IgM	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
on	O
post	O
-	O
vaccination	O
sera	B-FUNC
were	O
compared	O
with	O
the	O
efficacy	O
of	O
the	O
IBV	O
vaccination	O
against	O
homologous	O
challenge	O
of	O
the	O
same	O
broilers	O
.	O

In	O
contrast	O
,	O
the	O
Ser	O
(	O
32	O
)	O
amino	O
acid	O
substitution	O
totally	O
abolished	O
enzymatic	O
activity	O
while	O
receptor	B-FUNC
binding	I-FUNC
increased	O
,	O
as	O
observed	O
by	O
agglutination	O
of	O
Atlantic	O
salmon	O
red	O
blood	O
cells	O
.	O

Most	O
importantly	O
,	O
neutralization	O
antibodies	O
were	O
detected	O
in	O
sera	B-FUNC
after	O
i	O
.	O
p	O
.	O

To	O
explore	O
the	O
hypothesis	O
that	O
MHV	O
susceptibility	O
is	O
due	O
to	O
the	O
different	O
MHV	O
receptor	O
activities	O
of	O
1a	O
and	O
1b	O
,	O
we	O
established	O
a	O
chimeric	O
C57BL	O
/	O
6	O
mouse	O
(	O
cB61ba	O
)	O
in	O
which	O
a	O
part	O
of	O
the	O
N	O
-	O
terminal	O
immunoglobulin	B-FUNC
(	O
Ig	O
)-	O
like	O
domain	O
of	O
the	O
mCeacam1a	O
(	O
1a	O
)	O
gene	O
,	O
which	O
is	O
responsible	O
for	O
MHV	O
receptor	O
function	O
,	O
is	O
replaced	O
by	O
the	O
corresponding	O
region	O
of	O
mCeacam1b	O
(	O
1b	O
).	O

While	O
many	O
of	O
the	O
binding	B-FUNC
interactions	O
at	O
the	O
dimerization	O
interface	O
have	O
been	O
extensively	O
studied	O
,	O
those	O
that	O
are	O
important	O
for	O
long	O
-	O
range	O
control	O
are	O
not	O
well	O
-	O
understood	O
.	O

Hence	O
,	O
the	O
immunologic	O
enhancement	O
of	O
SNH	O
was	O
slightly	O
superior	O
to	O
that	O
of	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
adjuvant	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
the	O
-	O
123A	O
minor	O
allele	O
provided	O
stronger	O
binding	B-FUNC
affinity	O
to	O
nuclear	O
proteins	O
extracted	O
from	O
IFN	O
-	O
beta	O
-	O
untreated	O
cells	O
than	O
did	O
the	O
wild	O
-	O
type	O
allele	O
,	O
whereas	O
the	O
-	O
88T	O
allele	O
showed	O
preferential	O
binding	B-FUNC
after	O
IFN	O
-	O
beta	O
stimulation	O
.	O

TNF	O
-	O
alpha	O
was	O
completely	O
neutralized	O
in	O
3	O
of	O
the	O
4	O
animals	O
euthanized	O
at	O
4	O
HPI	B-FUNC
and	O
significantly	O
lower	O
than	O
in	O
the	O
PRCV	O
-	O
LPS	O
group	O
at	O
all	O
times	O
.	O

Overall	O
,	O
the	O
oxocarbazate	O
CID	O
23631927	O
was	O
a	O
subnanomolar	O
,	O
slow	O
-	O
binding	B-FUNC
,	O
reversible	O
inhibitor	O
of	O
human	O
cathepsin	O
L	O
that	O
blocked	O
SARS	O
-	O
CoV	O
and	O
Ebola	O
pseudotype	O
virus	O
entry	O
in	O
human	O
cells	O
.	O

TITLE	O
:	O
Viral	O
proteins	O
function	O
as	O
ion	B-FUNC
channels	I-FUNC
.	O

SUD	O
-	O
C	O
adopts	O
a	O
frataxin	O
like	O
fold	O
and	O
has	O
structural	O
similarity	O
to	O
DNA	O
-	O
binding	B-FUNC
domains	O
of	O
DNA	O
-	O
modifying	O
enzymes	O
.	O

p38	B-FUNC
activation	O
is	O
normal	O
and	O
STAT3	O
activation	O
is	O
depressed	O
,	O
which	O
may	O
contribute	O
to	O
maintenance	O
of	O
systemic	O
inflammation	O
.	O

TITLE	O
:	O
Migration	O
of	O
engrafted	O
neural	O
stem	O
cells	O
is	O
mediated	O
by	O
CXCL12	O
signaling	O
through	O
CXCR4	B-FUNC
in	O
a	O
viral	O
model	O
of	O
multiple	O
sclerosis	O
.	O

Moreover	O
,	O
small	O
molecule	O
-	O
mediated	O
antagonism	O
of	O
CXCR4	B-FUNC
,	O
but	O
not	O
CXCR7	B-FUNC
,	O
impaired	O
migration	O
and	O
proliferation	O
,	O
to	O
an	O
extent	O
similar	O
to	O
that	O
with	O
anti	O
-	O
CXCL12	O
treatment	O
.	O

These	O
data	O
highlight	O
the	O
importance	O
of	O
the	O
CXCL12	O
:	O
CXCR4	B-FUNC
pathway	O
in	O
regulating	O
homing	O
of	O
engrafted	O
stem	O
cells	O
to	O
sites	O
of	O
tissue	O
damage	O
within	O
the	O
CNS	O
of	O
mice	O
persistently	O
infected	O
with	O
a	O
neurotropic	O
virus	O
undergoing	O
immune	O
-	O
mediated	O
demyelination	O
.	O

To	O
determine	O
role	O
of	O
the	O
combination	O
of	O
Systemic	O
Inflammatory	O
Response	O
Syndrome	O
(	O
SIRS	O
)	O
score	O
and	O
serum	O
Interleukin	O
-	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
)	O
level	O
on	O
admission	O
as	O
predictor	O
of	O
illness	O
severity	O
and	O
outcome	O
of	O
Severe	O
Acute	O
Pancreatitis	O
(	O
SAP	O
).	O

SIRS	O
score	O
and	O
serum	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
concentration	O
were	O
measured	O
in	O
first	O
hour	O
after	O
admission	O
.	O

Viral	O
nucleic	O
acid	O
was	O
present	O
in	O
5	O
of	O
98	O
sera	B-FUNC
(	O
5	O
%)	O
from	O
a	O
single	O
colony	O
of	O
free	O
-	O
ranging	O
bats	O
.	O

To	O
this	O
end	O
,	O
keratinocyte	O
growth	O
factor	O
(	O
KGF	O
),	O
epithelial	O
growth	O
factor	O
(	O
EGF	B-FUNC
)	O
and	O
basic	O
fibroblast	B-FUNC
growth	I-FUNC
factor	I-FUNC
(	O
bFGF	O
)	O
are	O
emerging	O
as	O
the	O
most	O
important	O
candidates	O
.	O

The	O
binding	B-FUNC
ability	O
of	O
the	O
proteins	O
to	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
),	O
a	O
porcine	O
coronavirus	O
,	O
was	O
analyzed	O
by	O
ELISA	O
.	O

The	O
median	O
LIS	B-FUNC
and	O
PaO	O
(	O
2	O
)/	O
F	O
(	O
i	O
)	O
O	O
(	O
2	O
)	O
were	O
2	O
.	O
5	O
(	O
2	O
.	O
25	O
-	O
3	O
.	O
25	O
)	O
and	O
178	O
(	O
158	O
-	O
212	O
),	O
respectively	O
.	O

By	O
IF	O
,	O
Chlamydia	O
-	O
infected	O
cells	O
showed	O
normal	O
inclusions	O
after	O
39	O
hpi	B-FUNC
.	O

Like	O
its	O
PL2	O
(	O
pro	O
)	O
paralogs	O
from	O
several	O
coronaviruses	O
,	O
TGEV	O
PL1	O
(	O
pro	O
)	O
was	O
also	O
found	O
to	O
have	O
deubiquitinating	O
activity	O
in	O
an	O
in	O
vitro	O
cleavage	O
assay	O
,	O
implicating	O
it	O
in	O
counteracting	O
ubiquitin	B-FUNC
-	O
regulated	O
host	O
cell	O
pathways	O
,	O
likely	O
including	O
innate	O
immune	O
responses	O
.	O

CK	B-FUNC
-	I-FUNC
MM	I-FUNC
was	O
the	O
predominant	O
isoenzyme	O
in	O
the	O
serum	O
of	O
healthy	O
dogs	O
and	O
cats	O
,	O
followed	O
by	O
macro	O
-	O
CK2	O
and	O
CK	B-FUNC
-	I-FUNC
BB	I-FUNC
in	O
dogs	O
and	O
by	O
both	O
macroenzymes	O
in	O
cats	O
.	O

This	O
study	O
identified	O
the	O
electophoretic	O
distribution	O
of	O
CK	O
isoenzymes	O
and	O
macroenzymes	O
of	O
dogs	O
and	O
cats	O
and	O
provided	O
encouraging	O
data	O
about	O
the	O
possible	O
use	O
of	O
CK	B-FUNC
-	I-FUNC
BB	I-FUNC
as	O
a	O
biomarker	O
for	O
canine	O
neurologic	O
disorders	O
,	O
but	O
not	O
for	O
FIP	O
.	O

The	O
protein	O
is	O
synthesized	O
using	O
solid	O
phase	O
peptide	O
synthesis	O
and	O
reconstituted	O
into	O
artificial	O
lipid	O
bilayers	O
that	O
forms	O
cation	O
-	O
selective	O
ion	B-FUNC
channels	I-FUNC
with	O
a	O
main	O
conductance	O
level	O
of	O
8	O
.	O
9	O
±	O
0	O
.	O
8pS	O
at	O
elevated	O
temperature	O
(	O
38	O
.	O
5	O
°	O
C	O
).	O

Acanthopanacis	O
cortex	O
and	O
Torilis	O
fructus	O
might	O
exert	O
their	O
antiviral	O
activities	O
in	O
MHV	O
-	O
A59	O
-	O
infected	O
cells	O
by	O
inducing	O
cyclooxygenase	O
-	O
2	O
expression	O
via	O
the	O
activation	O
of	O
extracellular	O
signal	O
-	O
related	O
kinase	O
(	O
ERK	B-FUNC
)	O
and	O
p38	B-FUNC
or	O
ERK	B-FUNC
alone	O
,	O
respectively	O
.	O

TITLE	O
:	O
Association	O
between	O
mannose	O
-	O
binding	B-FUNC
lectin	O
gene	O
polymorphism	O
and	O
pediatric	O
cytomegalovirus	O
infection	O
.	O

Increased	O
vigilance	O
for	O
IAH	B-FUNC
is	O
needed	O
in	O
this	O
at	O
-	O
risk	O
population	O
.	O

ALI	O
was	O
confirmed	O
with	O
lung	O
tissue	O
injury	O
(	O
histopathological	O
examination	O
),	O
enhanced	O
lung	O
edema	O
(	O
wet	O
-	O
to	O
-	O
dry	O
weight	O
ratio	O
),	O
and	O
neutrophil	O
infiltration	O
(	O
myeloperoxidase	B-FUNC
activity	I-FUNC
)	O
at	O
6	O
h	O
after	O
LPS	O
exposure	O
.	O

TITLE	O
:	O
Lung	O
transplantation	O
for	O
severe	O
antineutrophilic	O
cytoplasmic	O
antibody	B-FUNC
-	O
associated	O
vasculitis	O
.	O

Furthermore	O
,	O
the	O
crystal	O
structure	O
of	O
HLA	O
-	O
A	O
*	O
2402	O
complexed	O
with	O
peptide	O
N1	O
was	O
determined	O
,	O
and	O
the	O
featured	O
peptide	O
was	O
characterized	O
with	O
two	O
unexpected	O
intrachain	O
hydrogen	O
bonds	O
which	O
augment	O
the	O
central	O
residues	O
to	O
bulge	O
out	O
of	O
the	O
binding	B-FUNC
groove	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
expression	O
of	O
secretory	O
type	O
II	O
phospholipase	B-FUNC
A	I-FUNC
(	O
2	O
)	O
(	O
sPLA	O
(	O
2	O
)-	O
II	O
)	O
in	O
lung	O
of	O
rats	O
with	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
complicating	O
severe	O
acute	O
pancreatitis	O
(	O
SAP	O
),	O
and	O
the	O
effect	O
of	O
Qingyi	O
decoction	O
(	O
QYT	O
)	O
on	O
ALI	O
.	O

Within	O
the	O
purpose	O
of	O
developing	O
new	O
antiseptics	O
molecules	O
,	O
the	O
antiseptic	O
virucidal	O
activity	O
of	O
two	O
calix	O
[	O
4	O
]	O
arene	O
derivatives	O
,	O
the	O
tetra	O
-	O
para	O
-	O
sulfonato	O
-	O
calix	O
[	O
4	O
]	O
arene	O
(	O
C	O
[	O
4	O
]	O
S	O
)	O
and	O
the	O
1	O
,	O
3	O
-	O
bis	B-FUNC
(	O
bithiazolyl	O
)-	O
tetra	O
-	O
para	O
-	O
sulfonato	O
-	O
calix	O
[	O
4	O
]	O
arene	O
(	O
C	O
[	O
4	O
]	O
S	O
-	O
BTZ	O
)	O
were	O
evaluated	O
toward	O
the	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
229E	O
).	O

The	O
use	O
of	O
adjuvants	O
resulted	O
in	O
higher	O
antibody	B-FUNC
titers	O
,	O
with	O
the	O
AS01	O
(	O
B	O
)-	O
adjuvanted	O
vaccine	O
being	O
slightly	O
more	O
immunogenic	O
than	O
the	O
AS03	O
(	O
A	O
)-	O
adjuvanted	O
vaccine	O
.	O

Plasma	O
levels	O
of	O
interleukin	O
(	O
IL	O
)-	O
6	O
,	O
TNF	O
-	O
α	O
,	O
MCP	B-FUNC
-	O
1	O
,	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
increased	O
at	O
2	O
h	O
.	O
Both	O
in	O
wild	O
type	O
and	O
iNOS	O
knockout	O
mice	O
,	O
hypertonic	O
saline	O
resuscitation	O
decreased	O
plasma	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
TNF	O
-	O
α	O
,	O
and	O
MCP	B-FUNC
-	O
1	O
levels	O
at	O
2	O
h	O
;	O
CD4	O
(+)	O
T	O
cells	O
in	O
spleen	O
and	O
thymus	O
decreased	O
at	O
24	O
,	O
48	O
,	O
and	O
72	O
h	O
,	O
and	O
Foxp3	O
(+)	O
Tregs	O
in	O
spleen	O
at	O
48	O
h	O
increased	O
,	O
however	O
,	O
hypertonic	O
saline	O
resuscitation	O
did	O
not	O
affect	O
the	O
Foxp3	O
(+).	O

The	O
residues	O
TyrA92	O
,	O
ProA134	O
,	O
PheA137	O
,	O
AspA138	O
and	O
TyrA140	O
had	O
important	O
roles	O
during	O
the	O
binding	B-FUNC
process	O
and	O
are	O
fully	O
or	O
partially	O
conserved	O
in	O
various	O
IBV	O
strains	O
.	O

Epitope	O
mapping	O
by	O
Western	O
blotting	O
showed	O
that	O
these	O
anti	O
-	O
SARS	O
-	O
CoV	O
NP	O
MAbs	O
bind	B-FUNC
to	O
distinct	O
domains	O
of	O
NP	O
.	O

The	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
II	O
(	O
APACHE	O
II	O
)	O
score	O
,	O
ECMO	O
flow	O
,	O
and	O
respiratory	O
parameters	O
,	O
such	O
as	O
PaO2	O
/	O
FiO2	O
(	O
P	O
/	O
F	O
ratio	O
),	O
pulmonary	O
compliance	O
,	O
and	O
Lung	O
Injury	O
Score	O
(	O
LIS	B-FUNC
)	O
before	O
and	O
after	O
the	O
introduction	O
of	O
ECMO	O
,	O
were	O
compared	O
among	O
patients	O
in	O
whom	O
ECMO	O
could	O
or	O
could	O
not	O
be	O
removed	O
.	O

In	O
these	O
cases	O
we	O
determined	O
H1N1	O
Inf	O
A	O
pandemic	O
variant	O
by	O
detection	O
of	O
Inf	O
A	O
Matrix	O
Protein	O
2	O
gene	O
M2	O
and	O
the	O
specific	O
H1	O
gene	O
for	O
influenza	O
pandemic	O
H1N1	O
2009	O
with	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
Inf	O
A	O
/	O
H1N1	O
(	O
Roche	O
).	O

Influenza	O
A	O
,	O
B	O
and	O
coronavirus	O
antibody	B-FUNC
titers	O
were	O
measured	O
in	O
257	O
subjects	O
with	O
recurrent	O
unipolar	O
and	O
bipolar	O
disorder	O
and	O
healthy	O
controls	O
,	O
by	O
SCID	O
.	O

ACoRN	O
Respiratory	O
Score	O
which	O
correlated	O
with	O
SNAP	B-FUNC
-	O
II	O
score	O
is	O
easy	O
to	O
use	O
and	O
may	O
be	O
helpful	O
in	O
facilitating	O
the	O
caregivers	O
in	O
local	O
hospital	O
to	O
identify	O
the	O
early	O
signs	O
and	O
make	O
the	O
transfer	O
decision	O
promptly	O
.	O

TITLE	O
:	O
Potent	O
and	O
persistent	O
antibody	B-FUNC
responses	O
against	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
of	O
SARS	O
-	O
CoV	O
spike	O
protein	O
in	O
recovered	O
patients	O
.	O

Unlike	O
the	O
nsp1	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
,	O
a	O
betacoronavirus	O
,	O
the	O
TGEV	O
nsp1	O
protein	O
was	O
unable	O
to	O
bind	B-FUNC
40S	O
ribosomal	O
subunits	O
or	O
promote	O
host	O
mRNA	O
degradation	O
.	O

Intravenous	O
immunoglobulin	B-FUNC
(	O
IVIG	O
)	O
was	O
used	O
in	O
all	O
4	O
patients	O
.	O

When	O
comparing	O
viral	O
ARDS	O
with	O
bacterial	O
ARDS	O
,	O
the	O
level	O
of	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
and	O
TNFα	O
was	O
significantly	O
higher	O
in	O
bacterial	O
ARDS	O
and	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
was	O
increased	O
only	O
in	O
viral	O
ARDS	O
.	O

TITLE	O
:	O
Zn	O
(	O
2	O
+)	O
inhibits	O
coronavirus	O
and	O
arterivirus	O
RNA	B-FUNC
polymerase	I-FUNC
activity	I-FUNC
in	O
vitro	O
and	O
zinc	O
ionophores	O
block	O
the	O
replication	O
of	O
these	O
viruses	O
in	O
cell	O
culture	O
.	O

Antibody	B-FUNC
-	O
dependent	O
enhancement	O
(	O
ADE	O
)	O
of	O
FIPV	O
infection	O
has	O
been	O
recognized	O
,	O
and	O
cellular	O
immunity	O
is	O
considered	O
to	O
play	O
an	O
important	O
role	O
in	O
preventing	O
the	O
onset	O
of	O
feline	O
infectious	O
peritonitis	O
.	O

Immunochemical	O
staining	O
with	O
monoclonal	O
antibody	B-FUNC
(	O
mAb	O
)	O
against	O
N	O
protein	O
of	O
SARS	O
-	O
CoV	O
was	O
used	O
to	O
determine	O
the	O
stomach	O
and	O
enteric	O
tissues	O
among	O
5	O
SARS	O
patients	O
with	O
their	O
nucleocapsid	O
antibody	B-FUNC
titer	O
ascended	O
obviously	O
after	O
1	O
(	O
st	O
)-	O
7	O
(	O
th	O
)	O
year	O
.	O

SARS	O
-	O
CoV	O
was	O
proved	O
to	O
be	O
still	O
present	O
in	O
stomach	O
and	O
enteric	O
tissues	O
of	O
SARS	O
patients	O
with	O
the	O
nucleocapsid	O
antibody	B-FUNC
titer	O
increased	O
significantly	O
after	O
the	O
7	O
(	O
th	O
)	O
year	O
.	O

Although	O
ribosomal	O
/	O
nucleic	B-FUNC
acid	I-FUNC
binding	I-FUNC
proteins	O
were	O
enriched	O
in	O
the	O
Golgi	O
-	O
fractions	O
of	O
mouse	O
hepatitis	O
virus	O
-	O
infected	O
cells	O
,	O
proteins	O
annotated	O
to	O
localize	O
to	O
several	O
organelles	O
of	O
the	O
secretory	O
pathway	O
were	O
overrepresented	O
among	O
the	O
proteins	O
that	O
were	O
depleted	O
from	O
these	O
fractions	O
upon	O
infection	O
.	O

The	O
structure	O
of	O
N	O
-	O
terminal	O
domain	O
of	O
MHV	O
N	O
protein	O
also	O
implicated	O
its	O
specific	O
affinity	O
with	O
transcriptional	O
regulatory	O
sequence	O
(	O
TRS	B-FUNC
)	O
RNA	O
.	O

ABSTRACT	O
:	O
Emerging	O
infectious	O
diseases	O
have	O
caused	O
a	O
global	O
effort	O
for	O
development	O
of	O
fast	B-FUNC
and	O
accurate	O
detection	O
techniques	O
.	O

Moreover	O
,	O
the	O
S1	O
region	O
of	O
the	O
TGEV	O
S	O
protein	O
was	O
dissected	O
,	O
with	O
the	O
aim	O
of	O
identifying	O
discrete	O
modules	O
displaying	O
unique	O
antigenic	O
sites	O
and	O
receptor	O
-	O
binding	B-FUNC
functions	O
.	O

Papain	O
treatment	O
identified	O
an	O
N	O
-	O
terminal	O
domain	O
(	O
D1	O
)	O
resistant	O
to	O
proteolysis	O
,	O
whereas	O
receptor	B-FUNC
binding	I-FUNC
defined	O
a	O
soluble	O
and	O
functional	O
APN	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
D3	O
).	O

Myeloperoxidase	O
(	O
MPO	B-FUNC
)	O
and	O
α	O
-	O
defensins	O
were	O
monitored	O
as	O
indices	O
of	O
neutrophil	O
activity	O
.	O

IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
eosinophil	O
cationic	O
protein	O
(	O
ECP	O
)	O
and	O
α	O
(	O
2	O
)-	O
macroglobulin	O
were	O
measured	O
as	O
indices	O
of	O
pro	O
-	O
inflammatory	O
cytokine	O
production	O
,	O
eosinophil	O
activity	O
,	O
and	O
plasma	O
exudation	O
.	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
papain	O
-	O
like	O
protease	O
(	O
PLpro	O
),	O
a	O
deubiquitinating	B-FUNC
enzyme	I-FUNC
,	O
reportedly	O
blocks	O
poly	O
I	O
:	O
C	O
-	O
induced	O
activation	O
of	O
interferon	O
regulatory	O
factor	O
3	O
and	O
nuclear	O
factor	O
kappa	O
B	O
,	O
reducing	O
interferon	O
(	O
IFN	O
)	O
induction	O
.	O

A	O
proteomics	O
approach	O
demonstrated	O
downregulation	O
of	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	B-FUNC
)	O
1	O
and	O
upregulation	O
of	O
ubiquitin	B-FUNC
-	O
conjugating	O
enzyme	O
(	O
UBC	O
)	O
E2	O
-	O
25k	O
as	O
inhibitory	O
mechanism	O
of	O
PLpro	O
on	O
IFN	O
-	O
α	O
-	O
induced	O
responses	O
.	O

IFN	O
-	O
α	O
treatment	O
significantly	O
induced	O
mRNA	O
expression	O
of	O
UBC	O
E2	O
-	O
25k	O
,	O
but	O
not	O
ERK1	B-FUNC
,	O
causing	O
time	O
-	O
dependent	O
decrease	O
of	O
ERK1	B-FUNC
,	O
but	O
not	O
ERK2	B-FUNC
,	O
in	O
PLpro	O
-	O
expressing	O
cells	O
.	O

Poly	O
-	O
ubiquitination	O
of	O
ERK1	B-FUNC
showed	O
a	O
relationship	O
between	O
ERK1	B-FUNC
and	O
ubiquitin	B-FUNC
proteasome	O
signalling	O
pathways	O
associated	O
with	O
IFN	O
antagonism	O
by	O
PLpro	O
.	O

Overall	O
results	O
proved	O
downregulation	O
of	O
ERK1	B-FUNC
by	O
ubiquitin	B-FUNC
proteasomes	O
and	O
suppression	O
of	O
interaction	O
between	O
ERK1	B-FUNC
and	O
STAT1	O
as	O
type	O
I	O
IFN	O
antagonist	O
function	O
of	O
SARS	O
-	O
CoV	O
PLpro	O
.	O

RESULTS	O
:	O
Expression	O
of	O
S	O
and	O
N	O
protein	O
were	O
confirmed	O
;	O
100	O
normal	O
adult	O
serum	O
were	O
analyzed	O
using	O
the	O
established	O
serological	O
detection	O
assay	O
,	O
in	O
which	O
HCoV	O
-	O
HKU1	O
S	O
antibody	B-FUNC
positive	O
rate	O
was	O
47	O
%,	O
N	O
antibody	B-FUNC
positive	O
rate	O
was	O
48	O
%,	O
Both	O
S	O
and	O
N	O
antibodies	O
positive	O
were	O
21	O
%,	O
Both	O
S	O
and	O
N	O
antibodies	O
negative	O
were	O
22	O
%.	O

Antibody	B-FUNC
responses	O
to	O
antigens	O
H1N1	O
,	O
H3N2	O
,	O
and	O
B	O
were	O
measured	O
in	O
blood	O
samples	O
at	O
vaccination	O
(	O
T0	O
)	O
and	O
after	O
1	O
month	O
(	O
T1	O
).	O

Although	O
NDV	O
and	O
IBV	O
challenges	O
were	O
not	O
performed	O
,	O
the	O
antibody	B-FUNC
responses	O
elicited	O
by	O
NDV	O
and	O
/	O
or	O
the	O
IBV	O
vaccinations	O
were	O
significantly	O
reduced	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
when	O
applied	O
in	O
combination	O
with	O
the	O
CEO	O
vaccine	O
.	O

Even	O
though	O
these	O
cells	O
are	O
highly	O
proinflammatory	O
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
expressed	O
by	O
these	O
cells	O
was	O
functional	O
.	O

These	O
data	O
support	O
the	O
conclusion	O
that	O
UDA	O
might	O
bind	B-FUNC
to	O
N	O
-	O
acetylglucosamine	O
-	O
like	O
residues	O
present	O
on	O
the	O
glycosylated	O
envelope	O
glycoproteins	O
,	O
thereby	O
preventing	O
virus	O
attachment	O
to	O
cells	O
.	O

TITLE	O
:	O
Role	O
of	O
CCR2	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
in	O
acute	O
lung	O
injury	O
:	O
a	O
new	O
mechanism	O
and	O
therapeutic	O
target	O
.	O

Many	O
cellular	O
proteins	O
interacting	O
with	O
regulatory	O
CoV	O
RNA	O
sequences	O
are	O
members	O
of	O
the	O
heterogeneous	O
nuclear	O
ribonucleoprotein	O
(	O
hnRNP	O
)	O
family	O
of	O
RNA	O
-	O
binding	B-FUNC
proteins	O
,	O
involved	O
in	O
mRNA	O
processing	O
and	O
transport	O
,	O
which	O
shuttle	O
between	O
the	O
nucleus	O
and	O
the	O
cytoplasm	O
.	O

In	O
the	O
context	O
of	O
CoV	O
RNA	O
synthesis	O
,	O
these	O
cellular	O
ribonucleoproteins	O
might	O
also	O
participate	O
in	O
RNA	O
-	O
protein	O
complexes	O
to	O
bring	O
into	O
physical	O
proximity	O
TRS	B-FUNC
-	O
L	O
and	O
distant	O
TRS	B-FUNC
-	O
B	O
,	O
as	O
proposed	O
for	O
CoV	O
discontinuous	O
transcription	O
.	O

Diagnoses	O
of	O
viral	O
infections	O
were	O
established	O
according	O
to	O
positive	O
results	O
in	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
and	O
influenza	O
rapid	O
diagnostic	O
testing	O
,	O
and	O
based	O
on	O
a	O
fourfold	O
increase	O
in	O
antibody	B-FUNC
titer	O
of	O
influenza	O
virus	O
antibody	B-FUNC
in	O
paired	O
sera	B-FUNC
.	O

The	O
nascent	O
minus	O
-	O
stranded	O
RNA	O
would	O
then	O
be	O
transferred	O
by	O
a	O
template	O
switch	O
process	O
to	O
the	O
TRS	B-FUNC
-	O
L	O
,	O
which	O
acts	O
as	O
the	O
acceptor	O
RNA	O
.	O

TRS	B-FUNC
-	O
L	O
mutations	O
altering	O
the	O
structure	O
and	O
the	O
stability	O
of	O
the	O
TRS	B-FUNC
-	O
L	O
hairpin	O
affected	O
replication	O
and	O
transcription	O
,	O
indicating	O
the	O
requirement	O
of	O
a	O
functional	O
RNA	O
hairpin	O
structure	O
in	O
these	O
processes	O
.	O

ABSTRACT	O
:	O
Luminex	O
xTAG	O
respiratory	O
viral	O
panel	O
FAST	B-FUNC
(	O
RVP	O
FAST	B-FUNC
)	O
assay	O
detects	O
17	O
human	O
respiratory	O
virus	O
strains	O
per	O
measurement	O
.	O

RVP	O
FAST	B-FUNC
showed	O
higher	O
sensitivity	O
(	O
83	O
.	O
3	O
-	O
100	O
%)	O
and	O
specificity	O
(	O
98	O
.	O
2	O
-	O
100	O
%)	O
than	O
NAT	O
.	O

TITLE	O
:	O
The	O
polypyrimidine	O
tract	O
-	O
binding	B-FUNC
protein	O
affects	O
coronavirus	O
RNA	O
accumulation	O
levels	O
and	O
relocalizes	O
viral	O
RNAs	O
to	O
novel	O
cytoplasmic	O
domains	O
different	O
from	O
replication	O
-	O
transcription	O
sites	O
.	O

Polypyrimidine	O
tract	O
-	O
binding	B-FUNC
protein	O
(	O
PTB	O
)	O
was	O
reproducibly	O
identified	O
in	O
association	O
with	O
positive	O
-	O
sense	O
RNAs	O
of	O
transmissible	O
gastroenteritis	O
coronavirus	O
(	O
TGEV	O
)	O
TRS	B-FUNC
-	O
L	O
and	O
TRS	B-FUNC
-	O
B	O
by	O
affinity	O
chromatography	O
and	O
mass	O
spectrometry	O
.	O

The	O
reactivities	O
of	O
236	O
naturally	O
infected	O
mouse	O
sera	B-FUNC
were	O
examined	O
;	O
227	O
samples	O
were	O
positive	O
by	O
MFI	O
using	O
S2	O
antigen	O
(	O
96	O
%	O
sensitivity	O
),	O
and	O
208	O
samples	O
were	O
positive	O
using	O
N	O
antigen	O
(	O
88	O
%	O
sensitivity	O
).	O

In	O
126	O
uninfected	O
mouse	O
sera	B-FUNC
,	O
including	O
34	O
ELISA	O
false	O
-	O
positive	O
sera	B-FUNC
,	O
only	O
7	O
samples	O
showed	O
false	O
-	O
positive	O
results	O
by	O
MFI	O
using	O
either	O
the	O
S2	O
or	O
N	O
antigen	O
(	O
94	O
%	O
specificity	O
).	O

Furthermore	O
,	O
in	O
contrast	O
to	O
the	O
reduction	O
of	O
ASC	O
in	O
the	O
CNS	O
,	O
neither	O
virus	O
-	O
specific	O
ASC	O
trafficking	O
to	O
bone	O
marrow	O
nor	O
antiviral	O
serum	O
antibody	B-FUNC
was	O
reduced	O
relative	O
to	O
levels	O
in	O
control	O
mice	O
.	O

Epitope	O
mapping	O
by	O
Pepscan	O
indicated	O
that	O
RdRp	B-FUNC
mAbs	O
recognized	O
four	O
non	O
-	O
overlapping	O
linear	O
epitopes	O
located	O
in	O
a	O
62	O
-	O
amino	O
acid	O
region	O
of	O
the	O
N	O
-	O
terminal	O
domain	O
,	O
suggesting	O
that	O
this	O
region	O
may	O
constitute	O
an	O
immunodominant	O
domain	O
.	O

The	O
availability	O
of	O
TGEV	O
RdRp	B-FUNC
mAbs	O
will	O
be	O
instrumental	O
to	O
study	O
coronavirus	O
replication	O
and	O
to	O
analyze	O
the	O
function	O
of	O
RdRp	B-FUNC
in	O
pathogenesis	O
.	O

TITLE	O
:	O
A	O
case	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
associated	O
with	O
novel	O
H1N1	O
treated	O
with	O
intravenous	O
immunoglobulin	B-FUNC
G	O
.	O
ABSTRACT	O
:	O
Influenza	O
A	O
""""	O
novel	O
H1N1	O
""""	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
a	O
serious	O
illness	O
that	O
poses	O
a	O
challenge	O
to	O
clinicians	O
managing	O
such	O
cases	O
.	O

ABSTRACT	O
:	O
The	O
use	O
of	O
peptides	O
from	O
a	O
phage	O
display	O
library	O
selected	O
by	O
binding	B-FUNC
to	O
a	O
given	O
antibody	B-FUNC
is	O
a	O
widespread	O
technique	O
to	O
probe	O
epitopes	O
of	O
antigenic	O
proteins	O
.	O

As	O
a	O
first	O
set	O
of	O
testing	O
results	O
,	O
the	O
localization	O
of	O
epitope	O
regions	O
in	O
eight	O
different	O
antigenic	O
proteins	O
for	O
which	O
experimental	O
data	O
on	O
their	O
antibody	B-FUNC
interactions	O
exist	O
is	O
correctly	O
identified	O
by	O
LocaPep	O
.	O

Lung	O
rest	B-FUNC
,	O
achieved	O
by	O
extracorporeal	O
carbon	O
dioxide	O
removal	O
(	O
ECCO₂R	O
),	O
allowed	O
weaning	O
from	O
mechanical	O
ventilation	O
,	O
closure	O
of	O
BPF	O
,	O
and	O
resumption	O
of	O
spontaneous	O
breathing	O
.	O

We	O
demonstrate	O
that	O
viral	O
expression	O
of	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
which	O
occurs	O
during	O
the	O
peak	O
of	O
virus	O
replication	O
and	O
at	O
the	O
site	O
of	O
disease	O
,	O
enhanced	O
survival	O
and	O
diminished	O
morbidity	O
in	O
rJ2	O
.	O
2	O
-	O
infected	O
wild	O
-	O
type	O
B6	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
(-/-)	O
mice	O
.	O

IL	O
-	O
1β	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
mRNA	O
expression	O
in	O
rat	O
lungs	O
was	O
measured	O
quantitatively	O
by	O
the	O
RT	O
-	O
PCR	O
method	O
and	O
confirmed	O
by	O
morphometric	O
studies	O
of	O
the	O
lungs	O
.	O

We	O
investigated	O
the	O
use	O
of	O
a	O
single	O
dose	O
of	O
2000	O
IU	O
of	O
hepatitis	O
B	O
immunoglobulin	B-FUNC
in	O
18	O
patients	O
among	O
a	O
population	O
of	O
54	O
kidney	O
transplant	O
recipients	O
from	O
HBcAb	O
-	O
positive	O
deceased	O
donors	O
.	O

Unexpectedly	O
,	O
MHV	O
NTD	O
contains	O
a	O
core	O
structure	O
that	O
has	O
the	O
same	O
β	O
-	O
sandwich	O
fold	O
as	O
human	O
galectins	O
(	O
S	O
-	O
lectins	O
)	O
and	O
additional	O
structural	O
motifs	O
that	O
bind	B-FUNC
to	O
the	O
N	O
-	O
terminal	O
Ig	O
-	O
like	O
domain	O
of	O
mCEACAM1a	O
.	O

Sugar	O
-	O
binding	B-FUNC
assays	O
reveal	O
that	O
galectin	O
-	O
like	O
NTDs	O
of	O
some	O
coronaviruses	O
such	O
as	O
human	O
coronavirus	O
OC43	O
and	O
bovine	O
coronavirus	O
bind	B-FUNC
sugars	O
.	O

We	O
propose	O
that	O
coronavirus	O
NTDs	O
originated	O
from	O
a	O
host	O
galectin	O
and	O
retained	O
sugar	O
-	O
binding	B-FUNC
functions	O
in	O
some	O
contemporary	O
coronaviruses	O
,	O
but	O
evolved	O
new	O
structural	O
features	O
in	O
MHV	O
for	O
mCEACAM1a	O
binding	B-FUNC
.	O

We	O
retrospectively	O
reviewed	O
71	O
inpatient	O
episodes	O
of	O
ACS	B-FUNC
in	O
patients	O
with	O
hemoglobin	O
SC	O
disease	O
over	O
a	O
20	O
-	O
year	O
period	O
.	O

In	O
protein	O
7	O
a	O
conserved	O
sequence	O
motif	O
that	O
potentially	O
mediates	O
binding	B-FUNC
to	O
protein	O
phosphatase	B-FUNC
1	O
catalytic	O
subunit	O
(	O
PP1c	O
),	O
a	O
key	O
regulator	O
of	O
the	O
cell	O
antiviral	O
defenses	O
,	O
was	O
identified	O
.	O

ABSTRACT	O
:	O
The	O
binding	B-FUNC
of	O
viruses	O
to	O
host	O
cells	O
is	O
the	O
first	O
step	O
in	O
determining	O
tropism	O
and	O
pathogenicity	O
.	O

When	O
comparing	O
the	O
binding	B-FUNC
of	O
recombinant	O
IBV	O
S1	O
proteins	O
derived	O
from	O
IBV	O
strains	O
with	O
known	O
differences	O
in	O
tissue	O
tropism	O
and	O
pathogenicity	O
,	O
we	O
observed	O
that	O
while	O
M41	O
S1	O
displayed	O
binding	B-FUNC
to	O
cilia	O
and	O
goblet	O
cells	O
of	O
the	O
chicken	O
respiratory	O
tract	O
,	O
S1	O
derived	O
from	O
the	O
vaccine	O
strain	O
H120	O
or	O
the	O
nonvirulent	O
Beaudette	O
strain	O
had	O
reduced	O
or	O
no	O
binding	B-FUNC
to	O
chicken	O
tissues	O
,	O
respectively	O
,	O
in	O
agreement	O
with	O
the	O
reduced	O
abilities	O
of	O
these	O
viruses	O
to	O
replicate	O
in	O
vivo	O
.	O

The	O
ensemble	O
of	O
succinylated	O
interferon	O
-	O
γ	O
with	O
two	O
modified	O
lysines	O
may	O
hold	O
promise	O
for	O
the	O
treatment	O
of	O
severe	O
viral	O
infections	O
with	O
fast	B-FUNC
courses	O
,	O
such	O
as	O
influenza	O
and	O
the	O
diseases	O
caused	O
by	O
the	O
Ebola	O
,	O
Marburg	O
,	O
SARS	O
,	O
and	O
other	O
viruses	O
.	O

In	O
addition	O
to	O
retroviruses	O
,	O
many	O
structural	O
proteins	O
of	O
unrelated	O
viruses	O
,	O
including	O
influenza	O
M1	O
,	O
NEP	O
and	O
NP	O
proteins	O
,	O
38	O
Borna	O
disease	O
virus	O
N	O
and	O
P	O
proteins28	O
,	O
56	O
and	O
coronavirus	O
N	O
protein	O
,	O
23	O
,	O
57	O
undergo	O
nuclear	O
localization	O
and	O
bind	B-FUNC
viral	O
RNAs	O
to	O
form	O
viral	O
ribonuclear	O
protein	O
(	O
RNP	O
)	O
complexes	O
that	O
are	O
exported	O
from	O
the	O
nucleus	O
for	O
packaging	O
into	O
virus	O
particles	O
.	O

TITLE	O
:	O
IFN	O
-	O
γ	O
-	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
-	O
expressing	O
virus	O
epitope	O
-	O
specific	O
Foxp3	O
(+)	O
T	O
reg	O
cells	O
in	O
the	O
central	O
nervous	O
system	O
during	O
encephalomyelitis	O
.	O

These	O
findings	O
reveal	O
a	O
new	O
theme	O
in	O
virology	O
wherein	O
many	O
different	O
virus	O
families	O
encode	O
proteins	O
that	O
bind	B-FUNC
and	O
perturb	O
the	O
function	O
of	O
cellular	O
PDZ	O
proteins	O
.	O

We	O
previously	O
reported	O
that	O
antibody	B-FUNC
elicited	O
by	O
a	O
SARS	O
-	O
CoV	O
vaccine	O
candidate	O
based	O
on	O
recombinant	O
full	O
-	O
length	O
Spike	O
-	O
protein	O
trimers	O
potentiated	O
infection	O
of	O
human	O
B	O
cell	O
lines	O
despite	O
eliciting	O
in	O
vivo	O
a	O
neutralizing	O
and	O
protective	O
immune	O
response	O
in	O
rodents	O
.	O

These	O
observations	O
prompted	O
us	O
to	O
investigate	O
the	O
mechanisms	O
underlying	O
antibody	B-FUNC
-	O
dependent	O
enhancement	O
(	O
ADE	O
)	O
of	O
SARS	O
-	O
CoV	O
infection	O
in	O
vitro	O
.	O

When	O
airborne	O
influenza	O
H3N2	O
virus	O
samples	O
were	O
collected	O
and	O
delivered	O
to	O
antibody	B-FUNC
-	O
modified	O
SiNW	O
devices	O
,	O
discrete	O
nanowire	O
conductance	O
changes	O
were	O
observed	O
within	O
seconds	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
human	O
coronavirus	O
NL63	O
(	O
HCoV	O
-	O
NL63	O
)	O
mediates	O
both	O
cell	O
attachment	O
by	O
binding	B-FUNC
to	O
its	O
receptor	O
hACE2	O
and	O
membrane	O
fusion	O
during	O
virus	O
entry	O
.	O

Our	O
results	O
showed	O
that	O
:	O
(	O
i	O
)	O
deletion	O
of	O
18aa	O
from	O
the	O
C	O
-	O
terminus	O
enhanced	O
the	O
S	O
protein	O
accumulation	O
and	O
virus	O
entry	O
,	O
which	O
might	O
be	O
due	O
to	O
the	O
deletion	O
of	O
intracellular	O
retention	O
signals	O
;	O
(	O
ii	O
)	O
further	O
deletion	O
to	O
residue	O
29	O
also	O
enhanced	O
the	O
amount	O
of	O
S	O
protein	O
on	O
the	O
cell	O
surface	O
and	O
in	O
virion	O
,	O
but	O
reduced	O
virus	O
entry	O
by	O
25	O
%,	O
suggesting	O
that	O
residues	O
19	O
-	O
29	O
contributes	O
to	O
membrane	O
fusion	O
;	O
(	O
iii	O
)	O
a	O
29aa	O
-	O
deletion	O
mutant	O
had	O
a	O
defect	O
in	O
anchoring	B-FUNC
on	O
the	O
plasma	O
membrane	O
,	O
which	O
led	O
to	O
a	O
dramatic	O
decrease	O
of	O
S	O
protein	O
in	O
virion	O
and	O
virus	O
entry	O
;	O
(	O
iv	O
)	O
a	O
total	O
of	O
15	O
residues	O
(	O
Y498	O
,	O
V499	O
,	O
V531	O
,	O
G534	O
,	O
G537	O
,	O
D538	O
,	O
S540	O
,	O
G575	O
,	O
S576	O
,	O
E582	O
,	O
W585	O
,	O
Y590	O
,	O
T591	O
,	O
V593	O
and	O
G594	O
)	O
within	O
RBD	O
were	O
important	O
for	O
receptor	B-FUNC
binding	I-FUNC
and	O
virus	O
entry	O
.	O

Moreover	O
,	O
docking	O
experiments	O
strongly	O
suggested	O
that	O
these	O
compounds	O
might	O
also	O
bind	B-FUNC
to	O
the	O
active	O
site	O
of	O
NendoU	O
,	O
thus	O
impairing	O
the	O
catalytic	B-FUNC
activity	I-FUNC
essential	O
for	O
the	O
coronavirus	O
life	O
cycle	O
.	O

Blunt	O
chest	O
injury	O
resulted	O
in	O
the	O
activation	O
of	O
circulating	O
neutrophils	O
,	O
as	O
characterized	O
by	O
a	O
decreased	O
expression	O
of	O
l	O
-	O
selectin	B-FUNC
(	O
CD62L	O
),	O
CXCR2	O
(	O
CD182b	O
)	O
and	O
C5aR	O
(	O
CD88	O
)	O
compared	O
to	O
control	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

IL	B-FUNC
-	I-FUNC
6	I-FUNC
levels	O
increased	O
to	O
a	O
maximum	O
mean	O
concentration	O
of	O
86	O
±	O
31	O
pg	O
/	O
ml	O
at	O
24	O
h	O
postinjury	O
.	O

RESULTS	O
:	O
Blunt	O
chest	O
injury	O
resulted	O
in	O
the	O
activation	O
of	O
circulating	O
neutrophils	O
,	O
as	O
characterized	O
by	O
a	O
decreased	O
expression	O
of	O
l	O
-	O
selectin	B-FUNC
(	O
CD62L	O
),	O
CXCR2	O
(	O
CD182b	O
)	O
and	O
C5aR	O
(	O
CD88	O
)	O
compared	O
to	O
control	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

Nasopharyngeal	O
specimens	O
from	O
children	O
less	O
than	O
16	O
years	O
old	O
who	O
were	O
suffering	O
from	O
acute	O
respiratory	O
diseases	O
were	O
tested	O
for	O
hMPV	O
and	O
HCoV	O
-	O
NL63	O
by	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
.	O

RESULTS	O
:	O
The	O
primary	O
endpoint	O
occurred	O
in	O
271	O
PAC	O
patients	O
versus	O
196	O
without	O
PAC	O
(	O
21	O
.	O
3	O
%	O
vs	O
.	O
15	O
.	O
4	O
%;	O
adjusted	O
odds	O
ratio	O
[	O
AOR	B-FUNC
],	O
1	O
.	O
68	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
],	O
1	O
.	O
24	O
to	O
2	O
.	O
26	O
;	O
P	O
<	O
0	O
.	O
001	O
).	O

Here	O
,	O
we	O
identified	O
ANXA2	O
as	O
a	O
RNA	B-FUNC
binding	I-FUNC
protein	O
(	O
RBP	O
)	O
that	O
binds	B-FUNC
IBV	O
(	O
Infectious	O
Bronchitis	O
Virus	O
)	O
pseudoknot	O
RNA	O
.	O

Among	O
those	O
,	O
3	O
-	O
iodobenzyloxy	O
-	O
substituted	O
derivative	O
5e	O
showed	O
the	O
most	O
potent	O
activity	O
against	O
HCV	O
(	O
EC	O
(	O
50	O
)	O
=	O
4	O
μM	O
)	O
as	O
well	O
as	O
SCV	O
(	O
IC	O
(	O
50	O
)	O
=	O
4	O
μM	O
for	O
ATPase	B-FUNC
activity	I-FUNC
,	O
11	O
μM	O
for	O
helicase	B-FUNC
activity	I-FUNC
)	O
and	O
this	O
might	O
be	O
used	O
as	O
a	O
platform	O
structure	O
for	O
future	O
development	O
of	O
the	O
multi	O
-	O
target	O
or	O
broad	O
-	O
spectrum	O
antivirals	O
.	O

Patients	O
were	O
diagnosed	O
through	O
genetic	O
screening	O
and	O
identification	O
of	O
mutations	O
shown	O
to	O
cause	O
fast	B-FUNC
channel	O
syndrome	O
.	O

ABSTRACT	O
:	O
One	O
-	O
hundred	O
and	O
thirty	O
confirmed	O
cases	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
were	O
recruited	O
to	O
evaluate	O
their	O
anti	O
-	O
SARS	O
-	O
coronavirus	O
(	O
CoV	O
)	O
antibody	B-FUNC
status	O
and	O
human	O
leukocyte	O
antigen	O
(	O
HLA	O
)	O
types	O
in	O
September	O
2006	O
,	O
3	O
y	O
after	O
the	O
SARS	O
outbreaks	O
in	O
Taiwan	O
.	O

Such	O
a	O
mechanism	O
allows	O
for	O
tight	O
temporal	O
control	O
over	O
fusion	O
by	O
protecting	O
the	O
activating	O
cleavage	O
site	O
from	O
premature	O
proteolysis	O
yet	O
allowing	O
efficient	O
cleavage	O
upon	O
binding	B-FUNC
to	O
the	O
receptor	O
on	O
target	O
cells	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
are	O
consistent	O
with	O
mitochondrial	O
AIF	O
and	O
cyclophilin	B-FUNC
D	O
being	O
central	O
in	O
HCoV	O
-	O
OC43	O
-	O
induced	O
PCD	O
,	O
while	O
caspases	O
appear	O
not	O
to	O
be	O
essential	O
.	O

The	O
current	O
study	O
investigated	O
the	O
ability	O
of	O
aerosolized	O
extracellular	O
superoxide	O
dismutase	O
(	O
EC	O
-	O
SOD	B-FUNC
)	O
to	O
protect	O
the	O
lungs	O
from	O
hyperoxic	O
injury	O
.	O

The	O
protective	O
effects	O
of	O
EC	O
-	O
SOD	B-FUNC
against	O
hyperoxia	O
were	O
further	O
confirmed	O
by	O
reduced	O
lung	O
edema	O
and	O
systemic	O
oxidative	O
stress	O
.	O

The	O
results	O
encourage	O
the	O
use	O
of	O
an	O
aerosol	O
therapy	O
with	O
EC	O
-	O
SOD	B-FUNC
in	O
intensive	O
care	O
units	O
to	O
reduce	O
oxidative	O
injury	O
in	O
patients	O
with	O
severe	O
hypoxemic	O
respiratory	O
failure	O
,	O
including	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

BToV	O
was	O
the	O
only	O
enteric	O
pathogen	O
detected	O
in	O
these	O
outbreaks	O
,	O
as	O
determined	O
by	O
electron	O
microscopy	O
,	O
reverse	O
transcription	O
-	O
PCR	O
,	O
bacteria	O
and	O
parasite	O
tests	O
of	O
fecal	O
samples	O
,	O
and	O
antibody	B-FUNC
tests	O
with	O
paired	O
sera	B-FUNC
.	O

The	O
present	O
study	O
suggests	O
that	O
MPO	B-FUNC
-	O
mediated	O
OCl	O
(-)	O
generation	O
affects	O
claudin	O
molecules	O
and	O
leads	O
to	O
protein	O
leakage	O
and	O
viral	O
spread	O
as	O
a	O
damage	O
factor	O
in	O
influenza	O
-	O
induced	O
ARDS	O
.	O

TITLE	O
:	O
Enveloped	O
virus	O
but	O
not	O
bacteria	O
block	O
IL	B-FUNC
-	I-FUNC
13	I-FUNC
responses	O
in	O
human	O
cord	O
blood	O
T	O
cells	O
in	O
vitro	O
.	O

ABSTRACT	O
:	O
Generation	O
of	O
antiviral	O
IgM	O
is	O
usually	O
considered	O
as	O
a	O
marker	O
of	O
a	O
short	O
-	O
lived	O
initial	O
antibody	B-FUNC
response	O
that	O
is	O
replaced	O
by	O
hypermutated	O
and	O
more	O
-	O
efficient	O
IgG	O
.	O
However	O
,	O
once	O
viruses	O
have	O
established	O
a	O
particular	O
niche	O
for	O
their	O
persistence	O
(	O
e	O
.	O
g	O
.,	O
within	O
the	O
CNS	O
),	O
the	O
immune	O
system	O
has	O
to	O
specifically	O
mobilize	O
a	O
broad	O
range	O
of	O
antimicrobial	O
effectors	O
to	O
contain	O
the	O
pathogen	O
in	O
the	O
long	O
term	O
.	O

We	O
show	O
here	O
that	O
whereas	O
antibody	B-FUNC
-	O
or	O
B	O
cell	O
-	O
deficient	O
mice	O
failed	O
to	O
contain	O
MHV	O
CNS	O
infection	O
and	O
developed	O
progressive	O
demyelinating	O
disease	O
,	O
germline	O
IgM	O
produced	O
in	O
activation	O
-	O
induced	O
cytidine	O
deaminase	O
-	O
deficient	O
mice	O
(	O
aicda	O
(-/-))	O
provided	O
long	O
-	O
term	O
protection	O
against	O
the	O
chronic	O
multiple	O
sclerosis	O
-	O
like	O
disease	O
.	O

Mutation	O
analysis	O
showed	O
that	O
Tyr170	O
in	O
TM4	O
is	O
important	O
for	O
potassium	B-FUNC
channel	I-FUNC
activity	I-FUNC
.	O

Mini	O
BAL	O
is	O
a	O
safe	O
,	O
fast	B-FUNC
and	O
easy	O
technique	O
for	O
obtaining	O
samples	O
from	O
the	O
inferior	O
airway	O
in	O
patients	O
with	O
ALI	O
or	O
ARDS	O
on	O
MV	O
.	O

These	O
mutations	O
either	O
strengthen	O
favorable	O
interactions	O
or	O
reduce	O
unfavorable	O
interactions	O
with	O
two	O
virus	O
-	O
binding	B-FUNC
hot	O
spots	O
on	O
ACE2	O
,	O
and	O
by	O
doing	O
so	O
,	O
they	O
enhance	O
viral	O
interactions	O
with	O
either	O
human	O
(	O
hACE2	O
)	O
or	O
civet	O
(	O
cACE2	O
)	O
ACE2	O
.	O

Our	O
findings	O
illustrate	O
the	O
ease	O
with	O
which	O
viruses	O
can	O
change	O
receptor	O
-	O
binding	B-FUNC
specificity	O
with	O
potential	O
consequences	O
for	O
host	O
-,	O
organ	O
and	O
/	O
or	O
cell	O
tropism	O
,	O
and	O
for	O
pathogenesis	O
.	O

TITLE	O
:	O
SARS	O
CoV	O
subunit	O
vaccine	O
:	O
antibody	B-FUNC
-	O
mediated	O
neutralisation	O
and	O
enhancement	O
.	O

Ectopic	O
expression	O
of	O
catalytically	O
active	O
PLP2	O
-	O
TM	O
blocks	O
STING	O
dimer	O
formation	O
and	O
negatively	O
regulates	O
assembly	O
of	O
STING	O
-	O
MAVS	O
-	O
TBK1	B-FUNC
/	O
IKKε	O
complexes	O
required	O
for	O
activation	O
of	O
IRF	O
-	O
3	O
.	O

TITLE	O
:	O
Temperature	O
-	O
sensitive	O
mutants	O
and	O
revertants	O
in	O
the	O
coronavirus	O
nonstructural	O
protein	O
5	O
protease	O
(	O
3CLpro	O
)	O
define	O
residues	O
involved	O
in	O
long	O
-	O
distance	O
communication	O
and	O
regulation	O
of	O
protease	B-FUNC
activity	I-FUNC
.	O

We	O
present	O
a	O
case	O
series	O
of	O
four	O
patients	O
who	O
developed	O
significant	O
intraperitoneal	O
fluid	O
accumulation	O
and	O
ACS	B-FUNC
at	O
the	O
general	O
pediatric	O
and	O
cardiac	O
intensive	O
care	O
units	O
in	O
a	O
tertiary	O
children	O
'	O
s	O
hospital	O
.	O

Molecular	O
clock	O
analysis	O
using	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
genes	O
dated	O
the	O
most	O
recent	O
common	O
ancestor	O
of	O
RbCoV	O
HKU14	O
to	O
around	O
2002	O
,	O
suggesting	O
that	O
this	O
virus	O
has	O
emerged	O
relatively	O
recently	O
.	O

Similarly	O
,	O
the	O
antibody	B-FUNC
response	O
against	O
infectious	O
bronchitis	O
vaccination	O
antigens	O
was	O
decreased	O
(	O
P	O
=	O
0	O
.	O
003	O
)	O
after	O
feeding	O
contaminated	O
diets	O
,	O
compared	O
with	O
the	O
controls	O
.	O

ABSTRACT	O
:	O
In	O
order	O
to	O
find	O
new	O
molecules	O
for	O
antiviral	O
drug	O
design	O
,	O
we	O
screened	O
102	O
ethyl	O
acetate	O
extracts	O
from	O
New	O
-	O
Caledonian	O
flora	O
for	O
antiviral	O
activity	O
against	O
the	O
dengue	O
2	O
virus	O
RNA	O
-	O
dependant	O
RNA	O
polymerase	O
(	O
DV	O
-	O
NS5	O
RdRp	B-FUNC
).	O

The	O
mean	O
HI	O
titres	O
to	O
ND	O
vaccine	O
was	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
lower	O
in	O
the	O
toxin	O
groups	O
at	O
all	O
the	O
intervals	O
,	O
and	O
the	O
antibody	B-FUNC
titres	O
in	O
IBV	O
infected	O
group	O
were	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
higher	O
than	O
that	O
of	O
T	O
-	O
2	O
toxin	O
fed	O
and	O
co	O
-	O
infected	O
with	O
IBV	O
group	O
but	O
were	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
lower	O
than	O
the	O
control	O
at	O
21	O
(	O
3	O
)	O
and	O
28	O
(	O
10	O
)	O
days	O
of	O
toxin	O
feeding	O
(	O
DTF	O
)	O
(	O
days	O
post	O
infection	O
(	O
DPI	O
)).	O

However	O
,	O
it	O
is	O
possible	O
that	O
the	O
rearing	O
of	O
wild	O
boars	O
in	O
fenced	O
estates	O
may	O
predispose	O
them	O
to	O
particular	O
infections	O
,	O
as	O
reflected	O
in	O
higher	O
antibody	B-FUNC
titres	O
.	O

Furthermore	O
,	O
it	O
also	O
inhibited	O
a	O
CXCR4	B-FUNC
-	O
tropic	O
replication	O
-	O
competent	O
strain	O
of	O
HIV	O
-	O
1	O
subtype	O
B	O
virus	O
.	O

All	O
vaccines	O
induced	O
serum	O
neutralizing	O
antibody	B-FUNC
with	O
increasing	O
dosages	O
and	O
/	O
or	O
alum	O
significantly	O
increasing	O
responses	O
.	O

RESULTS	O
:	O
All	O
vaccines	O
induced	O
serum	O
neutralizing	O
antibody	B-FUNC
with	O
increasing	O
dosages	O
and	O
/	O
or	O
alum	O
significantly	O
increasing	O
responses	O
.	O

Finally	O
,	O
the	O
functional	O
consequences	O
of	O
palmitoylation	O
are	O
discussed	O
regarding	O
binding	B-FUNC
of	O
proteins	O
to	O
membranes	O
or	O
membrane	O
rafts	O
,	O
entry	O
of	O
enveloped	O
viruses	O
into	O
target	O
cells	O
by	O
spike	O
-	O
mediated	O
membrane	O
fusion	O
as	O
well	O
as	O
assembly	O
and	O
release	O
of	O
virus	O
particles	O
from	O
infected	O
cells	O
.	O

ABSTRACT	O
:	O
Abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-FUNC
)	O
is	O
defined	O
as	O
an	O
elevated	O
intraabdominal	O
pressure	O
with	O
evidence	O
of	O
organ	O
dysfunction	O
.	O

This	O
hypothesis	O
is	O
supported	O
by	O
our	O
findings	O
that	O
in	O
vivo	O
administration	O
of	O
synthetic	O
TLR7	O
ligand	B-FUNC
leads	O
to	O
enhanced	O
type	O
I	O
IFN	O
production	O
,	O
particularly	O
in	O
female	O
Cd200	O
(-/-)	O
mice	O
and	O
that	O
CD200R	O
ligation	O
inhibits	O
TLR7	O
signaling	O
in	O
vitro	O
.	O

With	O
a	O
few	O
vaccine	O
antigens	O
,	O
it	O
also	O
promoted	O
a	O
Th1	O
-	O
biased	O
response	O
based	O
on	O
pronounced	O
induction	O
of	O
Th1	O
-	O
associated	O
IgG2a	O
and	O
IgG2b	O
antibody	B-FUNC
responses	O
and	O
the	O
upregulated	O
production	O
of	O
Th1	O
cytokines	O
,	O
including	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
,	O
IFN	O
-	O
γ	O
,	O
TNF	O
-	O
α	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
.	O

Encephalitis	O
induced	O
by	O
a	O
gliatropic	O
murine	O
coronavirus	O
was	O
used	O
as	O
a	O
model	O
to	O
assess	O
the	O
direct	O
contributions	O
of	O
neutrophils	O
,	O
IFN	O
-	O
γ	O
and	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
to	O
virus	O
-	O
induced	O
mortality	O
.	O

By	O
contrast	O
,	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
depletion	O
rescued	O
recipients	O
of	O
GKO	O
CD4	O
+	O
T	O
cells	O
from	O
rapid	O
mortality	O
without	O
diminishing	O
neutrophils	O
or	O
reducing	O
GM	O
-	O
CSF	O
,	O
associated	O
with	O
pathogenic	O
Th17	O
cells	O
in	O
CNS	O
autoimmune	O
models	O
.	O

TITLE	O
:	O
Increased	O
antibody	B-FUNC
affinity	O
confers	O
broad	O
in	O
vitro	O
protection	O
against	O
escape	O
mutants	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

We	O
show	O
that	O
ns2	O
has	O
2	O
',	O
5	B-FUNC
'-	I-FUNC
phosphodiesterase	I-FUNC
activity	I-FUNC
,	O
which	O
blocks	O
the	O
interferon	O
inducible	O
2	O
',	O
5	O
'-	O
oligoadenylate	O
synthetase	O
(	O
OAS	O
)-	O
RNase	O
L	O
pathway	O
to	O
facilitate	O
hepatitis	O
development	O
.	O

ABSTRACT	O
:	O
To	O
increase	O
immune	O
responses	O
of	O
plant	O
-	O
based	O
vaccines	O
in	O
intestine	O
mucosal	O
immune	O
systems	O
,	O
a	O
synthetic	O
neutralizing	O
epitope	O
(	O
sCOE	O
)	O
gene	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
was	O
fused	O
with	O
M	O
cell	O
-	O
targeting	O
ligand	B-FUNC
(	O
Co1	O
)	O
and	O
introduced	O
into	O
a	O
plant	O
expression	O
vector	O
under	O
the	O
control	O
of	O
rice	O
amylase	O
3D	O
promoter	O
.	O

Key	O
message	O
Neutralizing	O
epitope	O
from	O
porcine	O
epidemic	O
diarrhea	O
virus	O
-	O
M	O
cell	O
targeting	O
ligand	B-FUNC
fusion	O
protein	O
was	O
produced	O
in	O
transgenic	O
rice	O
calli	O
and	O
elicited	O
systemic	O
and	O
mucosal	O
immune	O
responses	O
by	O
oral	O
administration	O
in	O
mice	O
.	O

TITLE	O
:	O
Fast	B-FUNC
-	O
track	O
ventilation	O
strategy	O
to	O
cater	O
for	O
pandemic	O
patient	O
isolation	O
surges	O
.	O

Adoptive	O
transfer	O
of	O
TCRγδ	O
(+)	O
DN	O
T	O
cells	O
led	O
to	O
dramatically	O
decreased	O
survival	O
in	O
MHV	O
-	O
3	O
-	O
infected	O
mice	O
,	O
accompanied	O
by	O
deteriorated	O
histopathology	O
and	O
elevated	O
ALT	B-FUNC
and	O
AST	O
levels	O
.	O

Type	O
1	O
regulatory	O
T	O
cells	O
(	O
Tr1	O
cells	O
)	O
produce	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
while	O
T	O
helper	O
3	O
cells	O
(	O
Th3	O
)	O
produce	O
TGF	O
-	O
β	O
.	O

Both	O
classes	O
inhibit	O
the	O
RT	O
-	O
associated	O
polymerase	O
activity	O
:	O
the	O
NRTIs	O
compete	O
with	O
the	O
natural	O
dNTP	O
substrate	O
and	O
act	O
as	O
chain	O
terminators	O
,	O
while	O
the	O
NNRTIs	O
bind	B-FUNC
to	O
an	O
allosteric	O
pocket	O
and	O
inhibit	O
polymerization	O
noncompetitively	O
.	O

These	O
results	O
suggested	O
that	O
the	O
lipids	O
are	O
functionally	O
involved	O
in	O
E	O
protein	O
ion	B-FUNC
channel	I-FUNC
activity	I-FUNC
,	O
forming	O
a	O
protein	O
-	O
lipid	O
pore	O
,	O
a	O
novel	O
concept	O
for	O
CoV	O
E	O
protein	O
ion	O
channel	O
entity	O
.	O

Luciferase	O
activities	O
were	O
significantly	O
suppressed	O
in	O
cells	O
expressing	O
nsp1	O
together	O
with	O
the	O
mRNA	O
carrying	O
a	O
luciferase	O
gene	O
,	O
while	O
nsp1	O
failed	O
to	O
suppress	O
luciferase	O
activities	O
of	O
the	O
mRNA	O
flanked	O
by	O
the	O
5	O
'	O
UTR	O
of	O
SCoV	O
.	O
An	O
RNA	O
-	O
protein	B-FUNC
binding	I-FUNC
assay	O
and	O
RNA	O
decay	O
assay	O
revealed	O
that	O
nsp1	O
bound	O
to	O
stem	O
-	O
loop	O
1	O
(	O
SL1	O
)	O
in	O
the	O
5	O
'	O
UTR	O
of	O
SCoV	O
RNA	O
and	O
that	O
the	O
specific	O
interaction	O
with	O
nsp1	O
stabilized	O
the	O
mRNA	O
carrying	O
SL1	O
.	O

Further	O
computational	O
analysis	O
will	O
provide	O
framework	O
for	O
understanding	O
the	O
underlying	O
genetic	O
and	O
molecular	O
determinants	O
related	O
to	O
maturation	O
pathways	O
of	O
antiviral	O
bnAbs	O
that	O
could	O
be	O
useful	O
for	O
applying	O
novel	O
approaches	O
to	O
the	O
design	O
of	O
effective	O
vaccine	O
immunogens	O
and	O
antibody	B-FUNC
-	O
based	O
therapeutics	O
.	O

TITLE	O
:	O
Tanshinones	O
as	O
selective	O
and	O
slow	O
-	O
binding	B-FUNC
inhibitors	O
for	O
SARS	O
-	O
CoV	O
cysteine	O
proteases	O
.	O

IL	B-FUNC
-	I-FUNC
17	I-FUNC
mRNA	O
levels	O
in	O
liver	O
tissue	O
were	O
quantified	O
by	O
using	O
quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
,	O
and	O
cytokine	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
levels	O
in	O
liver	O
tissue	O
and	O
serum	O
were	O
determined	O
by	O
using	O
ELISA	O
in	O
MHV	O
-	O
3	O
-	O
induced	O
murine	O
fulminant	O
hepatitis	O
model	O
.	O

Moreover	O
,	O
a	O
time	O
course	O
study	O
showed	O
that	O
the	O
percentage	O
of	O
both	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
-	O
producing	O
CD4	O
(+)	O
T	O
cells	O
and	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
-	O
producing	O
CD8	O
(+)	O
T	O
cells	O
was	O
increased	O
remarkably	O
in	O
the	O
liver	O
starting	O
from	O
48	O
h	O
and	O
peaked	O
at	O
72	O
h	O
post	O
-	O
infection	O
.	O

There	O
was	O
a	O
close	O
correlation	O
between	O
hepatic	O
or	O
serum	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
concentration	O
and	O
the	O
severity	O
of	O
liver	O
injury	O
defined	O
by	O
ALT	B-FUNC
level	O
,	O
respectively	O
.	O

Th17	O
associated	O
cytokines	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
21	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
22	I-FUNC
,	O
were	O
also	O
increased	O
significantly	O
at	O
72	O
h	O
post	O
-	O
infection	O
.	O

RESULTS	O
:	O
Western	O
-	O
Bolt	O
results	O
show	O
that	O
all	O
the	O
six	O
fragments	O
have	O
reacted	O
with	O
the	O
SARS	O
patient	O
convalescent	O
sera	B-FUNC
,	O
but	O
the	O
PN360	O
and	O
PN301	O
showed	O
obvious	O
cross	O
-	O
reaction	O
with	O
sera	B-FUNC
from	O
SARS	O
-	O
CoV	O
-	O
negative	O
normal	O
adults	O
;	O
sensitivity	O
analysis	O
using	O
an	O
ELISA	O
coating	O
with	O
PN199	O
,	O
PN185	O
,	O
PN155b	O
,	O
PN125	O
as	O
antigen	O
showed	O
that	O
the	O
PN185	O
and	O
PN155b	O
are	O
better	O
than	O
PN125	O
.	O

Meanwhile	O
,	O
the	O
levels	O
of	O
CK	O
and	O
CK	B-FUNC
-	I-FUNC
MB	I-FUNC
were	O
elevated	O
in	O
patients	O
with	O
respiratory	O
failure	O
compared	O
by	O
non	O
-	O
failure	O
ones	O
,	O
but	O
decreased	O
in	O
the	O
ratios	O
of	O
CK	B-FUNC
-	I-FUNC
MB	I-FUNC
to	O
CK	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Using	O
the	O
Seeplex	O
®	O
RV15	O
ACE	O
Detection	O
kit	B-FUNC
,	O
viruses	O
were	O
detected	O
in	O
129	O
(	O
78	O
.	O
7	O
%)	O
patients	O
,	O
49	O
(	O
29	O
.	O
9	O
%)	O
were	O
co	O
-	O
infected	O
cases	O
.	O

RESULTS	O
:	O
BCoV	O
was	O
detected	O
in	O
nasal	O
swabs	O
and	O
pulmonary	O
lesions	O
using	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
qRT	O
-	O
PCR	O
)	O
assay	O
and	O
virus	O
isolation	O
.	O

Compared	O
with	O
atropine	O
group	O
,	O
penehyclidine	O
hydrochloride	O
sequential	O
to	O
atropine	O
group	O
had	O
a	O
low	O
death	O
rate	O
,	O
high	O
cure	O
rate	O
,	O
less	O
complications	O
,	O
ChE	O
activity	O
recover	O
fast	B-FUNC
,	O
short	O
hospital	O
days	O
,	O
and	O
the	O
hospitalization	O
expenses	O
were	O
lower	O
than	O
that	O
of	O
the	O
single	O
use	O
of	O
atropine	O
or	O
single	O
use	O
of	O
penehyclidine	O
hydrochloride	O
group	O
,	O
and	O
the	O
differences	O
were	O
statistically	O
significant	O
(	O
all	O
P	O
＜	O
0	O
.	O
01	O
).	O

ABSTRACT	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
nonstructural	O
protein	O
1	O
(	O
nsp1	O
)	O
binds	B-FUNC
to	O
the	O
40S	O
ribosomal	O
subunit	O
and	O
inhibits	O
translation	O
,	O
and	O
it	O
also	O
induces	O
a	O
template	O
-	O
dependent	O
endonucleolytic	O
cleavage	O
of	O
host	O
mRNAs	O
.	O

Geoffroy	O
'	O
s	O
cats	O
had	O
detectable	O
antibody	B-FUNC
to	O
canine	O
distemper	O
virus	O
(	O
CDV	O
),	O
feline	O
calicivirus	O
(	O
FCV	O
),	O
feline	O
coronavirus	O
,	O
feline	O
panleukopenia	O
virus	O
(	O
FPV	O
),	O
Toxoplasma	O
gondii	O
,	O
Leptospira	O
interrogans	O
(	O
serovars	O
Ictero	O
/	O
Icter	O
and	O
Ballum	O
),	O
and	O
Dirofilaria	O
immitis	O
.	O

APN	O
also	O
provides	O
an	O
exposed	O
outer	O
surface	O
for	O
coronavirus	O
binding	B-FUNC
,	O
without	O
its	O
physiological	O
functions	O
being	O
affected	O
.	O

The	O
aim	O
of	O
this	O
review	O
is	O
to	O
summarise	O
the	O
efforts	O
in	O
the	O
design	O
of	O
new	O
inhibitors	O
either	O
characterized	O
by	O
a	O
novel	O
mechanism	O
of	O
action	O
or	O
capable	O
of	O
blocking	O
both	O
RT	O
associated	O
functions	O
,	O
as	O
well	O
as	O
pointing	O
out	O
the	O
main	O
binding	B-FUNC
features	O
of	O
the	O
known	O
RT	O
inhibitors	O
.	O

RESULTS	O
:	O
The	O
level	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
increased	O
in	O
both	O
groups	O
,	O
but	O
was	O
significantly	O
higher	O
in	O
the	O
control	O
group	O
,	O
peaking	O
at	O
twenty	O
-	O
four	O
hours	O
(	O
mean	O
and	O
standard	O
deviation	O
,	O
623	O
.	O
74	O
±	O
610	O
.	O
35	O
pg	O
/	O
mL	O
versus	O
148	O
.	O
13	O
±	O
119	O
.	O
35	O
pg	O
/	O
mL	O
;	O
p	O
=	O
0	O
.	O
006	O
).	O

RESULTS	O
:	O
Six	O
series	O
of	O
new	O
AQ	O
derivatives	O
with	O
various	O
substituents	O
at	O
positions	O
1	O
,	O
2	O
,	O
3	O
and	O
4	O
of	O
the	O
AQ	O
ring	O
were	O
tested	O
,	O
and	O
new	O
analogs	O
able	O
to	O
inhibit	O
HIV	O
-	O
1	O
RT	O
-	O
associated	O
RNase	B-FUNC
H	I-FUNC
activity	I-FUNC
in	O
the	O
low	O
micromolar	O
range	O
were	O
found	O
.	O

When	O
the	O
proteins	O
are	O
induced	O
at	O
12	O
h	O
postinfection	O
(	O
hpi	B-FUNC
),	O
crescents	O
appear	O
at	O
the	O
periphery	O
of	O
the	O
electron	O
-	O
dense	O
virosomes	O
,	O
with	O
the	O
accumulated	O
vesicles	O
likely	O
contributing	O
to	O
their	O
formation	O
.	O

Upon	O
admission	O
,	O
the	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
score	O
II	O
(	O
APACHE	O
II	O
),	O
SAA	O
,	O
serum	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
and	O
interleukin	O
-	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
)	O
were	O
measured	O
,	O
as	O
well	O
as	O
on	O
the	O
first	O
,	O
3rd	O
and	O
7th	O
day	O
and	O
were	O
compared	O
between	O
the	O
two	O
groups	O
.	O

To	O
identify	O
the	O
immunoreactivities	O
of	O
the	O
three	O
structural	O
regions	O
of	O
the	O
NP	O
that	O
are	O
recognised	O
by	O
the	O
rabbit	O
polyclonal	O
antibody	B-FUNC
and	O
human	O
serum	O
,	O
the	O
antigenicities	O
of	O
three	O
protein	O
fragments	O
,	O
including	O
the	O
N	O
-	O
terminal	O
domain	O
(	O
aa	O
1	O
-	O
173	O
),	O
the	O
central	O
-	O
linker	O
region	O
(	O
aa	O
174	O
-	O
300	O
),	O
and	O
the	O
C	O
-	O
terminal	O
domain	O
(	O
aa	O
301	O
-	O
448	O
),	O
were	O
evaluated	O
by	O
Western	O
blot	O
.	O

Thirteen	O
effusions	O
,	O
one	O
plasma	O
and	O
three	O
undefined	O
samples	O
from	O
cats	O
with	O
FIP	O
,	O
which	O
gave	O
unexpectedly	O
low	O
FCoV	O
antibody	B-FUNC
titres	O
,	O
were	O
examined	O
by	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

However	O
,	O
five	O
samples	O
were	O
negative	O
by	O
RT	O
-	O
PCR	O
,	O
so	O
the	O
presence	O
of	O
virus	O
alone	O
may	O
not	O
explain	O
all	O
cases	O
of	O
false	O
-	O
negative	O
FCoV	O
antibody	B-FUNC
tests	O
,	O
although	O
it	O
is	O
a	O
possible	O
explanation	O
in	O
71	O
%	O
of	O
discordant	O
samples	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
subgenomic	O
mRNA	O
(	O
sgmRNA	O
)	O
synthesis	O
occurs	O
via	O
a	O
process	O
of	O
discontinuous	O
transcription	O
involving	O
transcription	O
regulatory	O
sequences	O
(	O
TRSs	O
)	O
located	O
in	O
the	O
5	O
'	O
leader	O
sequence	O
(	O
TRS	B-FUNC
-	O
L	O
)	O
and	O
upstream	O
of	O
each	O
structural	O
and	O
group	O
-	O
specific	O
gene	O
(	O
TRS	B-FUNC
-	O
B	O
).	O

A	O
multicomponent	O
Ugi	O
reaction	O
was	O
utilized	O
to	O
rapidly	O
explore	O
structure	O
-	O
activity	O
relationships	O
within	O
S	O
(	O
1	O
'),	O
S	O
(	O
1	O
),	O
and	O
S	O
(	O
2	O
)	O
enzyme	B-FUNC
binding	I-FUNC
pockets	O
.	O

TITLE	O
:	O
Roadmap	O
to	O
developing	O
a	O
recombinant	O
coronavirus	O
S	O
protein	O
receptor	O
-	O
binding	B-FUNC
domain	O
vaccine	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

This	O
vaccine	O
is	O
comprised	O
of	O
a	O
recombinant	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
the	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
and	O
formulated	O
on	O
alum	O
,	O
together	O
with	O
a	O
synthetic	O
glucopyranosyl	O
lipid	O
A	O
.	O
The	O
vaccine	O
would	O
induce	O
neutralizing	O
antibodies	O
without	O
causing	O
Th2	O
-	O
type	O
immunopathology	O
.	O

The	O
retrospective	O
observational	O
study	O
included	O
all	O
mechanically	O
ventilated	O
adult	O
patients	O
of	O
three	O
university	O
-	O
affiliated	O
hospitals	O
between	O
November	O
1	O
,	O
2009	O
and	O
March	O
1	O
2010	O
who	O
had	O
2009	O
H1N1	O
influenza	O
infection	O
confirmed	O
by	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
-	O
chain	O
-	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
from	O
nasopharyngeal	O
swab	O
specimens	O
and	O
respiratory	O
secretions	O
.	O

Since	O
this	O
HE	O
protein	O
possesses	O
an	O
acetyl	O
-	O
esterase	B-FUNC
activity	I-FUNC
that	O
removes	O
acetyl	O
groups	O
from	O
O	O
-	O
acetylated	O
sialic	O
acid	O
,	O
a	O
role	O
as	O
a	O
receptor	O
-	O
destroying	O
enzyme	O
has	O
been	O
postulated	O
.	O

TITLE	O
:	O
Astrocyte	O
-	O
derived	O
CXCL10	O
drives	O
accumulation	O
of	O
antibody	B-FUNC
-	O
secreting	O
cells	O
in	O
the	O
central	O
nervous	O
system	O
during	O
viral	O
encephalomyelitis	O
.	O

ABSTRACT	O
:	O
Microbial	O
infections	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
are	O
often	O
associated	O
with	O
local	O
accumulation	O
of	O
antibody	B-FUNC
(	O
Ab	O
)-	O
secreting	O
cells	O
(	O
ASC	O
).	O

This	O
indicates	O
that	O
the	O
key	O
nsp3a	O
binding	B-FUNC
determinants	O
localize	O
to	O
the	O
SR	O
-	O
rich	O
linker	O
,	O
a	O
finding	O
consistent	O
with	O
those	O
of	O
reverse	O
genetics	O
studies	O
.	O

Twenty	O
-	O
four	O
hours	O
after	O
heat	O
shock	O
,	O
both	O
IRAK1	O
and	O
TAK1	O
are	O
again	O
detergent	O
soluble	O
,	O
which	O
correlates	O
with	O
the	O
IL	O
-	O
1β	O
-	O
dependent	O
p38	B-FUNC
activation	O
.	O

The	O
cells	O
expressing	O
PEDV	O
E	O
protein	O
express	O
higher	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
than	O
control	O
cells	O
.	O

The	O
ND	O
,	O
IB	O
and	O
AI	O
antibody	B-FUNC
titers	O
and	O
the	O
lymphocyte	O
proliferation	O
were	O
enhanced	O
at	O
30	O
mg	O
/	O
mL	O
SPP	O
.	O

In	O
this	O
study	O
,	O
the	O
N	O
genes	O
of	O
15	O
PEDV	O
strains	O
were	O
amplified	O
by	O
RT	O
-	O
PCR	O
and	O
cloned	O
into	O
the	O
pMT	B-FUNC
-	O
19T	O
vector	O
,	O
sequenced	O
,	O
and	O
compared	O
to	O
each	O
other	O
as	O
well	O
as	O
to	O
PEDV	O
reference	O
strains	O
.	O

In	O
addition	O
,	O
kallistatin	O
levels	O
were	O
positively	O
correlated	O
with	O
anti	O
-	O
thrombin	O
III	O
and	O
protein	O
C	O
and	O
inversely	O
correlated	O
with	O
IL	O
-	O
1β	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
and	O
CRP	O
levels	O
.	O

Notably	O
,	O
the	O
ubiquitin	B-FUNC
-	O
binding	B-FUNC
surface	O
is	O
distant	O
from	O
the	O
catalytic	O
site	O
,	O
which	O
allowed	O
us	O
to	O
mutate	O
this	O
surface	O
to	O
significantly	O
reduce	O
DUB	O
activity	O
without	O
affecting	O
polyprotein	O
cleavage	O
.	O

The	O
main	O
objective	O
of	O
this	O
article	O
is	O
to	O
describe	O
the	O
association	O
between	O
IAH	B-FUNC
and	O
AP	O
and	O
to	O
emphasize	O
this	O
situation	O
in	O
clinical	O
praxis	O
as	O
well	O
(	O
Fig	O
.	O
1	O
,	O
Ref	O
.	O

For	O
primary	O
response	O
to	O
SRBC	O
administered	O
at	O
7	O
d	O
of	O
age	O
,	O
HYPER	O
chicks	O
recorded	O
higher	O
total	O
,	O
IgM	O
(	O
d	O
14	O
),	O
and	O
IgG	O
(	O
d	O
21	O
)	O
anti	O
-	O
SRBC	O
antibody	B-FUNC
titers	O
.	O

In	O
the	O
presence	O
of	O
nonphysiological	O
concentration	O
of	O
Ca	O
-	O
ions	O
the	O
channel	O
develops	O
channel	B-FUNC
activity	I-FUNC
.	O

The	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
,	O
which	O
is	O
a	O
major	O
structural	O
protein	O
of	O
CoVs	O
,	O
binds	B-FUNC
to	O
the	O
viral	O
RNA	O
genome	O
to	O
form	O
the	O
virion	O
core	O
and	O
results	O
in	O
the	O
formation	O
of	O
the	O
ribonucleoprotein	O
(	O
RNP	O
)	O
complex	O
.	O

To	O
assess	O
the	O
role	O
of	O
R106	O
in	O
RNA	B-FUNC
binding	I-FUNC
,	O
we	O
undertook	O
a	O
series	O
of	O
site	O
-	O
directed	O
mutagenesis	O
experiments	O
and	O
docking	O
simulations	O
to	O
characterize	O
the	O
interaction	O
between	O
R106	O
and	O
RNA	O
.	O

Amount	O
of	O
time	O
for	O
resolution	O
of	O
abdominal	O
pain	O
/	O
distention	O
,	O
recovery	O
to	O
normal	O
heart	O
and	O
respiratory	O
rates	O
,	O
amylase	O
and	O
blood	O
glucose	O
levels	O
,	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
scores	O
,	O
and	O
levels	O
of	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
α	O
,	O
interleukin	O
(	O
IL	O
)-	O
6	O
,	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
were	O
analyzed	O
and	O
recorded	O
for	O
all	O
5	O
subgroups	O
.	O

While	O
the	O
full	O
-	O
length	O
ectodomain	O
(	O
S	O
)	O
of	O
the	O
spike	O
protein	O
,	O
the	O
full	O
-	O
length	O
ectodomain	O
fused	O
to	O
foldon	O
(	O
S	O
-	O
foldon	O
),	O
the	O
S1	O
domain	O
(	O
S1	O
),	O
S1	O
-	O
foldon	O
,	O
and	O
the	O
S2	O
domain	O
(	O
S2	O
)	O
antigens	O
all	O
elicited	O
comparable	O
antibody	B-FUNC
titers	O
as	O
measured	O
by	O
ELISA	O
,	O
S	O
-	O
foldon	O
induced	O
a	O
significantly	O
higher	O
titer	O
of	O
neutralizing	O
antibody	B-FUNC
and	O
S2	O
protein	O
did	O
not	O
elicit	O
virus	O
neutralizing	O
antibodies	O
.	O

We	O
conducted	O
a	O
seroprevalence	O
study	O
on	O
archived	O
sera	B-FUNC
from	O
94	O
game	O
-	O
food	O
animal	O
handlers	O
at	O
a	O
wild	O
life	O
market	O
,	O
28	O
SARS	O
patients	O
,	O
and	O
152	O
healthy	O
blood	O
donors	O
in	O
Southern	O
China	O
to	O
assess	O
the	O
zoonotic	O
potential	O
and	O
evidence	O
for	O
intrusion	O
of	O
HCoV	O
-	O
EMC	O
and	O
related	O
viruses	O
into	O
humans	O
.	O

RESULTS	O
:	O
Two	O
(	O
2	O
.	O
1	O
%)	O
animal	O
handlers	O
had	O
IF	O
antibody	B-FUNC
titer	O
of	O
≥	O
1	O
:	O
20	O
against	O
both	O
HCoV	O
-	O
EMC	O
and	O
SARS	O
-	O
CoV	O
with	O
neutralizing	O
antibody	B-FUNC
titer	O
of	O
<	O
1	O
:	O
10	O
.	O

The	O
assay	O
uses	O
the	O
S1	O
receptor	O
-	O
binding	B-FUNC
subunit	O
of	O
the	O
spike	O
protein	O
of	O
hCoV	O
-	O
EMC	O
and	O
SARS	O
-	O
CoV	O
as	O
antigens	O
.	O

TITLE	O
:	O
The	O
papain	O
-	O
like	O
protease	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
negatively	O
regulates	O
type	O
I	O
interferon	O
pathway	O
by	O
acting	O
as	O
a	O
viral	O
deubiquitinase	B-FUNC
.	O

The	O
finding	O
of	O
oligoclonal	O
protein	O
electrophoresis	O
(>	O
80	O
%)	O
and	O
antibodies	O
in	O
serum	O
and	O
cerebrospinal	O
fluid	O
directed	O
against	O
the	O
NR1	O
subunit	O
of	O
the	O
NMDA	B-FUNC
receptor	I-FUNC
confirms	O
the	O
diagnosis	O
.	O

Later	O
in	O
infection	O
,	O
HCoV	O
-	O
EMC	O
induced	O
a	O
massive	O
dysregulation	O
of	O
the	O
host	O
transcriptome	O
,	O
to	O
a	O
much	O
greater	O
extent	O
than	O
SARS	O
-	O
CoV	O
.	O
Both	O
viruses	O
induced	O
a	O
similar	O
activation	O
of	O
pattern	O
recognition	O
receptors	O
and	O
the	O
interleukin	O
17	O
(	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
)	O
pathway	O
,	O
but	O
HCoV	O
-	O
EMC	O
specifically	O
down	O
-	O
regulated	O
the	O
expression	O
of	O
several	O
genes	O
within	O
the	O
antigen	O
presentation	O
pathway	O
,	O
including	O
both	O
type	O
I	O
and	O
II	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
genes	O
.	O

The	O
SARS	O
-	O
CoV	O
spike	O
1	O
(	O
S1	O
)	O
protein	O
containing	O
the	O
receptor	B-FUNC
binding	I-FUNC
region	O
(	O
RBD	O
)	O
was	O
used	O
as	O
an	O
immobilized	O
target	O
followed	O
by	O
incubation	O
with	O
a	O
12	O
-	O
mer	O
phage	O
display	O
random	O
peptide	O
library	O
.	O

Indirect	O
immunofluorescent	O
assay	O
(	O
IFA	O
)	O
and	O
double	O
-	O
antigen	O
sandwich	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
were	O
used	O
to	O
detect	O
the	O
SARS	O
coronavirus	O
-	O
specific	O
IgG	O
antibodies	O
in	O
sera	B-FUNC
of	O
1700	O
,	O
including	O
1453	O
general	O
populations	O
from	O
Hongkong	O
,	O
Marco	O
,	O
Guangzhou	O
and	O
Peking	O
and	O
257	O
SARS	O
patients	O
from	O
Guangzhou	O
and	O
Peking	O
.	O

The	O
HLH	O
continued	O
to	O
progress	O
after	O
discontinuation	O
of	O
blinatumomab	O
;	O
however	O
,	O
he	O
had	O
rapid	O
improvement	O
after	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
receptor	O
-	O
directed	O
therapy	O
with	O
tocilizumab	O
.	O

In	O
contrast	O
,	O
the	O
nsp14	O
could	O
not	O
modify	O
ATP	O
,	O
CTP	O
,	O
UTP	O
,	O
dATP	O
,	O
dCTP	O
,	O
dUTP	O
or	O
cap	O
analog	O
m7GpppA	O
.	O
Critical	O
residues	O
of	O
nsp14	O
essential	O
for	O
the	O
methyltransferase	B-FUNC
activity	I-FUNC
on	O
GTP	O
were	O
identified	O
,	O
which	O
include	O
F73	O
,	O
R84	O
,	O
W86	O
,	O
R310	O
,	O
D331	O
,	O
G333	O
,	O
P335	O
,	O
Y368	O
,	O
C414	O
,	O
and	O
C416	O
.	O

We	O
further	O
showed	O
that	O
the	O
methyltransferase	B-FUNC
activity	I-FUNC
of	O
GTP	O
was	O
universal	O
for	O
nsp14	O
of	O
other	O
coronaviruses	O
.	O

Serology	O
for	O
feline	O
coronavirus	O
antibody	B-FUNC
was	O
positive	O
with	O
an	O
elevated	O
alpha	O
-	O
1	O
acid	O
glycoprotein	O
.	O

In	O
vitro	O
antiviral	O
activity	O
was	O
tested	O
using	O
two	O
different	O
assay	O
strategies	O
:	O
(	O
1	O
)	O
blockage	O
of	O
the	O
binding	B-FUNC
of	O
virus	O
to	O
cells	O
(	O
simultaneous	O
-	O
treatment	O
assay	O
)	O
and	O
(	O
2	O
)	O
inhibition	O
of	O
viral	O
replication	O
(	O
post	O
-	O
treatment	O
assay	O
).	O

Compounds	O
1	O
-	O
5	O
were	O
completely	O
blocked	O
binding	B-FUNC
of	O
viral	O
spike	O
protein	O
to	O
sialic	O
acids	O
at	O
less	O
than	O
36	O
.	O
6	O
μM	O
concentrations	O
by	O
hemagglutination	O
inhibition	O
.	O

The	O
latter	O
function	O
of	O
N	O
was	O
shown	O
to	O
depend	O
on	O
both	O
of	O
the	O
RNA	O
-	O
binding	B-FUNC
domains	O
of	O
N	O
,	O
as	O
well	O
as	O
on	O
the	O
serine	O
-	O
and	O
arginine	O
-	O
rich	O
central	O
region	O
of	O
N	O
,	O
which	O
binds	B-FUNC
nsp3	O
.	O

We	O
examined	O
a	O
furin	O
cleavage	O
site	O
in	O
the	O
region	O
between	O
receptor	O
-	O
binding	B-FUNC
(	O
S1	O
)	O
and	O
fusion	O
(	O
S2	O
)	O
domains	O
of	O
the	O
spike	O
of	O
serotype	O
1	O
FCoV	O
.	O
FECV	O
sequences	O
were	O
compared	O
with	O
FIPV	O
sequences	O
.	O

Mode	O
of	O
inhibition	O
,	O
computational	O
solvent	O
mapping	O
,	O
and	O
molecular	O
docking	O
studies	O
suggest	O
that	O
these	O
fragments	O
bind	B-FUNC
adjacent	O
to	O
the	O
binding	B-FUNC
site	O
of	O
the	O
lead	O
inhibitors	O
and	O
further	O
stabilize	O
the	O
inhibitor	O
-	O
bound	O
state	O
.	O

(	O
15	O
)	O
N	O
relaxation	O
measurements	O
provided	O
the	O
first	O
information	O
on	O
the	O
dynamics	O
of	O
the	O
carbohydrate	O
recognition	O
domain	O
,	O
demonstrating	O
that	O
it	O
is	O
a	O
highly	O
flexible	O
domain	O
that	O
undergoes	O
ligand	B-FUNC
-	O
induced	O
conformational	O
and	O
dynamic	O
changes	O
that	O
may	O
explain	O
the	O
ability	O
of	O
DC	O
-	O
SIGNR	O
to	O
accommodate	O
a	O
range	O
of	O
glycans	O
on	O
viral	O
surfaces	O
.	O

A	O
combination	O
therapy	O
with	O
ribavirin	O
,	O
intravenous	O
immunoglobulin	B-FUNC
(	O
IVIG	O
)	O
and	O
steroid	O
under	O
ECMO	O
support	O
was	O
started	O
with	O
considerable	O
improvement	O
.	O

Overall	O
,	O
our	O
results	O
suggest	O
that	O
some	O
of	O
these	O
compounds	O
inhibit	O
the	O
HIV	O
-	O
1	O
RT	O
binding	B-FUNC
to	O
an	O
allosteric	O
site	O
previously	O
described	O
for	O
other	O
natural	O
compounds	O
and	O
are	O
potential	O
leads	O
for	O
further	O
drug	O
development	O
of	O
a	O
single	O
molecules	O
having	O
dual	O
inhibitory	O
activity	O
.	O

The	O
genome	O
and	O
the	O
immunoglobulin	B-FUNC
genes	O
in	O
rhesus	O
macaques	O
and	O
humans	O
are	O
highly	O
homologous	O
;	O
therefore	O
,	O
we	O
investigated	O
whether	O
neutralizing	O
mAbs	O
that	O
are	O
highly	O
homologous	O
to	O
those	O
of	O
humans	O
(	O
human	O
-	O
like	O
)	O
could	O
be	O
generated	O
.	O

Following	O
screening	O
an	O
antibody	B-FUNC
phage	O
display	O
library	O
derived	O
from	O
the	O
B	O
cells	O
of	O
immunized	O
monkeys	O
,	O
we	O
cloned	O
selected	O
macaque	O
immunoglobulin	B-FUNC
heavy	O
chain	O
and	O
light	O
chain	O
variable	O
regions	O
into	O
the	O
human	O
IgG	O
constant	O
region	O
,	O
which	O
generated	O
human	O
-	O
macaque	O
chimeric	O
mAbs	O
exhibiting	O
over	O
97	O
%	O
homology	O
to	O
human	O
antibodies	O
.	O

In	O
particular	O
,	O
mAb	O
4E6	O
demonstrated	O
sub	O
-	O
picomolar	O
binding	B-FUNC
affinity	O
to	O
HA	O
and	O
superior	O
in	O
vivo	O
protection	O
efficacy	O
without	O
the	O
loss	O
of	O
body	O
weight	O
and	O
obvious	O
lung	O
damage	O
.	O

Sequence	O
alignment	O
indicates	O
,	O
among	O
betacoronaviruses	O
,	O
a	O
possible	O
structural	O
conservation	O
for	O
the	O
region	O
homologous	O
to	O
the	O
MERS	O
-	O
CoV	O
RBD	O
core	O
,	O
but	O
a	O
high	O
variation	O
in	O
the	O
external	O
receptor	B-FUNC
binding	I-FUNC
motif	O
region	O
for	O
virus	O
-	O
specific	O
pathogenesis	O
such	O
as	O
receptor	O
recognition	O
.	O

Increasing	O
evidence	O
from	O
pre	O
-	O
clinical	O
studies	O
supports	O
preventive	O
and	O
therapeutic	O
effects	O
of	O
mesenchymal	O
stem	O
cells	O
(	O
MSCs	B-FUNC
,	O
also	O
called	O
mesenchymal	O
stromal	O
cells	O
)	O
in	O
ALI	O
/	O
ARDS	O
(	O
acute	O
respiratory	O
distress	O
syndrome	O
).	O

TITLE	O
:	O
Structure	O
of	O
MERS	O
-	O
CoV	O
spike	O
receptor	O
-	O
binding	B-FUNC
domain	O
complexed	O
with	O
human	O
receptor	O
DPP4	O
.	O

Our	O
results	O
show	O
that	O
MERS	O
-	O
CoV	O
RBD	O
consists	O
of	O
a	O
core	O
and	O
a	O
receptor	O
-	O
binding	B-FUNC
subdomain	O
.	O

The	O
receptor	O
-	O
binding	B-FUNC
subdomain	O
interacts	O
with	O
DPP4	O
β	O
-	O
propeller	O
but	O
not	O
its	O
intrinsic	O
hydrolase	O
domain	O
.	O

Mutagenesis	O
studies	O
have	O
identified	O
several	O
key	O
residues	O
in	O
the	O
receptor	O
-	O
binding	B-FUNC
subdomain	O
that	O
are	O
critical	O
for	O
viral	O
binding	B-FUNC
to	O
DPP4	O
and	O
entry	O
into	O
the	O
target	O
cell	O
.	O

In	O
four	O
western	O
Panama	O
clinics	O
,	O
we	O
tested	O
individuals	O
presenting	O
with	O
a	O
severe	O
febrile	O
prodrome	O
for	O
acute	O
hantavirus	O
(	O
HV	O
)	O
infection	O
by	O
immunoglobulin	B-FUNC
M	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
and	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
as	O
well	O
as	O
clinically	O
similar	O
infections	O
,	O
such	O
as	O
dengue	O
and	O
leptospirosis	O
.	O

Reporter	O
gene	O
expression	O
was	O
confirmed	O
by	O
fluorescence	O
microscopy	O
,	O
or	O
luciferase	B-FUNC
activity	I-FUNC
assays	O
,	O
for	O
all	O
successfully	O
rescued	O
rIBVs	O
following	O
infection	O
of	O
primary	O
chick	O
kidney	O
(	O
CK	O
)	O
cells	O
.	O

Furthermore	O
,	O
plasma	O
stromal	O
cell	O
-	O
derived	O
factor	O
-	O
1	O
and	O
vascular	B-FUNC
endothelial	I-FUNC
growth	I-FUNC
factor	I-FUNC
concentrations	O
were	O
higher	O
in	O
acute	O
lung	O
injury	O
than	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
at	O
24	O
hours	O
.	O

Matrix	O
metalloproteinase	O
-	O
9	O
and	O
soluble	O
kit	B-FUNC
ligand	B-FUNC
levels	O
in	O
bone	O
marrow	O
were	O
reduced	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
compared	O
with	O
acute	O
lung	O
injury	O
.	O

These	O
receptor	O
-	O
destroying	O
enzymes	O
promote	O
virus	O
release	O
from	O
infected	O
cells	O
and	O
neutralize	O
sialic	O
acid	O
-	O
containing	O
soluble	O
proteins	O
interfering	O
with	O
cell	B-FUNC
surface	I-FUNC
binding	I-FUNC
of	O
the	O
virus	O
.	O

Correlation	O
coefficients	O
were	O
significantly	O
positive	O
between	O
haptoglobin	O
and	O
interferon	O
-	O
γ	O
,	O
LBSA	O
and	O
TSA	B-FUNC
,	O
and	O
TSA	B-FUNC
and	O
LBSA	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Meanwhile	O
,	O
the	O
CD69	O
expression	O
in	O
hepatic	O
NK	O
cells	O
was	O
highly	O
correlated	O
with	O
the	O
serum	O
level	O
of	O
ALT	B-FUNC
and	O
AST	O
.	O

Surprisingly	O
,	O
this	O
length	O
was	O
found	O
to	O
vary	O
throughout	O
infection	O
from	O
~	O
45	O
nt	O
immediately	O
after	O
virus	O
entry	O
(	O
at	O
0	O
to	O
4	O
hpi	B-FUNC
)	O
to	O
~	O
65	O
nt	O
later	O
on	O
(	O
at	O
6	O
h	O
to	O
9	O
hpi	B-FUNC
)	O
and	O
from	O
~	O
65	O
nt	O
(	O
at	O
6	O
h	O
to	O
9	O
hpi	B-FUNC
)	O
to	O
~	O
30	O
nt	O
(	O
at	O
120	O
-	O
144	O
hpi	B-FUNC
).	O

We	O
took	O
sera	B-FUNC
from	O
animals	O
in	O
the	O
Middle	O
East	O
(	O
Oman	O
)	O
and	O
from	O
elsewhere	O
(	O
Spain	O
,	O
Netherlands	O
,	O
Chile	O
).	O

In	O
addition	O
,	O
the	O
mRNA	O
levels	O
of	O
the	O
pro	O
-	O
inflammatory	O
cytokines	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	O
-	O
1β	O
,	O
and	O
lipopolysaccharide	O
-	O
induced	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
α	O
factor	O
and	O
the	O
serum	O
levels	O
of	O
α1	O
-	O
acid	O
glycoprotein	O
,	O
which	O
is	O
a	O
major	O
acute	O
phase	O
protein	O
,	O
were	O
measured	O
.	O

Our	O
results	O
demonstrated	O
that	O
the	O
generated	O
MERS	O
-	O
CoV	O
pseudovirus	O
allows	O
for	O
single	O
-	O
cycle	O
infection	O
of	O
a	O
variety	O
of	O
cells	O
expressing	O
dipeptidyl	O
peptidase	O
-	O
4	O
(	O
DPP4	O
),	O
the	O
confirmed	O
receptor	O
for	O
MERS	O
-	O
CoV	O
.	O
Consistent	O
with	O
the	O
results	O
from	O
a	O
live	O
MERS	O
-	O
CoV	O
-	O
based	O
inhibition	O
assay	O
,	O
the	O
antisera	O
of	O
mice	O
vaccinated	O
with	O
a	O
recombinant	O
protein	O
containing	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
,	O
residues	O
377	O
-	O
662	O
)	O
of	O
MERS	O
-	O
CoV	O
S	O
fused	O
with	O
Fc	O
of	O
human	O
IgG	O
exhibited	O
neutralizing	O
antibody	B-FUNC
response	O
against	O
infection	O
of	O
MERS	O
-	O
CoV	O
pseudovirus	O
.	O

To	O
date	O
,	O
there	O
are	O
no	O
antiviral	O
drugs	O
or	O
specific	O
therapies	O
to	O
treat	O
MERS	O
-	O
CoV	O
.	O
To	O
rapidly	O
identify	O
potential	O
inhibitors	O
of	O
MERS	O
-	O
CoV	O
replication	O
,	O
we	O
expressed	O
the	O
papain	O
-	O
like	O
protease	O
(	O
PLpro	O
)	O
and	O
the	O
3	O
-	O
chymotrypsin	O
-	O
like	O
protease	O
(	O
3CLpro	O
)	O
from	O
MERS	O
-	O
CoV	O
and	O
developed	O
luciferase	O
-	O
based	O
biosensors	O
to	O
monitor	O
protease	B-FUNC
activity	I-FUNC
in	O
cells	O
.	O

However	O
,	O
existing	O
CoV	O
PLpro	O
inhibitors	O
were	O
unable	O
to	O
block	O
MERS	O
-	O
CoV	O
PLpro	O
activity	O
,	O
likely	O
due	O
to	O
the	O
divergence	O
of	O
the	O
amino	O
acid	O
sequence	O
in	O
the	O
drug	B-FUNC
binding	I-FUNC
site	O
.	O

A	O
defined	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
in	O
the	O
SARS	O
-	O
CoV	O
spike	O
protein	O
specifically	O
recognizes	O
its	O
host	O
receptor	O
,	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
).	O

Following	O
the	O
results	O
of	O
the	O
initial	O
genetic	O
screening	O
study	O
,	O
we	O
prospectively	O
followed	O
aquaporin	B-FUNC
-	O
1	O
leukocyte	O
expression	O
patterns	O
in	O
patients	O
with	O
ICU	O
-	O
acquired	O
sepsis	O
who	O
subsequently	O
developed	O
septic	O
shock	O
(	O
n	O
=	O
16	O
)	O
versus	O
critically	O
ill	O
patients	O
who	O
were	O
discharged	O
without	O
developing	O
sepsis	O
(	O
n	O
=	O
13	O
).	O

Aquaporin	B-FUNC
-	O
1	O
is	O
induced	O
in	O
leukocytes	O
of	O
patients	O
with	O
ICU	O
-	O
acquired	O
sepsis	O
and	O
exhibits	O
higher	O
expression	O
in	O
septic	O
shock	O
.	O

On	O
postoperative	O
day	O
(	O
POD	O
)	O
3	O
,	O
we	O
observed	O
severe	O
worsening	O
of	O
PPH	B-FUNC
:	O
mPAP	O
60	O
mm	O
Hg	O
,	O
WP	O
10	O
mm	O
Hg	O
,	O
CO	O
9	O
.	O
8	O
L	O
/	O
min	O
,	O
PVR	O
395	O
dyne	O
s	O
/	O
cm	O
(	O
5	O
),	O
TPG	O
50	O
mm	O
Hg	O
even	O
with	O
maximal	O
pulmonary	O
vasodilatatory	O
therapy	O
(	O
ambrisentan	O
5	O
mg	O
,	O
intravenous	O
sildenafil	O
20	O
mg	O
×	O
3	O
and	O
epoprostenol	O
22	O
ng	O
/	O
kg	O
/	O
min	O
,	O
iNO	O
).	O

Therefore	O
,	O
we	O
aimed	O
to	O
investigate	O
the	O
expression	O
of	O
IL	B-FUNC
-	I-FUNC
33	I-FUNC
in	O
murine	O
fulminant	O
hepatitis	O
induced	O
by	O
a	O
Toll	O
like	O
receptor	O
(	O
TLR3	O
)	O
viral	O
mimetic	O
,	O
poly	O
(	O
I	O
:	O
C	O
)	O
or	O
by	O
pathogenic	O
mouse	O
hepatitis	O
virus	O
(	O
L2	O
-	O
MHV3	O
).	O

The	O
CD1d	O
KO	O
(	O
NKT	O
deficient	O
)	O
mice	O
showed	O
hepatoprotection	O
against	O
poly	O
(	O
I	O
:	O
C	O
)-	O
induced	O
hepatitis	O
in	O
association	O
with	O
increased	O
number	O
of	O
IL	B-FUNC
-	I-FUNC
33	I-FUNC
expressing	O
hepatocytes	O
in	O
CD1d	O
KO	O
mice	O
than	O
WT	O
controls	O
.	O

The	O
LSEC	O
and	O
VEC	O
expressed	O
inducible	O
expression	O
of	O
IL	B-FUNC
-	I-FUNC
33	I-FUNC
following	O
L2	O
-	O
MHV3	O
infection	O
but	O
the	O
hepatocyte	O
-	O
specific	O
IL	B-FUNC
-	I-FUNC
33	I-FUNC
expression	O
was	O
only	O
evident	O
between	O
24	O
to	O
32h	O
of	O
post	O
infection	O
.	O

TITLE	O
:	O
Effects	O
of	O
dietary	O
vitamin	O
A	O
content	O
on	O
antibody	B-FUNC
responses	O
of	O
feedlot	O
calves	O
inoculated	O
intramuscularly	O
with	O
an	O
inactivated	O
bovine	O
coronavirus	O
vaccine	O
.	O

Real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
),	O
multiplex	O
PCR	O
techniques	O
,	O
traditional	O
Sanger	O
Sequencing	O
and	O
classical	O
viral	O
culture	O
methods	O
were	O
used	O
.	O

To	O
study	O
both	O
early	O
and	O
late	O
cytokine	O
responses	O
associated	O
with	O
MERS	O
-	O
CoV	O
infection	O
,	O
we	O
measured	O
the	O
mRNA	O
levels	O
of	O
eight	O
cytokine	O
genes	O
[	O
TNF	O
-	O
α	O
,	O
IL	O
-	O
1β	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
IFN	O
-	O
β	O
,	O
monocyte	O
chemotactic	O
protein	O
-	O
1	O
,	O
transforming	O
growth	O
factor	O
-	O
β	O
and	O
IFN	O
-	O
γ	O
-	O
induced	O
protein	O
(	O
IP	O
)-	O
10	O
]	O
in	O
cell	O
lysates	O
of	O
polarized	O
airway	O
epithelial	O
Calu	O
-	O
3	O
cells	O
infected	O
with	O
MERS	O
-	O
CoV	O
or	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
CoV	O
up	O
to	O
30	O
h	O
post	O
-	O
infection	O
.	O

The	O
X	O
-	O
ray	O
structure	O
of	O
SARS	O
-	O
CoV	O
3CLpro	O
bound	O
with	O
a	O
ML300	O
analog	O
highlights	O
a	O
unique	O
induced	O
-	O
fit	O
reorganization	O
of	O
the	O
S2	O
-	O
S4	O
binding	B-FUNC
pockets	O
leading	O
to	O
the	O
first	O
sub	O
-	O
micromolar	O
noncovalent	O
3CLpro	O
inhibitors	O
retaining	O
a	O
single	O
amide	O
bond	O
.	O

This	O
review	O
will	O
describe	O
the	O
current	O
use	O
of	O
inhaled	O
NO	O
in	O
clinical	O
practice	O
and	O
briefly	O
discuss	O
its	O
potential	O
role	O
for	O
the	O
treatment	O
of	O
chronic	O
PAH	B-FUNC
.	O

Thus	O
,	O
the	O
administration	O
of	O
a	O
feline	O
TNF	O
-	O
alpha	O
-	O
neutralizing	O
antibody	B-FUNC
to	O
cats	O
with	O
FIP	O
may	O
reduce	O
the	O
disease	O
progression	O
.	O

Thirteen	O
of	O
27	O
(	O
48	O
.	O
2	O
%)	O
hedgehog	O
sera	B-FUNC
contained	O
non	O
-	O
neutralizing	O
antibodies	O
against	O
MERS	O
-	O
CoV	O
.	O
The	O
animal	O
origins	O
of	O
this	O
betacoronavirus	O
clade	O
that	O
includes	O
MERS	O
-	O
CoV	O
may	O
thus	O
include	O
both	O
bat	O
and	O
nonbat	O
hosts	O
.	O

ABSTRACT	O
:	O
Although	O
intra	O
-	O
abdominal	O
hypertension	O
(	O
IAH	B-FUNC
)	O
and	O
abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-FUNC
)	O
are	O
associated	O
with	O
substantial	O
morbidity	O
and	O
mortality	O
among	O
critically	O
ill	O
adults	O
,	O
it	O
remains	O
unknown	O
if	O
prevention	O
or	O
treatment	O
of	O
these	O
conditions	O
improves	O
patient	O
outcomes	O
.	O

We	O
searched	O
electronic	O
bibliographic	O
databases	O
(	O
MEDLINE	O
,	O
EMBASE	O
,	O
PubMed	O
,	O
and	O
the	O
Cochrane	O
Database	O
from	O
1950	O
until	O
January	O
21	O
,	O
2013	O
)	O
and	O
reference	O
lists	O
of	O
included	O
articles	O
for	O
observational	O
studies	O
reporting	O
risk	O
factors	O
for	O
IAH	B-FUNC
or	O
ACS	B-FUNC
among	O
adult	O
ICU	O
patients	O
.	O

The	O
38	O
identified	O
risk	O
factors	O
for	O
IAH	B-FUNC
and	O
24	O
for	O
ACS	B-FUNC
could	O
be	O
clustered	O
into	O
three	O
themes	O
and	O
eight	O
subthemes	O
.	O

Large	O
volume	O
crystalloid	O
resuscitation	O
,	O
the	O
respiratory	O
status	O
of	O
the	O
patient	O
,	O
and	O
shock	O
/	O
hypotension	O
were	O
common	O
risk	O
factors	O
for	O
IAH	B-FUNC
and	O
ACS	B-FUNC
that	O
transcended	O
across	O
presenting	O
patient	O
populations	O
.	O

Using	O
the	O
five	O
best	O
-	O
performing	O
biomarkers	O
(	O
surfactant	O
protein	O
-	O
D	O
(	O
SP	O
-	O
D	O
),	O
receptor	O
for	O
advanced	O
glycation	O
end	O
-	O
products	O
(	O
RAGE	O
),	O
interleukin	O
-	O
8	O
(	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
),	O
club	O
cell	O
secretory	O
protein	O
(	O
CC	O
-	O
16	O
),	O
and	O
interleukin	O
-	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
))	O
the	O
area	O
under	O
the	O
receiver	O
operator	O
characteristic	O
curve	O
(	O
AUC	O
)	O
was	O
0	O
.	O
75	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
7	O
to	O
0	O
.	O
84	O
)	O
for	O
the	O
diagnosis	O
of	O
ARDS	O
.	O

Leukocytes	O
influx	O
into	O
the	O
lung	O
and	O
microvascular	O
leakage	O
were	O
assessed	O
by	O
lung	O
myeloperoxidase	B-FUNC
activity	I-FUNC
and	O
Evans	O
blue	O
dye	O
extravasation	O
,	O
respectively	O
.	O

Clearance	O
of	O
virus	O
was	O
associated	O
with	O
a	O
specific	O
antibody	B-FUNC
response	O
against	O
the	O
nucleocapsid	O
of	O
BdCoV	O
HKU22	O
.	O

Additionally	O
,	O
the	O
expression	O
of	O
apoptosis	O
-	O
associated	O
molecules	O
,	O
Fas	O
and	O
Fas	O
ligand	B-FUNC
(	O
FasL	O
)	O
in	O
the	O
infected	O
organs	O
from	O
TNFR1	O
(-/-)	O
mice	O
were	O
also	O
decreased	O
.	O

Furthermore	O
,	O
the	O
higher	O
antibody	B-FUNC
response	O
in	O
L10H	O
chickens	O
receiving	O
vaccine	O
and	O
FOS	O
makes	O
FOS	O
a	O
potential	O
adjuvant	O
candidate	O
in	O
an	O
IBV	O
vaccine	O
.	O

TITLE	O
:	O
Mapping	O
of	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
and	O
amino	O
acids	O
critical	O
for	O
attachment	O
in	O
the	O
spike	O
protein	O
of	O
avian	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
.	O

The	O
recombinant	O
S377	O
-	O
588	O
-	O
Fc	O
is	O
able	O
to	O
induce	O
in	O
the	O
vaccinated	O
mice	O
strong	O
MERS	O
-	O
CoV	O
S	O
-	O
specific	O
antibodies	O
,	O
which	O
blocks	O
the	O
binding	B-FUNC
of	O
RBD	O
to	O
DPP4	O
receptor	O
and	O
effectively	O
neutralizes	O
MERS	O
-	O
CoV	O
infection	O
.	O

False	O
positives	O
from	O
initial	O
HTS	O
hits	O
were	O
eliminated	O
by	O
a	O
secondary	O
orthogonal	O
binding	B-FUNC
analysis	O
using	O
surface	O
plasmon	O
resonance	O
(	O
SPR	O
).	O

TITLE	O
:	O
The	O
receptor	B-FUNC
binding	I-FUNC
domain	O
of	O
MERS	O
-	O
CoV	O
:	O
the	O
dawn	O
of	O
vaccine	O
and	O
treatment	O
development	O
.	O

TITLE	O
:	O
Yeast	O
-	O
expressed	O
recombinant	O
protein	O
of	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
in	O
SARS	O
-	O
CoV	O
spike	O
protein	O
with	O
deglycosylated	O
forms	O
as	O
a	O
SARS	O
vaccine	O
candidate	O
.	O

The	O
LXGG	O
consensus	O
cleavage	O
sites	O
in	O
the	O
N	O
terminus	O
of	O
pp1a	O
/	O
1ab	O
,	O
which	O
is	O
generally	O
essential	O
for	O
CoV	O
PLpro	O
-	O
mediated	O
processing	O
,	O
were	O
also	O
characterized	O
in	O
MERS	O
-	O
CoV	O
.	O
MERS	O
-	O
CoV	O
PLpro	O
,	O
like	O
human	O
SARS	O
-	O
CoV	O
PLpro	O
and	O
NL63	O
-	O
CoV	O
PLP2	O
,	O
is	O
a	O
viral	O
deubiquitinating	B-FUNC
enzyme	I-FUNC
.	O

Salivary	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
33	I-FUNC
concentrations	O
were	O
similar	O
in	O
the	O
two	O
OSAS	O
groups	O
(	O
P	O
>	O
0	O
.	O
05	O
),	O
which	O
were	O
statistically	O
higher	O
than	O
the	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
Aluminium	O
phosphide	O
(	O
AlP	O
)	O
is	O
a	O
highly	O
toxic	O
pesticide	O
that	O
inhibits	O
cytochrome	B-FUNC
oxidase	O
c	O
and	O
causes	O
oxidative	O
stress	O
.	O

Using	O
a	O
standard	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
neutralization	O
test	O
,	O
serial	O
sera	B-FUNC
from	O
three	O
sheep	O
and	O
three	O
horses	O
were	O
all	O
negative	O
while	O
sera	B-FUNC
from	O
9	O
of	O
11	O
dromedary	O
camels	O
from	O
Dubai	O
were	O
positive	O
for	O
antibodies	O
supported	O
by	O
similar	O
results	O
in	O
a	O
MERS	O
-	O
CoV	O
recombinant	O
partial	O
spike	O
protein	O
antibody	B-FUNC
ELISA	O
.	O

TITLE	O
:	O
Attenuation	O
and	O
restoration	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
mutant	O
lacking	O
2	O
'-	O
o	B-FUNC
-	I-FUNC
methyltransferase	I-FUNC
activity	I-FUNC
.	O

ABSTRACT	O
:	O
Mesenchymal	O
stem	O
/	O
stromal	O
cells	O
(	O
MSCs	B-FUNC
)	O
offer	O
considerable	O
promise	O
as	O
a	O
novel	O
therapeutic	O
strategy	O
for	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Coronavirus	O
N	O
proteins	O
contain	O
two	O
structurally	O
distinct	O
RNA	O
-	O
binding	B-FUNC
domains	O
,	O
an	O
unusual	O
characteristic	O
among	O
RNA	O
viruses	O
.	O

This	O
work	O
describes	O
the	O
interactions	O
of	O
the	O
two	O
RNA	O
-	O
binding	B-FUNC
domains	O
of	O
the	O
nucleocapsid	O
protein	O
of	O
a	O
model	O
coronavirus	O
,	O
mouse	O
hepatitis	O
virus	O
.	O

Importantly	O
,	O
mutations	O
that	O
alter	O
DUB	O
activity	O
but	O
not	O
viral	O
protease	B-FUNC
activity	I-FUNC
have	O
been	O
identified	O
and	O
arteriviruses	O
expressing	O
DUB	O
mutants	O
stimulated	O
higher	O
levels	O
of	O
acute	O
inflammatory	O
cytokines	O
after	O
infection	O
.	O

The	O
implementation	O
of	O
nosocomial	O
pneumonia	O
prevention	O
bundles	O
,	O
or	O
early	O
extubation	O
in	O
a	O
fast	B-FUNC
-	O
track	O
program	O
,	O
has	O
proven	O
to	O
be	O
effective	O
in	O
reducing	O
the	O
complication	O
rate	O
.	O

All	O
three	O
ICA	O
kits	O
were	O
capable	O
of	O
detecting	O
anti	O
-	O
FCoV	O
antibodies	O
;	O
however	O
,	O
non	O
-	O
specific	O
positive	O
reactions	O
of	O
anti	O
-	O
FCoV	O
antibody	B-FUNC
-	O
negative	O
plasma	O
samples	O
with	O
the	O
test	O
line	O
were	O
observed	O
in	O
2	O
ICA	O
kits	O
(	O
CJIgG	O
/	O
TNP	O
and	O
CJNP	O
/	O
TNP	O
),	O
in	O
which	O
rNP	O
was	O
used	O
as	O
the	O
test	O
line	O
.	O

It	O
inhibited	O
PACT	O
-	O
induced	O
activation	O
of	O
RIG	O
-	O
I	O
and	O
MDA5	O
but	O
did	O
not	O
affect	O
the	O
activity	O
of	O
downstream	O
effectors	O
such	O
as	O
RIG	O
-	O
I	O
,	O
MDA5	O
,	O
MAVS	O
,	O
TBK1	B-FUNC
,	O
and	O
IRF3	O
.	O

The	O
structure	O
also	O
revealed	O
an	O
N	O
-	O
cyclohexyl	O
-	O
2	O
-	O
aminethanesulfonic	O
acid	O
molecule	O
near	O
the	O
catalytic	O
triad	O
,	O
and	O
kinetic	O
studies	O
suggest	O
that	O
this	O
binding	B-FUNC
site	O
is	O
also	O
used	O
by	O
other	O
PLpro	O
inhibitors	O
.	O

Using	O
human	O
CoV	O
-	O
OC43	O
(	O
HCoV	O
-	O
OC43	O
)	O
as	O
a	O
model	O
for	O
CoV	O
,	O
we	O
present	O
the	O
3D	O
structure	O
of	O
HCoV	O
-	O
OC43	O
N	O
-	O
NTD	O
complexed	O
with	O
ribonucleoside	O
5	O
'-	O
monophosphates	O
to	O
identify	O
a	O
distinct	O
ribonucleotide	O
-	O
binding	B-FUNC
pocket	O
.	O

Finally	O
,	O
the	O
less	O
lipophilic	O
bis	B-FUNC
(	O
amide	O
)	O
3e	O
and	O
methoxypyridine	O
5c	O
exhibit	O
significantly	O
improved	O
metabolic	O
stability	O
and	O
are	O
viable	O
candidates	O
for	O
advancing	O
to	O
in	O
vivo	O
studies	O
.	O

These	O
data	O
provide	O
evidence	O
that	O
mouse	O
susceptibility	O
to	O
MHV	O
-	O
3	O
-	O
induced	O
FH	O
may	O
rely	O
on	O
C5a	O
/	O
C5aR	O
interactions	O
,	O
for	O
which	O
ERK1	B-FUNC
/	O
2	O
and	O
p38	B-FUNC
pathways	O
participate	O
in	O
up	O
-	O
regulating	O
Fgl2	O
expression	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
severe	O
cancer	O
cachexia	O
disrupts	O
the	O
acute	O
contraction	O
-	O
induced	O
response	O
to	O
low	O
-	O
frequency	O
muscle	B-FUNC
contraction	I-FUNC
[	O
low	O
-	O
frequency	O
stimulation	O
(	O
LoFS	O
)].	O

The	O
changes	O
in	O
the	O
expression	O
of	O
genes	O
related	O
to	O
eggshell	O
formation	O
(	O
collagen	O
types	O
I	O
and	O
V	O
,	O
and	O
CaBP	O
-	O
D28K	O
),	O
densities	O
of	O
cytotoxic	O
cells	O
(	O
CD8	O
(+)	O
and	O
TCR	O
-	O
γδ	O
(+)	O
T	O
cells	O
),	O
and	O
gene	O
expression	O
of	O
molecules	O
related	O
to	O
cytotoxic	O
immunoreaction	O
(	O
B	O
-	O
NK	O
,	O
perforin	O
,	O
granzyme	O
,	O
and	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
)	O
and	O
proinflammatory	O
cytokines	O
(	O
IL	O
-	O
1β	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IFN	O
-	O
γ	O
)	O
were	O
examined	O
by	O
quantitative	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
or	O
immunohistochemistry	O
in	O
the	O
isthmus	O
and	O
uterus	O
.	O

The	O
expression	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
receptor	O
,	O
but	O
not	O
IL	O
-	O
1β	O
receptor	O
,	O
was	O
identified	O
in	O
the	O
tubular	O
gland	O
cells	O
in	O
the	O
isthmus	O
and	O
uterus	O
.	O

METHODS	O
:	O
Nasopharyngeal	O
samples	O
were	O
collected	O
from	O
5235	O
adult	O
pilgrims	O
from	O
22	O
countries	O
and	O
screened	O
for	O
MERS	O
-	O
CoV	O
using	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
.	O

Nasopharyngeal	O
aspirate	O
and	O
sputum	O
samples	O
should	O
be	O
collected	O
for	O
diagnosis	O
,	O
preferably	O
using	O
reverse	O
transcriptase	B-FUNC
-	O
PCR	O
.	O

Despite	O
reduced	O
Il	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
Ccl5	O
,	O
and	O
Cxcl10	O
mRNA	O
,	O
protein	O
levels	O
remained	O
unaltered	O
.	O

These	O
data	O
also	O
suggest	O
that	O
viral	O
binding	B-FUNC
and	O
/	O
or	O
entry	O
may	O
be	O
required	O
for	O
this	O
effect	O
.	O

Furthermore	O
,	O
pigs	O
receiving	O
high	O
Zn	O
diet	O
showed	O
a	O
down	O
-	O
regulation	O
of	O
interferon	O
(	O
IFN	O
)-	O
α	O
,	O
oligoadenylate	O
synthetase	O
(	O
OAS	O
),	O
Zn	O
transporter	O
SLC39A4	O
(	O
ZIP4	O
),	O
but	O
up	O
-	O
regulation	O
of	O
metallothionein	O
-	O
1	O
(	O
MT1	B-FUNC
),	O
as	O
well	O
as	O
the	O
Zn	O
transporters	O
SLC30A1	O
(	O
ZnT1	O
)	O
and	O
SLC30A5	O
(	O
ZnT5	O
).	O

The	O
USP	B-FUNC
-	O
10	O
isolate	O
,	O
of	O
enteric	O
origin	O
,	O
was	O
inoculated	O
via	O
the	O
oral	O
oroculonasal	O
routes	O
into	O
IBV	O
-	O
antibody	B-FUNC
-	O
free	O
broilers	O
and	O
specific	O
pathogen	O
-	O
free	O
(	O
SPF	O
)	O
chickens	O
to	O
determine	O
tissue	O
tropism	O
and	O
pathogenicity	O
and	O
compared	O
with	O
an	O
IBV	O
variant	O
(	O
USP	B-FUNC
-	O
50	O
)	O
isolated	O
from	O
chickens	O
showing	O
signs	O
of	O
respiratory	O
disease	O
only	O
.	O

IL	O
-	O
37	O
expression	O
was	O
positively	O
associated	O
with	O
atopic	O
dermatitis	O
,	O
whereas	O
IFN	O
-	O
α	O
,	O
IL	B-FUNC
-	I-FUNC
13	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
28	I-FUNC
,	O
and	O
Tbet	O
expressions	O
were	O
negatively	O
associated	O
with	O
allergic	O
diseases	O
.	O

Hair	O
under	O
light	O
microscopy	O
showed	O
evenly	O
distributed	O
,	O
large	O
melanin	O
granules	O
,	O
suggestive	O
of	O
Chediak	O
-	O
Higashi	O
syndrome	O
(	O
CHS	B-FUNC
).	O

TITLE	O
:	O
[	O
The	O
use	O
of	O
extracorporeal	O
life	O
support	O
and	O
continuous	O
venovenous	O
haemodiafiltration	O
in	O
severe	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
,	O
calcium	B-FUNC
channel	I-FUNC
bloker	O
and	O
beta	O
-	O
blocker	O
multidrug	O
intoxication	O
].	O

Over	O
97	O
%	O
of	O
neutrophils	O
primed	O
ex	O
vivo	O
with	O
granulocyte	B-FUNC
macrophage	I-FUNC
colony	I-FUNC
-	I-FUNC
stimulating	I-FUNC
factor	I-FUNC
were	O
retained	O
on	O
first	O
pass	O
,	O
with	O
48	O
%	O
still	O
remaining	O
in	O
the	O
lungs	O
at	O
40	O
min	O
.	O

The	O
strength	O
of	O
binding	B-FUNC
kinetics	O
between	O
the	O
TFO	O
RNAs	O
and	O
their	O
target	O
regions	O
was	O
demonstrated	O
by	O
NanoITC	O
assay	O
.	O

Here	O
,	O
we	O
have	O
produced	O
a	O
neutralizing	O
monoclonal	O
antibody	B-FUNC
with	O
the	O
capacity	O
to	O
effectively	O
block	O
MERS	O
-	O
CoV	O
entry	O
into	O
permissive	O
human	O
cells	O
.	O

And	O
to	O
validate	O
this	O
kit	B-FUNC
(	O
RealStar	O
MERS	O
-	O
CoV	O
RT	O
-	O
PCR	O
kit	B-FUNC
1	O
.	O
0	O
,	O
Altona	O
Diagnostics	O
GmbH	O
,	O
Hamburg	O
,	O
Germany	O
)	O
using	O
clinical	O
samples	O
of	O
one	O
MERS	O
-	O
CoV	O
case	O
from	O
Munich	O
and	O
respiratory	O
samples	O
of	O
patients	O
with	O
other	O
respiratory	O
diseases	O
.	O

Infusion	O
of	O
AM	O
protected	O
against	O
MV	O
-	O
induced	O
lung	O
injury	O
(	O
66	O
%	O
reduction	O
of	O
pulmonary	O
permeability	O
p	O
<	O
0	O
.	O
01	O
;	O
prevention	O
of	O
pulmonary	O
restriction	O
)	O
and	O
against	O
VILI	O
-	O
induced	O
liver	O
and	O
gut	O
injury	O
in	O
pneumonia	O
(	O
91	O
%	O
reduction	O
of	O
AST	O
levels	O
p	O
<	O
0	O
.	O
05	O
,	O
96	O
%	O
reduction	O
of	O
alanine	O
aminotransaminase	O
(	O
ALT	B-FUNC
)	O
levels	O
p	O
<	O
0	O
.	O
05	O
,	O
abrogation	O
of	O
histopathological	O
changes	O
and	O
parenchymal	O
apoptosis	O
in	O
liver	O
and	O
gut	O
).	O

Here	O
,	O
we	O
used	O
a	O
well	O
-	O
characterized	O
nonimmune	O
human	O
Ab	O
-	O
phage	O
library	O
and	O
a	O
panning	O
strategy	O
with	O
proteoliposomes	O
and	O
cells	O
to	O
identify	O
seven	O
human	O
nAbs	O
against	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
the	O
MERS	O
-	O
CoV	O
Spike	O
protein	O
.	O

We	O
report	O
the	O
isolation	O
and	O
characterization	O
of	O
two	O
potent	O
human	O
RBD	O
-	O
specific	O
neutralizing	O
monoclonal	O
antibodies	O
(	O
MERS	O
-	O
4	O
and	O
MERS	O
-	O
27	O
)	O
derived	O
from	O
single	O
-	O
chain	O
variable	O
region	O
fragments	O
of	O
a	O
nonimmune	O
human	O
antibody	B-FUNC
library	O
.	O

After	O
serial	O
infections	O
,	O
mutant	O
viruses	O
,	O
in	O
general	O
,	O
incorporated	O
compensatory	O
mutations	O
within	O
E	O
gene	O
that	O
rendered	O
active	O
ion	B-FUNC
channels	I-FUNC
.	O

Five	O
HIV	O
-	O
1	O
RHIs	O
inhibited	O
PFV	O
RNase	B-FUNC
H	I-FUNC
activity	I-FUNC
at	O
low	O
-	O
micromolar	O
concentrations	O
similar	O
to	O
those	O
of	O
HIV	O
-	O
1	O
RNase	O
H	O
,	O
suggesting	O
pocket	O
similarity	O
of	O
the	O
RNase	O
H	O
domains	O
.	O

Clinical	O
data	O
,	O
systemic	O
(	O
C	O
reactive	O
protein	O
(	O
CRP	O
),	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
procalcitonin	O
,	O
amyloid	O
-	O
A	O
,	O
fibrinogen	O
)	O
and	O
lung	O
function	O
parameters	O
were	O
also	O
collected	O
.	O

A	O
putative	O
binding	B-FUNC
pocket	O
for	O
SSYA10	O
-	O
001	O
was	O
identified	O
and	O
shown	O
to	O
be	O
similar	O
in	O
SARS	O
-	O
CoV	O
,	O
MERS	O
-	O
CoV	O
,	O
and	O
MHV	O
helicases	O
.	O

In	O
addition	O
,	O
the	O
data	O
revealed	O
that	O
highly	O
virulent	O
HPAI	B-FUNC
virus	O
and	O
MERS	O
-	O
CoV	O
induce	O
repressive	O
histone	O
modifications	O
,	O
which	O
downregulate	O
expression	O
of	O
ISG	O
subsets	O
.	O

Here	O
we	O
examine	O
the	O
structural	O
basis	O
for	O
PLpro	O
'	O
s	O
ubiquitin	B-FUNC
chain	O
and	O
interferon	O
stimulated	O
gene	O
15	O
(	O
ISG15	O
)	O
specificity	O
.	O

We	O
show	O
that	O
PLpro	O
greatly	O
prefers	O
K48	O
-	O
to	O
K63	O
-	O
linked	O
ubiquitin	B-FUNC
chains	O
,	O
and	O
ISG15	O
-	O
based	O
substrates	O
to	O
those	O
that	O
are	O
mono	O
-	O
ubiquitinated	O
.	O

This	O
population	O
was	O
progressively	O
replaced	O
by	O
CD138	O
(-)	O
IgD	O
(-)	O
IgM	O
(+)	O
B	O
cells	O
,	O
isotype	O
-	O
switched	O
CD138	O
(-)	O
IgD	O
(-)	O
IgM	O
(-)	O
memory	O
B	O
cells	O
(	O
B	O
(	O
mem	O
)),	O
and	O
CD138	O
(+)	O
antibody	B-FUNC
-	O
secreting	O
cells	O
(	O
ASC	O
).	O

Overexpression	O
of	O
activin	B-FUNC
A	O
in	O
the	O
lung	O
causes	O
similar	O
histopathological	O
changes	O
as	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

Peak	O
activin	B-FUNC
A	O
and	O
activin	B-FUNC
A	O
/	O
FS	O
were	O
associated	O
with	O
ventilatory	O
support	O
free	O
-	O
days	O
,	O
severity	O
of	O
acute	O
illness	O
and	O
length	O
of	O
ICU	O
stay	O
(	O
P	O
<	O
0	O
.	O
05	O
for	O
all	O
).	O

We	O
will	O
include	O
comparative	O
preclinical	O
studies	O
(	O
randomized	O
and	O
non	O
-	O
randomized	O
)	O
of	O
acute	O
lung	O
injury	O
in	O
which	O
MSCs	B-FUNC
were	O
administered	O
and	O
outcomes	O
compared	O
to	O
animals	O
given	O
a	O
vehicle	O
control	O
.	O

Rather	O
,	O
it	O
limits	O
CNS	O
inflammation	O
and	O
impairs	O
control	O
of	O
CNS	O
virus	O
replication	O
via	O
induction	O
of	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
in	O
virus	O
-	O
specific	O
CD4	O
+	O
T	O
cells	O
.	O

Modeling	O
the	O
binding	B-FUNC
energies	O
of	O
MERS	O
-	O
CoV	O
spike	O
protein	O
RBD	O
to	O
DPP4	O
of	O
human	O
(	O
susceptible	O
)	O
or	O
hamster	O
(	O
nonsusceptible	O
)	O
identified	O
five	O
amino	O
acid	O
residues	O
involved	O
in	O
the	O
DPP4	O
-	O
RBD	O
interaction	O
.	O

TITLE	O
:	O
Differences	O
in	O
the	O
tissue	O
tropism	O
to	O
chicken	O
oviduct	O
epithelial	O
cells	O
between	O
avian	O
coronavirus	O
IBV	O
strains	O
QX	O
and	O
B1648	O
are	O
not	O
related	O
to	O
the	O
sialic	B-FUNC
acid	I-FUNC
binding	I-FUNC
properties	O
of	O
their	O
spike	O
proteins	O
.	O

This	O
attachment	O
was	O
sialic	O
acid	O
dependent	O
,	O
indicating	O
that	O
the	O
sugar	B-FUNC
binding	I-FUNC
property	O
of	O
IBV	O
spike	O
proteins	O
is	O
not	O
the	O
limiting	O
factor	O
for	O
differences	O
in	O
infection	O
efficiency	O
for	O
the	O
oviduct	O
of	O
the	O
corresponding	O
viruses	O
.	O

Molecular	O
docking	O
of	O
compound	O
8a	O
with	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
was	O
performed	O
to	O
understand	O
the	O
binding	B-FUNC
mode	O
between	O
these	O
inhibitors	O
and	O
the	O
active	O
site	O
of	O
RdRp	B-FUNC
and	O
to	O
rationalize	O
some	O
SARs	O
.	O

The	O
IFAT	O
and	O
ELISA	O
tests	O
were	O
best	O
for	O
obtaining	O
an	O
antibody	B-FUNC
titre	O
and	O
for	O
working	O
in	O
the	O
presence	O
of	O
virus	O
.	O

The	O
RIM	O
tests	O
were	O
the	O
best	O
for	O
obtaining	O
a	O
result	O
quickly	O
(	O
10	O
-	O
15	O
mins	O
);	O
of	O
these	O
,	O
the	O
Speed	O
F	O
-	O
Corona	O
was	O
the	O
most	O
sensitive	O
,	O
at	O
92	O
.	O
4	O
%,	O
followed	O
by	O
FASTest	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
;	O
84	O
.	O
6	O
%)	O
and	O
Anigen	O
Rapid	O
FCoV	O
antibody	B-FUNC
test	O
(	O
64	O
.	O
1	O
%).	O

The	O
AKAP7	O
PDE	B-FUNC
domain	O
or	O
N	O
-	O
terminally	O
truncated	O
AKAP7	O
(	O
both	O
lacking	O
a	O
nuclear	O
localization	O
motif	O
),	O
but	O
not	O
full	O
-	O
length	O
AKAP7	O
or	O
a	O
mutant	O
,	O
AKAP7	O
(	O
H185R	O
),	O
PDE	B-FUNC
domain	O
restored	O
the	O
infectivity	O
of	O
ns2	O
mutant	O
MHV	O
in	O
bone	O
marrow	O
macrophages	O
and	O
in	O
livers	O
of	O
infected	O
mice	O
.	O

The	O
unique	O
features	O
observed	O
in	O
the	O
crystal	O
structure	O
of	O
the	O
MERS	O
-	O
CoV	O
PL	O
(	O
pro	O
)	O
should	O
allow	O
the	O
design	O
of	O
antivirals	O
that	O
would	O
not	O
interfere	O
with	O
host	O
ubiquitin	B-FUNC
-	O
specific	O
proteases	O
.	O

Increased	O
IgG	O
and	O
IgA	O
resulted	O
in	O
the	O
activation	O
of	O
TGEV	O
-	O
neutralising	O
antibody	B-FUNC
activity	I-FUNC
in	O
vitro	O
.	O

The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
PEDV	O
is	O
a	O
type	O
1	O
transmembrane	O
envelope	O
glycoprotein	O
and	O
consists	O
of	O
the	O
S1	O
and	O
S2	O
domains	O
,	O
which	O
are	O
responsible	O
for	O
virus	O
binding	B-FUNC
and	O
fusion	O
,	O
respectively	O
.	O

This	O
ultimately	O
enhances	O
the	O
dynamical	O
stability	O
of	O
the	O
residues	O
constituting	O
the	O
catalytic	O
dyad	O
and	O
substrate	O
-	O
binding	B-FUNC
pockets	O
.	O

Theoretical	O
advantages	O
of	O
ECLS	O
for	O
respiratory	O
failure	O
include	O
the	O
ability	O
to	O
rest	B-FUNC
the	O
lungs	O
by	O
avoiding	O
injurious	O
mechanical	O
ventilator	O
settings	O
and	O
the	O
potential	O
to	O
facilitate	O
early	O
mobilization	O
,	O
which	O
may	O
be	O
advantageous	O
for	O
bridging	O
to	O
recovery	O
or	O
to	O
lung	O
transplantation	O
.	O

Furthermore	O
,	O
IgA	O
IBV	O
-	O
specific	O
antibody	B-FUNC
levels	O
significantly	O
increased	O
over	O
controls	O
3	O
days	O
earlier	O
in	O
tears	O
and	O
4	O
days	O
earlier	O
in	O
plasma	O
than	O
did	O
IgG	O
antibodies	O
.	O

IgA	O
antibody	B-FUNC
levels	O
were	O
higher	O
than	O
IgG	O
antibody	B-FUNC
levels	O
throughout	O
the	O
primary	O
response	O
in	O
tears	O
and	O
were	O
similar	O
in	O
magnitude	O
in	O
plasma	O
.	O

We	O
further	O
showed	O
that	O
the	O
nsp10	O
surface	O
interacting	O
with	O
nsp14	O
overlaps	O
with	O
the	O
surface	O
involved	O
in	O
the	O
nsp10	O
-	O
mediated	O
activation	O
of	O
nsp16	O
2	O
'-	O
O	B-FUNC
-	I-FUNC
methyltransferase	I-FUNC
activity	I-FUNC
,	O
suggesting	O
that	O
nsp10	O
is	O
a	O
major	O
regulator	O
of	O
SARS	O
-	O
CoV	O
replicase	O
function	O
.	O

More	O
than	O
90	O
%	O
of	O
the	O
recognizable	O
viral	O
reads	O
were	O
related	O
to	O
mammalian	O
viruses	O
and	O
the	O
rest	B-FUNC
to	O
bacterial	O
viruses	O
.	O

Three	O
primer	O
sets	O
were	O
designed	O
:	O
a	O
primer	O
pair	O
(	O
S1	O
and	O
S2	O
)	O
that	O
can	O
bind	B-FUNC
to	O
conserved	O
sequences	O
in	O
all	O
target	O
coronaviruses	O
,	O
a	O
CCoV	O
-	O
specific	O
primer	O
(	O
S3	O
),	O
and	O
a	O
TGEV	O
-	O
specific	O
primer	O
(	O
S4	O
).	O

The	O
modification	O
or	O
deletion	O
of	O
different	O
motifs	O
within	O
E	O
protein	O
,	O
including	O
the	O
transmembrane	O
domain	O
that	O
harbors	O
an	O
ion	B-FUNC
channel	I-FUNC
activity	I-FUNC
,	O
small	O
sequences	O
within	O
the	O
middle	O
region	O
of	O
the	O
carboxy	O
-	O
terminus	O
of	O
E	O
protein	O
,	O
and	O
its	O
most	O
carboxy	O
-	O
terminal	O
end	O
,	O
which	O
contains	O
a	O
PDZ	O
domain	O
-	O
binding	B-FUNC
motif	O
(	O
PBM	O
),	O
is	O
sufficient	O
to	O
attenuate	O
the	O
virus	O
.	O

He	O
was	O
treated	O
with	O
antibiotics	O
,	O
intravenous	O
immunoglobulin	B-FUNC
,	O
and	O
oxygen	O
by	O
nasal	O
cannula	O
.	O

These	O
studies	O
clearly	O
indicate	O
a	O
significant	O
change	O
in	O
the	O
conformation	O
of	O
the	O
Cyto3a	O
protein	O
after	O
binding	B-FUNC
with	O
calcium	O
.	O

Active	O
p38	B-FUNC
MAPK	B-FUNC
was	O
reduced	O
in	O
lungs	O
of	O
mice	O
infected	O
with	O
SARS	O
-	O
CoVs	O
lacking	O
E	O
protein	O
PBM	O
as	O
compared	O
with	O
the	O
parental	O
virus	O
,	O
leading	O
to	O
a	O
decreased	O
expression	O
of	O
inflammatory	O
cytokines	O
and	O
to	O
virus	O
attenuation	O
.	O

Interestingly	O
,	O
administration	O
of	O
a	O
p38	B-FUNC
MAPK	B-FUNC
inhibitor	O
led	O
to	O
an	O
increase	O
in	O
mice	O
survival	O
after	O
infection	O
with	O
SARS	O
-	O
CoV	O
,	O
confirming	O
the	O
relevance	O
of	O
this	O
pathway	O
in	O
SARS	O
-	O
CoV	O
virulence	O
.	O

Together	O
,	O
these	O
data	O
support	O
the	O
hypothesis	O
that	O
reduced	O
BDNF	O
signaling	O
and	O
respiratory	O
dysfunction	O
in	O
RTT	O
are	O
linked	O
,	O
and	O
establish	O
the	O
proof	O
-	O
of	O
-	O
concept	O
that	O
treatment	O
with	O
a	O
small	O
-	O
molecule	O
structural	O
mimetic	O
of	O
a	O
BDNF	O
loop	O
domain	O
and	O
a	O
TrkB	O
partial	O
agonist	O
can	O
acutely	O
reverse	O
abnormal	O
breathing	O
at	O
rest	B-FUNC
and	O
in	O
response	O
to	O
behavioral	O
arousal	O
in	O
symptomatic	O
RTT	O
mice	O
.	O

Probable	O
cases	O
of	O
secondary	O
transmission	O
were	O
identified	O
on	O
the	O
basis	O
of	O
reactivity	O
in	O
two	O
reverse	O
-	O
transcriptase	B-FUNC
-	O
polymerase	O
-	O
chain	O
-	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assays	O
with	O
independent	O
RNA	O
extraction	O
from	O
throat	O
swabs	O
or	O
reactivity	O
on	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
against	O
MERS	O
-	O
CoV	O
S1	O
antigen	O
,	O
supported	O
by	O
reactivity	O
on	O
recombinant	O
S	O
-	O
protein	O
immunofluorescence	O
and	O
demonstration	O
of	O
neutralization	O
of	O
more	O
than	O
50	O
%	O
of	O
the	O
infectious	O
virus	O
seed	O
dose	O
on	O
plaque	O
-	O
reduction	O
neutralization	O
testing	O
.	O

The	O
purified	O
recombinant	O
N	O
protein	O
based	O
single	O
serum	O
dilution	O
enzyme	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
was	O
developed	O
for	O
IBV	O
to	O
measure	O
specific	O
antibody	B-FUNC
in	O
the	O
sera	B-FUNC
of	O
chickens	O
.	O

A	O
linear	O
correlation	O
was	O
obtained	O
between	O
predicted	O
antibody	B-FUNC
titres	O
at	O
a	O
single	O
working	O
dilution	O
of	O
1	O
:	O
100	O
and	O
the	O
corresponding	O
serum	O
titres	O
observed	O
as	O
determined	O
by	O
the	O
standard	O
serial	O
dilution	O
method	O
.	O

The	O
developed	O
equation	O
was	O
then	O
used	O
to	O
extrapolate	O
predicated	O
ELISA	O
antibody	B-FUNC
titer	O
from	O
corrected	O
absorbance	O
readings	O
of	O
the	O
single	O
working	O
dilution	O
.	O

Our	O
simulations	O
,	O
comprising	O
the	O
free	O
enzyme	O
as	O
well	O
as	O
substrate	O
-	O
enzyme	O
and	O
inhibitor	O
-	O
enzyme	O
complexes	O
,	O
lead	O
us	O
to	O
predict	O
that	O
zwitterion	O
formation	O
is	O
fostered	O
by	O
substrate	O
binding	B-FUNC
but	O
not	O
inhibitor	O
binding	B-FUNC
.	O

TITLE	O
:	O
Use	O
of	O
intravenous	O
immunoglobulin	B-FUNC
in	O
a	O
disseminated	O
varicella	O
infection	O
in	O
an	O
immunocompromised	O
child	O
.	O

Immunoglobulin	B-FUNC
neutralize	O
virus	O
invasion	O
and	O
suppress	O
viremia	O
,	O
acting	O
synergistically	O
with	O
acyclovir	O
.	O

In	O
this	O
case	O
,	O
early	O
administration	O
of	O
acyclovir	O
and	O
a	O
high	O
-	O
dose	O
of	O
immunoglobulin	B-FUNC
,	O
combined	O
with	O
mechanical	O
respiratory	O
support	O
,	O
proved	O
adequate	O
for	O
treatment	O
of	O
this	O
severe	O
illness	O
.	O

The	O
structure	O
of	O
the	O
HKU4	O
-	O
RBD	O
/	O
hCD26	O
complex	O
revealed	O
a	O
hCD26	O
-	O
binding	B-FUNC
mode	O
similar	O
overall	O
to	O
that	O
observed	O
for	O
MERS	O
-	O
RBD	O
.	O

Our	O
own	O
work	O
has	O
shown	O
that	O
the	O
NS2B	O
/	O
3	O
protease	O
complex	O
of	O
the	O
flavivirus	O
dengue	O
virus	O
binds	B-FUNC
and	O
cleaves	O
STING	O
,	O
and	O
that	O
an	O
inability	O
to	O
degrade	O
murine	O
STING	O
may	O
contribute	O
to	O
host	O
restriction	O
in	O
this	O
virus	O
.	O

The	O
expression	O
patterns	O
of	O
the	O
plasma	O
vWF	O
and	O
serum	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
were	O
compared	O
between	O
different	O
groups	O
.	O

However	O
,	O
guiding	O
the	O
immune	O
system	O
through	O
the	O
exceptionally	O
complex	O
antibody	B-FUNC
maturation	O
pathways	O
to	O
elicit	O
known	O
bnAbs	O
remains	O
a	O
major	O
challenge	O
.	O

The	O
anti	O
-	O
apoptosis	O
action	O
of	O
BMSCs	O
was	O
reversed	O
by	O
SB216763	O
,	O
a	O
specific	O
inhibitor	O
of	O
GSK	B-FUNC
-	O
3β	O
that	O
also	O
activates	O
Wnt	O
/	O
β	O
-	O
catenin	O
signaling	O
.	O

Taken	O
together	O
,	O
mechanical	O
stretch	O
induces	O
Ca	O
(	O
2	O
+)	O
influx	O
independently	O
of	O
conventional	O
stretch	O
-	O
sensitive	O
ion	B-FUNC
channels	I-FUNC
,	O
the	O
actin	O
cytoskeleton	O
,	O
and	O
released	O
ATP	O
.	O

TITLE	O
:	O
Computer	O
aided	O
prediction	O
and	O
identification	O
of	O
potential	O
epitopes	O
in	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
)	O
of	O
spike	O
(	O
S	O
)	O
glycoprotein	O
of	O
MERS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
belongs	O
to	O
the	O
coronaviridae	O
family	O
.	O

In	O
this	O
study	O
,	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
)	O
of	O
Spike	O
(	O
S	O
)	O
glycoprotein	O
of	O
MERS	O
-	O
CoV	O
was	O
analyzed	O
through	O
Computational	O
Immunology	O
approach	O
to	O
identify	O
the	O
antigenic	O
determinants	O
(	O
epitopes	O
).	O

TITLE	O
:	O
Insulin	O
upregulates	O
the	O
expression	O
of	O
epithelial	B-FUNC
sodium	I-FUNC
channel	I-FUNC
in	O
vitro	O
and	O
in	O
a	O
mouse	O
model	O
of	O
acute	O
lung	O
injury	O
:	O
role	O
of	O
mTORC2	O
/	O
SGK1	O
pathway	O
.	O

Stimulation	O
of	O
epithelial	B-FUNC
sodium	I-FUNC
channel	I-FUNC
(	O
ENaC	O
)	O
promotes	O
Na	O
(+)	O
transport	O
,	O
a	O
rate	O
-	O
limiting	O
step	O
for	O
pulmonary	O
edema	O
reabsorption	O
.	O

In	O
addition	O
,	O
an	O
immunoprecipitation	O
study	O
demonstrated	O
that	O
SGK1	O
(	O
Ser422	O
)	O
phosphorylation	O
,	O
the	O
key	O
step	O
for	O
complete	O
SGK1	O
activation	O
by	O
insulin	O
,	O
was	O
conducted	O
through	O
PI3K	B-FUNC
/	O
mTORC2	O
pathway	O
.	O

This	O
illustrates	O
that	O
M	O
-	O
protein	O
perturbs	O
the	O
PDK1	B-FUNC
and	O
PKB	O
/	O
Akt	O
cell	O
survival	O
signalling	O
pathway	O
.	O

Immunoglobulin	B-FUNC
G	O
(	O
IgG	O
)	O
titres	O
peaked	O
3	O
weeks	O
after	O
the	O
onset	O
of	O
illness	O
,	O
whilst	O
IgM	O
levels	O
remained	O
constantly	O
elevated	O
during	O
the	O
follow	O
-	O
up	O
period	O
(	O
second	O
to	O
fifth	O
week	O
of	O
illness	O
).	O

Reverse	O
-	O
transcriptase	B-FUNC
PCR	O
was	O
used	O
to	O
generate	O
amplicons	O
for	O
sequence	O
analysis	O
.	O

Moreover	O
,	O
SHXB	O
-	O
infected	O
immature	O
Mo	O
-	O
DCs	O
showed	O
low	O
expression	O
of	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
and	O
IFN	O
-	O
γ	O
,	O
and	O
also	O
lost	O
the	O
ability	O
to	O
stimulate	O
T	O
cell	O
proliferation	O
.	O

The	O
perceptions	O
of	O
GPs	O
and	O
FPs	B-FUNC
on	O
how	O
serious	O
infectious	O
disease	O
outbreaks	O
affected	O
their	O
clinical	O
work	O
and	O
personal	O
lives	O
;	O
their	O
preparedness	O
for	O
a	O
serious	O
infectious	O
disease	O
outbreak	O
;	O
and	O
the	O
types	O
of	O
information	O
they	O
want	O
to	O
receive	O
and	O
the	O
sources	O
they	O
wanted	O
to	O
receive	O
information	O
from	O
during	O
a	O
serious	O
infectious	O
disease	O
outbreak	O
.	O

Twenty	O
-	O
three	O
pathogenic	O
respiratory	O
agents	O
,	O
18	O
respiratory	O
viruses	O
and	O
five	O
bacteria	O
were	O
investigated	O
using	O
multiplex	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
indirect	O
immunofluorescence	O
assay	O
(	O
IIF	O
).	O

TITLE	O
:	O
Crystal	O
structure	O
of	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
papain	O
-	O
like	O
protease	O
bound	O
to	O
ubiquitin	B-FUNC
facilitates	O
targeted	O
disruption	O
of	O
deubiquitinating	O
activity	O
to	O
demonstrate	O
its	O
role	O
in	O
innate	O
immune	O
suppression	O
.	O

Guided	O
by	O
this	O
structure	O
,	O
mutations	O
were	O
introduced	O
into	O
PL	O
(	O
pro	O
)	O
to	O
specifically	O
disrupt	O
Ub	O
binding	B-FUNC
without	O
affecting	O
viral	O
polyprotein	O
cleavage	O
,	O
as	O
determined	O
using	O
an	O
in	O
trans	O
nsp3	O
↓	O
4	O
cleavage	O
assay	O
.	O

In	O
spite	O
of	O
the	O
fast	B-FUNC
diagnostic	O
methods	O
and	O
effective	O
therapeutic	O
procedures	O
the	O
mortality	O
is	O
high	O
.	O

Protein	O
analysis	O
of	O
spinal	O
cord	O
extracts	O
taken	O
from	O
mice	O
6	O
days	O
post	O
-	O
inoculation	O
,	O
the	O
time	O
of	O
peak	O
inflammation	O
,	O
reveals	O
robust	O
expression	O
of	O
IFN	O
-	O
γ	O
,	O
IL	B-FUNC
-	I-FUNC
12	I-FUNC
and	O
mKC	O
.	O

Among	O
recombinant	O
spike	O
S1	O
,	O
S2	O
,	O
S3	O
,	O
and	O
nucleocapsid	O
N	O
protein	O
of	O
PEDV	O
,	O
S3	O
protein	O
presented	O
the	O
highest	O
antibody	B-FUNC
level	O
in	O
the	O
K	O
/	O
K	O
group	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
15	O
respiratory	O
viruses	O
in	O
children	O
with	O
acute	O
respiratory	O
tract	O
infections	O
(	O
ARTIs	O
)	O
using	O
multiplex	O
reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
),	O
and	O
to	O
analyze	O
the	O
clinical	O
and	O
epidemiological	O
features	O
of	O
these	O
viruses	O
.	O

Some	O
studies	O
have	O
indicated	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
protein	O
of	O
MERS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
is	O
a	O
good	O
candidate	O
antigen	O
for	O
a	O
MERS	O
-	O
CoV	O
subunit	O
vaccine	O
.	O

The	O
receptor	O
-	O
binding	B-FUNC
S1	O
subunit	O
of	O
coronavirus	O
spike	O
proteins	O
contains	O
two	O
distinctive	O
domains	O
,	O
the	O
N	O
-	O
terminal	O
domain	O
(	O
S1	O
-	O
NTD	O
)	O
and	O
the	O
C	O
-	O
terminal	O
domain	O
(	O
S1	O
-	O
CTD	O
),	O
both	O
of	O
which	O
can	O
function	O
as	O
receptor	O
-	O
binding	B-FUNC
domains	O
(	O
RBDs	O
).	O

Various	O
models	O
have	O
successfully	O
been	O
developed	O
to	O
elucidate	O
the	O
contribution	O
of	O
the	O
spike	O
in	O
binding	B-FUNC
of	O
the	O
virus	O
to	O
cells	O
,	O
entry	O
of	O
cell	O
culture	O
cells	O
and	O
organ	O
explants	O
,	O
and	O
the	O
in	O
vivo	O
tropism	O
and	O
pathogenesis	O
.	O

Here	O
we	O
review	O
the	O
CoV	O
-	O
receptor	O
complex	O
structures	O
reported	O
to	O
date	O
,	O
and	O
highlight	O
the	O
distinct	O
receptor	O
recognition	O
modes	O
,	O
common	O
features	O
,	O
and	O
key	O
determinants	O
of	O
the	O
binding	B-FUNC
specificity	O
.	O

Protection	O
against	O
eosinophilic	O
immunopathology	O
by	O
vaccines	O
containing	O
delta	O
inulin	O
adjuvants	O
correlated	O
better	O
with	O
enhanced	O
T	O
-	O
cell	O
gamma	O
interferon	O
(	O
IFN	O
-	O
γ	O
)	O
recall	O
responses	O
rather	O
than	O
reduced	O
interleukin	O
-	O
4	O
(	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
)	O
responses	O
,	O
suggesting	O
that	O
immunopathology	O
predominantly	O
reflects	O
an	O
inadequate	O
vaccine	O
-	O
induced	O
Th1	O
response	O
.	O

The	O
first	O
three	O
patients	O
were	O
treated	O
with	O
low	O
dose	O
MSCs	B-FUNC
(	O
1	O
million	O
cells	O
/	O
kg	O
predicted	O
bodyweight	O
[	O
PBW	O
]),	O
the	O
next	O
three	O
patients	O
received	O
intermediate	O
dose	O
MSCs	B-FUNC
(	O
5	O
million	O
cells	O
/	O
kg	O
PBW	O
),	O
and	O
the	O
final	O
three	O
patients	O
received	O
high	O
dose	O
MSCs	B-FUNC
(	O
10	O
million	O
cells	O
/	O
kg	O
PBW	O
).	O

Based	O
on	O
this	O
phase	O
1	O
experience	O
,	O
we	O
have	O
proceeded	O
to	O
phase	O
2	O
testing	O
of	O
MSCs	B-FUNC
for	O
moderate	O
to	O
severe	O
ARDS	O
with	O
a	O
primary	O
focus	O
on	O
safety	O
and	O
secondary	O
outcomes	O
including	O
respiratory	O
,	O
systemic	O
,	O
and	O
biological	O
endpoints	O
.	O

In	O
May	O
2011	O
,	O
the	O
MOH	O
replaced	O
paper	O
-	O
based	O
collection	O
with	O
an	O
electronic	O
data	O
collection	O
system	O
using	O
Field	O
Adapted	O
Survey	O
Toolkit	O
(	O
FAST	B-FUNC
)	O
on	O
HTC	O
Touch	O
Pro2	O
smartphones	O
at	O
four	O
sentinel	O
sites	O
.	O

IB	O
had	O
two	O
SNPs	O
associated	O
with	O
antibody	B-FUNC
levels	O
:	O
rs149988433	O
and	O
rs16170823	O
;	O
both	O
reached	O
chromosome	O
-	O
wide	O
significance	O
levels	O
and	O
they	O
were	O
near	O
the	O
USP7	O
and	O
TRIM27	O
genes	O
,	O
respectively	O
.	O

HIV	O
-	O
1	O
integrase	O
(	O
IN	O
)	O
and	O
reverse	O
transcriptase	B-FUNC
-	O
associated	O
ribonuclease	O
H	O
(	O
RNase	O
H	O
)	O
are	O
both	O
selective	O
targets	O
for	O
HIV	O
-	O
1	O
chemotherapy	O
,	O
and	O
the	O
identification	O
of	O
dual	O
IN	O
/	O
RNase	O
H	O
inhibitors	O
is	O
an	O
attractive	O
strategy	O
for	O
new	O
drug	O
development	O
.	O

TITLE	O
:	O
Identification	O
of	O
an	O
ideal	O
adjuvant	O
for	O
receptor	O
-	O
binding	B-FUNC
domain	O
-	O
based	O
subunit	O
vaccines	O
against	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
.	O

A	O
partial	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
gene	O
sequence	O
was	O
detected	O
in	O
feces	O
and	O
tissues	O
samples	O
from	O
the	O
fruit	O
bats	O
,	O
and	O
the	O
region	O
between	O
the	O
RdRp	B-FUNC
and	O
helicase	O
genes	O
could	O
also	O
be	O
amplified	O
from	O
fecal	O
samples	O
.	O

For	O
analysing	O
coronavirus	O
diversity	O
in	O
a	O
bat	O
species	O
-	O
rich	O
country	O
,	O
a	O
total	O
of	O
421	O
anal	O
swabs	O
/	O
faecal	O
samples	O
from	O
Costa	O
Rican	O
bats	O
were	O
screened	O
for	O
CoV	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
gene	O
sequences	O
by	O
a	O
pancoronavirus	O
PCR	O
.	O

ABSTRACT	O
:	O
In	O
addition	O
to	O
transporting	O
ions	O
,	O
the	O
multisubunit	O
Na	O
(+),	O
K	O
(+)-	O
ATPase	O
also	O
functions	O
by	O
relaying	O
cardiotonic	O
steroid	O
(	O
CTS	O
)-	O
binding	B-FUNC
-	O
induced	O
signals	O
into	O
cells	O
.	O

TITLE	O
:	O
Murine	O
coronavirus	O
ubiquitin	B-FUNC
-	O
like	O
domain	O
is	O
important	O
for	O
papain	O
-	O
like	O
protease	O
stability	O
and	O
viral	O
pathogenesis	O
.	O

Viral	O
proteins	O
with	O
ion	B-FUNC
channel	I-FUNC
activity	I-FUNC
are	O
collectively	O
termed	O
""""	O
viroporins	O
"""."	O

Antibody	B-FUNC
rates	O
of	O
decay	O
were	O
calculated	O
.	O

RESULTS	O
:	O
Calves	O
with	O
initial	O
antibody	B-FUNC
titers	O
against	O
BRSV	O
<	O
1	O
:	O
64	O
that	O
were	O
treated	O
for	O
BRD	O
had	O
a	O
slower	O
rate	O
of	O
anti	O
-	O
BRSV	O
antibody	B-FUNC
decay	O
than	O
did	O
similar	O
calves	O
that	O
were	O
not	O
treated	O
for	O
BRD	O
.	O

Vaccination	O
at	O
2	O
or	O
5	O
weeks	O
of	O
age	O
had	O
no	O
effect	O
on	O
the	O
rate	O
of	O
antibody	B-FUNC
decay	O
.	O

TITLE	O
:	O
Monoclonal	O
antibody	B-FUNC
to	O
N	O
protein	O
of	O
porcine	O
epidemic	O
diarrhea	O
virus	O
.	O

At	O
present	O
,	O
IF	O
is	O
still	O
the	O
most	O
frequently	O
used	O
method	O
in	O
most	O
Latin	O
American	O
countries	O
for	O
respiratory	O
viruses	O
diagnosis	O
due	O
to	O
its	O
low	O
cost	O
,	O
its	O
capability	O
to	O
process	O
a	O
high	O
number	O
of	O
samples	O
simultaneously	O
and	O
the	O
fast	B-FUNC
determination	O
of	O
results	O
for	O
the	O
most	O
frequent	O
viruses	O
,	O
which	O
are	O
available	O
within	O
5h	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
sensitivity	O
and	O
specificity	O
of	O
a	O
real	O
-	O
time	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
)	O
detecting	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
RNA	O
in	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
of	O
cats	O
with	O
and	O
without	O
neurological	O
and	O
/	O
or	O
ocular	O
signs	O
for	O
the	O
diagnosis	O
of	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
).	O

In	O
this	O
study	O
,	O
we	O
characterized	O
two	O
broadly	O
HIV	O
-	O
neutralizing	O
agents	O
,	O
human	O
monoclonal	O
antibody	B-FUNC
2G12	O
and	O
Galanthus	O
nivalis	O
lectin	O
(	O
GNA	O
),	O
for	O
their	O
viral	O
targeting	O
activities	O
.	O

In	O
contrast	O
,	O
nearly	O
all	O
camels	O
in	O
the	O
Middle	O
East	O
have	O
been	O
infected	O
with	O
MERS	O
-	O
CoV	O
.	O
Here	O
,	O
we	O
show	O
that	O
sera	B-FUNC
obtained	O
from	O
MERS	O
-	O
immune	O
camels	O
augment	O
the	O
kinetics	O
of	O
MERS	O
-	O
CoV	O
clearance	O
and	O
reduce	O
the	O
severity	O
of	O
pathological	O
changes	O
in	O
infected	O
lungs	O
,	O
with	O
efficacy	O
proportional	O
to	O
the	O
titer	O
of	O
MERS	O
-	O
CoV	O
-	O
neutralizing	O
serum	O
antibody	B-FUNC
.	O

nsp3	O
comprises	O
multiple	O
structural	O
domains	O
,	O
including	O
two	O
papain	O
-	O
like	O
proteases	O
(	O
PLPs	O
)	O
and	O
a	O
highly	O
conserved	O
ADP	O
-	O
ribose	O
-	O
1	O
″-	O
phosphatase	B-FUNC
(	O
ADRP	O
)	O
macrodomain	O
.	O

We	O
have	O
previously	O
shown	O
that	O
the	O
ubiquitin	B-FUNC
-	O
like	O
domain	O
at	O
the	O
amino	O
terminus	O
of	O
nsp3	O
is	O
essential	O
and	O
participates	O
in	O
a	O
critical	O
interaction	O
with	O
the	O
viral	O
nucleocapsid	O
protein	O
early	O
in	O
infection	O
.	O

Examined	O
strains	O
had	O
a	O
hemagglutinin	O
polymorphism	O
associated	O
with	O
enhanced	O
binding	B-FUNC
to	O
lower	O
respiratory	O
tract	O
receptors	O
.	O

Men	O
had	O
a	O
higher	O
antibody	B-FUNC
prevalence	O
than	O
did	O
women	O
(	O
11	O
[	O
0	O
·	O
25	O
%]	O
of	O
4341	O
vs	O
two	O
[	O
0	O
·	O
05	O
%]	O
of	O
4378	O
;	O
p	O
=	O
0	O
·	O
028	O
)	O
and	O
antibody	B-FUNC
prevalence	O
was	O
significantly	O
higher	O
in	O
central	O
versus	O
coastal	O
provinces	O
(	O
14	O
[	O
0	O
·	O
26	O
%]	O
of	O
5479	O
vs	O
one	O
[	O
0	O
·	O
02	O
%]	O
of	O
4529	O
;	O
p	O
=	O
0	O
·	O
003	O
).	O

Protection	O
studies	O
showed	O
that	O
the	O
percentage	O
of	O
antibody	B-FUNC
-	O
positive	O
chickens	O
,	O
which	O
were	O
vaccinated	O
with	O
rBeau	O
-	O
H120	O
(	O
S1	O
)	O
at	O
7	O
days	O
after	O
hatching	O
,	O
rose	O
to	O
90	O
%	O
at	O
21	O
days	O
post	O
-	O
inoculation	O
.	O

Particularly	O
,	O
S377	O
-	O
588	O
-	O
Fc	O
at	O
1	O
μg	O
elicited	O
strong	O
neutralizing	O
antibody	B-FUNC
responses	O
against	O
both	O
pseudotyped	O
and	O
live	O
MERS	O
-	O
CoV	O
similar	O
to	O
those	O
induced	O
at	O
5	O
and	O
20	O
μg	O
,	O
respectively	O
.	O

IgM	O
antibody	B-FUNC
was	O
positive	O
in	O
all	O
the	O
17	O
cases	O
,	O
which	O
included	O
9	O
male	O
cases	O
,	O
8	O
female	O
cases	O
,	O
and	O
their	O
age	O
was	O
from	O
2	O
months	O
to	O
10	O
years	O
.	O

Outpatients	O
with	O
ARI	O
were	O
assayed	O
for	O
presence	O
of	O
18	O
viruses	O
using	O
multiplex	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
MRT	O
-	O
PCR	O
)	O
to	O
simultaneously	O
detect	O
multiple	O
viruses	O
.	O

At	O
35	O
days	O
of	O
age	O
,	O
birds	O
were	O
slaughtered	O
and	O
blood	O
was	O
collected	O
for	O
investigating	O
the	O
antibody	B-FUNC
titre	O
against	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
and	O
clinical	O
chemical	O
parameters	O
.	O

Molecular	O
dynamics	O
further	O
confirmed	O
ligand	B-FUNC
stability	O
and	O
hydrogen	O
bonding	O
networks	O
.	O

The	O
stability	O
of	O
the	O
ligand	B-FUNC
was	O
subsequently	O
confirmed	O
by	O
molecular	O
dynamics	O
.	O

Interestingly	O
,	O
the	O
higher	O
dosages	O
of	O
genistein	O
suppressed	O
CBH	O
and	O
antibody	B-FUNC
responses	O
to	O
the	O
levels	O
seen	O
by	O
control	O
and	O
antibiotics	O
chicks	O
.	O

Mice	O
with	O
genetic	O
deficiency	O
of	O
CC	O
-	O
chemokine	O
receptor	O
(	O
CCR	B-FUNC
)	O
type	O
5	O
,	O
the	O
common	O
receptor	O
of	O
chemokine	O
(	O
C	O
-	O
C	O
motif	O
)	O
ligand	B-FUNC
(	O
CCL	B-FUNC
)	O
3	O
,	O
CCL4	O
,	O
and	O
CCL5	O
,	O
displayed	O
reduced	O
lung	O
damage	O
.	O

When	O
compared	O
with	O
conventional	O
antibody	B-FUNC
-	O
based	O
ELISA	O
,	O
phage	O
-	O
mediated	O
ELISA	O
was	O
more	O
sensitive	O
;	O
however	O
,	O
it	O
did	O
not	O
perform	O
better	O
than	O
semi	O
-	O
quantitative	O
RT	O
-	O
PCR	O
,	O
though	O
phage	O
-	O
mediated	O
ELISA	O
was	O
quicker	O
and	O
easier	O
to	O
set	O
up	O
.	O

Binding	B-FUNC
of	O
all	O
coronaviral	O
S1	O
proteins	O
was	O
dependent	O
on	O
sialic	O
acids	O
;	O
however	O
,	O
while	O
chicken	O
CoV	O
S1	O
preferred	O
sialic	O
acids	O
type	O
I	O
lactosamine	O
(	O
Gal	O
(	O
1	O
-	O
3	O
)	O
GlcNAc	O
)	O
over	O
type	O
II	O
(	O
Gal	O
(	O
1	O
-	O
4	O
)	O
GlcNAc	O
),	O
the	O
fine	O
glycan	O
specificities	O
of	O
pigeon	O
and	O
partridge	O
CoVs	O
were	O
different	O
,	O
as	O
chicken	O
CoV	O
S1	O
-	O
specific	O
sialylglycopolymers	O
could	O
not	O
block	O
their	O
binding	B-FUNC
to	O
tissues	O
.	O

Activation	O
of	O
MERS	O
-	O
CoV	O
3CL	O
(	O
pro	O
)	O
through	O
ligand	B-FUNC
-	O
induced	O
dimerization	O
appears	O
to	O
be	O
unique	O
within	O
the	O
genogroup	O
2c	O
and	O
may	O
potentially	O
increase	O
the	O
complexity	O
in	O
the	O
development	O
of	O
MERS	O
-	O
CoV	O
3CL	O
(	O
pro	O
)	O
inhibitors	O
as	O
antiviral	O
agents	O
.	O

Here	O
,	O
we	O
studied	O
determinants	O
of	O
binding	B-FUNC
of	O
enterotropic	O
avian	O
gammacoronaviruses	O
,	O
including	O
turkey	O
coronavirus	O
(	O
TCoV	O
),	O
guineafowl	O
coronavirus	O
(	O
GfCoV	O
),	O
and	O
quail	O
coronavirus	O
(	O
QCoV	O
),	O
which	O
are	O
evolutionarily	O
distant	O
from	O
respiratory	O
avian	O
coronaviruses	O
based	O
on	O
the	O
viral	O
attachment	O
protein	O
spike	O
(	O
S1	O
).	O

Networks	O
discussed	O
include	O
global	O
intergovernmental	O
organizations	O
and	O
recent	O
combined	O
efforts	O
of	O
these	O
organizations	O
;	O
Web	O
-	O
based	O
nongovernmental	O
systems	O
(	O
e	O
.	O
g	O
.,	O
ProMED	O
,	O
the	O
Program	O
for	O
Monitoring	O
Emerging	O
Diseases	O
);	O
and	O
networks	O
of	O
bilateral	O
or	O
multilateral	O
government	O
programs	O
(	O
e	O
.	O
g	O
.,	O
the	O
CDC	O
'	O
s	O
Global	O
Disease	O
Detection	O
[	O
GDD	O
]	O
platform	O
;	O
the	O
U	O
.	O
S	O
.	O
Department	O
of	O
Defense	O
'	O
s	O
Global	O
Emerging	O
Infections	O
Surveillance	O
and	O
Response	O
System	O
[	O
GEIS	O
];	O
regional	O
and	O
subregional	O
networks	O
;	O
and	O
the	O
U	O
.	O
S	O
.	O
Agency	O
for	O
International	O
Development	O
'	O
s	O
Emerging	O
Pandemic	O
Threats	O
[	O
EPT	B-FUNC
]	O
program	O
and	O
its	O
surveillance	O
component	O
,	O
PREDICT	O
).	O

Our	O
results	O
demonstrate	O
that	O
coronavirus	O
N	O
protein	O
could	O
function	O
as	O
a	O
VSR	O
through	O
its	O
double	B-FUNC
-	I-FUNC
stranded	I-FUNC
RNA	I-FUNC
binding	I-FUNC
activity	O
.	O

An	O
increase	O
in	O
antibody	B-FUNC
titer	O
was	O
assessed	O
for	O
4	O
coronavirus	O
strains	O
.	O

We	O
used	O
a	O
specific	O
inhibitor	O
PD98059	O
to	O
antagonize	O
phosphorylation	O
of	O
p42	O
/	O
p44	O
MAPK	B-FUNC
,	O
or	O
used	O
a	O
specific	O
inhibitor	O
SN203580	O
to	O
antagonize	O
phosphorylation	O
of	O
p38	B-FUNC
MAPK	B-FUNC
,	O
or	O
used	O
a	O
specific	O
inhibitor	O
SIS3	O
to	O
antagonize	O
phosphorylation	O
of	O
SMAD3	O
.	O

Activation	O
of	O
p38	B-FUNC
MAPK	B-FUNC
by	O
either	O
PDGF	B-FUNC
or	O
TGFβ1	O
induced	O
α	O
-	O
SMA	O
but	O
not	O
collagen	O
I	O
in	O
HLF	O
cells	O
,	O
while	O
activation	O
of	O
p42	O
/	O
p44	O
MAPK	B-FUNC
by	O
PDGF	B-FUNC
induced	O
collagen	O
I	O
but	O
not	O
α	O
-	O
SMA	O
in	O
HLF	O
cells	O
.	O

PDGF	B-FUNC
and	O
TGFβ1	O
regulate	O
ARDS	O
-	O
associated	O
lung	O
fibrosis	O
through	O
distinct	O
signaling	O
pathway	O
-	O
mediated	O
activation	O
of	O
fibrosis	O
-	O
related	O
proteins	O
.	O

We	O
then	O
examined	O
the	O
effects	O
of	O
these	O
inhibitors	O
on	O
the	O
activation	O
of	O
collagen	O
I	O
and	O
α	O
-	O
smooth	O
muscle	O
actin	O
(	O
α	O
-	O
SMA	O
)	O
induced	O
by	O
PDGF	B-FUNC
or	O
TGFβ1	O
stimulation	O
.	O

Rectal	O
swabs	O
were	O
collected	O
from	O
all	O
piglets	O
prior	O
to	O
inoculation	O
and	O
every	O
12	O
hours	O
postinoculation	O
(	O
hpi	B-FUNC
)	O
thereafter	O
,	O
with	O
4	O
control	O
and	O
5	O
challenged	O
piglets	O
euthanized	O
at	O
12	O
,	O
24	O
,	O
48	O
,	O
and	O
72	O
hpi	B-FUNC
.	O

In	O
the	O
present	O
study	O
,	O
we	O
found	O
that	O
PEDV	O
activates	O
ERK1	B-FUNC
/	O
2	O
early	O
in	O
infection	O
independently	O
of	O
viral	O
replication	O
.	O

Here	O
we	O
demonstrate	O
the	O
use	O
of	O
the	O
VelocImmune	O
technology	O
(	O
a	O
mouse	O
that	O
expresses	O
human	O
antibody	B-FUNC
-	O
variable	O
heavy	O
chains	O
and	O
κ	O
light	O
chains	O
)	O
alongside	O
the	O
VelociGene	O
technology	O
(	O
which	O
allows	O
for	O
rapid	O
engineering	O
of	O
the	O
mouse	O
genome	O
)	O
to	O
quickly	O
develop	O
and	O
evaluate	O
antibodies	O
against	O
an	O
emerging	O
viral	O
disease	O
.	O

Accelerated	O
virus	O
control	O
in	O
mice	O
lacking	O
the	O
anti	O
-	O
inflammatory	O
cytokine	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
was	O
associated	O
with	O
limited	O
initial	O
demyelination	O
,	O
but	O
low	O
viral	O
mRNA	O
persistence	O
similar	O
to	O
WT	O
mice	O
and	O
declining	O
antiviral	O
cellular	O
immunity	O
.	O

Here	O
,	O
we	O
use	O
the	O
known	O
structural	O
data	O
from	O
SARS	O
-	O
CoV	O
E	O
to	O
infer	O
the	O
residues	O
important	O
for	O
ion	B-FUNC
channel	I-FUNC
activity	I-FUNC
and	O
the	O
oligomerization	O
of	O
IBV	O
E	O
.	O
We	O
present	O
biochemical	O
data	O
for	O
the	O
formation	O
of	O
two	O
distinct	O
oligomeric	O
pools	O
of	O
IBV	O
E	O
in	O
transfected	O
and	O
infected	O
cells	O
and	O
the	O
residues	O
required	O
for	O
their	O
formation	O
.	O

The	O
X	O
domain	O
was	O
proposed	O
to	O
be	O
an	O
ADP	O
-	O
ribose	O
-	O
1	O
"""-"	O
phosphatase	B-FUNC
or	O
a	O
poly	O
(	O
ADP	O
-	O
ribose	O
)-	O
binding	B-FUNC
protein	O
,	O
whereas	O
SUD	O
-	O
NM	O
binds	B-FUNC
oligo	O
(	O
G	O
)-	O
nucleotides	O
capable	O
of	O
forming	O
G	O
-	O
quadruplexes	O
.	O

The	O
antibody	B-FUNC
,	O
named	O
LCA60	O
,	O
binds	B-FUNC
to	O
a	O
novel	O
site	O
on	O
the	O
spike	O
protein	O
and	O
potently	O
neutralizes	O
infection	O
of	O
multiple	O
MERS	O
-	O
CoV	O
isolates	O
by	O
interfering	O
with	O
the	O
binding	B-FUNC
to	O
the	O
cellular	O
receptor	O
CD26	O
.	O

Alogliptin	O
is	O
mainly	O
metabolized	O
by	O
cytochrome	B-FUNC
P450	I-FUNC
(	O
CYP2D6	O
)	O
and	O
CYP3A4	B-FUNC
.	O

In	O
contrast	O
,	O
the	O
expressions	O
of	O
Wnt5a	O
,	O
Fzd5	O
,	O
and	O
CaMKII	B-FUNC
were	O
up	O
-	O
regulated	O
in	O
the	O
lung	O
of	O
endotoxemic	O
rats	O
.	O

According	O
to	O
phylogenetic	O
analysis	O
of	O
the	O
full	O
-	O
length	O
genome	O
,	O
replicase	O
transcriptase	B-FUNC
complex	O
,	O
spike	O
protein	O
,	O
partial	O
S1	O
gene	O
and	O
M	O
protein	O
,	O
B1648	O
strain	O
clustered	O
with	O
the	O
non	O
-	O
Massachusetts	O
type	O
strains	O
NGA	O
/	O
A116E7	O
/	O
2006	O
,	O
UKr	O
27	O
-	O
11	O
,	O
QX	O
-	O
like	O
ITA	O
/	O
90254	O
/	O
2005	O
,	O
QX	O
-	O
like	O
CK	O
/	O
SWE	O
/	O
0658946	O
/	O
10	O
,	O
TN20	O
/	O
00	O
,	O
RF	O
-	O
27	O
/	O
99	O
,	O
RF	O
/	O
06	O
/	O
2007	O
and	O
SLO	O
/	O
266	O
/	O
05	O
.	O

In	O
vitro	O
studies	O
of	O
the	O
MSCs	B-FUNC
demonstrated	O
a	O
broad	O
anti	O
-	O
inflammatory	O
capacity	O
,	O
including	O
suppression	O
of	O
T	O
-	O
cell	O
responses	O
and	O
induction	O
of	O
regulatory	O
phenotypes	O
in	O
T	O
cells	O
,	O
monocytes	O
,	O
and	O
neutrophils	O
.	O

In	O
the	O
case	O
of	O
positive	O
-	O
stranded	O
RNA	O
viruses	O
belonging	O
to	O
the	O
order	O
Nidovirales	O
,	O
the	O
RdRp	B-FUNC
resides	O
in	O
a	O
replicase	O
subunit	O
that	O
is	O
unusually	O
large	O
.	O

We	O
used	O
recombinant	O
non	O
-	O
structural	O
protein	O
9	O
of	O
the	O
arterivirus	O
equine	O
arteritis	O
virus	O
(	O
EAV	O
)	O
and	O
different	O
biochemical	O
assays	O
,	O
including	O
irreversible	O
labeling	O
with	O
a	O
GTP	O
analog	O
followed	O
by	O
a	O
proteomics	O
analysis	O
,	O
to	O
demonstrate	O
the	O
manganese	O
-	O
dependent	O
covalent	O
binding	B-FUNC
of	O
guanosine	O
and	O
uridine	O
phosphates	O
to	O
a	O
lysine	O
/	O
histidine	O
residue	O
.	O

For	O
the	O
amplification	O
of	O
nucleocapsid	O
(	O
N	O
)	O
and	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
genes	O
,	O
hemi	O
-	O
nested	O
PCR	O
(	O
Invitrogen	O
,	O
ABD	O
)	O
was	O
conducted	O
,	O
followed	O
by	O
sequence	O
analysis	O
of	O
204	O
nucleotide	O
part	O
of	O
N	O
gene	O
.	O

ABSTRACT	O
:	O
The	O
spike	O
(	O
S	O
)	O
protein	O
of	O
the	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
plays	O
a	O
central	O
role	O
in	O
the	O
pathogenicity	O
,	O
the	O
immune	O
antibody	B-FUNC
production	O
,	O
serotype	O
and	O
the	O
tissue	O
tropism	O
.	O

We	O
describe	O
a	O
Siglec	O
-	O
targeting	O
platform	O
consisting	O
of	O
poly	O
(	O
lactic	O
-	O
co	O
-	O
glycolic	O
acid	O
)	O
nanoparticles	O
decorated	O
with	O
a	O
natural	O
Siglec	O
ligand	B-FUNC
,	O
di	O
(	O
α2	O
→	O
8	O
)	O
N	O
-	O
acetylneuraminic	O
acid	O
(	O
α2	O
,	O
8	O
NANA	O
-	O
NP	O
).	O

Specific	O
inhibition	O
of	O
complement	O
with	O
compstatin	O
down	O
-	O
regulated	O
sepsis	O
-	O
induced	O
fibrosis	O
genes	O
,	O
including	O
transforming	O
growth	O
factor	O
-	O
beta	O
(	O
TGF	O
-	O
β	O
),	O
connective	O
tissue	O
growth	O
factor	O
(	O
CTGF	O
),	O
tissue	O
inhibitor	O
of	O
metalloproteinase	O
1	O
(	O
TIMP1	O
),	O
various	O
collagens	O
and	O
chemokines	O
responsible	O
for	O
fibrocyte	O
recruitment	O
(	O
e	O
.	O
g	O
.	O
chemokine	O
(	O
C	O
-	O
C	O
motif	O
)	O
ligand	B-FUNC
2	O
(	O
CCL2	O
)	O
and	O
12	O
(	O
CCL12	O
)).	O

Whereas	O
,	O
the	O
viral	O
infection	O
in	O
IL	O
-	O
1β	O
receptor	O
-	O
I	O
deficient	O
(	O
IL	O
-	O
1R1	O
-/-)	O
or	O
IL	B-FUNC
-	I-FUNC
1R	I-FUNC
antagonist	O
(	O
IL	B-FUNC
-	I-FUNC
1Ra	I-FUNC
)	O
treated	O
mice	O
,	O
show	O
reductions	O
in	O
virus	O
replication	O
,	O
disease	O
progress	O
and	O
mortality	O
.	O

The	O
structure	O
of	O
Fab	O
m336	O
in	O
complex	O
with	O
the	O
MERS	O
-	O
CoV	O
receptor	O
-	O
binding	B-FUNC
domain	O
reveals	O
that	O
its	O
IGHV1	O
-	O
69	O
-	O
derived	O
heavy	O
chain	O
provides	O
more	O
than	O
85	O
%	O
binding	B-FUNC
surface	O
and	O
that	O
its	O
epitope	O
almost	O
completely	O
overlaps	O
with	O
the	O
receptor	O
-	O
binding	B-FUNC
site	O
.	O

Then	O
,	O
next	O
generation	O
sequencing	O
was	O
performed	O
on	O
9	O
hpi	B-FUNC
and	O
control	O
uninfected	O
cells	O
by	O
Illumina	O
analyzer	O
.	O

131	O
genes	O
from	O
apoptosis	O
cluster	O
(	O
80	O
down	O
-	O
regulated	O
and	O
51	O
up	O
-	O
regulated	O
)	O
along	O
with	O
increase	O
of	O
apoptosis	O
,	O
p53	O
,	O
p38	B-FUNC
MAPK	B-FUNC
,	O
VEGF	O
and	O
chemokines	O
/	O
cytokines	O
signaling	O
pathways	O
were	O
probably	O
involved	O
in	O
apoptosis	O
process	O
.	O

Both	O
mAbs	O
potently	O
bind	B-FUNC
to	O
MERS	O
-	O
RBD	O
and	O
block	O
virus	O
entry	O
in	O
vitro	O
with	O
high	O
efficacy	O
.	O

2E6	O
also	O
blocks	O
receptor	B-FUNC
binding	I-FUNC
,	O
and	O
competes	O
with	O
4C2	O
for	O
binding	B-FUNC
to	O
MERS	O
-	O
RBD	O
.	O

The	O
infected	O
suckling	O
pigs	O
have	O
higher	O
and	O
earlier	O
increases	O
in	O
serum	O
IFNα	O
,	O
but	O
lower	O
serum	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
and	O
TNFα	O
levels	O
compared	O
to	O
infected	O
weaned	O
pigs	O
.	O

In	O
the	O
absence	O
of	O
CCoV	O
-	O
I	O
laboratory	O
strain	O
,	O
we	O
used	O
feline	O
coronavirus	O
(	O
FCoV	O
)-	O
I	O
that	O
shares	O
high	O
sequence	O
homology	O
in	O
the	O
S	O
protein	O
with	O
CCoV	O
-	O
I	O
.	O
77	O
.	O
7	O
%	O
of	O
the	O
sera	B-FUNC
were	O
positive	O
for	O
neutralizing	O
anti	O
-	O
FCoV	O
-	O
I	O
antibodies	O
.	O

Particularly	O
,	O
compounds	O
4	O
,	O
11b	O
,	O
11c	O
,	O
13c	O
,	O
15a	O
,	O
18	O
and	O
21	O
resulted	O
active	O
against	O
BVDV	O
at	O
concentrations	O
ranging	O
from	O
1	O
.	O
3	O
to	O
5	O
μM	O
.	O
Compound	O
21	O
was	O
also	O
evaluated	O
for	O
its	O
activity	O
on	O
the	O
BVDV	O
RdRp	B-FUNC
.	O

Dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
)	O
is	O
the	O
receptor	O
for	O
cell	O
binding	B-FUNC
and	O
entry	O
.	O

Hence	O
,	O
the	O
role	O
of	O
the	O
RBM	O
is	O
a	O
bi	O
-	O
functional	O
bioactive	O
surface	O
that	O
can	O
be	O
demonstrated	O
by	O
antibodies	O
such	O
as	O
the	O
neutralizing	O
human	O
anti	O
-	O
SARS	O
monoclonal	O
antibody	B-FUNC
(	O
mAb	O
)	O
80R	O
which	O
targets	O
the	O
RBM	O
and	O
competes	O
with	O
the	O
ACE2	O
receptor	O
for	O
binding	B-FUNC
.	O

40	O
amino	O
acids	O
)	O
that	O
can	O
bind	B-FUNC
both	O
the	O
ACE2	O
receptor	O
and	O
the	O
neutralizing	O
mAb	O
80R	O
.	O

RESULTS	O
:	O
Of	O
the	O
total	O
sample	O
of	O
149	O
subjects	O
with	O
ACS	B-FUNC
,	O
118	O
(	O
79	O
.	O
2	O
%)	O
met	O
criteria	O
for	O
DSM	O
-	O
5	O
persistent	O
complex	O
bereavement	O
disorder	O
.	O

Moreover	O
to	O
compare	O
antigenic	O
similarity	O
of	O
genetically	O
diverse	O
MERS	O
-	O
CoV	O
clades	O
,	O
the	O
response	O
of	O
four	O
sera	B-FUNC
from	O
two	O
patients	O
sampled	O
at	O
two	O
time	O
periods	O
during	O
the	O
course	O
of	O
illness	O
were	O
tested	O
by	O
90	O
%	O
PRNT	O
.	O

The	O
loss	O
of	O
binding	B-FUNC
activity	O
was	O
manifested	O
as	O
a	O
20	O
%	O
decrease	O
in	O
the	O
minimum	O
on	O
-	O
rate	O
accompanied	O
with	O
a	O
70	O
%	O
increase	O
in	O
the	O
maximum	O
off	O
-	O
rate	O
.	O

Evaluation	O
of	O
available	O
SARS	O
-	O
based	O
immune	O
-	O
therapeutic	O
and	O
prophylactic	O
modalities	O
revealed	O
poor	O
efficacy	O
;	O
both	O
monoclonal	O
antibody	B-FUNC
and	O
vaccine	O
approaches	O
failed	O
to	O
neutralize	O
and	O
protect	O
from	O
infection	O
with	O
CoVs	O
using	O
the	O
novel	O
spike	O
protein	O
.	O

Genomic	O
average	O
depth	O
of	O
coverage	O
of	O
the	O
Ion	O
Torrent	O
PGM	B-FUNC
was	O
up	O
to	O
5679	O
fold	O
.	O

TITLE	O
:	O
The	O
tyrosine	O
kinase	B-FUNC
inhibitor	I-FUNC
imatinib	O
prevents	O
lung	O
injury	O
and	O
death	O
after	O
intravenous	O
LPS	O
in	O
mice	O
.	O

However	O
,	O
pretreatment	O
of	O
mice	O
with	O
imatinib	O
increased	O
lung	O
catalase	B-FUNC
activity	I-FUNC
and	O
decreased	O
intravenous	O
LPS	O
-	O
induced	O
lung	O
oxidant	O
injury	O
as	O
measured	O
by	O
γ	O
-	O
H2AX	O
,	O
a	O
marker	O
of	O
oxidant	O
-	O
induced	O
DNA	O
damage	O
,	O
lung	O
apoptosis	O
,	O
and	O
pulmonary	O
edema	O
.	O

TITLE	O
:	O
Recombinant	O
Receptor	B-FUNC
Binding	I-FUNC
Domain	O
Protein	O
Induces	O
Partial	O
Protective	O
Immunity	O
in	O
Rhesus	O
Macaques	O
Against	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Challenge	O
.	O

Robust	O
and	O
sustained	O
immunological	O
responses	O
(	O
including	O
neutralisation	O
antibody	B-FUNC
)	O
were	O
elicited	O
by	O
the	O
rRBD	O
vaccination	O
.	O

Genetically	O
engineered	O
immunoadhesin	O
(	O
DPP4	O
-	O
Fc	O
)	O
produced	O
in	O
green	O
plants	O
has	O
been	O
shown	O
to	O
be	O
able	O
to	O
bind	B-FUNC
to	O
MERS	O
-	O
CoV	O
(	O
Middle	O
East	O
Respiratory	O
Syndrome	O
),	O
preventing	O
the	O
virus	O
from	O
infecting	O
lung	O
cells	O
.	O

Based	O
on	O
the	O
analysis	O
of	O
a	O
fragment	O
of	O
the	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
gene	O
,	O
phylogenetic	O
analyses	O
show	O
that	O
alpha	O
-	O
CoVs	O
sequences	O
detected	O
in	O
French	O
bats	O
are	O
closely	O
related	O
to	O
other	O
European	O
bat	O
alpha	O
-	O
CoVs	O
.	O

Phylogeographic	O
analyses	O
of	O
RdRp	B-FUNC
sequences	O
show	O
that	O
several	O
CoVs	O
strains	O
circulate	O
in	O
European	O
bats	O
:	O
(	O
i	O
)	O
old	O
strains	O
detected	O
that	O
have	O
probably	O
diverged	O
a	O
long	O
time	O
ago	O
and	O
are	O
detected	O
in	O
different	O
bat	O
subspecies	O
;	O
(	O
ii	O
)	O
strains	O
detected	O
in	O
Myotis	O
and	O
Pipistrellus	O
bat	O
species	O
that	O
have	O
more	O
recently	O
diverged	O
.	O

However	O
,	O
available	O
ECMO	O
systems	O
are	O
large	O
and	O
not	O
well	O
designed	O
for	O
fast	B-FUNC
delivery	O
,	O
emergency	O
implantation	O
,	O
and	O
interhospital	O
transfer	O
.	O

This	O
study	O
examined	O
the	O
mechanism	O
underlying	O
this	O
phenomenon	O
by	O
measuring	O
the	O
expression	O
of	O
antiviral	O
genes	O
-	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
(	O
TNF	O
-	O
α	O
)	O
and	O
GTPase	O
myxovirus	O
resistance	O
1	O
(	O
MX1	O
)-	O
in	O
G6PD	O
-	O
knockdown	O
cells	O
upon	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
)	O
and	O
enterovirus	O
71	O
(	O
EV71	O
)	O
infection	O
.	O

Sensitive	O
,	O
validated	O
reverse	O
transcriptase	B-FUNC
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
rtPCR	O
)-	O
based	O
diagnostics	O
have	O
been	O
available	O
almost	O
from	O
the	O
start	O
of	O
the	O
emergence	O
of	O
MERS	O
.	O

In	O
essence	O
,	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
was	O
crucial	O
for	O
development	O
of	O
ALI	O
,	O
suggesting	O
a	O
potential	O
application	O
for	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
-	O
based	O
therapy	O
in	O
clinical	O
practice	O
.	O

RESULTS	O
:	O
For	O
the	O
comparable	O
ventilator	O
setting	O
,	O
as	O
compared	O
with	O
BIPAPSB	O
group	O
,	O
the	O
BIPAPAP	O
group	O
presented	O
higher	O
EELV	O
(	O
427	O
±	O
47	O
vs	O
.	O
366	O
±	O
38	O
ml	O
)	O
and	O
oxygenation	O
index	O
(	O
293	O
±	O
36	O
vs	O
.	O
226	O
±	O
31	O
mmHg	O
),	O
lower	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
(	O
216	O
.	O
6	O
±	O
48	O
.	O
0	O
vs	O
.	O
297	O
.	O
5	O
±	O
71	O
.	O
2	O
pg	O
/	O
ml	O
)	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
(	O
246	O
.	O
8	O
±	O
78	O
.	O
2	O
vs	O
.	O
357	O
.	O
5	O
±	O
69	O
.	O
3	O
pg	O
/	O
ml	O
)	O
in	O
plasma	O
,	O
and	O
lower	O
express	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
mRNA	O
(	O
15	O
.	O
0	O
±	O
3	O
.	O
8	O
vs	O
.	O
21	O
.	O
2	O
±	O
3	O
.	O
7	O
)	O
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
mRNA	O
(	O
18	O
.	O
9	O
±	O
6	O
.	O
8	O
vs	O
.	O
29	O
.	O
5	O
±	O
7	O
.	O
9	O
)	O
in	O
lung	O
tissues	O
.	O

The	O
leukocyte	O
stiffening	O
induced	O
by	O
cytokines	O
in	O
the	O
sera	B-FUNC
of	O
patients	O
might	O
play	O
a	O
role	O
in	O
the	O
sequestration	O
of	O
leukocytes	O
in	O
the	O
lung	O
capillary	O
beds	O
during	O
early	O
ARDS	O
.	O

Here	O
,	O
we	O
present	O
the	O
crystal	O
structure	O
of	O
the	O
MHV	O
ns2	O
PDE	B-FUNC
domain	O
and	O
demonstrate	O
a	O
PDE	B-FUNC
fold	O
similar	O
to	O
that	O
of	O
the	O
cellular	O
protein	O
,	O
a	O
kinase	O
anchoring	B-FUNC
protein	O
7	O
central	O
domain	O
(	O
AKAP7	O
(	O
CD	O
))	O
and	O
rotavirus	O
VP3	O
carboxy	O
-	O
terminal	O
domain	O
.	O

ABSTRACT	O
:	O
Mucolipidosis	O
(	O
ML	O
)	O
II	O
alpha	O
/	O
beta	O
is	O
an	O
autosomal	O
recessive	O
disease	O
caused	O
by	O
reduced	O
enzyme	B-FUNC
activity	I-FUNC
of	O
N	O
-	O
acetylglucosamine	O
-	O
1	O
-	O
phosphotransferase	O
.	O

The	O
two	O
most	O
enriched	O
GO	O
terms	O
emerging	O
from	O
the	O
comparison	O
of	O
uninfected	O
birds	O
between	O
the	O
two	O
lines	O
were	O
""""	O
Lymphocyte	O
activation	O
involved	O
in	O
immune	O
response	O
""""	O
and	O
""""	O
Somatic	O
recombination	O
of	O
immunoglobulin	B-FUNC
genes	O
involved	O
in	O
immune	O
response	O
""""	O
at	O
weeks	O
1	O
and	O
3	O
,	O
respectively	O
.	O

Alveolar	O
epithelial	O
injury	O
after	O
LPS	O
was	O
more	O
severe	O
in	O
smokers	O
than	O
non	O
-	O
smokers	O
,	O
with	O
increased	O
plasma	O
(	O
p	O
=	O
0	O
.	O
04	O
)	O
and	O
decreased	O
BAL	O
(	O
p	O
=	O
0	O
.	O
02	O
)	O
surfactant	O
protein	O
D	O
.	O
Finally	O
,	O
smokers	O
had	O
decreased	O
BAL	O
vascular	B-FUNC
endothelial	I-FUNC
growth	I-FUNC
factor	I-FUNC
(	O
VEGF	B-FUNC
)	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
with	O
increased	O
soluble	O
VEGF	B-FUNC
receptor	O
-	O
1	O
(	O
p	O
=	O
0	O
.	O
0001	O
).	O

These	O
results	O
strongly	O
suggested	O
that	O
the	O
anti	O
-	O
fTNF	O
-	O
alpha	O
antibody	B-FUNC
is	O
effective	O
for	O
the	O
treatment	O
of	O
FIP	O
.	O

ABSTRACT	O
:	O
We	O
analyzed	O
a	O
multi	O
-	O
drug	O
resistant	O
(	O
MR	O
)	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
(	O
RT	O
),	O
subcloned	O
from	O
a	O
patient	O
-	O
derived	O
subtype	O
CRF02_AG	O
,	O
harboring	O
45	O
amino	O
acid	O
exchanges	O
,	O
amongst	O
them	O
four	O
thymidine	O
analog	O
mutations	O
(	O
TAMs	O
)	O
relevant	O
for	O
high	O
-	O
level	O
AZT	O
(	O
azidothymidine	O
)	O
resistance	O
by	O
AZTMP	O
excision	O
(	O
M41L	O
,	O
D67N	O
,	O
T215Y	O
,	O
K219E	O
)	O
as	O
well	O
as	O
four	O
substitutions	O
of	O
the	O
AZTTP	O
discrimination	O
pathway	O
(	O
A62V	O
,	O
V75I	O
,	O
F116Y	O
and	O
Q151M	O
).	O

Lactate	O
dehydrogenase	O
levels	O
had	O
positive	O
correlations	O
with	O
AST	O
(	O
r	O
=	O
0	O
.	O
95	O
)	O
and	O
ALT	B-FUNC
(	O
r	O
=	O
0	O
.	O
87	O
)	O
(	O
all	O
p	O
<	O
0	O
.	O
01	O
).	O

Entry	O
of	O
coronaviruses	O
into	O
cells	O
is	O
mediated	O
by	O
the	O
transmembrane	O
spike	O
glycoprotein	O
S	O
,	O
which	O
forms	O
a	O
trimer	O
carrying	O
receptor	O
-	O
binding	B-FUNC
and	O
membrane	O
fusion	O
functions	O
.	O

Except	O
negative	O
result	O
of	O
antibody	B-FUNC
test	O
in	O
the	O
well	O
-	O
known	O
""""	O
acute	O
window	O
phase	O
""","	O
in	O
rare	O
cases	O
,	O
patients	O
do	O
not	O
develop	O
HIV	O
antibodies	O
despite	O
demonstrable	O
infection	O
.	O

The	O
samples	O
were	O
analyzed	O
for	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
parainfluenza	O
viruses	O
(	O
PIV	O
)	O
types	O
1	O
,	O
2	O
and	O
3	O
,	O
adenovirus	O
,	O
rhinovirus	O
,	O
influenza	O
viruses	O
types	O
A	O
and	O
B	O
and	O
coronavirus	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
reverse	O
transcriptase	B-FUNC
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

We	O
describe	O
the	O
case	O
of	O
a	O
83	O
-	O
year	O
-	O
old	O
patient	O
hospitalized	O
as	O
a	O
matter	O
of	O
urgency	O
in	O
intensive	O
care	O
for	O
which	O
C	O
.	O
ulcerans	O
was	O
isolated	O
in	O
pure	B-FUNC
culture	O
in	O
its	O
bronchial	O
samples	O
.	O

TITLE	O
:	O
Human	O
polyclonal	O
immunoglobulin	B-FUNC
G	O
from	O
transchromosomic	O
bovines	O
inhibits	O
MERS	O
-	O
CoV	O
in	O
vivo	O
.	O

Strategies	O
targeting	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
)	O
may	O
be	O
helpful	O
for	O
developing	O
vaccines	O
or	O
antiviral	O
drugs	O
for	O
PEDV	O
.	O

Ribosome	O
-	O
protected	O
mRNA	O
fragments	O
are	O
purified	O
,	O
subjected	O
to	O
deep	O
sequencing	O
and	O
mapped	O
back	O
to	O
the	O
transcriptome	O
to	O
give	O
a	O
global	O
""""	O
snap	B-FUNC
-	O
shot	O
""""	O
of	O
translation	O
.	O

Moreover	O
,	O
melanoma	O
differentiation	O
-	O
associated	O
protein	O
5	O
(	O
MDA5	O
),	O
laboratory	O
of	O
genetics	O
and	O
physiology	O
2	O
(	O
LGP2	O
),	O
stimulator	O
of	O
IFN	O
genes	O
(	O
STING	O
),	O
and	O
mitochondrial	O
antiviral	O
signaling	O
protein	O
(	O
MAVS	O
),	O
as	O
well	O
as	O
TANK	O
binding	B-FUNC
kinase	O
1	O
(	O
TBK1	B-FUNC
),	O
inhibitor	O
of	O
kappaB	O
kinase	O
(	O
IKK	B-FUNC
)	O
ε	O
,	O
IKKα	O
,	O
IKKβ	O
,	O
IFN	O
regulatory	O
factor	O
(	O
IRF	O
)	O
7	O
,	O
nuclear	O
factor	O
of	O
kappaB	O
(	O
NF	O
-	O
ĸB	O
),	O
IFN	O
-	O
α	O
,	O
IFN	O
-	O
β	O
,	O
various	O
interleukins	O
(	O
ILs	O
),	O
and	O
macrophage	O
inflammatory	O
protein	O
-	O
1β	O
(	O
MIP	O
-	O
1β	O
)	O
were	O
significantly	O
upregulated	O
in	O
the	O
trachea	O
and	O
downregulated	O
in	O
the	O
kidney	O
.	O

The	O
TGEV	O
spike	O
protein	O
is	O
capable	O
of	O
binding	B-FUNC
with	O
EGFR	B-FUNC
,	O
activating	O
the	O
downstream	O
phosphoinositide	O
-	O
3	O
kinase	O
(	O
PI3K	B-FUNC
),	O
then	O
causing	O
the	O
phosphorylation	O
of	O
cofilin	O
and	O
F	O
-	O
actin	O
polymerization	O
via	O
Rac1	O
/	O
Cdc42	O
GTPases	O
.	O

Additionally	O
,	O
lipid	O
rafts	O
act	O
as	O
signal	O
platforms	O
for	O
the	O
EGFR	B-FUNC
-	O
associated	O
signaling	O
cascade	O
and	O
correlate	O
with	O
the	O
adhesion	O
of	O
TGEV	O
.	O

In	O
the	O
pre	O
-	O
fusion	O
conformation	O
,	O
the	O
receptor	O
-	O
binding	B-FUNC
subunits	O
,	O
S1	O
,	O
rest	B-FUNC
above	O
the	O
fusion	O
-	O
mediating	O
subunits	O
,	O
S2	O
,	O
preventing	O
their	O
conformational	O
rearrangement	O
.	O

TITLE	O
:	O
Establishment	O
of	O
serological	O
test	O
to	O
detect	O
antibody	B-FUNC
against	O
ferret	O
coronavirus	O
.	O

TITLE	O
:	O
Inhibition	O
of	O
HIV	O
-	O
1	O
Reverse	O
Transcriptase	B-FUNC
Dimerization	O
by	O
Small	O
Molecules	O
.	O

Child	O
was	O
diagnosed	O
as	O
GBS	O
and	O
treated	O
with	O
intravenous	O
immunoglobulin	B-FUNC
.	O

In	O
this	O
context	O
,	O
owing	O
to	O
its	O
essential	O
role	O
in	O
HIV	O
genome	O
replication	O
,	O
the	O
reverse	O
transcriptase	B-FUNC
associated	O
ribonuclease	O
H	O
(	O
RNase	O
H	O
)	O
has	O
proven	O
to	O
be	O
an	O
appealing	O
target	O
.	O

Mechanistic	O
studies	O
suggested	O
selective	O
inhibition	O
of	O
the	O
RNase	O
H	O
through	O
binding	B-FUNC
to	O
an	O
innovative	O
allosteric	O
site	O
,	O
which	O
could	O
be	O
further	O
exploited	O
to	O
enrich	O
this	O
class	O
of	O
inhibitors	O
.	O

ABSTRACT	O
:	O
The	O
novel	O
emerging	O
coronavirus	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
binds	B-FUNC
to	O
its	O
receptor	O
,	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
),	O
via	O
14	O
interacting	O
amino	O
acids	O
.	O

The	O
N	O
-	O
terminal	O
subunit	O
of	O
spike	O
protein	O
(	O
S1	O
)	O
is	O
responsible	O
for	O
virus	O
binding	B-FUNC
to	O
the	O
cellular	O
receptor	O
and	O
contains	O
a	O
number	O
of	O
neutralizing	O
antibody	B-FUNC
epitopes	O
.	O

The	O
current	O
serological	O
assays	O
offered	O
at	O
veterinary	O
diagnostic	O
laboratories	O
for	O
detection	O
of	O
PEDV	O
-	O
specific	O
antibody	B-FUNC
are	O
based	O
on	O
the	O
U	O
.	O
S	O
.	O
PEDV	O
prototype	O
strain	O
.	O

TITLE	O
:	O
Does	O
Circulating	O
Antibody	B-FUNC
Play	O
a	O
Role	O
in	O
the	O
Protection	O
of	O
Piglets	O
against	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
?	O

Serum	O
,	O
colostrum	O
,	O
and	O
milk	O
were	O
tested	O
for	O
PEDV	O
IgG	O
,	O
IgA	O
,	O
and	O
virus	O
-	O
neutralizing	O
antibody	B-FUNC
.	O

The	O
data	O
were	O
evaluated	O
for	O
the	O
effects	O
of	O
systemic	O
PEDV	O
antibody	B-FUNC
levels	O
on	O
growth	O
,	O
body	O
temperature	O
,	O
fecal	O
shedding	O
,	O
survival	O
,	O
and	O
antibody	B-FUNC
response	O
.	O

The	O
analysis	O
showed	O
that	O
circulating	O
antibody	B-FUNC
partially	O
ameliorated	O
the	O
effect	O
of	O
PEDV	O
infection	O
.	O

Systemic	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
levels	O
and	O
leukocyte	O
counts	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
:	O
65	O
.	O
0	O
±	O
8	O
.	O
0	O
vs	O
.	O
151	O
.	O
8	O
±	O
22	O
.	O
3	O
;	O
leukocytes	O
:	O
10	O
.	O
2	O
±	O
0	O
.	O
9	O
vs	O
.	O
13	O
.	O
2	O
±	O
0	O
.	O
8	O
,	O
both	O
P	O
<	O
0	O
.	O
05	O
)	O
were	O
significantly	O
lower	O
in	O
BAC	O
-	O
positive	O
patients	O
.	O

Inappropriate	O
therapy	O
was	O
present	O
in	O
49	O
(	O
64	O
%)	O
cases	O
of	O
P	O
aeruginosa	O
CAP	O
,	O
including	O
17	O
/	O
22	O
(	O
77	O
%)	O
cases	O
of	O
MDR	B-FUNC
P	O
aeruginosa	O
CAP	O
.	O

Collectively	O
,	O
our	O
findings	O
suggest	O
a	O
common	O
and	O
conserved	O
mechanism	O
through	O
which	O
highly	O
pathogenic	O
MERS	O
-	O
CoV	O
and	O
SARS	O
-	O
CoV	O
harness	O
their	O
M	O
proteins	O
to	O
suppress	O
type	O
I	O
IFN	O
expression	O
at	O
the	O
level	O
of	O
TBK1	B-FUNC
-	O
dependent	O
phosphorylation	O
and	O
activation	O
of	O
IRF3	O
resulting	O
in	O
evasion	O
of	O
the	O
host	O
innate	O
antiviral	O
response	O
.	O

Only	O
four	O
months	O
were	O
required	O
from	O
the	O
initial	O
screening	O
of	O
B	O
cells	O
to	O
the	O
development	O
of	O
a	O
stable	O
CHO	B-FUNC
cell	O
line	O
suitable	O
for	O
the	O
production	O
of	O
clinical	O
grade	O
antibody	B-FUNC
,	O
thereby	O
delineating	O
a	O
rapid	O
pathway	O
for	O
the	O
development	O
of	O
antiviral	O
therapies	O
against	O
emerging	O
viruses	O
.	O

The	O
immune	O
protective	O
efficiency	O
of	O
YC2014	O
were	O
determined	O
by	O
testing	O
PEDV	O
neutralizing	O
antibodies	O
in	O
sera	B-FUNC
,	O
the	O
colostrum	O
and	O
the	O
milk	O
on	O
7th	O
day	O
after	O
farrowing	O
of	O
the	O
immunized	O
sows	O
.	O

It	O
was	O
previously	O
shown	O
that	O
a	O
major	O
determinant	O
of	O
PS	O
recognition	O
is	O
the	O
second	O
of	O
the	O
two	O
RNA	O
-	O
binding	B-FUNC
domains	O
of	O
the	O
viral	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
.	O

Spike	O
glycoprotein	O
of	O
coronavirus	O
is	O
responsible	O
for	O
induction	O
of	O
neutralizing	O
antibody	B-FUNC
response	O
.	O

We	O
also	O
found	O
that	O
PDCoV	O
infection	O
significantly	O
suppresses	O
the	O
activation	O
of	O
IFN	O
-	O
β	O
promoter	O
stimulated	O
by	O
IRF3	O
or	O
its	O
upstream	O
molecules	O
(	O
RIG	O
-	O
I	O
,	O
MDA5	O
,	O
IPS	O
-	O
1	O
,	O
TBK1	B-FUNC
,	O
IKKε	O
)	O
in	O
the	O
RIG	O
-	O
I	O
signaling	O
pathway	O
,	O
but	O
does	O
not	O
counteract	O
its	O
activation	O
by	O
the	O
constitutively	O
active	O
mutant	O
of	O
IRF3	O
(	O
IRF3	O
-	O
5D	O
).	O

We	O
initially	O
developed	O
a	O
three	O
-	O
dimensional	O
common	O
-	O
feature	O
pharmacophore	O
model	O
according	O
to	O
which	O
two	O
hydrogen	O
bond	O
acceptors	O
and	O
one	O
hydrophobic	O
aromatic	O
feature	O
are	O
shared	O
by	O
all	O
molecular	O
series	O
in	O
binding	B-FUNC
the	O
viral	O
polymerase	O
.	O

No	O
evidence	O
for	O
infection	O
resulted	O
from	O
inoculation	O
of	O
pigs	O
with	O
the	O
German	O
sample	O
that	O
contained	O
high	O
levels	O
of	O
PEDV	O
RNA	O
;	O
there	O
were	O
no	O
clinical	O
signs	O
,	O
excretion	O
of	O
viral	O
RNA	O
or	O
anti	O
-	O
PEDV	O
antibody	B-FUNC
production	O
.	O

TLR7	O
agonist	O
(	O
imiquimod	O
(	O
IMQ	O
))	O
concentration	O
-	O
dependently	O
induced	O
activation	O
of	O
ISRE	O
-,	O
NF	O
-	O
κB	O
-	O
and	O
AP	O
-	O
1	O
-	O
luciferase	O
reporters	O
,	O
as	O
well	O
as	O
the	O
production	O
of	O
IFN	O
-	O
α	O
,	O
IFN	O
-	O
β	O
,	O
TNF	O
-	O
α	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
in	O
human	O
promonocyte	O
cells	O
.	O

Structural	O
comparison	O
reveals	O
that	O
the	O
majority	O
of	O
residues	O
involved	O
in	O
(	O
R	O
)-	O
16	O
binding	B-FUNC
to	O
SARS	O
-	O
3CL	O
(	O
pro	O
)	O
are	O
conserved	O
in	O
PEDV	O
-	O
3CL	O
(	O
pro	O
);	O
however	O
,	O
the	O
sequence	O
variation	O
and	O
positional	O
difference	O
in	O
the	O
loop	O
forming	O
the	O
S2	O
pocket	O
may	O
account	O
for	O
large	O
observed	O
difference	O
in	O
IC50	O
values	O
.	O

Moreover	O
,	O
andrographolide	O
sulfonate	O
markedly	O
suppressed	O
the	O
activation	O
of	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	B-FUNC
)	O
as	O
well	O
as	O
p65	O
subunit	O
of	O
nuclear	O
factor	O
-	O
κB	O
(	O
NF	O
-	O
κB	O
).	O

Pre	O
-	O
treatment	O
with	O
the	O
phosphodiesterase	B-FUNC
antagonist	O
pentoxifyllinum	O
(	O
PTX	O
)	O
obviously	O
attenuated	O
lung	O
injury	O
and	O
reduced	O
the	O
mortality	O
of	O
mice	O
with	O
cecal	O
ligature	O
and	O
puncture	O
(	O
CLP	O
)‑	O
induced	O
ARDS	O
,	O
while	O
raising	O
cAMP	O
levels	O
.	O

We	O
show	O
that	O
(	O
i	O
)	O
common	O
principles	O
pertaining	O
to	O
the	O
stereochemistry	O
of	O
protein	O
-	O
carbohydrate	O
interactions	O
were	O
at	O
the	O
core	O
of	O
the	O
transition	O
in	O
lectin	O
ligand	B-FUNC
and	O
esterase	O
substrate	O
specificity	O
;	O
(	O
ii	O
)	O
in	O
consequence	O
,	O
the	O
switch	O
in	O
O	O
-	O
Ac	O
-	O
Sia	O
specificity	O
could	O
be	O
readily	O
accomplished	O
via	O
convergent	O
intramolecular	O
coevolution	O
with	O
only	O
modest	O
architectural	O
changes	O
in	O
lectin	O
and	O
esterase	O
domains	O
;	O
and	O
(	O
iii	O
)	O
a	O
single	O
,	O
inconspicuous	O
Ala	O
-	O
to	O
-	O
Ser	O
substitution	O
in	O
the	O
catalytic	O
site	O
was	O
key	O
to	O
the	O
emergence	O
of	O
the	O
type	O
II	O
HEs	O
.	O

TITLE	O
:	O
JNK	B-FUNC
and	O
p38	B-FUNC
mitogen	O
-	O
activated	O
protein	O
kinase	O
pathways	O
contribute	O
to	O
porcine	O
epidemic	O
diarrhea	O
virus	O
infection	O
.	O

Although	O
qPCR	O
is	O
used	O
to	O
detect	O
antigen	O
during	O
the	O
acute	O
disease	O
phase	O
,	O
there	O
is	O
no	O
equine	O
-	O
specific	O
antibody	B-FUNC
test	O
available	O
to	O
study	O
EqCoV	O
seroprevalence	O
in	O
various	O
horse	O
populations	O
.	O

Five	O
regions	O
of	O
the	O
PL	O
(	O
pro	O
)	O
bind	B-FUNC
to	O
two	O
areas	O
of	O
the	O
Ub	O
.	O

The	O
highly	O
conserved	O
S	O
-	O
adenosyl	O
-	O
l	O
-	O
methionine	O
(	O
SAM	O
)-	O
binding	B-FUNC
residues	O
of	O
the	O
DxG	O
motif	O
are	O
required	O
for	O
nsp14	O
N7	O
-	O
MTase	O
activity	O
in	O
vitro	O
However	O
,	O
the	O
requirement	O
for	O
CoV	O
N7	O
-	O
MTase	O
activity	O
and	O
the	O
importance	O
of	O
the	O
SAM	O
-	O
binding	B-FUNC
residues	O
during	O
viral	O
replication	O
have	O
not	O
been	O
determined	O
.	O

An	O
indirect	O
fluorescent	O
antibody	B-FUNC
(	O
IFA	O
)	O
test	O
was	O
also	O
developed	O
using	O
cell	O
culture	O
adapted	O
PDCoV	O
for	O
comparative	O
purposes	O
.	O

We	O
compared	O
the	O
antigenicity	O
of	O
the	O
vaccine	O
type	O
strain	O
and	O
newly	O
isolated	O
strains	O
by	O
means	O
of	O
a	O
neutralization	O
test	O
using	O
sera	B-FUNC
from	O
a	O
number	O
of	O
pigs	O
from	O
various	O
farms	O
;	O
the	O
results	O
revealed	O
that	O
they	O
are	O
antigenically	O
similar	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
the	O
similarity	O
of	O
group	O
I	O
and	O
II	O
viruses	O
using	O
sera	B-FUNC
from	O
individual	O
pigs	O
vaccinated	O
with	O
group	O
I	O
virus	O
.	O

While	O
target	O
selectivity	O
remains	O
a	O
challenge	O
for	O
the	O
discovery	O
of	O
useful	O
RNA	O
-	O
binding	B-FUNC
compounds	O
,	O
a	O
better	O
understanding	O
is	O
emerging	O
of	O
properties	O
that	O
define	O
RNA	O
targets	O
amenable	O
for	O
inhibition	O
by	O
small	O
molecule	O
ligands	O
.	O

Among	O
these	O
four	O
rHCoVs	O
-	O
OC43	O
,	O
rOC43	O
-	O
ns2DelRluc	O
(	O
generated	O
by	O
replacing	O
ns2	O
with	O
the	O
Rluc	O
gene	O
)	O
showed	O
robust	O
luciferase	B-FUNC
activity	I-FUNC
with	O
only	O
a	O
slight	O
impact	O
on	O
its	O
growth	O
characteristics	O
.	O

TITLE	O
:	O
Immunotherapeutic	O
implications	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
blockade	O
for	O
cytokine	O
storm	O
.	O

ABSTRACT	O
:	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
contributes	O
to	O
host	O
defense	O
against	O
infections	O
and	O
tissue	O
injuries	O
.	O

Sleep	O
disturbance	O
questionnaire	O
for	O
patients	O
with	O
ACS	B-FUNC
hospitalized	O
in	O
coronary	O
care	O
unit	O
(	O
CCU	O
)	O
was	O
identified	O
in	O
5	O
dimensions	O
and	O
assessed	O
for	O
validity	O
and	O
reliability	O
.	O

TNF	O
-	O
α	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
concentrations	O
in	O
the	O
alveolar	O
lavage	O
,	O
probability	O
of	O
survival	O
and	O
days	O
without	O
organ	O
failure	O
were	O
similar	O
in	O
both	O
groups	O
.	O

STAT1	O
downregulation	O
was	O
blocked	O
by	O
a	O
proteasome	O
inhibitor	O
but	O
not	O
by	O
an	O
autophagy	O
inhibitor	O
,	O
strongly	O
implicating	O
the	O
ubiquitin	B-FUNC
-	O
proteasome	O
targeting	O
degradation	O
system	O
.	O

Encouragingly	O
,	O
early	O
phase	O
clinical	O
trials	O
of	O
MSCs	B-FUNC
in	O
patients	O
with	O
ARDS	O
are	O
under	O
way	O
,	O
and	O
experience	O
with	O
these	O
cells	O
in	O
trials	O
for	O
other	O
diseases	O
suggests	O
that	O
the	O
cells	O
are	O
well	O
tolerated	O
.	O

Acute	O
respiratory	O
failure	O
manifesting	O
with	O
apneic	O
episodes	O
is	O
a	O
life	O
-	O
threatening	O
and	O
unpredictable	O
complication	O
of	O
SPS	B-FUNC
.	O

TITLE	O
:	O
Maternal	O
antibody	B-FUNC
decay	O
and	O
antibody	B-FUNC
-	O
mediated	O
immune	O
responses	O
in	O
chicken	O
pullets	O
fed	O
prebiotics	O
and	O
synbiotics	O
.	O

In	O
addition	O
,	O
specific	O
antibody	B-FUNC
response	O
against	O
SRBC	O
and	O
BSA	O
was	O
not	O
affected	O
by	O
diets	O
.	O

In	O
conclusion	O
,	O
supplementation	O
of	O
diet	O
with	O
SNB	O
improved	O
humoral	O
immunity	O
by	O
increasing	O
IgG	O
concentration	O
in	O
serum	O
,	O
and	O
modulated	O
the	O
adaptive	O
antibody	B-FUNC
-	O
mediated	O
immune	O
response	O
against	O
IBV	O
.	O

RESULTS	O
:	O
In	O
lung	O
tissue	O
interleukin	O
(	O
IL	O
)-	O
6	O
,	O
monocyte	O
chemo	O
attractant	B-FUNC
protein	O
-	O
1	O
(	O
MCP	B-FUNC
-	O
1	O
)	O
and	O
granulocyte	O
-	O
colony	O
stimulating	O
factor	O
(	O
G	O
-	O
CSF	O
)	O
was	O
elevated	O
in	O
both	O
C5	O
-/-	O
mice	O
and	O
wildtype	O
littermates	O
(	O
wt	O
),	O
whereas	O
caspase	O
-	O
3	O
was	O
reduced	O
in	O
lungs	O
after	O
DH	O
in	O
C5	O
-/-	O
mice	O
.	O

In	O
contrast	O
to	O
TGEV	O
,	O
PEDV	O
did	O
not	O
bind	B-FUNC
soluble	O
porcine	O
aminopeptidases	O
(	O
pAPs	O
)	O
and	O
infection	O
was	O
not	O
inhibited	O
by	O
the	O
soluble	O
form	O
of	O
pAPs	O
.	O

Abelson	O
Kinase	B-FUNC
Inhibitors	I-FUNC
Are	O
Potent	O
Inhibitors	O
of	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
Coronavirus	O
and	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Fusion	O
.	O

The	O
out	O
of	O
frame	O
deletion	O
predicted	O
loss	O
of	O
most	O
of	O
the	O
S2	O
subunit	O
of	O
the	O
spike	O
protein	O
leaving	O
the	O
S1	O
subunit	O
with	O
an	O
intact	O
receptor	B-FUNC
binding	I-FUNC
domain	O
.	O

Such	O
hepatic	O
inflammatory	O
disorders	O
correlated	O
with	O
disturbed	O
production	O
of	O
interleukin	O
-	O
10	O
(	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
)	O
and	O
vascular	O
factors	O
by	O
LSECs	O
.	O

This	O
study	O
aimed	O
at	O
determining	O
the	O
role	O
of	O
the	O
chemokine	O
(	O
C	O
-	O
C	O
motif	O
)	O
ligand	B-FUNC
(	O
CCL	B-FUNC
)	O
2	O
and	O
CCL7	O
in	O
ARDS	O
.	O

These	O
findings	O
suggested	O
that	O
the	O
degree	O
of	O
lung	O
injury	O
was	O
reduced	O
during	O
the	O
acute	O
inflammatory	O
reaction	O
when	O
NF	O
‑	O
κB	O
was	O
inhibited	O
,	O
and	O
that	O
the	O
expression	O
of	O
SMS2	B-FUNC
may	O
affect	O
the	O
induction	O
of	O
the	O
NF	O
‑	O
κB	O
pathway	O
by	O
LPS	O
through	O
CD14	O
.	O

General	O
strategies	O
to	O
design	O
specific	O
and	O
selective	O
drugs	O
targeting	O
helicase	O
for	O
the	O
treatment	O
of	O
viral	O
infections	O
could	O
act	O
via	O
one	O
or	O
more	O
of	O
the	O
following	O
mechanisms	O
:	O
inhibition	O
of	O
the	O
NTPase	B-FUNC
activity	I-FUNC
,	O
by	O
interferences	O
with	O
ATP	B-FUNC
binding	I-FUNC
and	O
therefore	O
by	O
limiting	O
the	O
energy	O
required	O
for	O
the	O
unwinding	O
and	O
translocation	O
,	O
or	O
by	O
allosteric	O
mechanism	O
and	O
therefore	O
by	O
stabilizing	O
the	O
conformation	O
of	O
the	O
enzyme	O
in	O
low	O
helicase	B-FUNC
activity	I-FUNC
state	O
;	O
inhibition	O
of	O
nucleic	O
acids	O
binding	B-FUNC
to	O
the	O
helicase	O
;	O
inhibition	O
of	O
coupling	O
of	O
ATP	O
hydrolysis	O
to	O
unwinding	O
;	O
inhibition	O
of	O
unwinding	O
by	O
sterically	O
blocking	O
helicase	O
translocation	O
.	O

We	O
identify	O
cellular	O
E3	O
ubiquitin	B-FUNC
ligase	O
ring	O
-	O
finger	O
and	O
CHY	O
zinc	O
-	O
finger	O
domain	O
-	O
containing	O
1	O
(	O
RCHY1	O
)	O
as	O
an	O
interacting	O
partner	O
of	O
the	O
viral	O
SARS	O
-	O
unique	O
domain	O
(	O
SUD	O
)	O
and	O
papain	O
-	O
like	O
protease	O
(	O
PL	O
(	O
pro	O
)),	O
and	O
,	O
as	O
a	O
consequence	O
,	O
the	O
involvement	O
of	O
cellular	O
p53	O
as	O
antagonist	O
of	O
coronaviral	O
replication	O
.	O

Of	O
the	O
443	O
tested	O
samples	O
,	O
12	O
(	O
2	O
.	O
7	O
%)	O
had	O
a	O
reactive	O
ELISA	O
result	O
,	O
and	O
9	O
of	O
the	O
12	O
had	O
reactive	O
indirect	O
fluorescent	O
antibody	B-FUNC
and	O
microneutralization	O
assay	O
titers	O
.	O

Many	O
intracellular	O
signaling	O
pathways	O
,	O
including	O
the	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PI3K	B-FUNC
)/	O
Akt	O
pathway	O
,	O
are	O
activated	O
by	O
viral	O
infection	O
.	O

The	O
PI3K	B-FUNC
/	O
Akt	O
pathway	O
is	O
an	O
important	O
cellular	O
pathway	O
that	O
has	O
been	O
shown	O
to	O
be	O
required	O
for	O
virus	O
replication	O
.	O

It	O
first	O
binds	B-FUNC
to	O
a	O
receptor	O
on	O
the	O
host	O
cell	O
surface	O
through	O
its	O
S1	O
subunit	O
and	O
then	O
fuses	O
viral	O
and	O
host	O
membranes	O
through	O
its	O
S2	O
subunit	O
.	O

Samples	O
were	O
pre	O
-	O
screened	O
,	O
using	O
a	O
quantitative	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
qRT	O
-	O
PCR	O
)	O
multiprobe	O
for	O
coronavirus	O
,	O
and	O
subjected	O
to	O
confirmatory	O
pancoronavirus	O
and	O
/	O
or	O
strain	O
-	O
specific	O
reverse	O
transcriptase	B-FUNC
(	O
RT	O
)-	O
PCR	O
followed	O
by	O
sequence	O
analysis	O
.	O

Evidence	O
of	O
antibody	B-FUNC
-	O
dependent	O
enhancement	O
(	O
ADE	O
)	O
of	O
SARS	O
-	O
CoV	O
infection	O
in	O
vitro	O
and	O
in	O
non	O
-	O
human	O
primates	O
clouds	O
the	O
prospects	O
for	O
a	O
safe	O
vaccine	O
.	O

Compared	O
to	O
the	O
three	O
-	O
antigen	O
test	O
kit	B-FUNC
,	O
the	O
multiplex	O
PCR	O
assays	O
yielded	O
100	O
%	O
sensitivity	O
and	O
more	O
than	O
83	O
%	O
specificity	O
for	O
detection	O
of	O
CAdV	O
-	O
2	O
and	O
CDV	O
,	O
but	O
not	O
for	O
CIV	O
.	O

Plasma	O
markers	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
and	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
are	O
associated	O
with	O
ARDS	O
in	O
patients	O
with	O
severe	O
TBI	O
.	O

We	O
identified	O
a	O
novel	O
player	O
in	O
the	O
immune	O
response	O
to	O
virus	O
infection	O
,	O
Kepi	O
,	O
an	O
inhibitory	O
subunit	O
of	O
the	O
protein	O
phosphatase	B-FUNC
1	O
(	O
PP1	O
)	O
complex	O
,	O
which	O
protects	O
against	O
SARS	O
-	O
CoV	O
pathogenesis	O
.	O

The	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
)	O
of	O
the	O
coronavirus	O
spike	O
(	O
S	O
)	O
protein	O
recognizes	O
host	O
receptors	O
to	O
mediate	O
virus	O
entry	O
and	O
is	O
therefore	O
a	O
key	O
factor	O
determining	O
the	O
viral	O
tropism	O
and	O
transmission	O
capacity	O
.	O

Our	O
data	O
shows	O
that	O
clinical	O
condition	O
may	O
suddenly	O
deteriorate	O
around	O
7	O
days	O
of	O
illness	O
and	O
the	O
serum	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
CXCL	O
-	O
10	O
was	O
significantly	O
elevated	O
in	O
MERS	O
-	O
CoV	O
patients	O
who	O
developed	O
severe	O
diseases	O
.	O

This	O
cross	O
-	O
sectional	O
study	O
was	O
conducted	O
based	O
on	O
antibody	B-FUNC
-	O
ELISA	O
of	O
bulk	O
tank	O
milk	O
(	O
BTM	O
)	O
from	O
1347	O
herds	O
in	O
two	O
neighboring	O
counties	O
in	O
western	O
Norway	O
.	O

The	O
remaining	O
local	O
dependence	O
in	O
the	O
residuals	O
show	O
that	O
the	O
antibody	B-FUNC
status	O
of	O
one	O
herd	O
is	O
influenced	O
by	O
the	O
antibody	B-FUNC
status	O
of	O
its	O
neighbors	O
,	O
indicating	O
the	O
importance	O
of	O
indirect	O
transmission	O
and	O
that	O
increased	O
biosecurity	O
routines	O
might	O
be	O
an	O
important	O
preventive	O
strategy	O
.	O

MERS	O
-	O
CoV	O
spike	O
protein	O
forms	O
a	O
trimer	O
,	O
and	O
its	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
serves	O
as	O
a	O
vaccine	O
target	O
.	O

extracts	O
inhibited	O
the	O
HIV	O
-	O
1	O
RT	O
-	O
associated	O
RNase	B-FUNC
H	I-FUNC
activity	I-FUNC
.	O

TITLE	O
:	O
Isatin	O
thiazoline	O
hybrids	O
as	O
dual	O
inhibitors	O
of	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
.	O

WQ	O
-	O
IDL	O
and	O
MT	O
-	O
WQ	O
-	O
IDL	O
were	O
also	O
more	O
effective	O
than	O
WQ	O
in	O
blocking	O
HIV	O
-	O
1	O
Env	O
-	O
mediated	O
membrane	O
fusion	O
and	O
had	O
higher	O
levels	O
of	O
binding	B-FUNC
affinity	O
with	O
NHR	O
peptide	O
N46	O
.	O

ABSTRACT	O
:	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
binds	B-FUNC
to	O
cellular	O
receptor	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
)	O
via	O
the	O
spike	O
(	O
S	O
)	O
protein	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
).	O

TITLE	O
:	O
Fibroblastic	O
reticular	O
cells	O
regulate	O
intestinal	O
inflammation	O
via	O
IL	B-FUNC
-	I-FUNC
15	I-FUNC
-	O
mediated	O
control	O
of	O
group	O
1	O
ILCs	O
.	O

Examination	O
of	O
the	O
predicted	O
structure	O
of	O
the	O
Arkansas	O
IBV	O
S1	O
spike	O
also	O
gave	O
insights	O
on	O
the	O
effect	O
of	O
polymorphisms	O
at	O
position	O
43	O
on	O
the	O
surface	O
availability	O
of	O
receptor	B-FUNC
binding	I-FUNC
residues	O
.	O

Using	O
real	O
time	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
of	O
pediatric	O
patients	O
revealed	O
that	O
9	O
out	O
of	O
552	O
(	O
1	O
.	O
6	O
%)	O
was	O
positive	O
in	O
the	O
Kingdom	O
of	O
Saudi	O
Arabia	O
.	O

TITLE	O
:	O
Feline	O
coronavirus	O
replication	O
is	O
affected	O
by	O
both	O
cyclophilin	B-FUNC
A	O
and	O
cyclophilin	B-FUNC
B	O
.	O
ABSTRACT	O
:	O
Feline	O
coronavirus	O
(	O
FCoV	O
)	O
causes	O
the	O
fatal	O
disease	O
feline	O
infectious	O
peritonitis	O
,	O
which	O
is	O
currently	O
incurable	O
by	O
drug	O
treatment	O
,	O
and	O
no	O
effective	O
vaccines	O
are	O
available	O
.	O

We	O
developed	O
5	O
scenarios	O
using	O
SPs	B-FUNC
and	O
an	O
observation	O
form	O
.	O

The	O
depletion	O
of	O
neutrophils	O
,	O
treatment	O
with	O
AMD3100	O
(	O
a	O
CXCR4	B-FUNC
antagonist	O
),	O
Pulmozyme	O
(	O
human	O
recombinant	O
DNase	O
)	O
or	O
Sivelestat	O
(	O
inhibitor	O
of	O
neutrophil	O
elastase	O
)	O
decreased	O
the	O
development	O
of	O
malaria	O
-	O
associated	O
ALI	O
/	O
ARDS	O
and	O
significantly	O
increased	O
mouse	O
survival	O
.	O

Areas	O
covered	O
:	O
This	O
review	O
illustrates	O
MERS	O
-	O
CoV	O
S	O
protein	O
'	O
s	O
structure	O
and	O
function	O
,	O
particularly	O
S1	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
and	O
S2	O
heptad	O
repeat	O
1	O
(	O
HR1	O
)	O
as	O
therapeutic	O
targets	O
,	O
and	O
summarizes	O
current	O
advancement	O
on	O
developing	O
anti	O
-	O
MERS	O
-	O
CoV	O
therapeutics	O
,	O
focusing	O
on	O
neutralizing	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
and	O
antiviral	O
peptides	O
.	O

An	O
empirical	O
population	O
placebo	O
response	O
model	O
was	O
conducted	O
,	O
and	O
a	O
population	O
PK	O
/	O
PD	O
model	O
was	O
explored	O
to	O
evaluate	O
the	O
relationship	O
between	O
dilmapimod	O
concentration	O
and	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
(	O
a	O
systemic	O
biomarker	O
of	O
p38	B-FUNC
inhibition	O
).	O

TITLE	O
:	O
Cryo	O
-	O
electron	O
microscopy	O
structures	O
of	O
the	O
SARS	O
-	O
CoV	O
spike	O
glycoprotein	O
reveal	O
a	O
prerequisite	O
conformational	O
state	O
for	O
receptor	B-FUNC
binding	I-FUNC
.	O

Bovine	O
and	O
sheep	O
sera	B-FUNC
were	O
seronegative	O
.	O

TITLE	O
:	O
Novel	O
chimeric	O
virus	O
-	O
like	O
particles	O
vaccine	O
displaying	O
MERS	O
-	O
CoV	O
receptor	O
-	O
binding	B-FUNC
domain	O
induce	O
specific	O
humoral	O
and	O
cellular	O
immune	O
response	O
in	O
mice	O
.	O

IFN	O
-	O
γ	O
,	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
secreting	O
cells	O
induced	O
by	O
the	O
RBD	O
were	O
detected	O
in	O
the	O
splenocytes	O
of	O
vaccinated	O
mice	O
by	O
ELISpot	O
.	O

Additionally	O
,	O
the	O
serum	O
level	O
of	O
granulocyte	B-FUNC
macrophage	I-FUNC
colony	I-FUNC
-	I-FUNC
stimulating	I-FUNC
factor	I-FUNC
(	O
GM	O
-	O
CSF	O
)	O
was	O
significantly	O
higher	O
in	O
CoV	O
-	O
CNS	O
infection	O
than	O
in	O
CoV	O
-	O
respiratory	O
tract	O
infection	O
.	O

Thus	O
,	O
a	O
fast	B-FUNC
and	O
inexpensive	O
method	O
for	O
the	O
detection	O
of	O
FCoV	O
could	O
be	O
beneficial	O
,	O
especially	O
in	O
multicat	O
environments	O
.	O

A	O
controversial	O
question	O
has	O
been	O
whether	O
DC	O
-	O
SIGN	O
functions	O
as	O
a	O
complete	O
receptor	O
for	O
both	O
binding	B-FUNC
and	O
internalization	O
of	O
dengue	O
virus	O
(	O
DENV	O
)	O
or	O
whether	O
it	O
is	O
solely	O
a	O
cell	O
surface	O
attachment	O
factor	O
,	O
requiring	O
either	O
hand	O
-	O
off	O
to	O
another	O
receptor	O
or	O
a	O
co	O
-	O
receptor	O
for	O
internalization	O
.	O

In	O
coronaviruses	O
several	O
smaller	O
,	O
non	O
-	O
enzymatic	O
nsps	O
were	O
characterized	O
that	O
direct	O
RdRp	B-FUNC
function	O
,	O
while	O
a	O
3	O
'-	O
to	O
-	O
5	O
'	O
exoribonuclease	B-FUNC
activity	I-FUNC
in	O
nsp14	O
was	O
implicated	O
in	O
fidelity	O
.	O

The	O
diagnostic	O
sensitivity	O
(	O
DSN	O
),	O
specificity	O
(	O
DSP	O
)	O
and	O
accuracy	O
of	O
the	O
nsp5	O
-	O
ELISA	O
were	O
93	O
.	O
11	O
%,	O
95	O
.	O
38	O
%	O
and	O
93	O
.	O
33	O
%,	O
respectively	O
,	O
compared	O
with	O
IFA	O
in	O
660	O
field	O
serum	O
samples	O
,	O
and	O
were	O
98	O
.	O
11	O
%,	O
95	O
.	O
00	O
%	O
and	O
97	O
.	O
62	O
%,	O
respectively	O
,	O
compared	O
with	O
the	O
commercial	O
IBV	O
ELISA	O
kit	B-FUNC
(	O
IDEXX	O
)	O
in	O
126	O
field	O
sera	B-FUNC
samples	O
.	O

The	O
MERS	O
-	O
CoV	O
S	O
nanoparticle	O
vaccine	O
produced	O
high	O
titer	O
anti	O
-	O
S	O
neutralizing	O
antibody	B-FUNC
and	O
protected	O
mice	O
from	O
MERS	O
-	O
CoV	O
infection	O
in	O
vivo	O
.	O

Detailed	O
analysis	O
showed	O
that	O
nsp5	O
cleaved	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
2	O
(	O
STAT2	O
)	O
but	O
not	O
Janus	O
kinase	O
1	O
(	O
JAK1	O
),	O
tyrosine	O
kinase	O
2	O
(	O
TYK2	O
),	O
STAT1	O
,	O
and	O
interferon	O
regulatory	O
factor	O
9	O
(	O
IRF9	O
),	O
key	O
molecules	O
of	O
the	O
JAK	B-FUNC
-	O
STAT	O
pathway	O
.	O

STAT2	O
cleavage	O
was	O
dependent	O
on	O
the	O
protease	B-FUNC
activity	I-FUNC
of	O
nsp5	O
.	O

This	O
flexibility	O
was	O
evident	O
in	O
either	O
the	O
free	O
form	O
or	O
when	O
bound	O
with	O
ubiquitin	B-FUNC
.	O

An	O
interesting	O
feature	O
is	O
the	O
dynamic	O
change	O
in	O
Ubl	O
,	O
which	O
shows	O
a	O
rigid	O
conformation	O
in	O
the	O
free	O
form	O
of	O
Plpro	O
but	O
is	O
fully	O
flexible	O
upon	O
the	O
binding	B-FUNC
of	O
ubiquitin	B-FUNC
.	O

Besides	O
,	O
variations	O
of	O
all	O
sagittal	O
-	O
lung	O
CT	O
measurements	O
were	O
significantly	O
larger	O
in	O
patients	O
with	O
ACOS	O
than	O
in	O
patients	O
with	O
pure	B-FUNC
COPD	O
(	O
P	O
values	O
all	O
<	O
0	O
.	O
001	O
)	O
and	O
showed	O
high	O
performance	O
in	O
differentiating	O
these	O
two	O
kinds	O
of	O
patient	O
,	O
with	O
diagnostic	O
sensitivities	O
ranging	O
from	O
76	O
.	O
4	O
to	O
97	O
.	O
2	O
%,	O
specificities	O
ranging	O
from	O
86	O
.	O
2	O
to	O
100	O
.	O
0	O
%,	O
and	O
accuracies	O
ranging	O
from	O
80	O
.	O
9	O
to	O
90	O
.	O
7	O
%.	O

Furthermore	O
,	O
smoking	O
may	O
be	O
associated	O
with	O
increased	O
risk	O
of	O
peritonsillar	O
abscess	O
(	O
PTA	B-FUNC
)	O
development	O
,	O
although	O
the	O
magnitude	O
of	O
the	O
association	O
has	O
not	O
been	O
estimated	O
.	O

However	O
,	O
GAS	O
is	O
only	O
recovered	O
from	O
approximately	O
20	O
%	O
of	O
PTA	B-FUNC
patients	O
.	O

The	O
identification	O
and	O
quantification	O
of	O
risk	O
factors	O
for	O
PTA	B-FUNC
development	O
constitutes	O
another	O
approach	O
to	O
reduce	O
the	O
incidence	O
of	O
PTA	B-FUNC
.	O

In	O
a	O
retrospective	O
study	O
on	O
all	O
847	O
PTA	B-FUNC
patients	O
admitted	O
to	O
the	O
ENT	O
department	O
at	O
Aarhus	O
University	O
Hospital	O
(	O
AUH	O
)	O
from	O
2001	O
to	O
2006	O
,	O
we	O
found	O
that	O
FN	O
was	O
the	O
most	O
prevalent	O
(	O
23	O
%)	O
bacterial	O
strain	O
in	O
pus	O
specimens	O
.	O

The	O
incidence	O
of	O
PTA	B-FUNC
was	O
highly	O
related	O
to	O
age	O
and	O
gender	O
.	O

This	O
association	O
between	O
PPA	O
and	O
PTA	B-FUNC
was	O
much	O
higher	O
than	O
previously	O
documented	O
.	O

We	O
therefore	O
suggest	O
that	O
combined	O
tonsillectomy	O
and	O
intrapharyngeal	O
incision	O
in	O
cases	O
where	O
PTA	B-FUNC
is	O
present	O
or	O
suspected	O
.	O

TITLE	O
:	O
Receptor	O
-	O
binding	B-FUNC
domain	O
of	O
MERS	O
-	O
CoV	O
with	O
optimal	O
immunogen	O
dosage	O
and	O
immunization	O
interval	O
protects	O
human	O
transgenic	O
mice	O
from	O
MERS	O
-	O
CoV	O
infection	O
.	O

The	O
choanal	O
cleft	O
of	O
each	O
bird	O
was	O
swabbed	O
at	O
7	O
and	O
10	O
days	O
postvaccination	O
,	O
and	O
real	O
-	O
time	O
reverse	O
-	O
transcriptase	B-FUNC
PCR	O
was	O
performed	O
.	O

The	O
benefit	O
of	O
quarantine	O
over	O
symptom	O
monitoring	O
is	O
generally	O
maximized	O
for	O
fast	B-FUNC
-	O
course	O
diseases	O
,	O
but	O
we	O
show	O
the	O
conditions	O
under	O
which	O
symptom	O
monitoring	O
alone	O
can	O
control	O
certain	O
outbreaks	O
.	O

The	O
data	O
revealed	O
that	O
,	O
in	O
HCoV	O
-	O
infected	O
(	O
but	O
not	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
-	O
treated	O
)	O
cells	O
,	O
an	O
extensive	O
set	O
of	O
genes	O
was	O
activated	O
without	O
inducible	O
p65	O
NF	O
-	O
κB	O
being	O
recruited	O
.	O

Consistently	O
,	O
unlike	O
TGEV	O
-	O
S1	O
,	O
PEDV	O
-	O
S1	O
exhibited	O
no	O
binding	B-FUNC
to	O
cell	O
-	O
surface	O
expressed	O
APN	O
or	O
to	O
a	O
soluble	O
version	O
of	O
APN	O
.	O

However	O
,	O
knowledge	O
of	O
antibody	B-FUNC
epitopes	O
,	O
their	O
nature	O
and	O
location	O
in	O
the	O
spike	O
structure	O
,	O
and	O
the	O
mechanisms	O
by	O
which	O
the	O
antibodies	O
interfere	O
with	O
infection	O
is	O
scarce	O
.	O

Here	O
we	O
describe	O
the	O
generation	O
and	O
characterization	O
of	O
10	O
neutralizing	O
and	O
nonneutralizing	O
mouse	O
monoclonal	O
antibodies	O
raised	O
against	O
the	O
S1	O
receptor	B-FUNC
binding	I-FUNC
subunit	O
of	O
the	O
S	O
protein	O
.	O

By	O
expression	O
of	O
different	O
S1	O
protein	O
fragments	O
,	O
six	O
antibody	B-FUNC
epitope	O
classes	O
distributed	O
over	O
the	O
five	O
structural	O
domains	O
of	O
the	O
S1	O
subunit	O
were	O
identified	O
.	O

Our	O
observations	O
picture	O
the	O
antibody	B-FUNC
epitope	O
landscape	O
of	O
the	O
PEDV	O
S1	O
subunit	O
and	O
reveal	O
that	O
its	O
cell	O
attachment	O
domains	O
are	O
key	O
targets	O
of	O
neutralizing	O
antibodies	O
.	O

The	O
overall	O
structures	O
resemble	O
that	O
from	O
other	O
coronaviruses	O
including	O
HKU1	O
,	O
MHV	O
and	O
NL63	O
reported	O
recently	O
,	O
with	O
the	O
exception	O
of	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
).	O

TITLE	O
:	O
Overactive	O
Epidermal	B-FUNC
Growth	I-FUNC
Factor	I-FUNC
Receptor	O
Signaling	O
Leads	O
to	O
Increased	O
Fibrosis	O
after	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
Coronavirus	O
Infection	O
.	O

Importantly	O
,	O
we	O
show	O
that	O
during	O
infection	O
,	O
the	O
EGFR	B-FUNC
ligands	O
amphiregulin	O
and	O
heparin	O
-	O
binding	B-FUNC
EGF	B-FUNC
-	O
like	O
growth	O
factor	O
(	O
HB	O
-	O
EGF	B-FUNC
)	O
are	O
upregulated	O
,	O
and	O
exogenous	O
addition	O
of	O
these	O
ligands	O
during	O
infection	O
leads	O
to	O
enhanced	O
lung	O
disease	O
and	O
altered	O
wound	O
healing	O
dynamics	O
.	O

Specific	O
inhibitors	O
for	O
TGF	O
-	O
βRI	O
,	O
p38	B-FUNC
MAPK	B-FUNC
,	O
MEK	O
,	O
and	O
STAT3	O
proved	O
that	O
SARS	O
-	O
CoV	O
PLpro	O
induced	O
TGF	O
-	O
β1	O
-	O
dependent	O
up	O
-	O
regulation	O
of	O
Type	O
I	O
collagen	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Included	O
in	O
these	O
studies	O
is	O
the	O
first	O
insight	O
into	O
a	O
coronavirus	O
PLP	O
'	O
s	O
interface	O
with	O
ISG15	O
via	O
SARS	O
-	O
CoV	O
PLpro	O
in	O
complex	O
with	O
the	O
principle	O
binding	B-FUNC
domain	O
of	O
human	O
ISG15	O
(	O
hISG15	O
)	O
and	O
mouse	O
ISG15s	O
(	O
mISG15s	O
).	O

Following	O
culturing	O
and	O
subcloning	O
,	O
a	O
strain	O
,	O
1B9	O
,	O
secreting	O
neutralizing	O
antibody	B-FUNC
,	O
was	O
obtained	O
.	O

The	O
antibody	B-FUNC
recognizes	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
of	O
MERS	O
-	O
CoV	O
S	O
glycoprotein	O
and	O
interferes	O
with	O
the	O
interaction	O
between	O
viral	O
S	O
and	O
the	O
human	O
cellular	O
receptor	O
human	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
).	O

A	O
retrospective	O
study	O
of	O
children	O
with	O
HCoV	O
detected	O
by	O
reverse	O
-	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
was	O
performed	O
for	O
a	O
community	O
cohort	O
and	O
a	O
children	O
'	O
s	O
hospital	O
in	O
the	O
same	O
community	O
from	O
January	O
2013	O
to	O
December	O
2014	O
.	O

Our	O
studies	O
showed	O
that	O
IL	B-FUNC
-	I-FUNC
33	I-FUNC
administration	O
in	O
a	O
MHV	O
-	O
3	O
infection	O
promoted	O
survival	O
during	O
FH	O
,	O
with	O
a	O
significant	O
reduction	O
in	O
FGL2	O
expression	O
and	O
liver	O
inflammation	O
.	O

In	O
conclusion	O
,	O
our	O
research	O
suggests	O
that	O
IL	B-FUNC
-	I-FUNC
33	I-FUNC
protects	O
against	O
viral	O
fulminant	O
hepatitis	O
in	O
mice	O
by	O
antagonizing	O
expression	O
of	O
the	O
pro	O
-	O
coagulant	O
protein	O
FGL2	O
.	O

Although	O
antibody	B-FUNC
secreting	O
cells	O
(	O
ASC	O
)	O
within	O
the	O
inflamed	O
CNS	O
have	O
been	O
extensively	O
examined	O
,	O
memory	O
B	O
cell	O
(	O
Bmem	O
)	O
characterization	O
has	O
been	O
limited	O
as	O
they	O
do	O
not	O
secrete	O
antibody	B-FUNC
without	O
stimulation	O
.	O

The	O
results	O
indicated	O
that	O
the	O
PEDV	O
suppressed	O
protein	O
synthesis	O
of	O
IPEC	O
-	O
J2	O
cells	O
through	O
down	O
-	O
regulation	O
of	O
the	O
PI3K	B-FUNC
-	O
AKT	O
/	O
mTOR	O
signaling	O
pathways	O
.	O

In	O
this	O
randomised	O
,	O
open	O
-	O
label	O
,	O
multicentre	O
,	O
phase	O
2	O
trial	O
,	O
29	O
academic	O
medical	O
centres	O
in	O
the	O
USA	O
assessed	O
the	O
safety	O
and	O
efficacy	O
of	O
anti	O
-	O
influenza	O
plasma	O
with	O
haemagglutination	O
inhibition	O
antibody	B-FUNC
titres	O
of	O
1	O
:	O
80	O
or	O
more	O
to	O
the	O
infecting	O
strain	O
.	O

TITLE	O
:	O
Myeloid	O
-	O
epithelial	O
cross	O
talk	O
coordinates	O
synthesis	O
of	O
the	O
tissue	O
-	O
protective	O
cytokine	O
leukemia	B-FUNC
inhibitory	I-FUNC
factor	I-FUNC
during	O
pneumonia	O
.	O

Leukemia	B-FUNC
inhibitory	I-FUNC
factor	I-FUNC
(	O
LIF	B-FUNC
),	O
a	O
member	O
of	O
the	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
cytokine	O
family	O
,	O
is	O
a	O
critical	O
determinant	O
of	O
lung	O
tissue	O
protection	O
during	O
pneumonia	O
,	O
but	O
the	O
cellular	O
sources	O
of	O
LIF	B-FUNC
and	O
the	O
signaling	O
pathways	O
leading	O
to	O
its	O
production	O
in	O
the	O
infected	O
lung	O
are	O
not	O
known	O
.	O

Comparing	O
the	O
normal	O
transcription	O
regulatory	O
sequence	O
(	O
TRS	B-FUNC
),	O
3	O
variant	O
TRS	B-FUNC
sequences	O
upstream	O
the	O
spike	O
(	O
S	O
),	O
ORF3	O
,	O
and	O
ORF8	O
genes	O
were	O
found	O
in	O
the	O
genome	O
of	O
AcCoV	O
-	O
JC34	O
.	O

GJ	O
proteins	O
,	O
connexin	B-FUNC
43	O
(	O
Cx43	O
)	O
and	O
connexin	B-FUNC
47	O
(	O
Cx47	O
),	O
play	O
a	O
crucial	O
role	O
in	O
production	O
and	O
maintenance	O
of	O
CNS	O
myelin	O
.	O

The	O
protein	O
contains	O
a	O
frataxin	O
fold	O
or	O
double	O
-	O
wing	O
motif	O
,	O
which	O
is	O
an	O
α	O
+	O
β	O
fold	O
that	O
is	O
associated	O
with	O
protein	O
/	O
protein	O
interactions	O
,	O
DNA	B-FUNC
binding	I-FUNC
,	O
and	O
metal	B-FUNC
ion	I-FUNC
binding	I-FUNC
.	O

Antibody	B-FUNC
titers	O
in	O
4	O
of	O
6	O
patients	O
who	O
had	O
mild	O
illness	O
were	O
undetectable	O
even	O
though	O
most	O
had	O
evidence	O
of	O
pneumonia	O
.	O

Among	O
them	O
,	O
there	O
are	O
the	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
(	O
RT	O
)-	O
associated	O
ribonuclease	O
H	O
(	O
RNase	O
H	O
)	O
function	O
and	O
the	O
cellular	O
α	O
-	O
glucosidase	O
,	O
involved	O
in	O
the	O
control	O
mechanisms	O
of	O
N	O
-	O
linked	O
glycoproteins	O
formation	O
in	O
the	O
endoplasmic	O
reticulum	O
.	O

We	O
tested	O
254	O
respiratory	O
specimens	O
and	O
cultured	O
viral	O
strains	O
using	O
the	O
Luminex	O
xTAG	O
RVP	O
Fast	B-FUNC
v2	O
assay	O
(	O
Luminex	O
Molecular	O
Diagnostics	O
,	O
Canada	O
)	O
and	O
Anyplex	O
II	O
RV16	O
detection	O
kit	B-FUNC
and	O
compared	O
the	O
results	O
.	O

The	O
xTAG	O
RVP	O
Fast	B-FUNC
v2	O
assay	O
showed	O
comparable	O
capabilities	O
compared	O
with	O
the	O
other	O
assays	O
;	O
it	O
will	O
be	O
useful	O
for	O
identifying	O
respiratory	O
viral	O
infections	O
in	O
patients	O
with	O
respiratory	O
symptoms	O
.	O

We	O
queried	O
the	O
electronic	O
medical	O
records	O
with	O
the	O
diagnostic	O
codes	O
for	O
SCD	O
with	O
acute	O
chest	O
syndrome	O
(	O
ACS	B-FUNC
),	O
pulmonary	O
embolism	O
,	O
or	O
acute	O
respiratory	O
distress	O
syndrome	O
admitted	O
to	O
our	O
hospital	O
from	O
2008	O
to	O
2016	O
to	O
identify	O
patients	O
suspected	O
of	O
having	O
FES	O
.	O

CHS	B-FUNC
is	O
a	O
life	O
-	O
threatening	O
disorder	O
characterized	O
by	O
hypoventilation	O
during	O
sleep	O
.	O

Patients	O
with	O
ACO	O
had	O
a	O
better	O
quality	O
of	O
life	O
(	O
St	O
.	O
George	O
'	O
s	O
Respiratory	O
Questionnaire	O
for	O
COPD	O
score	O
=	O
31	O
.	O
0	O
±	O
18	O
.	O
0	O
[	O
mean	O
±	O
standard	O
deviation	O
])	O
than	O
those	O
with	O
pure	B-FUNC
COPD	O
(	O
35	O
.	O
3	O
±	O
19	O
.	O
1	O
)	O
(	O
P	O
=	O
0	O
.	O
002	O
).	O

We	O
found	O
that	O
α	O
-	O
bis	B-FUNC
-	O
LNCs	O
(	O
30	O
,	O
50	O
,	O
and	O
100	O
mg	O
kg	O

ABSTRACT	O
:	O
Mannose	B-FUNC
binding	I-FUNC
lectin	I-FUNC
(	O
MBL	O
)	O
is	O
a	O
collagenous	O
C	O
-	O
type	O
lectin	O
,	O
which	O
plays	O
an	O
important	O
role	O
in	O
innate	O
immunity	O
.	O

We	O
examined	O
sera	B-FUNC
from	O
100	O
wild	O
raccoons	O
in	O
Japan	O
for	O
antibodies	O
to	O
six	O
canine	O
viruses	O
with	O
veterinary	O
significance	O
to	O
assess	O
their	O
potential	O
as	O
reservoirs	O
.	O

Of	O
the	O
human	O
sera	B-FUNC
,	O
18	O
(	O
2	O
.	O
4	O
%)	O
were	O
positive	O
on	O
ELISA	O
but	O
negative	O
by	O
PRNT	O
.	O

Agarose	O
gel	O
electrophoresis	O
of	O
three	O
diarrheic	O
fecal	O
samples	O
yielded	O
from	O
the	O
25	O
samples	O
desired	O
amplicons	O
that	O
were	O
488	O
base	B-FUNC
pairs	I-FUNC
and	O
sequencing	O
substantiated	O
that	O
have	O
BCoV	O
.	O
The	O
sequence	O
alignment	O
indicated	O
that	O
nucleotide	O
and	O
amino	O
acid	O
sequences	O
,	O
the	O
three	O
TWD	O
isolated	O
in	O
Thailand	O
,	O
were	O
more	O
quite	O
homologous	O
to	O
each	O
other	O
(	O
amino	O
acid	O
at	O
position	O
39	O
of	O
TWD1	O
,	O
TWD3	O
was	O
proline	O
,	O
but	O
TWD2	O
was	O
serine	O
)	O
and	O
closely	O
related	O
to	O
OK	O
-	O
0514	O
-	O
3strain	O
(	O
virulent	O
respiratory	O
strain	O
;	O
RBCoV	O
).	O
The	O
amino	O
acid	O
sequencing	O
identities	O
among	O
TWD1	O
,	O
TWD2	O
,	O
TWD3	O
,	O
and	O
OK	O
-	O
0514	O
-	O
3	O
strain	O
were	O
96	O
.	O
0	O
to	O
96	O
.	O
6	O
%,	O
those	O
at	O
which	O
T3I	O
,	O
H65N	O
,	O
D87G	O
,	O
H127Y	O
,	O
andQ136R	O
were	O
changed	O
.	O

ABSTRACT	O
:	O
We	O
evaluated	O
the	O
clinical	O
characteristics	O
,	O
cytokine	O
/	O
chemokine	O
concentrations	O
,	O
viral	O
shedding	O
and	O
antibody	B-FUNC
kinetics	O
in	O
30	O
patients	O
with	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
),	O
including	O
6	O
non	O
-	O
survivors	O
admitted	O
to	O
3	O
MERS	O
-	O
designated	O
hospitals	O
.	O

To	O
determine	O
the	O
genetic	O
relationships	O
of	O
the	O
18	O
sequences	O
obtained	O
in	O
this	O
study	O
and	O
previously	O
known	O
coronaviruses	O
,	O
the	O
nucleotide	O
sequences	O
of	O
a	O
392	O
-	O
nt	O
region	O
of	O
the	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	B-FUNC
)	O
gene	O
were	O
analyzed	O
phylogenetically	O
.	O

TITLE	O
:	O
Recovery	O
from	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
is	O
associated	O
with	O
antibody	B-FUNC
and	O
T	O
-	O
cell	O
responses	O
.	O

Our	O
studies	O
suggest	O
a	O
potential	O
mechanism	O
for	O
fusion	O
initiation	O
through	O
sequential	O
receptor	O
-	O
binding	B-FUNC
events	O
and	O
provide	O
a	O
foundation	O
for	O
the	O
structure	O
-	O
based	O
design	O
of	O
coronavirus	O
vaccines	O
.	O

In	O
series	O
1	O
,	O
animals	O
were	O
treated	O
with	O
vehicle	O
or	O
0	O
.	O
7	O
μmol	O
/	O
kg	O
of	O
AMD3100	O
(	O
CXCR4	B-FUNC
antagonist	O
)	O
and	O
in	O
series	O
2	O
with	O
vehicle	O
,	O
0	O
.	O
7	O
or	O
3	O
.	O
5	O
μmol	O
/	O
kg	O
ubiquitin	B-FUNC
(	O
non	O
-	O
cognate	O
CXCR4	B-FUNC
agonist	O
)	O
within	O
5	O
minutes	O
of	O
reperfusion	O
.	O

TITLE	O
:	O
Enhanced	O
inflammation	O
in	O
New	O
Zealand	O
white	O
rabbits	O
when	O
MERS	O
-	O
CoV	O
reinfection	O
occurs	O
in	O
the	O
absence	O
of	O
neutralizing	O
antibody	B-FUNC
.	O

At	O
most	O
time	O
points	O
,	O
the	O
titer	O
of	O
IBV	O
-	O
specific	O
antibodies	O
,	O
lymphocyte	O
proliferation	O
,	O
and	O
IL	O
-	O
1β	O
,	O
IL	B-FUNC
-	I-FUNC
2	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
and	O
TNF	O
-	O
α	O
mRNA	O
expression	O
levels	O
were	O
higher	O
in	O
three	O
APS	O
groups	O
than	O
in	O
the	O
vaccine	O
control	O
group	O
,	O
and	O
these	O
increases	O
were	O
dose	O
-	O
dependent	O
.	O

RESULTS	O
At	O
the	O
calf	O
level	O
,	O
serum	O
anti	O
-	O
BCV	O
antibody	B-FUNC
abundance	O
was	O
not	O
associated	O
with	O
BCV	O
shedding	O
,	O
but	O
BCV	O
shedding	O
was	O
positively	O
associated	O
with	O
BRD	O
incidence	O
before	O
and	O
after	O
weaning	O
.	O

The	O
serum	O
levels	O
of	O
nine	O
cytokines	O
were	O
significantly	O
higher	O
in	O
patients	O
with	O
asthma	O
than	O
in	O
HCs	B-FUNC
,	O
and	O
the	O
levels	O
of	O
IL	O
-	O
17A	O
and	O
SCF	B-FUNC
were	O
significantly	O
different	O
between	O
uncontrolled	O
and	O
well	O
-	O
controlled	O
patient	O
groups	O
(	O
p	O
=	O
0	O
.	O
003	O
).	O

The	O
two	O
methods	O
can	O
be	O
used	O
to	O
monitor	O
the	O
PDCoV	O
epidemiology	O
in	O
the	O
levels	O
of	O
PDCoV	O
specific	O
RNA	O
or	O
antibody	B-FUNC
,	O
helping	O
better	O
prevent	O
and	O
control	O
PDCoV	O
.	O

TITLE	O
:	O
Role	O
of	O
the	O
inflammasome	O
-	O
related	O
cytokines	O
Il	B-FUNC
-	I-FUNC
1	I-FUNC
and	O
Il	B-FUNC
-	I-FUNC
18	I-FUNC
during	O
infection	O
with	O
murine	O
coronavirus	O
.	O

The	O
cytokines	O
secreted	O
following	O
inflammasome	O
activation	O
,	O
which	O
include	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
,	O
regulate	O
cells	O
of	O
both	O
the	O
innate	O
and	O
adaptive	O
immune	O
system	O
,	O
guiding	O
the	O
subsequent	O
immune	O
responses	O
.	O

Mice	O
lacking	O
IL	B-FUNC
-	I-FUNC
1	I-FUNC
signaling	O
experienced	O
elevated	O
viral	O
replication	O
but	O
similar	O
survival	O
compared	O
to	O
wild	O
-	O
type	O
controls	O
.	O

These	O
data	O
suggest	O
that	O
inflammasome	O
signaling	O
is	O
largely	O
protective	O
during	O
murine	O
coronavirus	O
infection	O
,	O
in	O
large	O
part	O
due	O
to	O
the	O
pro	O
-	O
inflammatory	O
effects	O
of	O
IL	B-FUNC
-	I-FUNC
18	I-FUNC
.	O

Further	O
,	O
mutational	O
and	O
binding	B-FUNC
free	O
energy	O
analyses	O
suggested	O
that	O
in	O
addition	O
to	O
K63	O
and	O
K67	O
,	O
two	O
other	O
residues	O
,	O
K27	O
and	O
W45	O
,	O
might	O
also	O
be	O
crucial	O
for	O
p4a	O
-	O
dsRNA	O
stability	O
.	O

TITLE	O
:	O
Identification	O
of	O
sialic	O
acid	O
-	O
binding	B-FUNC
function	O
for	O
the	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
spike	O
glycoprotein	O
.	O

A	O
successful	O
viral	O
infection	O
requires	O
fusion	O
between	O
virus	O
and	O
host	O
cells	O
carried	O
out	O
by	O
the	O
surface	O
spike	O
glycoprotein	O
or	O
S	O
protein	O
of	O
CoV	O
.	O
Current	O
models	O
propose	O
that	O
the	O
S2	O
subunit	O
of	O
S	O
protein	O
assembled	O
into	O
a	O
hexameric	O
helical	O
bundle	O
exposing	O
hydrophobic	O
fusogenic	O
peptides	O
or	O
fusion	O
peptides	O
(	O
FPs	B-FUNC
)	O
for	O
membrane	O
insertion	O
.	O

In	O
an	O
in	O
vitro	O
model	O
of	O
antibody	B-FUNC
-	O
dependent	O
enhancement	O
of	O
FIPV	O
infection	O
,	O
diphyllin	O
nanoparticles	O
showed	O
a	O
prominent	O
antiviral	O
effect	O
against	O
the	O
feline	O
coronavirus	O
.	O

During	O
2013	O
-	O
2016	O
,	O
a	O
total	O
of	O
42351	O
throat	O
swabs	O
were	O
examined	O
for	O
presence	O
of	O
influenza	O
viruses	O
and	O
MERS	O
-	O
CoV	O
in	O
Iranian	O
general	O
population	O
and	O
pilgrims	O
returning	O
from	O
Mecca	O
and	O
Karbala	O
with	O
SARI	O
by	O
using	O
one	O
step	O
RT	O
-	O
PCR	O
kit	B-FUNC
.	O

In	O
our	O
previous	O
electron	O
spin	O
resonance	O
spectroscopic	O
studies	O
,	O
the	O
membrane	O
-	O
ordering	O
effect	O
of	O
influenza	O
virus	O
,	O
HIV	O
,	O
and	O
Dengue	O
virus	O
FPs	B-FUNC
has	O
been	O
consistently	O
observed	O
.	O

Higher	O
titer	O
of	O
HA7	O
-	O
binding	B-FUNC
antibody	B-FUNC
during	O
the	O
first	O
14	O
days	O
after	O
disease	O
onset	O
were	O
associated	O
with	O
a	O
shorter	O
virus	O
-	O
positive	O
continuation	O
period	O
,	O
which	O
is	O
an	O
important	O
risk	O
predictor	O
(	O

This	O
association	O
protected	O
IBV	O
particles	O
from	O
antibody	B-FUNC
-	O
dependent	O
complement	O
-	O
mediated	O
lysis	O
.	O

TITLE	O
:	O
Cryo	O
-	O
Electron	O
Microscopy	O
Structure	O
of	O
Porcine	O
Deltacoronavirus	O
Spike	O
Protein	O
in	O
the	O
Prefusion	O
State	O
ABSTRACT	O
:	O
Coronavirus	O
spike	O
proteins	O
from	O
different	O
genera	O
are	O
divergent	O
,	O
although	O
they	O
all	O
mediate	O
coronavirus	O
entry	O
into	O
cells	O
by	O
binding	B-FUNC
to	O
host	O
receptors	O
and	O
fusing	O
viral	O
and	O
cell	O
membranes	O
.	O

Intramuscular	O
PEDV	O
exposure	O
did	O
not	O
result	O
in	O
a	O
detectable	O
antibody	B-FUNC
response	O
in	O
EXP	O
-	O
IM	O
-	O
1b	O
pigs	O
.	O

We	O
were	O
not	O
able	O
to	O
detect	O
differences	O
in	O
systemic	O
plasma	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
levels	O
between	O
the	O
two	O
groups	O
(	O
n	O
=	O
75	O
;	O
p	O
=	O
0	O
.	O
15	O
).	O

In	O
light	O
of	O
the	O
selective	O
binding	B-FUNC
affinity	O
between	O
viral	O
pathogens	O
and	O
cells	O
,	O
nanoparticles	O
cloaked	O
in	O
cellular	O
membranes	O
are	O
herein	O
employed	O
for	O
virus	O
targeting	O
.	O

CSF	O
antibody	B-FUNC
was	O
detected	O
in	O
28	O
cats	O
,	O
which	O
were	O
divided	O
into	O
2	O
groups	O
;	O
15	O
with	O
CSF	O
titer	O
of	O
1	O
:	O
80	O
or	O
lower	O
and	O
13	O
with	O
CSF	O
titer	O
of	O
1	O
:	O
640	O
or	O
higher	O
.	O

Based	O
on	O
many	O
preclinical	O
studies	O
,	O
mesenchymal	O
stem	O
cells	O
(	O
MSCs	B-FUNC
)	O
have	O
great	O
potential	O
as	O
a	O
therapeutic	O
strategy	O
for	O
ALI	O
,	O
clinical	O
trials	O
are	O
underway	O
,	O
and	O
studies	O
on	O
the	O
therapeutic	O
effects	O
of	O
MSCs	B-FUNC
progressively	O
deep	O
into	O
the	O
molecular	O
mechanism	O
and	O
continue	O
to	O
make	O
new	O
progress	O
.	O

Respiratory	O
virus	O
in	O
upper	O
and	O
/	O
or	O
lower	O
respiratory	O
tract	O
(	O
URT	O
and	O
LRT	O
)	O
specimens	O
were	O
tested	O
using	O
Luminex	O
xTAG	O
RVP	O
Fast	B-FUNC
v1	O
assay	O
.	O

TITLE	O
:	O
Inhibition	O
of	O
Cytosolic	O
Phospholipase	B-FUNC
A	I-FUNC
ABSTRACT	O
:	O
Coronavirus	O
replication	O
is	O
associated	O
with	O
intracellular	O
membrane	O
rearrangements	O
in	O
infected	O
cells	O
,	O
resulting	O
in	O
the	O
formation	O
of	O
double	O
-	O
membrane	O
vesicles	O
(	O
DMVs	O
)	O
and	O
other	O
membranous	O
structures	O
that	O
are	O
referred	O
to	O
as	O
replicative	O
organelles	O
(	O
ROs	O
).	O

In	O
addition	O
,	O
the	O
use	O
of	O
the	O
Co1	O
ligand	B-FUNC
elicited	O
a	O
splenocyte	O
proliferative	O
response	O
more	O
effectively	O
in	O
comparison	O
with	O
the	O
COE	O
antigen	O
alone	O
and	O
supported	O
a	O
skewed	O
T	O
helper	O
2	O
type	O
of	O
immune	O
response	O
against	O
PEDV	O
.	O

The	O
optimal	O
cutoff	O
point	O
,	O
the	O
corresponding	O
limit	O
of	O
quantification	O
(	O
LoQ	O
)	O
and	O
the	O
limit	O
of	O
detection	O
(	O
LoD	B-FUNC
)	O
were	O
statistical	O
established	O
based	O
on	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curve	O
analysis	O
.	O

We	O
investigated	O
the	O
role	O
of	O
estradiol	O
on	O
the	O
generation	O
of	O
interleukin	O
(	O
IL	O
)-	O
1β	O
,	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
vascular	B-FUNC
endothelial	I-FUNC
growth	I-FUNC
factor	I-FUNC
(	O
VEGF	O
),	O
and	O
cytokine	O
-	O
induced	O
neutrophil	O
chemoattractant	O
1	O
(	O
CINC	O
-	O
1	O
)	O
in	O
a	O
female	O
rat	O
model	O
of	O
intestinal	O
IR	O
.	O

TITLE	O
:	O
Coronaviruses	O
and	O
arteriviruses	O
display	O
striking	O
differences	O
in	O
their	O
cyclophilin	B-FUNC
A	O
-	O
dependence	O
during	O
replication	O
in	O
cell	O
culture	O
.	O

Since	O
the	O
RBD	O
domain	O
of	O
HKU4	O
but	O
not	O
HKU5	O
can	O
bind	B-FUNC
to	O
the	O
human	O
DPP4	O
receptor	O
for	O
MERS	O
-	O
CoV	O
,	O
it	O
is	O
possible	O
to	O
suggest	O
also	O
for	O
IT	O
-	O
batCoVs	O
the	O
absence	O
of	O
DPP4	O
-	O
binding	B-FUNC
potential	O
.	O

Compared	O
with	O
severe	O
pneumonia	O
without	O
ARDS	O
development	O
,	O
patients	O
with	O
ARDS	O
development	O
had	O
shorter	O
disease	O
duration	O
before	O
admission	O
,	O
higher	O
lung	O
injury	O
score	O
(	O
LIS	B-FUNC
),	O
serum	O
fibrinogen	O
(	O
FiB	O
),	O
and	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
),	O
lower	O
Marshall	O
score	O
,	O
sequential	O
organ	O
failure	O
assessment	O
score	O
and	O
proportion	O
of	O
cardiovascular	O
and	O
gastrointestinal	O
diseases	O
,	O
but	O
similar	O
mortality	O
.	O

Patients	O
may	O
present	O
with	O
ACS	B-FUNC
or	O
may	O
develop	O
this	O
complication	O
during	O
the	O
course	O
of	O
a	O
hospitalization	O
for	O
acute	O
vaso	O
-	O
occlusive	O
crises	O
(	O
VOC	O
).	O

The	O
localization	O
of	O
more	O
negative	O
Ppl	B-FUNC
proportionally	O
increases	O
dependent	O
lung	O
stretch	O
by	O
drawing	O
gas	O
either	O
from	O
other	O
lung	O
regions	O
(	O
e	O
.	O
g	O
.,	O
nondependent	O
lung	O
[	O
pendelluft	O
])	O
or	O
from	O
the	O
ventilator	O
.	O

Recent	O
studies	O
suggest	O
that	O
MHV	O
infection	O
alters	O
gap	O
junction	O
protein	O
connexin	B-FUNC
43	O
(	O
Cx43	O
)-	O
mediated	O
intercellular	O
communication	O
in	O
brain	O
and	O
primary	O
cultured	O
astrocytes	O
.	O

We	O
report	O
the	O
safety	O
of	O
a	O
fully	O
human	O
polyclonal	O
IgG	O
antibody	B-FUNC
(	O
SAB	O
-	O
301	O
)	O
produced	O
from	O
the	O
hyperimmune	O
plasma	O
of	O
transchromosomic	O
cattle	O
immunised	O
with	O
a	O
MERS	O
coronavirus	O
vaccine	O
.	O

Blood	O
samples	O
were	O
collected	O
from	O
birds	O
1	O
week	O
after	O
each	O
vaccination	O
to	O
determine	O
antibody	B-FUNC
titers	O
.	O

The	O
pathogenesis	O
of	O
AEP	O
and	O
CEP	B-FUNC
remains	O
unclear	O
.	O

Taken	O
together	O
,	O
these	O
data	O
demonstrate	O
that	O
PEDV	O
-	O
induced	O
EGFR	B-FUNC
activation	O
serves	O
as	O
a	O
negative	O
regulator	O
of	O
the	O
type	O
I	O
interferon	O
response	O
and	O
provides	O
a	O
novel	O
therapeutic	O
target	O
for	O
virus	O
infection	O
.	O

Since	O
the	O
introduction	O
of	O
SECD	O
,	O
research	O
has	O
focused	O
on	O
investigating	O
viral	O
pathogenesis	O
through	O
experimental	O
inoculation	O
,	O
increasing	O
maternal	O
antibody	B-FUNC
for	O
neonatal	O
protection	O
,	O
understanding	O
transmission	O
risks	O
through	O
feed	O
and	O
transportation	O
,	O
and	O
outlining	O
the	O
importance	O
of	O
biosecurity	O
in	O
preventing	O
SECD	O
introduction	O
and	O
spread	O
.	O

To	O
prepare	O
for	O
large	O
scale	O
-	O
manufacture	O
of	O
the	O
vaccine	O
antigen	O
,	O
we	O
have	O
further	O
developed	O
a	O
high	O
-	O
yield	O
monoclonal	O
suspension	O
CHO	B-FUNC
cell	O
line	O
.	O

Replacement	O
of	O
H209	O
with	O
Ala	O
had	O
no	O
effect	O
on	O
receptor	B-FUNC
binding	I-FUNC
,	O
but	O
in	O
murine	O
17Cl	O
.	O
1	O
cells	O
mutant	O
H209A	O
MHV	O
-	O
A59	O
showed	O
delayed	O
growth	O
kinetics	O
and	O
was	O
readily	O
outcompeted	O
by	O
wild	O
-	O
type	O
virus	O
when	O
mixed	O
together	O
,	O
indicating	O
that	O
the	O
H209A	O
mutation	O
caused	O
a	O
defect	O
in	O
virus	O
fitness	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
serum	O
PCT	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
TNF	O
-	O
α	O
or	O
CD4	O
CRRT	O
in	O
the	O
early	O
stage	O
of	O
bundle	O
therapy	O
for	O
severe	O
pneumonia	O
is	O
not	O
only	O
suggested	O
to	O
remove	O
inflammatory	O
mediators	O
and	O
improve	O
immune	O
function	O
,	O
but	O
an	O
opportunity	O
and	O
effective	O
way	O
to	O
reduce	O
complications	O
and	O
delay	O
rapid	O
progression	O
of	O
severe	O
pneumonia	O
.	O

Replication	O
of	O
PEDV	O
was	O
inhibited	O
by	O
silencing	O
the	O
expression	O
of	O
hnRNP	O
A1	O
in	O
CCL	B-FUNC
-	O
81	O
cells	O
,	O
suggesting	O
the	O
positive	O
effect	O
of	O
hnRNP	O
A1	O
on	O
PEDV	O
infection	O
.	O

TITLE	O
:	O
Monoclonal	O
Antibodies	O
and	O
Antibody	B-FUNC
Like	O
Fragments	O
Derived	O
from	O
Immunised	O
Phage	O
Display	O
Libraries	O
.	O

Although	O
time	O
consuming	O
,	O
immunisation	O
still	O
remains	O
the	O
preferred	O
route	O
for	O
the	O
isolation	O
of	O
high	O
-	O
affinity	O
antibodies	O
and	O
antibody	B-FUNC
-	O
like	O
fragments	O
.	O

The	O
selection	O
of	O
binding	B-FUNC
fragments	O
from	O
phage	O
display	O
libraries	O
has	O
proven	O
significant	O
for	O
routine	O
isolation	O
of	O
invaluable	O
peptides	O
,	O
antibodies	O
,	O
and	O
antibody	B-FUNC
-	O
like	O
domains	O
for	O
diagnostic	O
and	O
therapeutic	O
applications	O
.	O

We	O
found	O
that	O
imatinib	O
and	O
two	O
specific	O
Abl	O
kinase	B-FUNC
inhibitors	I-FUNC
,	O
GNF2	O
and	O
GNF5	O
,	O
reduce	O
IBV	O
titres	O
by	O
blocking	O
the	O
first	O
round	O
of	O
virus	O
infection	O
.	O

TITLE	O
:	O
Enteroviruses	O
Remodel	O
Autophagic	O
Trafficking	O
through	O
Regulation	O
of	O
Host	O
SNARE	B-FUNC
Proteins	O
to	O
Promote	O
Virus	O
Replication	O
and	O
Cell	O
Exit	O
.	O

An	O
orphan	O
SNARE	B-FUNC
,	O
SNAP47	O
,	O
is	O
shown	O
to	O
have	O
a	O
previously	O
unknown	O
role	O
in	O
autophagy	O
,	O
and	O
SNAP47	O
promotes	O
the	O
replication	O
of	O
EV	O
-	O
D68	O
.	O

Severity	O
of	O
injury	O
was	O
determined	O
by	O
protein	O
content	O
and	O
MPO	B-FUNC
activity	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
),	O
the	O
expression	O
of	O
inflammatory	O
cytokines	O
and	O
histopathology	O
.	O

Inhibition	O
of	O
the	O
hepatocyte	B-FUNC
growth	I-FUNC
factor	I-FUNC
pathway	O
in	O
epithelial	O
cells	O
and	O
hepatocyte	B-FUNC
growth	I-FUNC
factor	I-FUNC
production	O
in	O
macrophages	O
both	O
reversed	O
this	O
effect	O
.	O

The	O
trimeric	O
IBV	O
spike	O
ectodomain	O
contains	O
three	O
receptor	O
-	O
binding	B-FUNC
S1	O
heads	O
and	O
a	O
trimeric	O
membrane	O
-	O
fusion	O
S2	O
stalk	O
.	O

ABSTRACT	O
:	O
To	O
study	O
the	O
roles	O
of	O
hypervariable	O
regions	O
(	O
HVRs	O
)	O
in	O
receptor	O
-	O
binding	B-FUNC
subunit	O
S1	O
of	O
the	O
spike	O
protein	O
,	O
we	O
manipulated	O
the	O
genome	O
of	O
the	O
IBV	O
Beaudette	O
strain	O
using	O
a	O
reverse	O
genetics	O
system	O
to	O
construct	O
seven	O
recombinant	O
strains	O
by	O
separately	O
or	O
simultaneously	O
replacing	O
the	O
three	O
HVRs	O
of	O
the	O
Beaudette	O
strain	O
with	O
the	O
corresponding	O
fragments	O
from	O
a	O
QX	O
-	O
like	O
nephropathogenic	O
isolate	O
ck	O
/	O
CH	O
/	O
LDL	O
/	O
091022	O
from	O
China	O
.	O

ECMO	O
is	O
a	O
complex	O
network	O
that	O
provides	O
oxygenation	O
and	O
ventilation	O
and	O
allows	O
the	O
lungs	O
to	O
rest	B-FUNC
and	O
recover	O
from	O
respiratory	O
failure	O
,	O
while	O
minimizing	O
iatrogenic	O
ventilator	O
-	O
induced	O
lung	O
injury	O
.	O

PEDV	O
-	O
specific	O
IgG	O
,	O
IgA	O
and	O
neutralizing	O
antibody	B-FUNC
(	O
NA	O
)	O
responses	O
were	O
detected	O
in	O
ORFV	O
-	O
PEDV	O
-	O
S	O
-	O
immunized	O
and	O
ORFV	O
-	O
PEDV	O
-	O
S	O
-	O
immunized	O
/	O
PEDV	O
-	O
exposed	O
gilts	O
.	O

Although	O
both	O
types	O
of	O
vaccine	O
could	O
induce	O
specific	O
immunoglobulin	B-FUNC
G	O
against	O
MERS	O
-	O
CoV	O
,	O
neutralizing	O
antibodies	O
against	O
MERS	O
-	O
CoV	O
were	O
induced	O
only	O
by	O
heterologous	O
prime	O
-	O
boost	O
immunization	O
and	O
homologous	O
immunization	O
with	O
spike	O
protein	O
nanoparticles	O
.	O

Here	O
,	O
we	O
found	O
that	O
ectopic	O
expression	O
of	O
accessory	O
protein	O
NS6	O
significantly	O
inhibits	O
Sendai	O
virus	O
-	O
induced	O
interferon	O
beta	O
(	O
IFN	O
-	O
β	O
)	O
production	O
as	O
well	O
as	O
the	O
activation	O
of	O
transcription	O
factors	O
IRF3	O
and	O
NF	O
-	O
κB	O
.	O
Interestingly	O
,	O
NS6	O
does	O
not	O
impede	O
the	O
IFN	O
-	O
β	O
promoter	O
activation	O
mediated	O
via	O
key	O
molecules	O
in	O
the	O
RIG	O
-	O
I	O
-	O
like	O
receptor	O
(	O
RLR	O
)	O
signaling	O
pathway	O
,	O
specifically	O
RIG	O
-	O
I	O
,	O
MDA5	O
,	O
and	O
their	O
downstream	O
molecules	O
MAVS	O
,	O
TBK1	B-FUNC
,	O
IKKε	O
,	O
and	O
IRF3	O
.	O

Using	O
Au	O
NP	O
-	O
modified	O
graphene	O
nanosheet	O
(	O
Au	O
-	O
GN	O
)	O
as	O
the	O
substrate	O
,	O
antibody	B-FUNC
-	O
antigen	O
reaction	O
as	O
the	O
recognition	O
unit	O
,	O
rolling	O
circle	O
amplification	O
(	O
RCA	O
)	O
for	O
signal	O
enhancement	O
,	O
and	O
assembled	O
cascade	O
Ru	O
-	O
DNA	O
nanotags	O
as	O
signal	O
label	O
,	O
the	O
proposed	O
platform	O
behaved	O
with	O
good	O
specificity	O
and	O
sensitivity	O
.	O

These	O
self	O
-	O
binding	B-FUNC
sequences	O
represent	O
opportunities	O
for	O
the	O
development	O
of	O
biochemical	O
tools	O
and	O
/	O
or	O
therapeutics	O
.	O

Nsp	O
3	O
is	O
a	O
multi	O
-	O
functional	O
protein	O
containing	O
a	O
conserved	O
ADP	O
-	O
ribose	O
-	O
1	O
″-	O
phosphatase	B-FUNC
(	O
ADRP	O
)	O
domain	O
.	O

LIS	B-FUNC
,	O
Modified	O
LIS	B-FUNC
and	O
PaO2	O
/	O
FiO2	O
ratio	O
predicted	O
outcome	O
as	O
well	O
as	O
need	O
for	O
mechanical	O
ventilation	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
degradation	O
,	O
subcellular	O
localisation	O
,	O
and	O
function	O
of	O
TGEV	O
N	O
protein	O
by	O
examining	O
its	O
effects	O
on	O
cycle	O
progression	O
,	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
,	O
interleukin	O
-	O
8	O
(	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
)	O
expression	O
,	O
and	O
cell	O
survival	O
.	O

Genetically	O
modified	O
new	O
vaccine	O
candidates	O
were	O
able	O
to	O
elicit	O
a	O
strong	O
antibody	B-FUNC
(	O
Ab	O
)	O
response	O
to	O
the	O
YSNIGVCK	O
epitope	O
,	O
which	O
correlated	O
with	O
an	O
increased	O
ability	O
to	O
neutralize	O
the	O
CO	O
strain	O
of	O
PEDV	O
.	O

However	O
,	O
the	O
mechanisms	O
of	O
the	O
dimerization	O
and	O
nucleic	B-FUNC
acid	I-FUNC
binding	I-FUNC
of	O
nsp9	O
remain	O
elusive	O
.	O

In	O
addition	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
microscale	O
thermophoresis	O
analysis	O
indicate	O
that	O
the	O
monomeric	O
forms	O
of	O
PDCoV	O
nsp9	O
and	O
PEDV	O
nsp9	O
still	O
have	O
nucleic	B-FUNC
acid	I-FUNC
binding	I-FUNC
affinity	O
,	O
although	O
it	O
is	O
lower	O
than	O
that	O
of	O
the	O
wild	O
type	O
.	O

H7N9	O
-	O
specific	O
antibody	B-FUNC
concentrations	O
declined	O
over	O
time	O
,	O
and	O
protective	O
antibodies	O
persisted	O
longer	O
in	O
severely	O
ill	O
patients	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
and	O
patients	O
presenting	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
than	O
in	O
patients	O
with	O
mild	O
disease	O
.	O

TITLE	O
:	O
A	O
Novel	O
Nanobody	O
Targeting	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
Receptor	O
-	O
Binding	B-FUNC
Domain	O
Has	O
Potent	O
Cross	O
-	O
Neutralizing	O
Activity	O
and	O
Protective	O
Efficacy	O
against	O
MERS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
The	O
newly	O
emerged	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
continues	O
to	O
infect	O
humans	O
and	O
camels	O
,	O
calling	O
for	O
efficient	O
,	O
cost	O
-	O
effective	O
,	O
and	O
broad	O
-	O
spectrum	O
strategies	O
to	O
control	O
its	O
spread	O
.	O

The	O
binding	B-FUNC
site	O
of	O
the	O
Nbs	O
on	O
the	O
RBD	O
was	O
mapped	O
to	O
be	O
around	O
residue	O
Asp539	O
,	O
which	O
is	O
part	O
of	O
a	O
conserved	O
conformational	O
epitope	O
at	O
the	O
receptor	O
-	O
binding	B-FUNC
interface	O
.	O

A	O
higher	O
IAH	B-FUNC
grade	O
was	O
more	O
likely	O
in	O
patients	O
with	O
severe	O
AP	O
(	O
42	O
per	O
cent	O
for	O
grade	O
I	O
versus	O
84	O
per	O
cent	O
for	O
grade	O
IV	O
)	O
and	O
acute	O
critical	O
pancreatitis	O
(	O
9	O
versus	O
25	O
per	O
cent	O
;	O
P	O
=	O
0	O
·	O
001	O
).	O

Serum	O
cytokine	O
interleukin	O
(	O
IL	O
)-	O
2	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
-	O
α	O
concentrations	O
were	O
significantly	O
higher	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
both	O
the	O
4	O
%	O
and	O
6	O
%	O
FVW	O
grousp	O
than	O
in	O
the	O
control	O
and	O
antibiotic	O
groups	O
;	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
was	O
significantly	O
higher	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
FVW	O
groups	O
than	O
in	O
the	O
control	O
group	O
;	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
was	O
significantly	O
higher	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
6	O
%	O
FVW	O
group	O
than	O
in	O
the	O
control	O
and	O
antibiotic	O
groups	O
.	O

In	O
the	O
CD81	O
protein	O
network	O
,	O
we	O
identified	O
five	O
proteins	O
which	O
are	O
HCV	O
entry	O
factors	O
or	O
facilitators	O
including	O
epidermal	B-FUNC
growth	I-FUNC
factor	I-FUNC
receptor	O
(	O
EGFR	B-FUNC
).	O

TITLE	O
:	O
Characterization	O
of	O
a	O
bafinivirus	O
exoribonuclease	B-FUNC
activity	I-FUNC
.	O

Two	O
doses	O
of	O
the	O
nasal	O
spray	O
H7N9	O
vaccine	O
induced	O
higher	O
titers	O
of	O
HI	O
(	O
6	O
.	O
7	O
±	O
0	O
.	O
67	O
vs	O
.	O
5	O
.	O
3	O
±	O
1	O
.	O
16	O
,	O
P	O
=	O
0	O
.	O
004	O
)	O
and	O
anti	O
-	O
HA	O
IgG	O
in	O
sera	B-FUNC
(	O
19	O
.	O
26	O
±	O
0	O
.	O
67	O
vs	O
.	O
13	O
.	O
97	O
±	O
0	O
.	O
82	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
and	O
of	O
anti	O
-	O
HA	O
sIgA	O
(	O
7	O
.	O
13	O
±	O
2	O
.	O
54	O
vs	O
.	O
0	O
,	O
P	O
=	O
0	O
.	O
0000	O
)	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
than	O
one	O
dose	O
of	O
intramuscular	O
H7N9	O
vaccine	O
3	O
weeks	O
after	O
the	O
last	O
immunization	O
.	O

TITLE	O
:	O
Design	O
,	O
synthesis	O
,	O
docking	O
studies	O
and	O
biological	O
screening	O
of	O
2	O
-	O
thiazolyl	O
substituted	O
-	O
2	O
,	O
3	O
-	O
dihydro	O
-	O
1H	O
-	O
naphtho	O
[	O
1	O
,	O
2	O
-	O
e	O
][	O
1	O
,	O
3	O
]	O
oxazines	O
as	O
potent	O
HIV	O
-	O
1	O
reverse	O
transcriptase	B-FUNC
inhibitors	O
.	O

Docking	O
studies	O
of	O
these	O
molecules	O
revealed	O
their	O
high	O
affinity	O
binding	B-FUNC
to	O
several	O
amino	O
acids	O
of	O
HIV	O
-	O
1	O
RT	O
which	O
are	O
less	O
sensitive	O
to	O
point	O
mutations	O
.	O

In	O
contrast	O
to	O
humans	O
,	O
MERS	O
-	O
CoV	O
-	O
exposed	O
dromedaries	O
develop	O
only	O
very	O
mild	O
infections	O
and	O
exceptionally	O
potent	O
virus	O
-	O
neutralizing	O
antibody	B-FUNC
responses	O
.	O

These	O
HCAbs	O
are	O
devoid	O
of	O
light	O
chains	O
and	O
have	O
long	O
complementarity	O
-	O
determining	O
regions	O
with	O
unique	O
epitope	O
binding	B-FUNC
properties	O
,	O
allowing	O
them	O
to	O
recognize	O
and	O
bind	B-FUNC
with	O
high	O
affinity	O
to	O
epitopes	O
not	O
recognized	O
by	O
conventional	O
antibodies	O
.	O

ABSTRACT	O
:	O
The	O
trimeric	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
surface	O
spike	O
(	O
S	O
)	O
glycoprotein	O
consisting	O
of	O
three	O
S1	O
-	O
S2	O
heterodimers	O
binds	B-FUNC
the	O
cellular	O
receptor	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
and	O
mediates	O
fusion	O
of	O
the	O
viral	O
and	O
cellular	O
membranes	O
through	O
a	O
pre	O
-	O
to	O
postfusion	O
conformation	O
transition	O
.	O

Binding	B-FUNC
of	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
)	O
of	O
the	O
spike	O
(	O
S	O
)	O
glycoprotein	O
to	O
dipeptidyl	O
peptidase	O
4	O
is	O
the	O
critical	O
step	O
in	O
MERS	O
-	O
CoV	O
infection	O
of	O
a	O
host	O
cell	O
.	O

qPCR	O
was	O
performed	O
to	O
analyze	O
PEDV	O
binding	B-FUNC
to	O
Vero	O
E6	O
cells	O
with	O
neutralizing	O
antibody	B-FUNC
.	O

Using	O
this	O
joint	O
analysis	O
of	O
the	O
molecular	B-FUNC
function	I-FUNC
and	O
phylogeny	O
,	O
our	O
results	O
suggested	O
that	O
SARS	O
-	O
CoV	O
-	O
cpsR	O
-	O
19	O
could	O
play	O
a	O
role	O
in	O
SARS	O
-	O
CoV	O
infection	O
or	O
pathogenesis	O
.	O

AAbV	O
was	O
shown	O
to	O
encode	O
a	O
functional	O
main	O
proteinase	B-FUNC
,	O
and	O
a	O
translational	O
readthrough	O
signal	O
.	O

However	O
,	O
the	O
visual	O
assessment	O
of	O
viral	O
cytopathic	O
effects	O
by	O
operators	O
to	O
determine	O
antibody	B-FUNC
titers	O
or	O
for	O
viral	O
quantification	O
is	O
a	O
tedious	O
,	O
subjective	O
and	O
time	O
-	O
consuming	O
process	O
,	O
especially	O
when	O
high	O
volume	O
testing	O
is	O
involved	O
.	O

High	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
analyses	O
showed	O
that	O
TGEV	O
infection	O
leads	O
to	O
reduced	O
arginine	O
uptake	O
at	O
48	O
hours	O
post	O
-	O
infection	O
(	O
hpi	B-FUNC
).	O

Weaned	O
piglets	O
orally	O
immunized	O
with	O
coated	O
PEDV	O
-	O
loaded	O
microspheres	O
developed	O
higher	O
levels	O
of	O
PEDV	O
-	O
specific	O
antibodies	O
(	O
IgG	O
and	O
IgA	O
)	O
in	O
their	O
sera	B-FUNC
and	O
saliva	O
than	O
those	O
negative	O
control	O
groups	O
(	O
p	O
<	O
0	O
.	O
001	O
or	O
p	O
<	O
0	O
.	O
01	O
).	O

TITLE	O
:	O
Tannic	O
acid	O
protects	O
against	O
experimental	O
acute	O
lung	O
injury	O
through	O
downregulation	O
of	O
TLR4	O
and	O
MAPK	B-FUNC
.	O

The	O
data	O
revealed	O
that	O
differentially	O
expressed	O
mRNAs	O
and	O
ncRNAs	O
were	O
primarily	O
enriched	O
in	O
inflammation	O
-	O
related	O
pathways	O
and	O
ssc_circ_009380	O
promoted	O
activation	O
of	O
NF	O
-	O
κB	O
pathway	O
by	O
binding	B-FUNC
miR	O
-	O
22	O
during	O
TGEV	O
-	O
induced	O
inflammation	O
.	O

Herein	O
,	O
we	O
show	O
that	O
distinct	O
IAV	O
strains	O
reduced	O
the	O
functions	O
of	O
the	O
epithelial	B-FUNC
sodium	I-FUNC
channel	I-FUNC
(	O
ENaC	O
)	O
and	O
the	O
cystic	O
fibrosis	O
transmembrane	O
regulator	O
(	O
CFTR	O
)	O
in	O
murine	O
respiratory	O
and	O
alveolar	O
epithelia	O
in	O
vivo	O
,	O
as	O
assessed	O
by	O
measurements	O
of	O
nasal	O
potential	O
differences	O
and	O
single	O
-	O
cell	O
electrophysiology	O
.	O

Prolyl	O
hydroxylase	O
domain	O
(	O
PHD	B-FUNC
)-	O
2	O
protein	O
,	O
a	O
major	O
PHD	B-FUNC
in	O
ECs	O
,	O
plays	O
a	O
critical	O
role	O
in	O
intracellular	O
oxygen	O
homeostasis	O
,	O
angiogenesis	O
,	O
and	O
pulmonary	O
hypertension	O
.	O

Thus	O
,	O
we	O
successfully	O
produced	O
a	O
monoclonal	O
antibody	B-FUNC
directed	O
against	O
the	O
RBD	O
domain	O
of	O
the	O
S	O
protein	O
which	O
could	O
be	O
used	O
in	O
the	O
development	O
of	O
diagnostics	O
and	O
therapeutic	O
applications	O
in	O
the	O
future	O
.	O

Totals	O
of	O
16	O
/	O
30	O
CWs	O
and	O
0	O
/	O
30	O
healthy	O
control	O
donors	O
were	O
seropositive	O
by	O
MERS	O
-	O
CoV	O
-	O
specific	O
ELISA	O
and	O
/	O
or	O
neutralizing	O
antibody	B-FUNC
titer	O
,	O
and	O
an	O
additional	O
four	O
CWs	O
were	O
seronegative	O
but	O
contained	O
virus	O
-	O
specific	O
T	O
cells	O
in	O
their	O
blood	O
.	O

Interestingly	O
,	O
high	O
titers	O
of	O
virus	O
-	O
neutralizing	O
antibodies	O
in	O
sera	B-FUNC
were	O
detected	O
at	O
21	O
DPI	O
.	O

The	O
contents	O
of	O
γ	O
-	O
IFN	O
,	O
IL	O
-	O
1β	O
,	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
in	O
animals	O
immunized	O
with	O
GNP	O
-	O
antigen	O
conjugates	O
were	O
found	O
to	O
be	O
higher	O
than	O
those	O
in	O
intact	O
animals	O
or	O
in	O
animals	O
given	O
the	O
antigen	O
alone	O
.	O

We	O
confirm	O
that	O
changes	O
D510G	O
and	O
I529T	O
reduce	O
S	O
protein	B-FUNC
binding	I-FUNC
to	O
DPP4	O
but	O
show	O
that	O
this	O
reduction	O
only	O
translates	O
into	O
diminished	O
viral	O
entry	O
when	O
expression	O
of	O
DPP4	O
on	O
target	O
cells	O
is	O
low	O
.	O

In	O
contrast	O
,	O
changes	O
D510G	O
and	O
I529T	O
increased	O
resistance	O
of	O
S	O
protein	O
-	O
driven	O
entry	O
to	O
neutralization	O
by	O
monoclonal	O
antibodies	O
and	O
sera	B-FUNC
from	O
MERS	O
patients	O
.	O

The	O
levels	O
of	O
IL	B-FUNC
-	I-FUNC
33	I-FUNC
and	O
MMP2	O
/	O
9	O
in	O
BALF	O
increased	O
in	O
all	O
the	O
ALI	O
rats	O
with	O
severe	O
lung	O
injury	O
.	O

LPS	O
-	O
induced	O
IL	B-FUNC
-	I-FUNC
33	I-FUNC
autocrine	O
upregulated	O
the	O
expression	O
of	O
MMP2	O
and	O
MMP9	O
through	O
activating	O
STAT3	O
.	O

The	O
IL	B-FUNC
-	I-FUNC
33	I-FUNC
/	O
STAT3	O
/	O
MMP2	O
/	O
9	O
regulatory	O
pathway	O
is	O
activated	O
in	O
alveolar	O
macrophages	O
during	O
acute	O
lung	O
injury	O
,	O
which	O
may	O
exacerbate	O
the	O
pulmonary	O
inflammation	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
reveals	O
that	O
neboviruses	O
circulate	O
widely	O
in	O
dairy	O
cows	O
in	O
China	O
and	O
exhibit	O
a	O
unique	O
evolution	O
of	O
RdRp	B-FUNC
.	O

Larger	O
trials	O
are	O
needed	O
to	O
assess	O
efficacy	O
,	O
and	O
the	O
viability	O
of	O
MSCs	B-FUNC
must	O
be	O
improved	O
.	O

TITLE	O
:	O
A	O
high	O
-	O
throughput	O
inhibition	O
assay	O
to	O
study	O
MERS	O
-	O
CoV	O
antibody	B-FUNC
interactions	O
using	O
image	O
cytometry	O
.	O

The	O
ability	O
of	O
monoclonal	O
antibodies	O
to	O
inhibit	O
MERS	O
-	O
CoV	O
S	O
binding	B-FUNC
was	O
then	O
tested	O
.	O

The	O
application	O
of	O
mesenchymal	O
stem	O
cells	O
(	O
MSCs	B-FUNC
)	O
for	O
ARDS	O
as	O
well	O
as	O
IRI	O
in	O
various	O
organs	O
,	O
therefore	O
,	O
has	O
been	O
interested	O
and	O
extensively	O
investigated	O
in	O
animal	O
models	O
with	O
promising	O
results	O
.	O

The	O
rest	B-FUNC
of	O
the	O
ORFs	O
of	O
these	O
2	O
IBV	O
isolates	O
showed	O
99	O
.	O
9	O
%	O
nucleotide	O
similarity	O
.	O

Out	O
of	O
145	O
sera	B-FUNC
that	O
scored	O
negative	O
in	O
the	O
IDEXX	O
IBV	O
Ab	O
Test	O
,	O
131	O
also	O
scored	O
negative	O
in	O
the	O
ELISA	O
-	O
rN	O
,	O
indicating	O
a	O
specificity	O
of	O
90	O
.	O
34	O
%.	O

Sera	B-FUNC
that	O
tested	O
negative	O
in	O
the	O
ELISA	O
-	O
rN	O
and	O
positive	O
in	O
the	O
commercial	O
test	O
also	O
reacted	O
with	O
the	O
rN	O
protein	O
in	O
Western	O
blot	O
.	O

TITLE	O
:	O
Onset	O
of	O
Takotsubo	O
Syndrome	O
during	O
the	O
Clinical	O
Course	O
of	O
Anti	O
-	O
Neutrophil	O
Cytoplasmic	O
Antibody	B-FUNC
-	O
Associated	O
Vasculitis	O
:	O
A	O
Case	O
Report	O
.	O

Pre	O
-	O
existing	O
medical	O
conditions	O
(	O
adjusted	O
Odds	O
ratio	O
(	O
aOR	B-FUNC
)=	O
2	O
.	O
43	O
,	O
95	O
%	O
confidence	O
interval	O
:	O
(	O
CI	O
)	O
[	O
1	O
.	O
11	O
-	O
5	O
.	O
33	O
])	O
and	O
hospitalized	O
patients	O
(	O
aOR	O
=	O
29	O
.	O
99	O
,	O
95	O
%	O
CI	O
[	O
1	O
.	O
80	O
-	O
48	O
.	O
65	O
])	O
were	O
the	O
strongest	O
risk	O
predictors	O
of	O
death	O
from	O
MERS	O
.	O

The	O
sialic	O
acid	O
glyco	O
-	O
epitope	O
recognized	O
by	O
TER	O
-	O
119	O
on	O
erythrocytes	O
was	O
sensitive	O
to	O
the	O
sialic	O
acid	O
O	O
-	O
acetyl	O
esterase	B-FUNC
activity	I-FUNC
of	O
the	O
hemagglutinin	O
-	O
esterase	O
from	O
bovine	O
coronavirus	O
but	O
not	O
to	O
the	O
corresponding	O
enzyme	O
from	O
the	O
influenza	O
C	O
virus	O
.	O

TITLE	O
:	O
Combining	O
a	O
Fusion	O
Inhibitory	O
Peptide	O
Targeting	O
the	O
MERS	O
-	O
CoV	O
S2	O
Protein	O
HR1	O
Domain	O
and	O
a	O
Neutralizing	O
Antibody	B-FUNC
Specific	O
for	O
the	O
S1	O
Protein	O
Receptor	O
-	O
Binding	B-FUNC
Domain	O
(	O
RBD	O
)	O
Showed	O
Potent	O
Synergism	O
against	O
Pseudotyped	O
MERS	O
-	O
CoV	O
with	O
or	O
without	O
Mutations	O
in	O
RBD	O
.	O

However	O
,	O
when	O
the	O
C5a	O
-	O
C5aR1	O
axis	O
was	O
blocked	O
by	O
an	O
anti	O
-	O
C5aR1	O
antibody	B-FUNC
(	O
Ab	O
),	O
expression	O
of	O
caspase	O
-	O
1	O
and	O
IL	O
-	O
1β	O
fell	O
.	O

Both	O
patients	O
were	O
diagnosed	O
with	O
AE	O
-	O
IPF	O
accompanying	O
acute	O
pertussis	O
infection	O
based	O
on	O
chest	O
computed	O
tomography	O
and	O
serum	O
pertussis	O
toxin	O
antibody	B-FUNC
>	O
100	O
EU	O
/	O
mL	O
.	O
Both	O
patients	O
were	O
treated	O
with	O
macrolide	O
antibiotics	O
and	O
systemic	O
corticosteroids	O
.	O

LCA60	O
is	O
a	O
MERS	O
-	O
CoV	O
-	O
neutralizing	O
monoclonal	O
antibody	B-FUNC
isolated	O
from	O
a	O
convalescent	O
MERS	O
patient	O
.	O

Decompressive	O
laparotomy	O
is	O
the	O
first	O
treatment	O
option	O
for	O
both	O
most	O
forms	O
of	O
pneumoperitoneum	O
and	O
ACS	B-FUNC
;	O
nevertheless	O
,	O
this	O
issue	O
is	O
controversial	O
.	O

Five	O
days	O
post	O
-	O
challenge	O
,	O
viral	O
load	O
,	O
clinical	O
signs	O
,	O
ciliostasis	O
,	O
tracheal	O
histopathology	O
,	O
and	O
antibody	B-FUNC
titers	O
in	O
serum	O
and	O
tears	O
were	O
evaluated	O
.	O

TITLE	O
:	O
Coronavirus	O
Endoribonuclease	B-FUNC
Activity	I-FUNC
in	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
Suppresses	O
Type	O
I	O
and	O
Type	O
III	O
Interferon	O
Responses	O
.	O

The	O
most	O
variable	O
part	O
of	O
the	O
S	O
gene	O
is	O
its	O
fragment	O
encoding	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
the	O
S	O
protein	O
which	O
is	O
responsible	O
for	O
receptor	B-FUNC
binding	I-FUNC
.	O

Biotinylated	O
secondary	O
antibodies	O
were	O
used	O
,	O
and	O
the	O
bound	O
primary	O
antibody	B-FUNC
was	O
visualized	O
using	O
an	O
ABC	O
amplification	O
kit	B-FUNC
.	O

Critically	O
,	O
patients	O
who	O
eventually	O
died	O
of	O
SARS	O
(	O
hereafter	O
referred	O
to	O
as	O
deceased	O
patients	O
)	O
displayed	O
similarly	O
accumulated	O
pulmonary	O
proinflammatory	O
,	O
absence	O
of	O
wound	O
-	O
healing	O
macrophages	O
,	O
and	O
faster	O
neutralizing	O
antibody	B-FUNC
responses	O
.	O

Our	O
findings	O
reveal	O
a	O
mechanism	O
responsible	O
for	O
virus	O
-	O
mediated	O
ALI	O
,	O
define	O
a	O
pathological	O
consequence	O
of	O
viral	O
specific	O
antibody	B-FUNC
response	O
,	O
and	O
provide	O
a	O
potential	O
target	O
for	O
treatment	O
of	O
SARS	O
-	O
CoV	O
or	O
other	O
virus	O
-	O
mediated	O
lung	O
injury	O
.	O

ABSTRACT	O
:	O
Synthetic	O
cannabinoids	O
(	O
SCs	B-FUNC
)	O
belong	O
to	O
the	O
group	O
of	O
new	O
psychoactive	O
substances	O
(	O
NPS	O
)	O
which	O
appear	O
sprayed	O
on	O
herbal	O
mixtures	O
on	O
the	O
""""	O
street	O
""""	O
drug	O
market	O
and	O
are	O
intended	O
for	O
smoking	O
like	O
marijuana	O
.	O

Both	O
toxicological	O
analysis	O
of	O
deceased	O
blood	O
and	O
urine	O
samples	O
and	O
chemical	O
analysis	O
of	O
the	O
herbal	O
mixture	O
seized	O
revealed	O
presence	O
of	O
two	O
SCs	B-FUNC
-	O
5F	O
-	O
ADB	O
and	O
FUB	O
-	O
AMB	O
.	O

ABSTRACT	O
:	O
The	O
main	O
immunogenic	O
protein	O
of	O
the	O
porcine	O
epidemic	O
diarrhea	O
virus	O
(	O
PEDV	O
)	O
is	O
the	O
spike	O
protein	O
(	O
S	O
protein	O
),	O
which	O
plays	O
an	O
important	O
role	O
in	O
receptor	B-FUNC
binding	I-FUNC
,	O
membrane	O
fusion	O
,	O
and	O
viral	O
invasion	O
of	O
the	O
host	O
.	O

The	O
dynamic	O
changes	O
of	O
PAP	B-FUNC
were	O
observed	O
in	O
these	O
neonates	O
.	O

RESULTS	O
:	O
Immunization	O
of	O
hDPP4	O
Tg	O
+	O
mice	O
with	O
a	O
single	O
dose	O
of	O
rAd5	O
-	O
S1	O
/	O
F	O
/	O
CD40L	O
elicited	O
as	O
robust	O
and	O
significant	O
specific	O
immunoglobulin	B-FUNC
G	O
and	O
neutralizing	O
antibodies	O
as	O
those	O
induced	O
with	O
2	O
doses	O
of	O
rAd5	O
-	O
S1	O
.	O

NS4a	O
has	O
been	O
previously	O
characterized	O
as	O
a	O
dsRNA	B-FUNC
binding	I-FUNC
protein	O
,	O
while	O
NS4b	O
is	O
a	O
2	O
',	O
5	O
'-	O
phosphodiesterase	B-FUNC
with	O
structural	O
and	O
enzymatic	O
similarity	O
to	O
NS2	O
encoded	O
by	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
).	O

Three	O
days	O
after	O
initiation	O
of	O
ECMO	O
,	O
the	O
patient	O
developed	O
jaundice	O
,	O
with	O
increase	O
of	O
bilirubin	O
,	O
Gamma	O
-	O
glutamyltransferase	O
and	O
Alkaline	O
phosphatase	B-FUNC
,	O
without	O
elevation	O
of	O
alanine	O
aminotransferase	O
and	O
INR	O
.	O

Furthermore	O
,	O
strong	O
antibody	B-FUNC
responses	O
to	O
PEDV	O
were	O
verified	O
in	O
the	O
sera	B-FUNC
and	O
colostrum	O
of	O
immunized	O
sows	O
with	O
the	O
prime	O
-	O
boost	O
treatment	O
and	O
their	O
offspring	O
.	O

An	O
overexpression	O
and	O
knockdown	O
assay	O
indicated	O
that	O
CH25H	O
has	O
significant	O
antiviral	O
action	O
against	O
PEDV	O
,	O
and	O
a	O
CH25H	O
mutant	O
(	O
CH25H	O
-	O
M	O
)	O
that	O
lacks	O
hydroxylase	B-FUNC
activity	I-FUNC
also	O
retains	O
antiviral	O
activity	O
to	O
a	O
lesser	O
extent	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
immunogenicities	O
of	O
five	O
different	O
forms	O
of	O
the	O
MERS	O
-	O
CoV	O
S	O
glycoprotein	O
were	O
compared	O
:	O
the	O
full	O
-	O
length	O
S	O
glycoprotein	O
,	O
the	O
full	O
-	O
length	O
S	O
glycoprotein	O
with	O
the	O
transmembrane	O
domain	O
of	O
the	O
G	O
glycoprotein	O
of	O
VSV	O
(	O
S	O
-	O
G	O
),	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
the	O
S	O
glycoprotein	O
,	O
the	O
membrane	O
-	O
fused	O
RBD	O
(	O
the	O
RBD	O
fused	O
with	O
the	O
transmembrane	O
domain	O
of	O
the	O
VSV	O
G	O
glycoprotein	O
(	O
RBD	O
-	O
G	O
)),	O
and	O
the	O
RBD	O
fused	O
with	O
Fc	O
of	O
human	O
IgG1	O
(	O
RBD	O
-	O
Fc	O
).	O

However	O
,	O
the	O
effects	O
of	O
VIP	O
on	O
the	O
activation	O
of	O
murine	O
fibroblast	O
and	O
expression	O
of	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
receptor	O
(	O
IL	B-FUNC
-	I-FUNC
17R	I-FUNC
)	O
in	O
ARDS	O
remain	O
unclear	O
.	O

Overlapping	O
12	O
-	O
mer	O
peptides	O
(	O
n	O
=	O
28	O
,	O
426	O
)	O
across	O
the	O
entire	O
Pp1ab	O
were	O
arrayed	O
on	O
peptide	O
chips	O
and	O
reacted	O
with	O
pooled	O
sera	B-FUNC
from	O
coronavirus	O
seropositive	O
cats	O
and	O
from	O
one	O
seronegative	O
cat	O
.	O

The	O
ceruloplasmin	B-FUNC
activity	I-FUNC
and	O
the	O
transferrin	O
saturation	O
in	O
blood	O
plasma	O
by	O
iron	O
were	O
determined	O
by	O
G	O
.	O
Babenko	O
'	O
s	O
method	O
.	O

These	O
symptoms	O
were	O
associated	O
with	O
fevers	O
,	O
and	O
24	O
hours	O
prior	O
to	O
admission	O
,	O
he	O
developed	O
intermittent	O
chest	O
pain	O
at	O
rest	B-FUNC
,	O
radiating	O
to	O
the	O
back	O
,	O
worsening	O
in	O
the	O
supine	O
position	O
.	O

In	O
this	O
study	O
,	O
a	O
total	O
of	O
190	O
faecal	O
samples	O
from	O
dairy	O
calves	O
with	O
diarrhoea	O
were	O
collected	O
from	O
14	O
farms	O
in	O
six	O
Chinese	O
provinces	O
,	O
and	O
BCoV	O
was	O
detected	O
in	O
18	O
.	O
95	O
%	O
(	O
36	O
/	O
190	O
)	O
of	O
the	O
samples	O
by	O
reverse	O
transcriptase	B-FUNC
polymerase	O
chain	O
reaction	O
.	O

Although	O
OA	O
reduced	O
SOD	B-FUNC
,	O
CAT	O
,	O
and	O
GSH	O
levels	O
in	O
lung	O
tissue	O
,	O
the	O
vitamins	O
and	O
LDMP	O
markedly	O
enhanced	O
the	O
levels	O
except	O
for	O
HDMP	O
.	O

Compared	O
with	O
the	O
survival	O
group	O
,	O
the	O
death	O
group	O
was	O
older	O
(	O
years	O
old	O
:	O
58	O
.	O
50	O
±	O
14	O
.	O
86	O
vs	O
.	O
46	O
.	O
67	O
±	O
13	O
.	O
40	O
),	O
APACHE	O
II	O
score	O
was	O
higher	O
(	O
21	O
.	O
50	O
±	O
3	O
.	O
93	O
vs	O
.	O
13	O
.	O
58	O
±	O
4	O
.	O
12	O
),	O
neutral	O
red	O
phagocytosis	O
ability	O
and	O
alkaline	B-FUNC
phosphatase	I-FUNC
activity	I-FUNC
of	O
alveolar	O
macrophages	O
were	O
significantly	O
decreased	O
(	O
A	O
value	O
:	O
0	O
.	O
265	O
±	O
0	O
.	O
050	O
vs	O
.	O
0	O
.	O
338	O
±	O
0	O
.	O
016	O
;	O
μmol	O
/	O
L	O
:	O
12	O
.	O
06	O
±	O
1	O
.	O
24	O
vs	O
.	O
17	O
.	O
96	O
±	O
3	O
.	O
90	O
),	O
and	O
the	O
length	O
of	O
ICU	O
stay	O
was	O
significantly	O
longer	O
(	O
days	O
:	O
22	O
.	O
00	O
±	O
14	O
.	O
59	O
vs	O
.	O
11	O
.	O
50	O
±	O
3	O
.	O
17	O
),	O
hospitalization	O
cost	O
was	O
significantly	O
increased	O
(	O
10	O
thousand	O
Yuan	O
:	O
24	O
.	O
17	O
±	O
11	O
.	O
02	O
vs	O
.	O
13	O
.	O
44	O
±	O
3	O
.	O
53	O
),	O
the	O
total	O
hospitalization	O
time	O
was	O
shorter	O
(	O
days	O
:	O
25	O
.	O
25	O
±	O
15	O
.	O
01	O
vs	O
.	O
35	O
.	O
67	O
±	O
8	O
.	O
58	O
),	O
and	O
the	O
difference	O
was	O
statistically	O
significant	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
).	O

The	O
expression	O
of	O
nucleotide	O
-	O
binding	B-FUNC
oligomerization	O
domain	O
containing	O
2	O
(	O
Nod2	O
),	O
type	O
I	O
interferons	O
,	O
(	O
IFNs	O
),	O
and	O
proinflammatory	O
mediators	O
was	O
enhanced	O
in	O
S	O
RBD	O
-	O
HBD	O
2	O
-	O
treated	O
THP	O
-	O
1	O
cells	O
.	O

Analysis	O
of	O
sera	B-FUNC
absorption	O
and	O
isolated	O
monoclonal	O
antibodies	O
from	O
immunized	O
mice	O
demonstrated	O
that	O
the	O
potent	O
and	O
broad	O
neutralizing	O
activity	O
was	O
largely	O
attributed	O
to	O
antibodies	O
targeting	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
)	O
of	O
the	O
S	O
protein	O
.	O

Herein	O
,	O
we	O
generated	O
a	O
bacterial	O
outer	O
membrane	O
vesicles	O
(	O
OMVs	O
)-	O
based	O
vaccine	O
presenting	O
the	O
antigenic	O
stable	O
chimeric	O
fusion	O
protein	O
of	O
the	O
H1	O
-	O
type	O
haemagglutinin	O
(	O
HA	O
)	O
of	O
the	O
pandemic	O
influenza	O
A	O
virus	O
(	O
H1N1	O
)	O
strain	O
from	O
2009	O
(	O
H1N1pdm09	O
)	O
and	O
the	O
receptor	B-FUNC
binding	I-FUNC
domain	O
(	O
RBD	O
)	O
of	O
the	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
(	O
OMVs	O
-	O
H1	O
/	O
RBD	O
).	O

We	O
show	O
that	O
the	O
ligand	B-FUNC
binds	B-FUNC
with	O
fast	B-FUNC
kinetics	O
to	O
a	O
surface	O
-	O
exposed	O
groove	O
and	O
that	O
interactions	O
at	O
the	O
identified	O
site	O
are	O
essential	O
for	O
S	O
-	O
mediated	O
viral	O
entry	O
into	O
host	O
cells	O
,	O
but	O
free	O
monosaccharide	O
does	O
not	O
trigger	O
fusogenic	O
conformational	O
changes	O
.	O

In	O
addition	O
to	O
the	O
suppression	O
of	O
lung	O
-	O
infiltrated	O
immune	O
cells	O
,	O
MSCs	B-FUNC
have	O
potential	O
to	O
differentiate	O
into	O
alveolar	O
epithelial	O
cells	O

All	O
samples	O
were	O
tested	O
for	O
influenza	O
viruses	O
,	O
whereas	O
about	O
38	O
,	O
000	O
samples	O
were	O
tested	O
for	O
influenza	O
and	O
a	O
panel	O
of	O
respiratory	O
viruses	O
using	O
Fast	B-FUNC
Track	O
Diagnostics	O
(	O
FTD	O
)	O
RT	O
-	O
PCR	O
kit	B-FUNC
.	O

Chicken	O
sera	B-FUNC
were	O
screened	O
for	O
anti	O
-	O
NDV	O
antibodies	O
by	O
ELISA	O
.	O

The	O
increased	O
antibody	B-FUNC
was	O
capable	O
of	O
neutralizing	O
NDV	O
and	O
IBV	O
.	O

AAV	O
-	O
Pck2	O
overexpression	O
in	O
leg	O
muscles	O
of	O
male	O
C57BL6	O
/	O
J	O
mice	O
for	O
4	O
weeks	O
(	O
6	O
-	O
10	O
weeks	O
of	O
age	O
)	O
increased	O
Pck2	O
mRNA	O
(~	O
100	O
-	O
fold	O
),	O
protein	O
(	O
not	O
quantifiable	O
)	O
and	O
enzyme	B-FUNC
activity	I-FUNC
(~	O
3	O
-	O
fold	O
).	O

Fraxin	O
might	O
increase	O
the	O
superoxide	O
dismutase	O
(	O
SOD	B-FUNC
)	O
activity	O
to	O
avoid	O
oxidative	O
damage	O
.	O

Receptor	B-FUNC
binding	I-FUNC
induces	O
the	O
membrane	O
-	O
binding	B-FUNC
potential	O
of	O
the	O
trimer	O
,	O
in	O
which	O
at	O
least	O
one	O
HR	O
motif	O
forms	O
a	O
packed	O
-	O
hairpin	O
structure	O
,	O
while	O
membrane	O
fusion	O
subunits	O
are	O
covered	O
by	O
the	O
receptor	O
-	O
binding	B-FUNC
subunit	O
,	O
thereby	O
preventing	O
the	O
spike	O
protein	O
from	O
forming	O
the	O
typical	O
homotrimeric	O
prehairpin	O
structure	O
predicted	O
by	O
the	O
current	O
model	O
of	O
class	O
I	O
viral	O
fusion	O
protein	O
.	O

Here	O
,	O
we	O
designed	O
recombinant	O
replication	O
-	O
deficient	O
adenovirus	O
-	O
based	O
vaccines	O
expressing	O
the	O
N	O
-	O
terminal	O
domain	O
(	O
rAd	O
/	O
NTD	O
)	O
and	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
rAd	O
/	O
RBD	O
)	O
of	O
the	O
MERS	O
-	O
CoV	O
S1	O
subunit	O
and	O
full	O
-	O
length	O
Spike	O
protein	O
(	O
rAd	O
/	O
Spike	O
).	O

Mechanism	O
studies	O
demonstrated	O
that	O
these	O
title	O
triterpenoids	O
could	O
bind	B-FUNC
tightly	O
to	O
the	O
viral	O
envelope	O
HA	O
to	O
block	O
the	O
attachment	O
of	O
viruses	O
to	O
host	O
cells	O
,	O
which	O
was	O
consistent	O
with	O
docking	O
studies	O
.	O

Interestingly	O
,	O
site	O
-	O
directed	O
mutagenesis	O
found	O
that	O
PDCoV	O
nsp15	O
mutants	O
(	O
H129A	O
,	O
H234A	O
,	O
K269A	O
)	O
lacking	O
endoribonuclease	B-FUNC
activity	I-FUNC
also	O
suppress	O
SEV	O
-	O
induced	O
IFN	O
-	O
β	O
production	O
and	O
NF	O
-	O
κB	O
activation	O
,	O
suggesting	O
that	O
the	O
endoribonuclease	B-FUNC
activity	I-FUNC
is	O
not	O
required	O
for	O
its	O
ability	O
to	O
antagonize	O
IFN	O
-	O
β	O
production	O
.	O

The	O
binding	B-FUNC
mode	O
of	O
the	O
shortlisted	O
peptides	O
was	O
measured	O
based	O
on	O
the	O
number	O
of	O
clusters	O
which	O
forms	O
in	O
a	O
protein	O
-	O
peptide	O
docking	O
using	O
Piper	O
.	O

We	O
conclude	O
that	O
seven	O
peptides	O
,	O
namely	O
,	O
AP00225	O
,	O
AP00180	O
,	O
AP00549	O
,	O
AP00744	O
,	O
AP00729	O
,	O
AP00764	O
,	O
and	O
AP00223	O
,	O
could	O
possibly	O
have	O
binding	B-FUNC
with	O
the	O
active	O
site	O
of	O
the	O
MERS	O
-	O
CoV	O
spike	O
protein	O
.	O

TITLE	O
:	O
Glycine	O
29	O
Is	O
Critical	O
for	O
Conformational	O
Changes	O
of	O
the	O
Spike	O
Glycoprotein	O
of	O
Mouse	O
Hepatitis	O
Virus	O
A59	O
Triggered	O
by	O
either	O
Receptor	B-FUNC
Binding	I-FUNC
or	O
High	O
pH	O
.	O
ABSTRACT	O
:	O
Mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
uses	O
its	O
N	O
-	O
terminal	O
domain	O
(	O
NTD	O
)	O
of	O
the	O
viral	O
spike	O
(	O
S	O
)	O
protein	O
to	O
bind	B-FUNC
the	O
host	O
receptor	O
mouse	O
carcinoembryonic	O
antigen	O
-	O
related	O
cell	O
adhesion	O
molecule	O
1a	O
(	O
mCEACAM1a	O
)	O
and	O
mediate	O
virus	O
entry	O
.	O

In	O
contrast	O
,	O
replacement	O
of	O
G29	O
with	O
P	O
,	O
a	O
turn	O
-	O
prone	O
residue	O
with	O
a	O
strict	O
conformation	O
,	O
hindered	O
virus	O
entry	O
and	O
conformational	O
changes	O
of	O
the	O
S	O
protein	O
triggered	O
by	O
either	O
receptor	B-FUNC
binding	I-FUNC
or	O
pH	O
8	O
.	O
0	O
,	O
suggesting	O
that	O
the	O
structural	O
turn	O
around	O
G29	O
and	O
its	O
flexibility	O
are	O
critical	O
.	O

Besides	O
,	O
the	O
immune	O
responses	O
and	O
potential	O
antibody	B-FUNC
dependent	O
enhancement	O
of	O
MERS	O
-	O
CoV	O
infection	O
are	O
extensively	O
reviewed	O
.	O

In	O
addition	O
,	O
ORF8b	O
also	O
strongly	O
inhibits	O
Tank	O
-	O
binding	B-FUNC
kinase	O
1	O
(	O
TBK1	B-FUNC
)-	O
mediated	O
induction	O
of	O
NF	O
-	O
κB	O
signaling	O
.	O

Serum	O
lactate	O
,	O
aspartate	O
transaminase	O
(	O
AST	O
)	O
and	O
alanine	O
transaminase	O
(	O
ALT	B-FUNC
)	O
were	O
significantly	O
elevated	O
among	O
non	O
survivors	O
.	O

According	O
to	O
western	O
blots	O
,	O
serum	O
antibody	B-FUNC
interactions	O
with	O
the	O
S1	O
protein	O
were	O
relatively	O
more	O
sensitive	O
and	O
specific	O
than	O
ORF3C	O
,	O
E	O
and	O
Ac	O
.	O

Keywords	O
:	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
);	O
live	O
L	O
.	O
acidophilus	O
oral	O
vaccine	O
;	O
SIgA	O
antibody	B-FUNC
;	O
IgG	O
antibody	B-FUNC
;	O
IFN	O
-	O
γ	O
;	O
IL	B-FUNC
-	I-FUNC
4	I-FUNC
.	O

Hexokinase	O
2	O
(	O
HK2	B-FUNC
)	O
and	O
interleukin	O
6	O
(	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
)	O
were	O
identified	O
as	O
the	O
targets	O
of	O
miR	O
-	O
22	O
.	O

We	O
also	O
use	O
deletion	O
mapping	O
to	O
identify	O
a	O
151	O
-	O
nt	O
region	O
within	O
the	O
packaging	O
signal	O
sequence	O
that	O
is	O
critical	O
for	O
N	O
-	O
protein	O
-	O
RNA	B-FUNC
binding	I-FUNC
,	O
and	O
conversely	O
,	O
we	O
show	O
that	O
both	O
the	O
N	O
-	O
terminal	O
and	O
C	O
-	O
terminal	O
domains	O
of	O
the	O
N	O
protein	O
are	O
necessary	O
for	O
recognizing	O
the	O
packaging	O
RNA	O
.	O

The	O
purified	O
SΔTM	O
forms	O
small	O
nanoparticles	O
as	O
well	O
as	O
the	O
full	O
-	O
length	O
S	O
protein	O
and	O
has	O
the	O
ability	O
to	O
bind	B-FUNC
human	O
dipeptidyl	O
peptidase	O
4	O
(	O
DPP4	O
),	O
which	O
is	O
a	O
receptor	O
of	O
MERS	O
-	O
CoV	O
.	O
These	O
results	O
indicate	O
that	O
bioactive	O
SΔTM	O
was	O
expressed	O
in	O
silkworm	O
larvae	O
.	O

ABSTRACT	O
:	O
The	O
well	O
-	O
known	O
immunosuppressive	O
drug	O
cyclosporin	O
A	O
inhibits	O
replication	O
of	O
various	O
viruses	O
including	O
coronaviruses	O
by	O
binding	B-FUNC
to	O
cellular	O
cyclophilins	O
thus	O
inactivating	O
their	O
cis	O
-	O
trans	O
peptidyl	O
-	O
prolyl	O
isomerase	O
function	O
.	O

TITLE	O
:	O
The	O
human	O
coronavirus	O
HCoV	O
-	O
229E	O
S	O
-	O
protein	O
structure	O
and	O
receptor	B-FUNC
binding	I-FUNC
.	O

TITLE	O
:	O
Protostemonine	O
alleviates	O
heat	O
-	O
killed	O
methicillin	O
-	O
resistant	O
Staphylococcus	O
aureus	O
-	O
induced	O
acute	O
lung	O
injury	O
through	O
MAPK	B-FUNC
and	O
NF	O
-	O
κB	O
signaling	O
pathways	O
.	O

PSN	O
treatment	O
significantly	O
attenuated	O
HKMRSA	O
-	O
induced	O
pathological	O
injury	O
,	O
pulmonary	O
neutrophil	O
infiltration	O
,	O
tissue	O
permeability	O
and	O
the	O
production	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
(	O
TNF	O
-	O
α	O
,	O
IL	O
-	O
1β	O
and	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
)	O
in	O
murine	O
ALI	O
model	O
.	O

ABSTRACT	O
:	O
Described	O
herein	O
is	O
a	O
new	O
approach	O
to	O
mitigate	O
CYP3A4	B-FUNC
induction	O
.	O

In	O
this	O
unconventional	O
approach	O
,	O
a	O
fine	O
-	O
tuning	O
of	O
the	O
dihedral	O
angle	O
between	O
the	O
C4	O
phenyl	O
and	O
the	O
dihydropyrimidine	O
core	O
of	O
the	O
heteroaryldihydropyrimidine	O
(	O
HAP	O
)	O
class	O
of	O
capsid	O
inhibitors	O
successfully	O
altered	O
the	O
structure	O
-	O
activity	O
-	O
relationships	O
(	O
SARs	O
)	O
of	O
the	O
unwanted	O
CYP3A4	B-FUNC
induction	O
and	O
the	O
desired	O
HBV	O
capsid	O
inhibition	O
to	O
more	O
favorable	O
values	O
.	O

TITLE	O
:	O
Engineering	O
a	O
Novel	O
Antibody	B-FUNC
-	O
Peptide	O
Bispecific	O
Fusion	O
Protein	O
Against	O
MERS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
In	O
recent	O
years	O
,	O
tremendous	O
efforts	O
have	O
been	O
made	O
in	O
the	O
engineering	O
of	O
bispecific	O
or	O
multi	O
-	O
specific	O
antibody	B-FUNC
-	O
based	O
therapeutics	O
by	O
combining	O
two	O
or	O
more	O
functional	O
antigen	O
-	O
recognizing	O
elements	O
into	O
a	O
single	O
construct	O
.	O

We	O
found	O
that	O
one	O
of	O
these	O
fusion	O
proteins	O
,	O
designated	O
as	O
m336	O
diabody	O
-	O
pep	O
,	O
exhibited	O
more	O
potent	O
inhibitory	O
activity	O
than	O
the	O
antibody	B-FUNC
or	O
the	O
peptide	O
alone	O
against	O
pseudotyped	O
MERS	O
-	O
CoV	O
infection	O
and	O
MERS	O
-	O
CoV	O
S	O
protein	O
-	O
mediated	O
cell	O
-	O
cell	O
fusion	O
,	O
suggesting	O
its	O
potential	O
to	O
be	O
developed	O
as	O
an	O
effective	O
bispecific	O
immunotherapeutic	O
for	O
clinical	O
use	O
.	O

Further	O
,	O
we	O
found	O
that	O
chemically	O
inhibiting	O
or	O
activating	O
AhR	O
reciprocally	O
modulated	O
the	O
expression	O
levels	O
of	O
cytokines	O
induced	O
by	O
infection	O
,	O
specifically	O
,	O
interleukin	O
1β	O
(	O
IL	O
-	O
1β	O
),	O
IL	B-FUNC
-	I-FUNC
10	I-FUNC
,	O
and	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
alpha	O
(	O
TNF	O
-	O
α	O
),	O
consistent	O
with	O
a	O
role	O
for	O
AhR	O
activation	O
in	O
the	O
host	O
response	O
to	O
MHV	O
infection	O
.	O

According	O
to	O
the	O
management	O
suggestions	O
of	O
the	O
American	O
Centers	O
of	O
Disease	O
Control	O
,	O
uses	O
of	O
corticosteroids	O
and	O
plasmapheresis	O
are	O
either	O
preferred	O
or	O
avoided	O
and	O
intravenous	O
immunoglobulin	B-FUNC
also	O
has	O
no	O
clear	O
indication	O
in	O
the	O
treatment	O
for	O
acute	O
flaccid	O
myelitis	O
.	O

TITLE	O
:	O
Molecular	O
Basis	O
of	O
Binding	B-FUNC
between	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
and	O
CD26	O
from	O
Seven	O
Bat	O
Species	O
.	O

Vaccination	O
against	O
influenza	O
will	O
lead	O
to	O
lower	O
infection	O
rates	O
and	O
fewer	O
complications	O
,	O
even	O
if	O
the	O
vaccine	O
is	O
poorly	O
matched	O
to	O
circulating	O
viral	O
strains	O
,	O
with	O
maternal	O
vaccination	O
offering	O
infants	O
protection	O
via	O
antibody	B-FUNC
transmission	O
through	O
the	O
placenta	O
and	O
breast	O
milk	O
.	O

Infections	O
are	O
initiated	O
via	O
binding	B-FUNC
of	O
the	O
MERS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
glycoprotein	O
to	O
sialosides	O
and	O
dipeptidyl	O
-	O
peptidase	O
4	O
(	O
the	O
attachment	O
and	O
entry	O
receptors	O
,	O
respectively	O
).	O

Docking	O
and	O
site	O
-	O
directed	O
mutagenesis	O
studies	O
have	O
suggested	O
that	O
compound	O
5	O
binds	B-FUNC
to	O
a	O
previously	O
described	O
HIV	O
-	O
1	O
IN	O
allosteric	O
pocket	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
how	O
a	O
neutralizing	O
monoclonal	O
antibody	B-FUNC
(	O
MAb	O
),	O
which	O
targets	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)	O
coronavirus	O
spike	O
,	O
mediates	O
viral	O
entry	O
using	O
pseudovirus	O
entry	O
and	O
biochemical	O
assays	O
.	O

TITLE	O
:	O
Crystallization	O
and	O
Structural	O
Determination	O
of	O
the	O
Receptor	O
-	O
Binding	B-FUNC
Domain	O
of	O
MERS	O
-	O
CoV	O
Spike	O
Glycoprotein	O
.	O

In	O
this	O
chapter	O
,	O
we	O
describe	O
the	O
isolation	O
,	O
amplification	O
,	O
and	O
titration	O
of	O
MERS	O
-	O
CoV	O
,	O
as	O
well	O
as	O
detailed	O
MN	O
assay	O
to	O
measure	O
nAb	O
levels	O
in	O
sera	B-FUNC
from	O
different	O
mammalian	O
species	O
.	O

In	O
this	O
chapter	O
,	O
we	O
describe	O
a	O
validated	O
and	O
optimized	O
indirect	O
ELISA	O
protocol	O
based	O
on	O
recombinant	O
S1	O
subunit	O
(	O
amino	O
acids	O
1	O
-	O
725	O
)	O
of	O
MERS	O
-	O
CoV	O
for	O
qualitative	O
and	O
quantitative	O
determination	O
of	O
MERS	O
-	O
CoV	O
-	O
binding	B-FUNC
antibodies	O
.	O

Lnc	O
-	O
MALAT1	O
expression	O
was	O
positively	O
correlated	O
with	O
APACHE	O
II	O
score	O
,	O
SOFA	O
score	O
,	O
and	O
inflammatory	O
factors	O
levels	O
including	O
C	O
-	O
reactive	O
protein	O
,	O
procalcitonin	O
,	O
TNF	O
-	O
α	O
,	O
IL	O
-	O
1β	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
and	O
IL	B-FUNC
-	I-FUNC
17	I-FUNC
.	O

Moreover	O
,	O
a	O
cell	O
-	O
mediated	O
immune	O
response	O
was	O
promoted	O
in	O
immunized	O
mice	O
,	O
and	O
the	O
neutralizing	O
antibody	B-FUNC
inhibited	O
both	O
the	O
vaccine	O
strain	O
and	O
the	O
emerging	O
PEDV	O
isolate	O
.	O

Of	O
67	O
patients	O
with	O
A	O
(	O
H7N9	O
)	O
virus	O
infection	O
,	O
HAI	O
antibody	B-FUNC
titers	O
reached	O
40	O
on	O
average	O
11	O
days	O
after	O
illness	O
onset	O
and	O
peaked	O
at	O
a	O
titer	O
of	O
290	O
after	O
three	O
months	O
,	O
and	O
average	O
titers	O
of	O
≥	O
80	O
and	O
≥	O
40	O
were	O
present	O
until	O
11	O
months	O
and	O
22	O
months	O
respectively	O
.	O

In	O
silico	O
molecular	O
docking	O
of	O
the	O
most	O
potent	O
compounds	O
was	O
performed	O
to	O
the	O
active	O
binding	B-FUNC
site	O
of	O
MERS	O
-	O
CoV	O
helicase	O
nsp13	O
.	O

For	O
the	O
29	O
serum	O
samples	O
from	O
Bactrian	O
camels	O
in	O
Dubai	O
tested	O
by	O
the	O
MERS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
-	O
based	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
S	O
-	O
ELISA	O
)	O
and	O
neutralization	O
antibody	B-FUNC
test	O
,	O
14	O
(	O
48	O
%)	O
and	O
12	O
(	O
41	O
%),	O
respectively	O
,	O
were	O
positive	O
for	O
MERS	O
-	O
CoV	O
antibodies	O
.	O

For	O
the	O
11	O
sera	B-FUNC
from	O
hybrid	O
camels	O
in	O
Dubai	O
tested	O
with	O
the	O
S	O
-	O
ELISA	O
and	O
neutralization	O
antibody	B-FUNC
test	O
,	O
6	O
(	O
55	O
%)	O
and	O
9	O
(	O
82	O
%),	O
respectively	O
,	O
were	O
positive	O
for	O
MERS	O
-	O
CoV	O
antibodies	O
.	O

In	O
addition	O
,	O
dual	O
-	O
luciferase	O
reporter	O
assays	O
revealed	O
that	O
ubiquitin	B-FUNC
-	O
specific	O
protease	O
47	O
(	O
USP47	O
),	O
a	O
deubiquitinase	B-FUNC
-	O
encoding	O
gene	O
,	O
was	O
a	O
target	O
for	O
gga	O
-	O
miR	O
-	O
30d	O
.	O

Importantly	O
,	O
structural	O
analysis	O
suggests	O
that	O
2019	O
-	O
nCoV	O
might	O
be	O
able	O
to	O
bind	B-FUNC
to	O
the	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
receptor	O
in	O
humans	O
.	O

Positive	O
immunoglobulin	B-FUNC
M	O
antibodies	O
for	O
EBV	O
were	O
supportive	O
of	O
an	O
acute	O
EBV	O
infection	O
,	O
which	O
was	O
the	O
most	O
probable	O
trigger	O
of	O
HLH	O
.	O

The	O
recently	O
characterized	O
E	O
protein	O
ion	B-FUNC
channel	I-FUNC
activity	I-FUNC
(	O
EIC	O
)	O
has	O
also	O
been	O
implicated	O
in	O
modulating	O
viral	O
pathogenesis	O
.	O

ABSTRACT	O
:	O
The	O
novel	O
coronavirus	O
pneumonia	O
(	O
NCP	B-FUNC
)	O
continues	O
to	O
spread	O
throughout	O
the	O
country	O
,	O
and	O
the	O
prevention	O
and	O
control	O
of	O
the	O
epidemic	O
has	O
entered	O
a	O
critical	O
period	O
.	O

ABSTRACT	O
:	O
Since	O
December	O
2019	O
,	O
an	O
epidemic	O
of	O
novel	O
coronavirus	O
pneumonia	O
(	O
NCP	B-FUNC
)	O
has	O
occurred	O
in	O
China	O
.	O

ABSTRACT	O
:	O
The	O
New	O
Coronavirus	O
Pneumonia	O
(	O
NCP	B-FUNC
,	O
also	O
named	O
as	O
COVID	O
-	O
19	O
by	O
WHO	O
on	O
Feb	O
11	O
2020	O
,	O
is	O
now	O
causing	O
a	O
severe	O
public	O
health	O
emergency	O
in	O
China	O
since	O
.	O

Combination	O
of	O
Ribavirin	O
and	O
Interferon	O
-	O
α	O
is	O
recommended	O
by	O
the	O
5	O
(	O
th	O
)	O
edition	O
National	O
Health	O
Commission	O
'	O
s	O
Regimen	O
(	O
Revised	O
Edition	O
)	O
because	O
of	O
the	O
effect	O
on	O
MERS	O
(	O
Middle	O
East	O
Respiratory	O
Syndrome	O
),	O
and	O
the	O
effectiveness	O
of	O
Lopinavir	O
/	O
Ritonavir	O
and	O
Remdisivir	O
needs	O
to	O
be	O
confirmed	O
by	O
randomized	O
controlled	O
trial	O
(	O
RCT	O
),	O
given	O
the	O
situation	O
of	O
no	O
specific	O
antivirus	O
drug	O
on	O
NCP	B-FUNC
is	O
unavailable	O
.	O

ABSTRACT	O
:	O
Through	O
literature	O
review	O
and	O
group	O
discussion	O
,	O
Special	O
Expert	O
Group	O
for	O
Control	O
of	O
the	O
Epidemic	O
of	O
Novel	O
Coronavirus	O
Pneumonia	O
of	O
the	O
Chinese	O
Preventive	O
Medicine	O
Association	O
formulated	O
an	O
update	O
on	O
the	O
epidemiological	O
characteristics	O
of	O
novel	O
coronavirus	O
pneumonia	O
(	O
NCP	B-FUNC
).	O

ABSTRACT	O
:	O
Novel	O
coronavirus	O
pneumonia	O
(	O
NCP	B-FUNC
)	O
is	O
a	O
highly	O
infectious	O
disease	O
,	O
has	O
a	O
long	O
incubation	O
period	O
and	O
a	O
variety	O
of	O
clinical	O
manifestations	O
,	O
which	O
has	O
a	O
significant	O
impact	O
on	O
public	O
health	O
and	O
life	O
.	O

Functional	O
neutralizing	O
antibodies	O
were	O
not	O
stimulated	O
as	O
often	O
as	O
binding	B-FUNC
antibodies	O
,	O
explaining	O
in	O
part	O
a	O
susceptibility	O
to	O
reinfection	O
with	O
HCoV	O
.	O
Monitoring	O
binding	B-FUNC
antibodies	O
may	O
be	O
more	O
sensitive	O
for	O
the	O
serologic	O
detection	O
of	O
HCoV	O
infections	O
.	O

As	O
surgeons	O
specialized	O
in	O
the	O
treatment	O
of	O
gastrointestinal	O
tumors	O
,	O
we	O
should	O
always	O
be	O
aware	O
of	O
the	O
prevention	O
for	O
NCP	B-FUNC
and	O
incorporate	O
this	O
awareness	O
into	O
every	O
detail	O
of	O
clinical	O
practice	O
.	O

We	O
believe	O
that	O
with	O
the	O
unprecedentedly	O
joint	O
efforts	O
of	O
doctors	O
and	O
patients	O
,	O
we	O
will	O
eventually	O
win	O
this	O
war	O
against	O
NCP	B-FUNC
.	O

For	O
patients	O
who	O
need	O
breathing	O
support	O
during	O
transportation	O
,	O
placing	O
an	O
HME	B-FUNC
between	O
ventilator	O
and	O
patient	O
;	O
(	O
10	O
)	O
PSV	O
is	O
recommended	O
for	O
implementing	O
spontaneous	O
breathing	O
trial	O
(	O
SBT	O
),	O
avoid	O
using	O
T	O
-	O
piece	O
to	O
do	O
SBT	O
.	O

TITLE	O
:	O
[	O
Technologies	O
and	O
requirements	O
of	O
protection	O
and	O
disinfection	O
in	O
key	O
places	O
during	O
the	O
novel	O
coronavirus	O
pneumonia	O
(	O
NCP	B-FUNC
)	O
outbreak	O
].	O

This	O
study	O
could	O
provide	O
reference	O
for	O
rapid	O
response	O
and	O
emergency	O
management	O
for	O
the	O
prevention	O
and	O
control	O
of	O
NCP	B-FUNC
in	O
the	O
departments	O
of	O
stomatology	O
.	O

For	O
selective	O
pressure	O
analysis	O
fast	B-FUNC
-	O
unconstrained	O
Bayesian	O
approximation	O
(	O
FUBAR	O
)	O
was	O
used	O
.	O

(	O
2	O
)	O
Colonoscopy	O
examination	O
may	O
cause	O
cross	O
infection	O
of	O
NCP	B-FUNC
to	O
patients	O
and	O
doctors	O
.	O

We	O
will	O
share	O
the	O
treatment	O
experience	O
of	O
severe	O
NCP	B-FUNC
with	O
the	O
first	O
-	O
line	O
treatment	O
experience	O
.	O

Pretreatment	O
of	O
HNE	O
and	O
HTE	O
cells	O
with	O
glycopyrronium	O
or	O
formoterol	O
decreased	O
viral	O
RNA	O
levels	O
and	O
/	O
or	O
titers	O
,	O
the	O
expression	O
of	O
the	O
HCoV	O
-	O
229E	O
receptor	O
CD13	O
,	O
the	O
number	O
and	O
fluorescence	O
intensity	O
of	O
acidic	O
endosomes	O
where	O
HCoV	O
-	O
229E	O
RNA	O
enters	O
the	O
cytoplasm	O
,	O
and	O
the	O
infection	O
-	O
induced	O
production	O
of	O
cytokines	O
,	O
including	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
IL	B-FUNC
-	I-FUNC
8	I-FUNC
,	O
and	O
IFN	O
-	O
β	O
.	O

Twenty	O
-	O
one	O
common	O
-	O
type	O
and	O
nine	O
severe	O
-	O
type	O
NCP	B-FUNC
patients	O
were	O
enrolled	O
.	O

Lopinavir	O
(	O
LPV	O
)	O
is	O
an	O
effective	O
agent	O
that	O
inhibits	O
the	O
protease	B-FUNC
activity	I-FUNC
of	O
coronavirus	O
.	O

For	O
all	O
the	O
other	O
types	O
of	O
NCP	B-FUNC
,	O
the	O
lesion	O
was	O
in	O
the	O
right	O
upper	O
lobe	O
in	O
30	O
cases	O
,	O
right	O
middle	O
lobe	O
in	O
22	O
,	O
right	O
lower	O
lobe	O
in	O
39	O
,	O
left	O
upper	O
lobe	O
in	O
33	O
and	O
left	O
lower	O
lobe	O
in	O
36	O
.	O

ABSTRACT	O
:	O
In	O
December	O
2019	O
,	O
the	O
2019	O
novel	O
coronavirus	O
pneumonia	O
(	O
NCP	B-FUNC
,	O
officially	O
named	O
Coronavirus	O
Disease	O
2019	O
(	O
COVID	O
-	O
19	O
)	O
by	O
the	O
World	O
Health	O
Organization	O
)	O
broke	O
out	O
in	O
Wuhan	O
,	O
Hubei	O
,	O
and	O
it	O
quickly	O
spread	O
to	O
the	O
whole	O
country	O
and	O
abroad	O
.	O

Vehicle	O
,	O
nafithromycin	O
(	O
100	O
mg	O
/	O
kg	O
),	O
azithromycin	O
(	O
600	O
mg	O
/	O
kg	O
)	O
and	O
dexamethasone	O
(	O
20	O
mg	O
/	O
kg	O
)	O
were	O
administered	O
orally	O
,	O
1	O
h	O
prior	O
to	O
LPS	O
challenge	O
and	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
fluid	O
was	O
collected	O
thereafter	O
at	O
18	O
,	O
24	O
and	O
48	O
h	O
to	O
determine	O
the	O
total	O
cell	O
count	O
,	O
total	O
protein	O
,	O
myeloperoxidase	O
(	O
MPO	B-FUNC
),	O
tumor	B-FUNC
necrosis	I-FUNC
factor	I-FUNC
(	O
TNF	O
)-	O
α	O
and	O
interleukin	O
(	O
IL	O
)-	O
6	O
.	O

TITLE	O
:	O
Improved	O
molecular	O
diagnosis	O
of	O
COVID	O
-	O
19	O
by	O
the	O
novel	O
,	O
highly	O
sensitive	O
and	O
specific	O
COVID	O
-	O
19	O
-	O
RdRp	B-FUNC
/	O
Hel	O
real	O
-	O
time	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
assay	O
validated	O
ABSTRACT	O
:	O
On	O
31	O

Here	O
,	O
we	O
summarize	O
the	O
potential	O
monoclonal	O
antibody	B-FUNC
based	O
therapeutic	O
intervention	O
for	O
COVID	O
-	O
19	O
by	O
considering	O
the	O
existing	O
knowledge	O
on	O
the	O
neutralizing	O
monoclonal	O
antibodies	O
against	O
similar	O
coronaviruses	O
SARS	O
-	O
CoV	O
and	O
MERS	O
-	O
CoV	O
.	O
Further	O
research	O
on	O
COVID	O
-	O
19	O
pathogenesis	O
could	O
identify	O
appropriate	O
therapeutic	O
targets	O
to	O
develop	O
specific	O
anti	O
-	O
virals	O
against	O
this	O
newly	O
emerging	O
pathogen	O
.	O

The	O
respondents	O
who	O
had	O
low	O
trust	O
in	O
the	O
government	O
had	O
higher	O
affective	O
(	O
aOR	B-FUNC
2	O
.	O
19	O
-	O
3	O
.	O
11	O
;	O
95	O
CI	O
1	O
.	O
44	O
to	O
4	O
.	O
67	O
)	O
and	O
cognitive	O
(	O
aOR	B-FUNC
3	O
.	O
55	O
-	O
5	O
.	O
41	O
;	O
95	O
CI	O
1	O
.	O
44	O
to	O
9	O
.	O
01	O
)	O
risk	O
perceptions	O
.	O

The	O
respondents	O
who	O
had	O
low	O
trust	O
in	O
the	O
government	O
had	O
higher	O
affective	O
(	O
aOR	B-FUNC
2	O
.	O
19	O
-	O
3	O
.	O
11	O
;	O
95	O
CI	O
1	O
.	O
44	O
to	O
4	O
.	O
67	O
)	O
and	O
cognitive	O
(	O
aOR	B-FUNC
3	O
.	O
55	O
-	O
5	O
.	O
41	O
;	O
95	O
CI	O
1	O
.	O
44	O
to	O
9	O
.	O
01	O
)	O
risk	O
perceptions	O
.	O

Finally	O
,	O
we	O
show	O
that	O
the	O
sera	B-FUNC
from	O
convalescent	O
SARS	O
patients	O
cross	O
-	O
neutralized	O
SARS	O
-	O
2	O
-	O
S	O
-	O
driven	O
entry	O
.	O

ABSTRACT	O
:	O
Since	O
the	O
middle	O
of	O
December	O
2019	O
,	O
human	O
-	O
to	O
-	O
human	O
transmission	O
of	O
novel	O
coronavirus	O
pneumonia	O
(	O
NCP	B-FUNC
)	O
has	O
occurred	O
among	O
close	O
contacts	O
.	O

This	O
is	O
most	O
evident	O
for	O
antibodies	O
targeting	O
cancer	O
cells	O
inducing	O
antibody	B-FUNC
-	O
dependent	O
killing	O
or	O
phagocytosis	O
but	O
is	O
also	O
true	O
to	O
some	O
degree	O
for	O
the	O
mAbs	O
that	O
neutralise	O
or	O
remove	O
small	O
macromolecules	O
such	O
as	O
cytokines	O
or	O
other	O
immunoglobulins	O
.	O

Chest	O
computed	O
tomography	O
offers	O
fast	B-FUNC
and	O
convenient	O
evaluation	O
of	O
patients	O
with	O
suspected	O
2019	O
-	O
novel	O
coronavirus	O
pneumonia	O
.	O

TITLE	O
:	O
Hypothesis	O
:	O
angiotensin	O
-	O
converting	O
enzyme	B-FUNC
inhibitors	I-FUNC
and	O
angiotensin	O
receptor	O
blockers	O
may	O
increase	O
the	O
risk	O
of	O
severe	O
COVID	O
-	O
19	O
.	O

More	O
importantly	O
,	O
conventional	O
assays	O
rely	O
on	O
simple	O
Ab	O
-	O
antigen	B-FUNC
binding	I-FUNC
assays	O
,	O
which	O
may	O
not	O
result	O
in	O
identifying	O
the	O
most	O
potent	O
nAbs	O
,	O
as	O
the	O
strongest	O
binder	O
may	O
not	O
be	O
the	O
most	O
potent	O
nAb	O
.	O

We	O
here	O
aim	O
to	O
describe	O
the	O
time	O
kinetics	O
of	O
various	O
antibodies	O
produced	O
against	O
the	O
2019	O
novel	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
-	O
2	O
)	O
and	O
evaluate	O
the	O
potential	O
of	O
antibody	B-FUNC
testing	O
to	O
diagnose	O
COVID	O
-	O
19	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
characteristics	O
and	O
clinical	O
value	O
of	O
chest	O
computed	O
tomography	O
(	O
CT	O
)	O
images	O
of	O
novel	O
coronavirus	O
pneumonia	O
(	O
NCP	B-FUNC
).	O

TITLE	O
:	O
Characterization	O
of	O
the	O
receptor	O
-	O
binding	B-FUNC
domain	O
(	O
RBD	O
)	O
of	O
2019	O
novel	O
coronavirus	O
:	O
implication	O
for	O
development	O
of	O
RBD	O
protein	O
as	O
a	O
viral	O
attachment	O
inhibitor	O
and	O
vaccine	O
.	O

RESULTS	O
:	O
LH	O
significantly	O
inhibited	O
SARS	O
-	O
CoV	O
-	O
2	O
replication	O
in	O
Vero	O
E6	O
cells	O
and	O
markedly	O
reduced	O
pro	O
-	O
inflammatory	O
cytokines	O
(	O
TNF	O
-	O
α	O
,	O
IL	B-FUNC
-	I-FUNC
6	I-FUNC
,	O
CCL	B-FUNC
-	O
2	O
/	O
MCP	B-FUNC
-	O
1	O
and	O
CXCL	O
-	O
10	O
/	O
IP	O
-	O
10	O
)	O
production	O
at	O
the	O
mRNA	O
levels	O
.	O

Our	O
data	O
suggests	O
that	O
2019	O
-	O
nCoV	O
is	O
newly	O
spilled	O
coronavirus	O
into	O
humans	O
in	O
China	O
is	O
closely	O
related	O
to	O
SARS	O
-	O
CoV	O
,	O
which	O
has	O
only	O
12	O
.	O
8	O
%	O
of	O
difference	O
with	O
SARS	O
-	O
CoV	O
in	O
S	O
protein	O
and	O
has	O
83	O
.	O
9	O
%	O
similarity	O
in	O
minimal	O
receptor	O
-	O
binding	B-FUNC
domain	O
with	O
SARS	O
-	O
CoV	O
.	O
Addition	O
of	O
a	O
novel	O
glycosylation	O
sites	O
were	O
observed	O
in	O
2019	O
-	O
nCoV	O
.	O
In	O
addition	O
,	O
antigenic	O
analysis	O
proposes	O
that	O
great	O
antigenic	O
differences	O
exist	O
between	O
both	O
the	O
viral	O
strains	O
,	O
but	O
some	O
of	O
the	O
epitopes	O
were	O
found	O
to	O
be	O
similar	O
between	O
both	O
the	O
S	O
proteins	O
.	O

